US20140194383A1 - Monomers capable of dimerizing in an aqueous solution, and methods of using same - Google Patents
Monomers capable of dimerizing in an aqueous solution, and methods of using same Download PDFInfo
- Publication number
- US20140194383A1 US20140194383A1 US14/110,056 US201214110056A US2014194383A1 US 20140194383 A1 US20140194383 A1 US 20140194383A1 US 201214110056 A US201214110056 A US 201214110056A US 2014194383 A1 US2014194383 A1 US 2014194383A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- group
- monomer
- unsubstituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000178 monomer Substances 0.000 title claims abstract description 280
- 238000000034 method Methods 0.000 title claims description 98
- 239000007864 aqueous solution Substances 0.000 title description 7
- 230000000447 dimerizing effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 48
- 239000012736 aqueous medium Substances 0.000 claims abstract description 23
- 239000000539 dimer Substances 0.000 claims abstract description 23
- 238000001727 in vivo Methods 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 138
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 76
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000001931 aliphatic group Chemical group 0.000 claims description 69
- 229910052736 halogen Inorganic materials 0.000 claims description 62
- 150000002367 halogens Chemical group 0.000 claims description 62
- 125000005647 linker group Chemical group 0.000 claims description 56
- 125000001424 substituent group Chemical group 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 125000005843 halogen group Chemical group 0.000 claims description 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 36
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 125000004429 atom Chemical group 0.000 claims description 30
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 125000002252 acyl group Chemical group 0.000 claims description 26
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 21
- 239000002207 metabolite Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical group O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 318
- 238000006243 chemical reaction Methods 0.000 description 174
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 171
- 238000005160 1H NMR spectroscopy Methods 0.000 description 152
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 88
- 238000004128 high performance liquid chromatography Methods 0.000 description 87
- -1 boronate diester Chemical class 0.000 description 86
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 71
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
- 239000000047 product Substances 0.000 description 67
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 66
- 239000012043 crude product Substances 0.000 description 65
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 63
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 53
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 53
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- MRFONSPCWQUCAX-UHFFFAOYSA-N tert-butyl n-[(3-piperidin-4-ylphenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C2CCNCC2)=C1 MRFONSPCWQUCAX-UHFFFAOYSA-N 0.000 description 44
- 238000003556 assay Methods 0.000 description 42
- 239000011734 sodium Substances 0.000 description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 38
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 102000001400 Tryptase Human genes 0.000 description 37
- 108060005989 Tryptase Proteins 0.000 description 37
- 238000004440 column chromatography Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 238000005400 testing for adjacent nuclei with gyration operator Methods 0.000 description 29
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- 238000002953 preparative HPLC Methods 0.000 description 25
- 238000003756 stirring Methods 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 23
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 23
- 238000000746 purification Methods 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- 229960001866 silicon dioxide Drugs 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 150000002009 diols Chemical class 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 20
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000002775 capsule Substances 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- 230000003993 interaction Effects 0.000 description 16
- 102220005241 rs33951465 Human genes 0.000 description 16
- 229910015845 BBr3 Inorganic materials 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000002750 tryptase inhibitor Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 11
- 210000003630 histaminocyte Anatomy 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000010626 work up procedure Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910000085 borane Inorganic materials 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 239000002024 ethyl acetate extract Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 125000002015 acyclic group Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000005620 boronic acid group Chemical group 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
- 150000003840 hydrochlorides Chemical class 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 108020001580 protein domains Proteins 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000014400 SH2 domains Human genes 0.000 description 6
- 108050003452 SH2 domains Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000000021 kinase assay Methods 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 235000011056 potassium acetate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013638 trimer Substances 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 5
- ACWUGSRELMTOFJ-UHFFFAOYSA-N 2-cyclobutylideneacetic acid Chemical compound OC(=O)C=C1CCC1 ACWUGSRELMTOFJ-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000003302 alkenyloxy group Chemical group 0.000 description 5
- 125000005133 alkynyloxy group Chemical group 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000004850 protein–protein interaction Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- SXDXUPKVDBZOPR-UHFFFAOYSA-N 1-hydroxypyrrolidin-2-ol Chemical group OC1CCCN1O SXDXUPKVDBZOPR-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- MBCTXMUNGXCIBB-UHFFFAOYSA-N 3-(6-methyl-2,4-dioxo-1h-pyrimidin-5-yl)prop-2-enoic acid Chemical compound CC=1NC(=O)NC(=O)C=1C=CC(O)=O MBCTXMUNGXCIBB-UHFFFAOYSA-N 0.000 description 4
- PGSWEKYNAOWQDF-UHFFFAOYSA-N 3-methylcatechol Chemical group CC1=CC=CC(O)=C1O PGSWEKYNAOWQDF-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000000395 SH3 domains Human genes 0.000 description 4
- 108050008861 SH3 domains Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229960003907 linezolid Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- IJFXRHURBJZNAO-UHFFFAOYSA-N meta--hydroxybenzoic acid Natural products OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- FURIRWDMXYIWLS-QGLTVNCISA-N n-[[(5s)-3-[4-(3,4-dihydroxypyrrolidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CC(O)C(O)C1 FURIRWDMXYIWLS-QGLTVNCISA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 150000002924 oxiranes Chemical class 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- BWFJEOPYZUBFRM-UHFFFAOYSA-N spiro[2h-1-benzofuran-3,4'-piperidine]-5-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OCC21CCNCC2 BWFJEOPYZUBFRM-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- CSWYJBIHGRLJRM-UHFFFAOYSA-N tert-butyl n-[[3-[1-[3-(3,4-dihydroxy-4-methyl-2-oxopyrrolidin-1-yl)benzoyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)N2C(C(O)C(C)(O)C2)=O)=C1 CSWYJBIHGRLJRM-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- XIKGRPKDQDFXLF-UHFFFAOYSA-N 2-hydroxy-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(O)=C(C=O)C=C1OC XIKGRPKDQDFXLF-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091008885 GPCRs class E Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 159000000021 acetate salts Chemical class 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 230000003185 calcium uptake Effects 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004405 heteroalkoxy group Chemical group 0.000 description 3
- 125000005368 heteroarylthio group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000670 ligand binding assay Methods 0.000 description 3
- TZZNULRWBXZDLM-UHFFFAOYSA-N methyl 3-(3,4-dihydroxy-4-methyl-2-oxopyrrolidin-1-yl)benzoate Chemical compound COC(=O)C1=CC=CC(N2C(C(O)C(C)(O)C2)=O)=C1 TZZNULRWBXZDLM-UHFFFAOYSA-N 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- LYGSSCZKYHFTMS-UHFFFAOYSA-N n-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-2-(1-hydroxycyclobutyl)-2-oxoacetamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NC(=O)C(=O)C3(O)CCC3)C=CC=2)=C1 LYGSSCZKYHFTMS-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical class CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 2
- YEMKCEWDYHXCSC-UHFFFAOYSA-N (2,2-dimethyl-4h-benzo[g][1,3]benzodioxin-9-yl) trifluoromethanesulfonate Chemical compound C1=CC(OS(=O)(=O)C(F)(F)F)=C2C=C(OC(C)(C)OC3)C3=CC2=C1 YEMKCEWDYHXCSC-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GDMJXXLVTYSBBE-UHFFFAOYSA-N 1,2-benzoxaborole Chemical compound C1=CC=C2OB=CC2=C1 GDMJXXLVTYSBBE-UHFFFAOYSA-N 0.000 description 2
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 2
- SZPQTEWIRPXBTC-KFOWTEFUSA-N 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H]1O SZPQTEWIRPXBTC-KFOWTEFUSA-N 0.000 description 2
- MLZQZMGZQROPCV-UHFFFAOYSA-N 1-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-3,4-dihydroxy-4-methylpyrrolidin-2-one;hydrochloride Chemical compound Cl.O=C1C(O)C(C)(O)CN1C1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 MLZQZMGZQROPCV-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 2
- BNDMBANHBSJMKH-UHFFFAOYSA-N 2,2-dimethyl-4h-benzo[g][1,3]benzodioxin-9-ol Chemical compound C1=CC(O)=C2C=C(OC(C)(C)OC3)C3=CC2=C1 BNDMBANHBSJMKH-UHFFFAOYSA-N 0.000 description 2
- PIHRLFGNZWHKIO-UHFFFAOYSA-N 2-(6-oxo-[1,3]dioxolo[4,5-g]chromen-8-yl)acetic acid Chemical compound C1=C2OCOC2=CC2=C1OC(=O)C=C2CC(=O)O PIHRLFGNZWHKIO-UHFFFAOYSA-N 0.000 description 2
- QCYGFCYJOHAJMS-UHFFFAOYSA-N 2-(7,8-dihydroxy-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound OC1=C(O)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QCYGFCYJOHAJMS-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 2
- SAPAUOFSCLCQJB-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(O)=O)=C1 SAPAUOFSCLCQJB-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- XZPABFKZRALOPV-UHFFFAOYSA-N 6,7-dimethoxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C1C=C(OC)C(OC)=C2 XZPABFKZRALOPV-UHFFFAOYSA-N 0.000 description 2
- GCARUNVWBWVAJT-UHFFFAOYSA-N 6-(hydroxymethyl)naphthalene-1,7-diol Chemical compound C1=CC(O)=C2C=C(O)C(CO)=CC2=C1 GCARUNVWBWVAJT-UHFFFAOYSA-N 0.000 description 2
- HDAQKLAKMZNBQB-UHFFFAOYSA-N 6-[(2-methoxyphenyl)methyl-methylamino]-n-[8-[6-[(2-methoxyphenyl)methyl-methylamino]hexanoyl-methylamino]octyl]-n-methylhexanamide Chemical compound COC1=CC=CC=C1CN(C)CCCCCC(=O)N(C)CCCCCCCCN(C)C(=O)CCCCCN(C)CC1=CC=CC=C1OC HDAQKLAKMZNBQB-UHFFFAOYSA-N 0.000 description 2
- IGDXBFZUBGQGMM-UHFFFAOYSA-N 7,8-dimethoxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C(OC)C(OC)=CC=C21 IGDXBFZUBGQGMM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VNZHOIDQBPFEJU-OAQYLSRUSA-N N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide Chemical compound C1CN(C(=O)CNC(=O)[C@H](NC(N)=N)CC(C)C)CCC1C1=CC(C=2C(=C(Cl)C(OCC=3OC(=CC=3)C(O)=O)=CC=2)Cl)=NN1C VNZHOIDQBPFEJU-OAQYLSRUSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 102000000470 PDZ domains Human genes 0.000 description 2
- 108050008994 PDZ domains Proteins 0.000 description 2
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- UZMPYXSDDZXMAI-OHKKONBVSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@@H](OP(O)(O)=O)C(O)[C@@H](OP(O)(O)=O)[C@H]1O UZMPYXSDDZXMAI-OHKKONBVSA-N 0.000 description 2
- PCRWEOZPGRCLPP-UHFFFAOYSA-N [2-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-1-benzothiophen-4-yl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC3=CC=CC(=C3C=2)B(O)O)=C1 PCRWEOZPGRCLPP-UHFFFAOYSA-N 0.000 description 2
- IZXCHHBTDFQRFB-UHFFFAOYSA-N [2-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-1h-indol-4-yl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2NC3=CC=CC(=C3C=2)B(O)O)=C1 IZXCHHBTDFQRFB-UHFFFAOYSA-N 0.000 description 2
- IHGFIDLMVKGING-UHFFFAOYSA-N [2-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-1h-indol-6-yl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2NC3=CC(=CC=C3C=2)B(O)O)=C1 IHGFIDLMVKGING-UHFFFAOYSA-N 0.000 description 2
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000010822 cell death assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 101150098203 grb2 gene Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- OSYXXQUUGMLSGE-UHFFFAOYSA-N methyl 2-methyloxirane-2-carboxylate Chemical compound COC(=O)C1(C)CO1 OSYXXQUUGMLSGE-UHFFFAOYSA-N 0.000 description 2
- CWQYVTPJYUNQRM-UHFFFAOYSA-N methyl 2-phenyloxirane-2-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OC)CO1 CWQYVTPJYUNQRM-UHFFFAOYSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- BKYAAWFKMFQUQD-ZDUSSCGKSA-N n-[[(5s)-3-[4-(2,5-dihydropyrrol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CC=CC1 BKYAAWFKMFQUQD-ZDUSSCGKSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003911 phosphatidylinositol 4-phosphates Chemical class 0.000 description 2
- 150000003912 phosphatidylinositol 5-phosphates Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000015585 poly-pyrimidine tract binding protein Human genes 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102200031723 rs137852944 Human genes 0.000 description 2
- 102220278166 rs937875134 Human genes 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 2
- 229950009641 sparsomycin Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FPJWPCUVQHLEFA-UHFFFAOYSA-N tert-butyl n-(spiro[2h-1-benzofuran-3,4'-piperidine]-5-ylmethyl)carbamate Chemical compound C12=CC(CNC(=O)OC(C)(C)C)=CC=C2OCC21CCNCC2 FPJWPCUVQHLEFA-UHFFFAOYSA-N 0.000 description 2
- FZRKJAVIBDMSPM-UHFFFAOYSA-N tert-butyl n-[[3-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(O)C=CC=2)=C1 FZRKJAVIBDMSPM-UHFFFAOYSA-N 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 235000016804 zinc Nutrition 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- XLSYLQDVLAXIKK-NXEZZACHSA-N (1r,2s)-2-amino-3-fluoro-1-(4-methylsulfonylphenyl)propan-1-ol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@H](N)CF)C=C1 XLSYLQDVLAXIKK-NXEZZACHSA-N 0.000 description 1
- TWUSDDMONZULSC-QMTHXVAHSA-N (1s,2r)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@H](O)[C@@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-QMTHXVAHSA-N 0.000 description 1
- UNXQGBMZYKHQCO-NVHWNKAKSA-N (2'r,3s,3'r,5'r)-6-chloro-3'-(3-chlorophenyl)-n-[(3s)-3,4-dihydroxybutyl]-5'-(2,2-dimethylpropyl)-5-fluoro-2-oxospiro[1h-indole-3,4'-pyrrolidine]-2'-carboxamide Chemical compound C1([C@H]2[C@@H](N[C@@H]([C@@]22C3=CC(F)=C(Cl)C=C3NC2=O)CC(C)(C)C)C(=O)NCC[C@H](O)CO)=CC=CC(Cl)=C1 UNXQGBMZYKHQCO-NVHWNKAKSA-N 0.000 description 1
- YXEWPGYLMHXLPS-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl)methyl propanoate Chemical compound CCC(=O)OCN1C(=O)C=CC1=O YXEWPGYLMHXLPS-UHFFFAOYSA-N 0.000 description 1
- XBANOGLOZZLEEW-AJLKJCTESA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-3-phenylpro Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](C(O)=O)C(C)(C)C)NC(=O)[C@@H](N)CCCCN)C1=CN=CN1 XBANOGLOZZLEEW-AJLKJCTESA-N 0.000 description 1
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
- KNAYYBRIBNEIAL-WNEUIUNWSA-N (2s,4r)-2-amino-4-[(e)-3-naphthalen-2-ylprop-2-enyl]pentanedioic acid Chemical compound C1=CC=CC2=CC(/C=C/C[C@H](C[C@H](N)C(O)=O)C(O)=O)=CC=C21 KNAYYBRIBNEIAL-WNEUIUNWSA-N 0.000 description 1
- BLZIYDWBKOOBIK-CHWFTXMASA-N (3r,4as,6r,8as)-6-(2h-tetrazol-5-ylmethoxymethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid Chemical compound C([C@H]1C[C@H]2C[C@@H](NC[C@H]2CC1)C(=O)O)OCC=1N=NNN=1 BLZIYDWBKOOBIK-CHWFTXMASA-N 0.000 description 1
- LNDYQNTTYXLTNH-RTBBDAMFSA-N (3s,4ar,6r,8ar)-6-[2-(2h-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid;hydrate Chemical compound O.C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)CC=1N=NNN=1 LNDYQNTTYXLTNH-RTBBDAMFSA-N 0.000 description 1
- JTJFLYDAECYPJL-AWEZNQCLSA-N (5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-[(2-oxo-3h-pyrrol-1-yl)methyl]-1,3-oxazolidin-2-one Chemical compound FC1=CC(N2C(O[C@@H](CN3C(CC=C3)=O)C2)=O)=CC=C1N1CCOCC1 JTJFLYDAECYPJL-AWEZNQCLSA-N 0.000 description 1
- VXIWZOWWQMRVRF-NSHDSACASA-N (5s)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](CN)CN1C(C=C1F)=CC=C1N1CCOCC1 VXIWZOWWQMRVRF-NSHDSACASA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- LTNLNNNAQAMQMQ-SNAWJCMRSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-(3,4,5-trihydroxyphenyl)prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(O)C(O)=C(O)C=2)=C1 LTNLNNNAQAMQMQ-SNAWJCMRSA-N 0.000 description 1
- XZNDYJUPWJQBCW-BQYQJAHWSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 XZNDYJUPWJQBCW-BQYQJAHWSA-N 0.000 description 1
- SVDZHJHXNDKPFF-WEVVVXLNSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-(4-cyclopropyl-3-hydroxyphenyl)prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(O)C(C3CC3)=CC=2)=C1 SVDZHJHXNDKPFF-WEVVVXLNSA-N 0.000 description 1
- SLDAXIKXYFAJNR-SOFGYWHQSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 SLDAXIKXYFAJNR-SOFGYWHQSA-N 0.000 description 1
- IZXUEIXGDXNJOR-BQYQJAHWSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-[3-hydroxy-2-(hydroxymethyl)phenyl]prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C(=C(O)C=CC=2)CO)=C1 IZXUEIXGDXNJOR-BQYQJAHWSA-N 0.000 description 1
- RHZLAUHJDJLGTE-VQHVLOKHSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-[3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl]prop-2-en-1-one Chemical compound C1=C(O)C(C(C)(O)C)=CC=C1\C=C\C(=O)N1CCC(C=2C=C(CN)C=CC=2)CC1 RHZLAUHJDJLGTE-VQHVLOKHSA-N 0.000 description 1
- MCWLCZAZHIKHER-FNORWQNLSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-[3-hydroxy-4-(hydroxymethyl)phenyl]prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(O)C(CO)=CC=2)=C1 MCWLCZAZHIKHER-FNORWQNLSA-N 0.000 description 1
- NDCZXVKPCZQFMV-FNORWQNLSA-N (e)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-[4-hydroxy-3-(hydroxymethyl)phenyl]prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(CO)C(O)=CC=2)=C1 NDCZXVKPCZQFMV-FNORWQNLSA-N 0.000 description 1
- XMFSZSUKPFBOFV-RTXAENKXSA-N (e)-3-(3,4-dihydroxyphenyl)-n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)\C=C\C1=CC=C(O)C(O)=C1 XMFSZSUKPFBOFV-RTXAENKXSA-N 0.000 description 1
- HYAAPUQAORMHHQ-MOESHBJCSA-N (e)-3-(3,4-dihydroxyphenyl)-n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 HYAAPUQAORMHHQ-MOESHBJCSA-N 0.000 description 1
- UXKYJAJDDGGMSY-SNAWJCMRSA-N (e)-3-(5-methyl-2,4-dioxo-1h-pyrimidin-6-yl)-n-propylprop-2-enamide Chemical compound CCCNC(=O)\C=C\C=1NC(=O)NC(=O)C=1C UXKYJAJDDGGMSY-SNAWJCMRSA-N 0.000 description 1
- ZPPMLFXUUUTENC-ONEGZZNKSA-N (e)-n-(3-hydroxypropyl)-3-(5-methyl-2,4-dioxo-1h-pyrimidin-6-yl)prop-2-enamide Chemical compound CC1=C(\C=C\C(=O)NCCCO)NC(=O)NC1=O ZPPMLFXUUUTENC-ONEGZZNKSA-N 0.000 description 1
- MSZSRDYMBIMFFI-HWKANZROSA-N (e)-n-[(3,4-dihydroxyphenyl)methyl]-3-(5-methyl-2,4-dioxo-1h-pyrimidin-6-yl)prop-2-enamide Chemical compound N1C(=O)NC(=O)C(C)=C1\C=C\C(=O)NCC1=CC=C(O)C(O)=C1 MSZSRDYMBIMFFI-HWKANZROSA-N 0.000 description 1
- BOIHOMIKGIVJJQ-FNORWQNLSA-N (e)-n-[(3,4-dimethoxyphenyl)methyl]-3-(5-methyl-2,4-dioxo-1h-pyrimidin-6-yl)prop-2-enamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)\C=C\C1=C(C)C(=O)NC(=O)N1 BOIHOMIKGIVJJQ-FNORWQNLSA-N 0.000 description 1
- VYZXIQFRVDJOQY-BQYQJAHWSA-N (e)-n-benzyl-3-(5-methyl-2,4-dioxo-1h-pyrimidin-6-yl)prop-2-enamide Chemical compound N1C(=O)NC(=O)C(C)=C1\C=C\C(=O)NCC1=CC=CC=C1 VYZXIQFRVDJOQY-BQYQJAHWSA-N 0.000 description 1
- VOAAOCWLJBGRLO-ALCCZGGFSA-N (z)-1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C/C=2C=C(O)C(O)=CC=2)=C1 VOAAOCWLJBGRLO-ALCCZGGFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- YYPJDZBKEOJEKB-UHFFFAOYSA-N 1-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-3-(3,3,3-trifluoro-2-hydroxypropyl)urea;hydrochloride Chemical compound Cl.NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NC(=O)NCC(O)C(F)(F)F)C=CC=2)=C1 YYPJDZBKEOJEKB-UHFFFAOYSA-N 0.000 description 1
- IJNMOOAOYRWQKP-UHFFFAOYSA-N 1-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-(3-fluoro-4-hydroxyphenyl)ethanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C=C(F)C(O)=CC=2)=C1 IJNMOOAOYRWQKP-UHFFFAOYSA-N 0.000 description 1
- QSQOGKONVJDRNH-UHFFFAOYSA-N 1-bromo-4-iodo-2-methylbenzene Chemical compound CC1=CC(I)=CC=C1Br QSQOGKONVJDRNH-UHFFFAOYSA-N 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- DCXFSVQKFGAAIB-NVXWUHKLSA-N 1-n-[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]-4-hydroxy-3-n-methoxybenzene-1,3-dicarboxamide Chemical compound C1=C(O)C(C(=O)NOC)=CC(C(=O)N[C@H](CF)[C@H](O)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 DCXFSVQKFGAAIB-NVXWUHKLSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 1
- RFBVBRVVOPAAFS-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(CO)(CO)C2=O RFBVBRVVOPAAFS-UHFFFAOYSA-N 0.000 description 1
- NIBFJPXGNVPNHK-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-4-carbaldehyde Chemical group C1=CC(C=O)=C2OC(F)(F)OC2=C1 NIBFJPXGNVPNHK-UHFFFAOYSA-N 0.000 description 1
- LLYONXXBSIPLPO-UHFFFAOYSA-N 2,2-dimethyl-4h-benzo[g][1,3]benzodioxine-9-carbonitrile Chemical compound C1=CC(C#N)=C2C=C(OC(C)(C)OC3)C3=CC2=C1 LLYONXXBSIPLPO-UHFFFAOYSA-N 0.000 description 1
- UCTUXUGXIFRVGX-UHFFFAOYSA-N 2,3,4-trimethoxybenzaldehyde Chemical class COC1=CC=C(C=O)C(OC)=C1OC UCTUXUGXIFRVGX-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 1
- VPXVPJQOPRBXPO-UHFFFAOYSA-N 2,5-bis[6-[ethyl-[(2-methoxyphenyl)methyl]amino]hexylamino]cyclohexa-2,5-diene-1,4-dione Chemical compound C=1C=CC=C(OC)C=1CN(CC)CCCCCCNC(C(C=1)=O)=CC(=O)C=1NCCCCCCN(CC)CC1=CC=CC=C1OC VPXVPJQOPRBXPO-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- CSTJVNHANTYEMY-JRZJBTRGSA-N 2-(2,3-dihydroxyphenyl)-n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)CC1=CC=CC(O)=C1O CSTJVNHANTYEMY-JRZJBTRGSA-N 0.000 description 1
- QDTVKZBGVDWZHA-INIZCTEOSA-N 2-(2,3-dihydroxyphenyl)-n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound OC1=CC=CC(CC(=O)NC[C@@H]2OC(=O)N(C2)C=2C=C(F)C(N3CCOCC3)=CC=2)=C1O QDTVKZBGVDWZHA-INIZCTEOSA-N 0.000 description 1
- ZYURKEKWQVAKKR-IBYPIGCZSA-N 2-(3,4-dihydroxyphenyl)-n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)CC1=CC=C(O)C(O)=C1 ZYURKEKWQVAKKR-IBYPIGCZSA-N 0.000 description 1
- OIZYZBJZLBMSOL-INIZCTEOSA-N 2-(3,4-dihydroxyphenyl)-n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound C1=C(O)C(O)=CC=C1CC(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 OIZYZBJZLBMSOL-INIZCTEOSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- COHIEJLWRGREHV-YRNVUSSQSA-N 2-[(5e)-5-[(4-bromophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methylbutanoic acid Chemical compound O=C1N(C(C(C)C)C(O)=O)C(=S)S\C1=C\C1=CC=C(Br)C=C1 COHIEJLWRGREHV-YRNVUSSQSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- IVCMXNODUHRAND-UHFFFAOYSA-N 2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-1-(1-hydroxycyclobutyl)ethanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCC(=O)C3(O)CCC3)C=CC=2)=C1 IVCMXNODUHRAND-UHFFFAOYSA-N 0.000 description 1
- FQVYHSSZIDCDEL-ZRZAMGCNSA-N 2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-1-[(3s,4r)-3,4-dihydroxypyrrolidin-1-yl]ethanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCC(=O)N3C[C@@H](O)[C@@H](O)C3)C=CC=2)=C1 FQVYHSSZIDCDEL-ZRZAMGCNSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZYIGSNHXZGXOHP-ZRZAMGCNSA-N 2-[4-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-1-[(3r,4s)-3,4-dihydroxypyrrolidin-1-yl]ethanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC(OCC(=O)N3C[C@@H](O)[C@@H](O)C3)=CC=2)=C1 ZYIGSNHXZGXOHP-ZRZAMGCNSA-N 0.000 description 1
- ADOHEWVFRZKRHE-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium Chemical compound CC(=O)OCC[N+](C)(C)C.CC(=O)OCC[N+](C)(C)C ADOHEWVFRZKRHE-UHFFFAOYSA-N 0.000 description 1
- PIXJURSCCVBKRF-UHFFFAOYSA-N 2-amino-3-(5-tert-butyl-3-oxo-4-isoxazolyl)propanoic acid Chemical compound CC(C)(C)C=1ONC(=O)C=1CC([NH3+])C([O-])=O PIXJURSCCVBKRF-UHFFFAOYSA-N 0.000 description 1
- SOJUSNIBPPMLCC-UHFFFAOYSA-N 2-amino-7-(furan-2-yl)-7,8-dihydro-6h-quinazolin-5-one Chemical compound C1C2=NC(N)=NC=C2C(=O)CC1C1=CC=CO1 SOJUSNIBPPMLCC-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- UIOMNPYQUBMBOJ-UHFFFAOYSA-N 2-hydroxy-3,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1OC UIOMNPYQUBMBOJ-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 description 1
- YELLAPKUWRTITI-UHFFFAOYSA-N 3,5-dihydroxynaphthalene-2-carboxylic acid Chemical compound C1=CC(O)=C2C=C(O)C(C(=O)O)=CC2=C1 YELLAPKUWRTITI-UHFFFAOYSA-N 0.000 description 1
- ZTYHAPBLEAJFHC-UHFFFAOYSA-N 3-(3,4-dihydroxy-4-methyl-2-oxopyrrolidin-1-yl)benzoic acid Chemical compound O=C1C(O)C(C)(O)CN1C1=CC=CC(C(O)=O)=C1 ZTYHAPBLEAJFHC-UHFFFAOYSA-N 0.000 description 1
- XWDGSKMQENQYAE-FUBQLUNQSA-N 3-(3,4-dihydroxyphenyl)-n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)CCC1=CC=C(O)C(O)=C1 XWDGSKMQENQYAE-FUBQLUNQSA-N 0.000 description 1
- YEZSOGZIUIVGBU-KRWDZBQOSA-N 3-(3,4-dihydroxyphenyl)-n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]propanamide Chemical compound C1=C(O)C(O)=CC=C1CCC(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 YEZSOGZIUIVGBU-KRWDZBQOSA-N 0.000 description 1
- QIKYAZAHNUPHFN-UHFFFAOYSA-N 3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.CCN=C=NCCCN(C)C QIKYAZAHNUPHFN-UHFFFAOYSA-N 0.000 description 1
- QBHNHFLAJBTFTA-UHFFFAOYSA-N 3-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]benzenecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1 QBHNHFLAJBTFTA-UHFFFAOYSA-N 0.000 description 1
- CAEGZIDXAHAHRA-UHFFFAOYSA-N 3-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-7,8-dihydroxy-4-methylchromen-2-one Chemical compound O=C1OC=2C(O)=C(O)C=CC=2C(C)=C1CC(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 CAEGZIDXAHAHRA-UHFFFAOYSA-N 0.000 description 1
- TYWITVUPYRZUNO-PSWAGMNNSA-N 3-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-1-[(3r,4s)-3,4-dihydroxypyrrolidin-1-yl]propan-1-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCCC(=O)N3C[C@@H](O)[C@@H](O)C3)C=CC=2)=C1 TYWITVUPYRZUNO-PSWAGMNNSA-N 0.000 description 1
- XCPOSAHMFCPLCN-UHFFFAOYSA-N 3-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-2-cyclopentyl-2-hydroxypropanoic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCC(O)(C3CCCC3)C(O)=O)C=CC=2)=C1 XCPOSAHMFCPLCN-UHFFFAOYSA-N 0.000 description 1
- HZLOXVKVSIJKDT-UHFFFAOYSA-N 3-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-2-hydroxy-2-methylpropanoic acid Chemical compound OC(=O)C(O)(C)COC1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 HZLOXVKVSIJKDT-UHFFFAOYSA-N 0.000 description 1
- VYLGMOZZXGMRHN-UHFFFAOYSA-N 3-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenoxy]-2-hydroxy-2-phenylpropanoic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(OCC(O)(C(O)=O)C=3C=CC=CC=3)C=CC=2)=C1 VYLGMOZZXGMRHN-UHFFFAOYSA-N 0.000 description 1
- FAJSAWYONYHQQJ-UHFFFAOYSA-N 3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-6,7-dihydroxychromen-2-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(OC3=CC(O)=C(O)C=C3C=2)=O)=C1 FAJSAWYONYHQQJ-UHFFFAOYSA-N 0.000 description 1
- DNUZYNJTPRXIIB-UHFFFAOYSA-N 3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-7,8-dihydroxychromen-2-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(OC3=C(O)C(O)=CC=C3C=2)=O)=C1 DNUZYNJTPRXIIB-UHFFFAOYSA-N 0.000 description 1
- MFTGLACGZNLTEE-UHFFFAOYSA-N 3-[5-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]indol-1-yl]-2-hydroxy-2-methylpropanoic acid Chemical compound C=1C=C2N(CC(O)(C)C(O)=O)C=CC2=CC=1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 MFTGLACGZNLTEE-UHFFFAOYSA-N 0.000 description 1
- HZJYXSWZWTYRKH-UHFFFAOYSA-N 3-[5-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]indol-1-yl]-2-hydroxy-2-phenylpropanoic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3C=CN(CC(O)(C(O)=O)C=4C=CC=CC=4)C3=CC=2)=C1 HZJYXSWZWTYRKH-UHFFFAOYSA-N 0.000 description 1
- DSNYFUKBGJZWFP-UHFFFAOYSA-N 3-[6-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]indol-1-yl]-2-hydroxy-2-methylpropanoic acid Chemical compound C1=C2N(CC(O)(C)C(O)=O)C=CC2=CC=C1C(=O)N(CC1)CCC1C1=CC=CC(CN)=C1 DSNYFUKBGJZWFP-UHFFFAOYSA-N 0.000 description 1
- XJJSMVDPUOYWRR-UHFFFAOYSA-N 3-[6-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]indol-1-yl]-2-hydroxy-2-phenylpropanoic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C3N(CC(O)(C(O)=O)C=4C=CC=CC=4)C=CC3=CC=2)=C1 XJJSMVDPUOYWRR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- IPICFSFUAKDZEI-UHFFFAOYSA-N 3-methyl-2-[2-[[3-methyl-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyloxy]butanoyl]amino]propanoyloxy]butanoic acid Chemical compound CC(C)C(C(O)=O)OC(=O)C(C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)OC(C)(C)C IPICFSFUAKDZEI-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- WFFZGYRTVIPBFN-UHFFFAOYSA-N 3h-indene-1,2-dione Chemical class C1=CC=C2C(=O)C(=O)CC2=C1 WFFZGYRTVIPBFN-UHFFFAOYSA-N 0.000 description 1
- QFRLDZGQEZCCJZ-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NNC(=O)N1C1=CC=C(OCCO2)C2=C1 QFRLDZGQEZCCJZ-UHFFFAOYSA-N 0.000 description 1
- QGZLWPRZRRZMIQ-GMUIIQOCSA-N 4-(aminomethyl)-n-[[4-[2-[(3r)-3-hydroxy-4-oxopyrrolidin-1-yl]-2-oxoethoxy]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1OCC(=O)N1CC(=O)[C@H](O)C1 QGZLWPRZRRZMIQ-GMUIIQOCSA-N 0.000 description 1
- ZFVQRZHSZQZJOF-STYNFMPRSA-N 4-(aminomethyl)-n-[[4-[2-[(3r,4r)-3,4-dihydroxypyrrolidin-1-yl]-2-oxoethoxy]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1OCC(=O)N1C[C@@H](O)[C@H](O)C1 ZFVQRZHSZQZJOF-STYNFMPRSA-N 0.000 description 1
- QGZLWPRZRRZMIQ-FERBBOLQSA-N 4-(aminomethyl)-n-[[4-[2-[(3s)-3-hydroxy-4-oxopyrrolidin-1-yl]-2-oxoethoxy]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1OCC(=O)N1CC(=O)[C@@H](O)C1 QGZLWPRZRRZMIQ-FERBBOLQSA-N 0.000 description 1
- DHDLJKODIFBHQC-HLRBRJAUSA-N 4-(aminomethyl)-n-[[4-[2-[(3s,4s)-3,4-dihydroxypyrrolidin-1-yl]-2-oxoethyl]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1CC(=O)N1C[C@H](O)[C@@H](O)C1 DHDLJKODIFBHQC-HLRBRJAUSA-N 0.000 description 1
- FRTSYKRVFDUTOM-FSRHSHDFSA-N 4-(aminomethyl)-n-[[4-[3-[(3r)-3-hydroxy-4-oxopyrrolidin-1-yl]-3-oxopropoxy]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1OCCC(=O)N1CC(=O)[C@H](O)C1 FRTSYKRVFDUTOM-FSRHSHDFSA-N 0.000 description 1
- FRTSYKRVFDUTOM-FYZYNONXSA-N 4-(aminomethyl)-n-[[4-[3-[(3s)-3-hydroxy-4-oxopyrrolidin-1-yl]-3-oxopropoxy]phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(CN)=CC=C1C(=O)NCC(C=C1)=CC=C1OCCC(=O)N1CC(=O)[C@@H](O)C1 FRTSYKRVFDUTOM-FYZYNONXSA-N 0.000 description 1
- AODYDRQTUWUTPG-SOFGYWHQSA-N 4-[(e)-3-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-hydroxy-n-methoxybenzamide Chemical compound C1=C(O)C(C(=O)NOC)=CC=C1\C=C\C(=O)N1CCC(C=2C=C(CN)C=CC=2)CC1 AODYDRQTUWUTPG-SOFGYWHQSA-N 0.000 description 1
- GNBZWALWWUXCKJ-FNORWQNLSA-N 4-[(e)-3-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-hydroxybenzamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(O)C(C(N)=O)=CC=2)=C1 GNBZWALWWUXCKJ-FNORWQNLSA-N 0.000 description 1
- PUWYQBOAAMFGKY-HZQGFHJZSA-N 4-[(e)-3-[[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]amino]-3-oxoprop-1-enyl]-2-hydroxy-n-methoxybenzamide Chemical compound C1=C(O)C(C(=O)NOC)=CC=C1\C=C\C(=O)N[C@H](CF)[C@H](O)C1=CC=C(S(C)(=O)=O)C=C1 PUWYQBOAAMFGKY-HZQGFHJZSA-N 0.000 description 1
- GIBSDSYVKQQPDG-VVOXDCDMSA-N 4-[(e)-3-[[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]amino]-3-oxoprop-1-enyl]-2-hydroxybenzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@@H](O)[C@@H](CF)NC(=O)\C=C\C1=CC=C(C(N)=O)C(O)=C1 GIBSDSYVKQQPDG-VVOXDCDMSA-N 0.000 description 1
- UEWJGKMSTJGAFF-JGIVAVPZSA-N 4-[(e)-3-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methylamino]-3-oxoprop-1-enyl]-2-hydroxy-n-methoxybenzamide Chemical compound C1=C(O)C(C(=O)NOC)=CC=C1\C=C\C(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 UEWJGKMSTJGAFF-JGIVAVPZSA-N 0.000 description 1
- GDSLMALLNHMDSB-UHFFFAOYSA-N 4-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-6,7-dihydroxychromen-2-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C=3C=C(O)C(O)=CC=3OC(=O)C=2)=C1 GDSLMALLNHMDSB-UHFFFAOYSA-N 0.000 description 1
- GDBAFZBJPZDNBJ-UHFFFAOYSA-N 4-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-2-hydroxy-n-methoxybenzamide Chemical compound C1=C(O)C(C(=O)NOC)=CC=C1C(=O)N1CCC(C=2C=C(CN)C=CC=2)CC1 GDBAFZBJPZDNBJ-UHFFFAOYSA-N 0.000 description 1
- XKWBADTZOAQZRU-UHFFFAOYSA-N 4-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-2-hydroxybenzamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(O)C(C(N)=O)=CC=2)=C1 XKWBADTZOAQZRU-UHFFFAOYSA-N 0.000 description 1
- FYAKLZKQJDBBKW-UHFFFAOYSA-N 4-bromo-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1O FYAKLZKQJDBBKW-UHFFFAOYSA-N 0.000 description 1
- WWYFPDXEIFBNKE-UHFFFAOYSA-M 4-carboxybenzyl alcohol Chemical compound OCC1=CC=C(C([O-])=O)C=C1 WWYFPDXEIFBNKE-UHFFFAOYSA-M 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- GKTOUGVJSDXWEM-FNORWQNLSA-N 5-[(e)-3-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-hydroxybenzamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(C(O)=CC=2)C(N)=O)=C1 GKTOUGVJSDXWEM-FNORWQNLSA-N 0.000 description 1
- BSYWCLCURNKAAN-VVOXDCDMSA-N 5-[(e)-3-[[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]amino]-3-oxoprop-1-enyl]-2-hydroxybenzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@@H](O)[C@@H](CF)NC(=O)\C=C\C1=CC=C(O)C(C(N)=O)=C1 BSYWCLCURNKAAN-VVOXDCDMSA-N 0.000 description 1
- WQYNUYIUPWDILP-MOESHBJCSA-N 5-[(e)-3-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methylamino]-3-oxoprop-1-enyl]-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)N)=CC(\C=C\C(=O)NC[C@@H]2OC(=O)N(C2)C=2C=C(F)C(N3CCOCC3)=CC=2)=C1 WQYNUYIUPWDILP-MOESHBJCSA-N 0.000 description 1
- FVUBRDNKYNQEOY-UHFFFAOYSA-N 5-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-2-hydroxy-n-methoxybenzamide Chemical compound C1=C(O)C(C(=O)NOC)=CC(C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 FVUBRDNKYNQEOY-UHFFFAOYSA-N 0.000 description 1
- MZEVDNHTLIGKHW-UHFFFAOYSA-N 5-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-2-hydroxybenzamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C(O)=CC=2)C(N)=O)=C1 MZEVDNHTLIGKHW-UHFFFAOYSA-N 0.000 description 1
- AXXYLTBQIQBTES-BYPYZUCNSA-N 5-iodowillardiine Chemical compound OC(=O)[C@@H](N)CN1C=C(I)C(=O)NC1=O AXXYLTBQIQBTES-BYPYZUCNSA-N 0.000 description 1
- PXPDAEXMMPTAON-UHFFFAOYSA-N 8-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-[1,3]dioxolo[4,5-g]chromen-6-one Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C=3C=C4OCOC4=CC=3OC(=O)C=2)=C1 PXPDAEXMMPTAON-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- BGYNLOSBKBOJJD-IUCAKERBSA-N Aeroplysinin 1 Chemical compound COC1=C(Br)[C@H](O)[C@](O)(CC#N)C=C1Br BGYNLOSBKBOJJD-IUCAKERBSA-N 0.000 description 1
- 108010079677 Agatoxins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010017443 B 43 Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- LQSLBVXESNRILG-VDGAXYAQSA-N Boc-Gln-Ala-Arg-7-amino-4-methylcoumarin Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)OC(C)(C)C)C)=CC=C21 LQSLBVXESNRILG-VDGAXYAQSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102220573536 C-C motif chemokine 5_T31A_mutation Human genes 0.000 description 1
- 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101150099575 CDC37 gene Proteins 0.000 description 1
- CBPBJKQTVKFOOQ-UHFFFAOYSA-N CGP 28-392 Chemical compound CCOC(=O)C1=C(C)NC(COC2=O)=C2C1C1=CC=CC=C1OC(F)F CBPBJKQTVKFOOQ-UHFFFAOYSA-N 0.000 description 1
- 101100327050 Caenorhabditis elegans cbp-1 gene Proteins 0.000 description 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
- 101100130886 Candida albicans (strain SC5314 / ATCC MYA-2876) MNT1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102100024539 Chymase Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100036444 Clathrin interactor 1 Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102220618753 Cyclin-dependent kinase 2_T14A_mutation Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 102220602493 Deleted in azoospermia-like_T12A_mutation Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000011107 Diacylglycerol Kinase Human genes 0.000 description 1
- 108010062677 Diacylglycerol Kinase Proteins 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101800000155 Epiregulin Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 241000782205 Guibourtia conjugata Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 101001046660 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
- 101000851951 Homo sapiens Clathrin interactor 1 Proteins 0.000 description 1
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101001091256 Homo sapiens Kinesin-like protein KIF13B Proteins 0.000 description 1
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798942 Homo sapiens Target of Myb protein 1 Proteins 0.000 description 1
- 101000772173 Homo sapiens Tubby-related protein 1 Proteins 0.000 description 1
- 101000717428 Homo sapiens UV excision repair protein RAD23 homolog A Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- BGYNLOSBKBOJJD-BDAKNGLRSA-N Isoaeroplysinin-1 Natural products COC1=C(Br)[C@@H](O)[C@](O)(CC#N)C=C1Br BGYNLOSBKBOJJD-BDAKNGLRSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 102100034863 Kinesin-like protein KIF13B Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 102000046985 LST8 Homolog mTOR Associated Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 125000005855 N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010072083 NSC 668036 Proteins 0.000 description 1
- 101150097297 Nedd4 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IXBQSRWSVIBXNC-HSKGSTCASA-N Nodularin Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C\C)/C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 IXBQSRWSVIBXNC-HSKGSTCASA-N 0.000 description 1
- IXBQSRWSVIBXNC-UHFFFAOYSA-N Nodularin Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(C)C(C(O)=O)NC(=O)C(=CC)N(C)C(=O)CCC(C(O)=O)NC(=O)C(C)C1C=CC(C)=CC(C)C(OC)CC1=CC=CC=C1 IXBQSRWSVIBXNC-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 1
- PDJARQSWGDDFHH-PSWAGMNNSA-N PQIP Chemical compound C1CN(C)CCN1[C@@H]1C[C@H](C=2N3C=CN=C(N)C3=C(C=3C=C4N=C(C=CC4=CC=3)C=3C=CC=CC=3)N=2)C1 PDJARQSWGDDFHH-PSWAGMNNSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102220510109 Phospholipid scramblase 3_T21D_mutation Human genes 0.000 description 1
- 206010034962 Photopsia Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100029837 Probetacellulin Human genes 0.000 description 1
- 102100025498 Proepiregulin Human genes 0.000 description 1
- 101710088675 Proline-rich peptide Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100037516 Protein polybromo-1 Human genes 0.000 description 1
- 102220493650 Protein polybromo-1_T56A_mutation Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102100021672 Pumilio homolog 1 Human genes 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 101100454113 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KRE2 gene Proteins 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 101150067005 Sgk3 gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102100034024 Target of Myb protein 1 Human genes 0.000 description 1
- 101710115678 Target of rapamycin complex subunit LST8 Proteins 0.000 description 1
- RFCWHQNNCOJYTR-IRCAEPKSSA-N Tautomycin Chemical compound O([C@H]([C@H](CC1)C)[C@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@@H](OC)[C@H](OC(=O)C[C@@H](O)C=2C(OC(=O)C=2C)=O)C(C)C)[C@@]21CC[C@@H](C)[C@H](CC[C@H](C)C(C)=O)O2 RFCWHQNNCOJYTR-IRCAEPKSSA-N 0.000 description 1
- RFCWHQNNCOJYTR-UHFFFAOYSA-N Tautomycin Natural products CC=1C(=O)OC(=O)C=1C(O)CC(=O)OC(C(C)C)C(OC)C(O)CC(=O)C(C)C(O)CCC(C)C(C(CC1)C)OC21CCC(C)C(CCC(C)C(C)=O)O2 RFCWHQNNCOJYTR-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229940122598 Tryptase inhibitor Drugs 0.000 description 1
- 102100029293 Tubby-related protein 1 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100020845 UV excision repair protein RAD23 homolog A Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 229930186114 Variolin Natural products 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 1
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 1
- OGKBOGSFBLUOHR-JXMROGBWSA-N [(e)-2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]ethenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(\C=C\B(O)O)C=CC=2)=C1 OGKBOGSFBLUOHR-JXMROGBWSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JWMLLUKVPBBKGE-UHFFFAOYSA-N [2-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]phenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C=2C(=CC=CC=2)B(O)O)=C1 JWMLLUKVPBBKGE-UHFFFAOYSA-N 0.000 description 1
- DXGKQDXCWHVNBP-BQYQJAHWSA-N [3-[(e)-3-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-oxoprop-1-enyl]phenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=C(C=CC=2)B(O)O)=C1 DXGKQDXCWHVNBP-BQYQJAHWSA-N 0.000 description 1
- SAPYICCVIRSSFU-UHFFFAOYSA-N [3-[1-(3-aminobenzoyl)piperidin-4-yl]phenyl]methylcarbamic acid Chemical compound NC1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CNC(O)=O)C=CC=2)=C1 SAPYICCVIRSSFU-UHFFFAOYSA-N 0.000 description 1
- SSAGOLYPMHXYHH-UHFFFAOYSA-N [3-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-4-fluorophenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C(=CC=C(C=2)B(O)O)F)=C1 SSAGOLYPMHXYHH-UHFFFAOYSA-N 0.000 description 1
- AFKHIBBJWOZEMY-UHFFFAOYSA-N [3-[3-(5-carbamimidoylspiro[2h-1-benzofuran-3,4'-piperidine]-1'-carbonyl)phenyl]phenyl]boronic acid Chemical compound C12=CC(C(=N)N)=CC=C2OCC1(CC1)CCN1C(=O)C(C=1)=CC=CC=1C1=CC=CC(B(O)O)=C1 AFKHIBBJWOZEMY-UHFFFAOYSA-N 0.000 description 1
- QDDXACYJGRXHBY-UHFFFAOYSA-N [3-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]phenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C=2C=C(C=CC=2)B(O)O)=C1 QDDXACYJGRXHBY-UHFFFAOYSA-N 0.000 description 1
- OQPWOJMMIVBHSD-UHFFFAOYSA-N [3-[3-[4-[5-(aminomethyl)-2-fluorophenyl]piperidine-1-carbonyl]phenyl]phenyl]boronic acid Chemical compound NCC1=CC=C(F)C(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C=2C=C(C=CC=2)B(O)O)=C1 OQPWOJMMIVBHSD-UHFFFAOYSA-N 0.000 description 1
- JSAYYPQWKPHCGN-UHFFFAOYSA-N [3-[3-[5-(aminomethyl)spiro[2h-1-benzofuran-3,4'-piperidine]-1'-carbonyl]phenyl]phenyl]boronic acid Chemical compound C12=CC(CN)=CC=C2OCC1(CC1)CCN1C(=O)C(C=1)=CC=CC=1C1=CC=CC(B(O)O)=C1 JSAYYPQWKPHCGN-UHFFFAOYSA-N 0.000 description 1
- NHBBWNYRTJXEQO-FPYGCLRLSA-N [4-[(e)-3-(5-carbamimidoylspiro[2h-1-benzofuran-3,4'-piperidine]-1'-yl)-3-oxoprop-1-enyl]phenyl]boronic acid Chemical compound C12=CC(C(=N)N)=CC=C2OCC1(CC1)CCN1C(=O)\C=C\C1=CC=C(B(O)O)C=C1 NHBBWNYRTJXEQO-FPYGCLRLSA-N 0.000 description 1
- NJZAYGUCGNCBGU-RMKNXTFCSA-N [4-[(e)-3-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-3-oxoprop-1-enyl]phenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)\C=C\C=2C=CC(=CC=2)B(O)O)=C1 NJZAYGUCGNCBGU-RMKNXTFCSA-N 0.000 description 1
- FKHMCIISWHBNTH-UHFFFAOYSA-N [4-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-3-fluorophenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C(=CC(=CC=2)B(O)O)F)=C1 FKHMCIISWHBNTH-UHFFFAOYSA-N 0.000 description 1
- AEIIXHNHZRUMNY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(1-benzofuran-4-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=3C=COC=3C=CC=2)=C1 AEIIXHNHZRUMNY-UHFFFAOYSA-N 0.000 description 1
- PMEVUEUIAFDIHH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2,3,4-trihydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(=C(O)C(O)=CC=2)O)=C1 PMEVUEUIAFDIHH-UHFFFAOYSA-N 0.000 description 1
- QRSDVRUNUZZEME-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2,3-dihydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(=C(O)C=CC=2)O)=C1 QRSDVRUNUZZEME-UHFFFAOYSA-N 0.000 description 1
- XMROGMOWIWBCMY-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2,4,5-trihydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C(=CC(O)=C(O)C=2)O)=C1 XMROGMOWIWBCMY-UHFFFAOYSA-N 0.000 description 1
- CQCSUDYCECOVLZ-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(2-bromo-1-benzothiophen-4-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=3C=C(Br)SC=3C=CC=2)=C1 CQCSUDYCECOVLZ-UHFFFAOYSA-N 0.000 description 1
- GAVKPTDEXCJKLU-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3,4,5-trihydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 GAVKPTDEXCJKLU-UHFFFAOYSA-N 0.000 description 1
- XQLYZSVVUMUWIB-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3,4-dichlorophenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1 XQLYZSVVUMUWIB-UHFFFAOYSA-N 0.000 description 1
- SIVJHWHJXZXTCO-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-chloro-4,5-dihydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(Cl)C(O)=C(O)C=2)=C1 SIVJHWHJXZXTCO-UHFFFAOYSA-N 0.000 description 1
- AFPGRCBMUASFMH-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(3-hydroxyphenyl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(O)C=CC=2)=C1 AFPGRCBMUASFMH-UHFFFAOYSA-N 0.000 description 1
- VPBUSJRMRVABAT-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(4-bromo-1-benzothiophen-2-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2SC3=CC=CC(Br)=C3C=2)=C1 VPBUSJRMRVABAT-UHFFFAOYSA-N 0.000 description 1
- DTUIEKLPNXTXKM-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-(5-hydroxy-1h-indol-2-yl)methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2NC3=CC=C(O)C=C3C=2)=C1 DTUIEKLPNXTXKM-UHFFFAOYSA-N 0.000 description 1
- UODAFZVSCYVFDT-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)phenyl]methanone Chemical compound C1C(O)(C)C(C)(O)CN1C1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CN)C=CC=2)=C1 UODAFZVSCYVFDT-UHFFFAOYSA-N 0.000 description 1
- XFMAOWFRAWAFLJ-FGZHOGPDSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[(3r,4r)-3,4-dihydroxypyrrolidine-1-carbonyl]phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C(=O)N2C[C@@H](O)[C@H](O)C2)=C1 XFMAOWFRAWAFLJ-FGZHOGPDSA-N 0.000 description 1
- ABURCQOQVCASCJ-SZPZYZBQSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[(3r,4s)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)N2C[C@@H](O)[C@@H](O)C2)=C1 ABURCQOQVCASCJ-SZPZYZBQSA-N 0.000 description 1
- XFMAOWFRAWAFLJ-SZPZYZBQSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-[(3r,4s)-3,4-dihydroxypyrrolidine-1-carbonyl]phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(C=CC=2)C(=O)N2C[C@@H](O)[C@@H](O)C2)=C1 XFMAOWFRAWAFLJ-SZPZYZBQSA-N 0.000 description 1
- YULKHIXPABKGCX-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[3-hydroxy-4-(hydroxymethyl)phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(O)C(CO)=CC=2)=C1 YULKHIXPABKGCX-UHFFFAOYSA-N 0.000 description 1
- HONIYYXWHJNNMO-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[4-(1-hydroxy-3h-2,1-benzoxaborol-5-yl)phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC(=CC=2)C=2C=C3COB(O)C3=CC=2)=C1 HONIYYXWHJNNMO-UHFFFAOYSA-N 0.000 description 1
- LIQYTCZNNVPUPQ-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[4-hydroxy-3-(hydroxymethyl)phenyl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(CO)C(O)=CC=2)=C1 LIQYTCZNNVPUPQ-UHFFFAOYSA-N 0.000 description 1
- MWEMQBHJEJGOGR-UHFFFAOYSA-N [4-[3-(aminomethyl)phenyl]piperidin-1-yl]-[7-hydroxy-6-(hydroxymethyl)naphthalen-1-yl]methanone Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C3=CC(O)=C(CO)C=C3C=CC=2)=C1 MWEMQBHJEJGOGR-UHFFFAOYSA-N 0.000 description 1
- IJMRLWBWPUEWRT-UHFFFAOYSA-N [4-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]-1-benzothiophen-2-yl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=3C=C(SC=3C=CC=2)B(O)O)=C1 IJMRLWBWPUEWRT-UHFFFAOYSA-N 0.000 description 1
- GTJYURJAGCGYOB-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-fluorophenyl]piperidin-1-yl]-(6,7-dihydroxynaphthalen-1-yl)methanone Chemical compound NCC1=CC=C(F)C(C2CCN(CC2)C(=O)C=2C3=CC(O)=C(O)C=C3C=CC=2)=C1 GTJYURJAGCGYOB-UHFFFAOYSA-N 0.000 description 1
- GGCZKEAJHXYUPE-UHFFFAOYSA-N [5-(aminomethyl)spiro[2h-1-benzofuran-3,4'-piperidine]-1'-yl]-(3,4-dihydroxyphenyl)methanone Chemical compound C12=CC(CN)=CC=C2OCC1(CC1)CCN1C(=O)C1=CC=C(O)C(O)=C1 GGCZKEAJHXYUPE-UHFFFAOYSA-N 0.000 description 1
- DYVKJZPSAYQODA-UHFFFAOYSA-N [5-(aminomethyl)spiro[2h-1-benzofuran-3,4'-piperidine]-1'-yl]-(3-chloro-4,5-dihydroxyphenyl)methanone Chemical compound C12=CC(CN)=CC=C2OCC1(CC1)CCN1C(=O)C1=CC(O)=C(O)C(Cl)=C1 DYVKJZPSAYQODA-UHFFFAOYSA-N 0.000 description 1
- NABXOVVMSIKOFF-UHFFFAOYSA-N [5-(aminomethyl)spiro[2h-1-benzofuran-3,4'-piperidine]-1'-yl]-[4-(2,3-dihydroxypropoxy)phenyl]methanone;hydrochloride Chemical compound Cl.C12=CC(CN)=CC=C2OCC1(CC1)CCN1C(=O)C1=CC=C(OCC(O)CO)C=C1 NABXOVVMSIKOFF-UHFFFAOYSA-N 0.000 description 1
- WOHZFVOUISNXMD-UHFFFAOYSA-N [5-[2-[4-[3-(aminomethyl)phenyl]piperidin-1-yl]-2-oxoethyl]-2-fluorophenyl]boronic acid Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)CC=2C=C(C(F)=CC=2)B(O)O)=C1 WOHZFVOUISNXMD-UHFFFAOYSA-N 0.000 description 1
- JMDDNPSQWFJSLT-UHFFFAOYSA-N [8-[4-[5-(aminomethyl)-2-fluorophenyl]piperidine-1-carbonyl]naphthalen-2-yl]boronic acid Chemical compound NCC1=CC=C(F)C(C2CCN(CC2)C(=O)C=2C3=CC(=CC=C3C=CC=2)B(O)O)=C1 JMDDNPSQWFJSLT-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BGYNLOSBKBOJJD-UHFFFAOYSA-N aeroplysinin-I Natural products COC1=C(Br)C(O)C(O)(CC#N)C=C1Br BGYNLOSBKBOJJD-UHFFFAOYSA-N 0.000 description 1
- JICBRHIOKVTMPJ-SYWRHQDJSA-N alb-109564 Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=C(SC)C=C21 JICBRHIOKVTMPJ-SYWRHQDJSA-N 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 108010075875 amyloid beta-protein (16-20) Proteins 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 101150088806 atpA gene Proteins 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- YBXNDAZSWWEJQF-UHFFFAOYSA-N benzyl 5-[(2-methylpropan-2-yl)oxycarbonylamino]spiro[2h-1-benzofuran-3,4'-piperidine]-1'-carboxylate Chemical compound C12=CC(NC(=O)OC(C)(C)C)=CC=C2OCC1(CC1)CCN1C(=O)OCC1=CC=CC=C1 YBXNDAZSWWEJQF-UHFFFAOYSA-N 0.000 description 1
- FWEXLAWMYDGKIM-UHFFFAOYSA-N benzyl 5-cyanospiro[2h-1-benzofuran-3,4'-piperidine]-1'-carboxylate Chemical compound C1CC2(C3=CC(=CC=C3OC2)C#N)CCN1C(=O)OCC1=CC=CC=C1 FWEXLAWMYDGKIM-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MGQGLCKLWVLHEZ-UHFFFAOYSA-N benzyl n-[(3-piperidin-4-ylphenyl)methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC(C=1)=CC=CC=1C1CCNCC1 MGQGLCKLWVLHEZ-UHFFFAOYSA-N 0.000 description 1
- OOZQWJBJYMPTCB-UHFFFAOYSA-N benzyl n-[[3-[1-(3-aminobenzoyl)piperidin-4-yl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(CNC(=O)OCC=3C=CC=CC=3)C=CC=2)=C1 OOZQWJBJYMPTCB-UHFFFAOYSA-N 0.000 description 1
- DIXKHPAKVRJLQW-UHFFFAOYSA-N benzyl n-[[3-[1-[3-[(2-cyclobutylideneacetyl)amino]benzoyl]piperidin-4-yl]phenyl]methyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC(C=1)=CC=CC=1C(CC1)CCN1C(=O)C(C=1)=CC=CC=1NC(=O)C=C1CCC1 DIXKHPAKVRJLQW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000005854 carbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960002559 chlorotrianisene Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 125000005852 di-N,N—(C1-C2)alkylamino(C2-C3)alkyl group Chemical group 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 229960003839 dienestrol Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- DVSDDICSXBCMQJ-UHFFFAOYSA-N diethyl 2-acetylbutanedioate Chemical compound CCOC(=O)CC(C(C)=O)C(=O)OCC DVSDDICSXBCMQJ-UHFFFAOYSA-N 0.000 description 1
- ZSANYRMTSBBUCA-UHFFFAOYSA-N diethyl 3-oxopentanedioate Chemical compound CCOC(=O)CC(=O)CC(=O)OCC ZSANYRMTSBBUCA-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VZFRNCSOCOPNDB-AJKFJWDBSA-N domoic acid Chemical compound OC(=O)[C@@H](C)\C=C\C=C(/C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AJKFJWDBSA-N 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 102000007336 epsin Human genes 0.000 description 1
- 108010032643 epsin Proteins 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PXQTXTMGVPKEQV-GQCTYLIASA-N ethyl (e)-3-(3-formyl-4-hydroxyphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(O)C(C=O)=C1 PXQTXTMGVPKEQV-GQCTYLIASA-N 0.000 description 1
- FGCGWHVDPBOFJE-UHFFFAOYSA-N ethyl 2-cyclobutylideneacetate Chemical compound CCOC(=O)C=C1CCC1 FGCGWHVDPBOFJE-UHFFFAOYSA-N 0.000 description 1
- JFMXTWOMFXZWCP-UHFFFAOYSA-N ethyl 3-(2-bromophenyl)benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)Br)=C1 JFMXTWOMFXZWCP-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 239000003008 fumonisin Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- VZFRNCSOCOPNDB-OXYNIABMSA-N isodomoic acid D Natural products CC(C=C/C=C(/C)C1CNC(C1CC(=O)O)C(=O)O)C(=O)O VZFRNCSOCOPNDB-OXYNIABMSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HTWQUGILRGGBDZ-UHFFFAOYSA-N methanol;thionyl dichloride Chemical compound OC.ClS(Cl)=O HTWQUGILRGGBDZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- UUPXCHMBEAHLHL-UHFFFAOYSA-N methyl 3-(3-methyl-5-oxo-2h-pyrrol-1-yl)benzoate Chemical compound COC(=O)C1=CC=CC(N2C(C=C(C)C2)=O)=C1 UUPXCHMBEAHLHL-UHFFFAOYSA-N 0.000 description 1
- ADSJCWKOKYOJSZ-UHFFFAOYSA-N methyl 3-formyl-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(C=O)=C1 ADSJCWKOKYOJSZ-UHFFFAOYSA-N 0.000 description 1
- FZIBCCGGICGWBP-UHFFFAOYSA-N methyl 3-methylbut-2-enoate Chemical compound COC(=O)C=C(C)C FZIBCCGGICGWBP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- KNPNGMXRGITFLE-UHFFFAOYSA-N methylperoxy(phenyl)borinic acid Chemical compound COOB(O)C1=CC=CC=C1 KNPNGMXRGITFLE-UHFFFAOYSA-N 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000005232 molecular self-assembly Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 description 1
- HQLRLEDKKITPIL-WUJWULDRSA-N n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]-2,3-dihydroxybenzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)C1=CC=CC(O)=C1O HQLRLEDKKITPIL-WUJWULDRSA-N 0.000 description 1
- WEXUWEPSZPTSDW-VYIIXAMBSA-N n-[(1s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]-3,4-dihydroxybenzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](O)C(CF)NC(=O)C1=CC=C(O)C(O)=C1 WEXUWEPSZPTSDW-VYIIXAMBSA-N 0.000 description 1
- RTRIXVOSRYRSBP-VXKWHMMOSA-N n-[(1s,2s)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine Chemical compound N([C@H]1CCC[C@H]1C=1C=CC=CC=1)C1=NCCCCCCCCCCC1 RTRIXVOSRYRSBP-VXKWHMMOSA-N 0.000 description 1
- KWQWWUXRGIIBAS-UHFFFAOYSA-N n-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 KWQWWUXRGIIBAS-UHFFFAOYSA-N 0.000 description 1
- FUKAFILBDRAARP-UHFFFAOYSA-N n-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-2,3-dihydroxybenzamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NC(=O)C=3C(=C(O)C=CC=3)O)C=CC=2)=C1 FUKAFILBDRAARP-UHFFFAOYSA-N 0.000 description 1
- OWXRLVBSOIVTFC-UHFFFAOYSA-N n-[3-[4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl]phenyl]-2-hydroxy-2-(1-hydroxycyclobutyl)acetamide Chemical compound NCC1=CC=CC(C2CCN(CC2)C(=O)C=2C=C(NC(=O)C(O)C3(O)CCC3)C=CC=2)=C1 OWXRLVBSOIVTFC-UHFFFAOYSA-N 0.000 description 1
- GWAJDAVDKDQPQE-AWEZNQCLSA-N n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-2,3-dihydroxybenzamide Chemical compound OC1=CC=CC(C(=O)NC[C@@H]2OC(=O)N(C2)C=2C=C(F)C(N3CCOCC3)=CC=2)=C1O GWAJDAVDKDQPQE-AWEZNQCLSA-N 0.000 description 1
- FYJUFPOBRMOSMR-HNNXBMFYSA-N n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-3,4-dihydroxybenzamide Chemical compound C1=C(O)C(O)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 FYJUFPOBRMOSMR-HNNXBMFYSA-N 0.000 description 1
- CCNGAOWITPPFPY-KRWDZBQOSA-N n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-3-hydroxy-4-(hydroxymethyl)benzamide Chemical compound C1=C(O)C(CO)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=C(F)C(N3CCOCC3)=CC=2)C1 CCNGAOWITPPFPY-KRWDZBQOSA-N 0.000 description 1
- INAJMVRIYOBKFL-KRWDZBQOSA-N n-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-4-hydroxy-3-(hydroxymethyl)benzamide Chemical compound C1=C(O)C(CO)=CC(C(=O)NC[C@@H]2OC(=O)N(C2)C=2C=C(F)C(N3CCOCC3)=CC=2)=C1 INAJMVRIYOBKFL-KRWDZBQOSA-N 0.000 description 1
- PRRIVJTYQGYUOK-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-4-[2-(2,3-dihydroxypropanoylamino)acetyl]piperazine-1-carboxamide Chemical compound C1=CC(CN)=CC=C1CNC(=O)N1CCN(C(=O)CNC(=O)C(O)CO)CC1 PRRIVJTYQGYUOK-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 108010065793 nodularin Proteins 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 108010036904 peptidimer-c Proteins 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000003915 phosphatidylinositol 4,5-bisphosphates Chemical class 0.000 description 1
- 229910000065 phosphene Inorganic materials 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- TURAMGVWNUTQKH-UHFFFAOYSA-N propa-1,2-dien-1-one Chemical group C=C=C=O TURAMGVWNUTQKH-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200144986 rs121918346 Human genes 0.000 description 1
- 102220086468 rs141649676 Human genes 0.000 description 1
- 102200038856 rs150565592 Human genes 0.000 description 1
- 102220005293 rs35960772 Human genes 0.000 description 1
- 102220128896 rs376207606 Human genes 0.000 description 1
- 102220060547 rs786203080 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- FCCGJTKEKXUBFZ-UHFFFAOYSA-N rucaparib phosphate Chemical compound OP(O)(O)=O.C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 FCCGJTKEKXUBFZ-UHFFFAOYSA-N 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical group OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 229930189723 salinosporamide Natural products 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000009991 second messenger activation Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 108010059709 shepherdin Proteins 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- ZRRGOUHITGRLBA-UHFFFAOYSA-N stattic Chemical compound [O-][N+](=O)C1=CC=C2C=CS(=O)(=O)C2=C1 ZRRGOUHITGRLBA-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940041030 streptogramins Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 229960002300 zeranol Drugs 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 1
- 108091058550 ω-conotoxin Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Definitions
- protein-protein interactions For example, signaling pathways are used by cells to generate biological responses to external or internal stimuli.
- a few thousand gene products control both ontogeny/development of higher organisms and sophisticated behavior by their many different cell types. These gene products can work in different combinations to achieve their goals and often do so through protein-protein interactions.
- Such proteins possess modular protein domains that recognize, bind, and/or modify certain motifs. Protein-protein and protein-nucleic acid recognition often function through protein interactions domains, for example, such as the SH2, SH3, and PDZ domains. These protein-interaction domains may represent a meaningful area for developing targeted therapies.
- Other macromolecular interactions that may serve as potential targets for effective therapies include protein-nucleic acid interactions, protein-carbohydrate interactions, and protein-lipid interactions.
- Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media.
- such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer).
- Contemplated monomers may include a ligand moiety (e.g. a pharmacophore for the target biomolecule), a linker element, and a connector element that joins the ligand moiety and the linker element.
- a ligand moiety e.g. a pharmacophore for the target biomolecule
- linker element e.g. a pharmacophore for the target biomolecule
- a connector element that joins the ligand moiety and the linker element.
- contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g
- a first monomer capable of forming a biologically useful multimer when in contact with a second monomer in an aqueous media is provided.
- the first monomer is represented by the formula:
- the second monomer has a boronic acid or oxaborole moiety capable of binding with the Z 1 moiety of Formula I to form the multimer.
- a method of administering a pharmaceutically effective amount of a multimeric compound to a patient in need thereof comprises administering to the patient thereof an amount of a first monomer as described above and an amount of a boronic acid or oxaborole monomer in amounts effective such that the pharmaceutically effective amount of the resulting multimer is formed in vivo.
- a therapeutic multimer compound formed from the multimerization in an aqueous media of a first monomer is provided.
- the multimer is represented by the formula:
- a method of modulating two or more target biomolecule domains substantially simultaneously comprises contacting an aqueous composition comprising said biomolecule domains with a first monomer represented by:
- said first monomer and said second monomer forms a dimer that binds to the first target biomolecule domain and the second target biomolecule domain.
- a method of treating a disease associated with two or more target biomolecule domains in a patient in need thereof comprises administering to said patient a first monomer represented by:
- X 2 is a second ligand moiety capable of binding to a second target biomolecule domain, wherein upon administration, said first monomer and said second monomer forms a dimer in vivo that binds to the first target biomolecule domain and the second target biomolecule domain.
- a first monomer capable of forming a biologically useful dimer when in contact with a second monomer in vivo is provided.
- the first monomer is represented by the formula:
- a therapeutic dimerized compound formed from the dimerization in an aqueous media of a first monomer is provided.
- the first monomer is represented by:
- X 3 is a first ligand moiety capable of binding to a first target biomolecule
- Y 3 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- X 4 is a second ligand moiety capable of binding to a second target biomolecule
- Y 4 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- a method of treating a disease associated with two or more target biomolecule domains in a patient in need thereof comprises administering to said patient two or more monomers each independently selected from the group represented by:
- X 3 is a first ligand moiety capable of binding to a first target biomolecule
- Y 3 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- X 4 is a second ligand moiety capable of binding to a second target biomolecule
- Y 4 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- Z 3 is as shown below, wherein upon administration, said first monomer and said second monomer forms a dimer in vivo that binds to the first target biomolecule domain and the second target biomolecule domain.
- a first monomer capable of forming a biologically useful trimer when in contact with a second monomer and a third monomer in an aqueous media is provided.
- the first monomer is represented by the formula:
- FIG. 1A shows an x-ray co-crystal structure of a multimer bound to adjacent subunits of mast cell beta-tryptase-II, according to an embodiment.
- the cationic aminomethyl-phenyl-piperidine moieties of the multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the linker elements are joined by a cyclic tetrahedral sp 3 boronate diester linkage;
- FIG. 1B shows the chemical structure of the multimer bound to tryptase in FIG. 1A , according to an embodiment
- FIG. 2A shows dose response curves for T2 & T35 monomers and for T2 and T35 combined in a 1:1 ratio of T2:T35, according to an embodiment
- FIG. 2B shows a reaction scheme for the formation of the 1:1 multimer in FIG. 2A , according to an embodiment
- FIG. 3 shows the tryptase-bound state of the 1:1 multimer of T2:T35 shown in FIG. 1A , according to an embodiment
- FIG. 4A shows an x-ray co crystal structure of a multimer bound to adjacent subunits of mast cell beta-tryptase, according to an embodiment.
- the cationic aminomethyl-phenyl-piperidine moieties of a 1:1 T27:T10 multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the multimer is joined by a cyclic planar sp 2 boronic acid diester linkage;
- FIG. 4B shows a reaction scheme for the formation of the 1:1 multimer in FIG. 4A , according to an embodiment
- FIG. 5A shows an x-ray co-crystal structure of a T92+T35 heterodimer at pH5.5 and pH6.5 bound to tryptase, according to an embodiment.
- the structure confirms the sp 3 state of the phenolic-hydroxamate/boronate complex bound to tryptase under both conditions;
- FIG. 5B shows a reaction scheme for the formation of the 1:1 multimer in FIG. 5A , according to an embodiment
- FIG. 6A shows an x-ray co-crystal structure of a T55 homodimer bound to tryptase, according to an embodiment.
- the cationic aminomethyl-phenyl-piperidine moieties of the multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the monomers are joined by a covalent spiroketal linkage;
- FIG. 6B shows a reaction scheme for the formation of the 1:1 multimer in FIG. 6A , according to an embodiment.
- Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media.
- such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer).
- Contemplated monomers may include a ligand moiety (e.g. a pharmacophore moiety), a linker element, and a connector element that joins the ligand moiety and the linker element.
- contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
- contemplated monomers may be separate or separatable in a solid or in an aqueous media under one set of conditions, and when placed in an aqueous media having one or more biomolecules, with another (e.g., under a different set of conditions), can 1) form a multimer through the linker on each monomer; and either: 2a) bind to the biomolecule in two or more locations (e.g.
- protein domains through each ligand moiety of the respective monomer or 2b) bind to two or more biomolecules through each ligand moiety of the respective monomer.
- disclosed monomers may interact with another appropriate monomer (i.e. a monomeric pair) in an aqueous media (e.g., in vivo) to form a multimer (e.g. a dimer) that can bind to two separate target biomolecule domains (e.g. protein domains).
- the ligand moiety of a contemplated monomer may be a pharmacophore or a ligand moiety that is e.g., capable of binding to a biomolecule, such as for example, a protein, e.g. a specific protein domain, a component of a biological cell such as ribosome (composed of proteins and nucleic acids), or an enzyme active site (e.g. a protease, such as tryptase).
- the linker element comprises a functional group capable of forming a chemical bond with another linker element.
- the linker moiety may also serve as a signaling entity or “reporter,” and in some instances the assembly of two or more linkers can produce a fluorescent entity or fluorophore with properties distinct from the individual linker moiety.
- a plurality of monomers, each comprising a linker element may react to form a multimer connected by the linker elements.
- the multimer may be formed in vivo.
- the multimer may have enhanced properties relative to the monomers that form the multimer. For example, in certain embodiments, the multimer may bind to a target with greater affinity than any of the monomers that form the multimer. Also described are methods of making the compositions and methods of administering the compositions.
- a plurality of monomers may assemble to form a multimer.
- the multimer may be used for a variety of purposes. For example, in some instances, the multimer may be used to perturb a biological system. As described in more detail below, in some embodiments, the multimer may bind to a target biomolecule, such as a protein, nucleic acid, or polysaccharide. In certain embodiments, the multimer may be used as a pharmaceutical.
- the multimer may form in vivo upon administration of suitable monomers to a subject.
- the multimer may be capable of interacting with a relatively large target site as compared to the individual monomers that form the multimer.
- a target may comprise, in some embodiments, two protein domains separated by a distance such that a multimer, but not a monomer, may be capable of binding to both domains essentially simultaneously.
- contemplated multimers may bind to a target with greater affinity as compared to a monomer binding affinity alone.
- a contemplated multimer may advantageously exhibit enhanced properties relative to the monomers that form the multimer.
- a multimer may have improved binding properties as compared to the monomers alone.
- a multimer may have improved signaling properties.
- the fluorescent properties of a multimer may be different as compared to a monomer.
- the fluorescent brightness of a multimer at a particular wavelength may be greater than the fluorescent brightness at the same wavelength of the monomers that form the multimer.
- a difference in signaling properties between the multimer and the monomers that form the multimer may be used to detect formation of the multimer.
- detection of the formation of the multimer may be used to screen monomers, as discussed in more detail below.
- the multimers may be used for imaging or as diagnostic agents.
- a multimer may be a homomultimer (i.e., a multimer formed from two or more essentially identical monomers) or may be a heteromultimer (i.e., a multimer formed from two or more substantially different monomers).
- a contemplated multimer may comprise 2 to about 10 monomers, for example, a multimer may be a dimer, a trimer, a tetramer, or a pentamer.
- a monomer may comprise a ligand moiety, a linker element, and a connector element that associates the ligand moiety with the linker element.
- the linker element of a first monomer may combine with the linker element of a second monomer.
- the linker element may comprise a functional group that can react with a functional group of another linker element to form a bond linking the monomers.
- the linker element of a first monomer may be substantially the same as the linker element of a second monomer.
- the linker element of a first monomer may be substantially different than the linker element of a second monomer.
- the ligand moiety may be a pharmacophore.
- the ligand moiety (e.g., a pharmacophore) may bind to a target molecule with a dissociation constant of less than 1 mM, in some embodiments less than 500 microM, in some embodiments less than 300 microM, in some embodiments less than 100 microM, in some embodiments less than 10 microM, in some embodiments less than 1 microM, in some embodiments less than 100 nM, in some embodiments less than 10 nM, and in some embodiments less than 1 nM.
- the IC 50 of the first monomer against a first target biomolecule and the IC 50 of the second monomer against a second target biomolecule may be greater than the apparent IC 50 of a combination of the monomers against the first target biomolecule and the second target biomolecule.
- the combination of monomers may be any suitable ratio.
- the ratio of the first monomer to the second monomer may be between 10:1 to 1:10, in some embodiments between 5:1 and 1:5, and in some embodiments between 2:1 and 1:2.
- the ratio of the first monomer to the second monomer may be essentially 1:1.
- the ratio of the smaller of the IC 50 of the first monomer and the second monomer to the apparent IC 50 of the multimer may be at least 3.0.
- the ratio of the smaller IC 50 of the first monomer or the second monomer to the apparent IC 50 of the multimer may be at least 10.0. In some embodiments, the ratio of the smaller IC 50 of the first monomer or the second monomer to the apparent IC 50 of the multimer may be at least 30.0.
- the apparent IC 50 resulting from an essentially equimolar combination of monomers against the first target biomolecule and the second target biomolecule is at least about 3 to 10 fold lower, at least about 10 to 30 fold lower, at least about 30 fold lower, or at least about 40 to 50 fold lower than the lowest of the IC 50 of the second monomer against the second target biomolecule or the IC 50 of the first monomer against the first target biomolecule.
- the affinity of the multimer for the target biomolecule(s) are less than 1 ⁇ M, in some embodiments less than 1 nM, in some embodiments less than 1 ⁇ M, in some embodiments less than 1 fM, and in some embodiments less than 1 aM, and in some embodiments less than 1 zM.
- Affinities of heterodimerizing monomers for the target biomolecule can be assessed through the testing of the respective monomers in appropriate assays for the target activity or biology because they do not typically self-associate.
- the testing of homodimerizing monomers may not, in some embodiments, afford an affinity for the monomeric or dimeric state, but rather the observed effect (e.g. IC 50 ) is a result of the monomer-dimer dynamics and equilibrium, with the apparent binding affinity (or IC 50 ) being e.g., a weighted measure of the monomer and dimeric inhibitory effects upon the target.
- the pH of the aqueous fluid in which the multimer forms may be between pH 1 and 9, in some embodiments between pH 1 and 3, in some embodiments between pH 3 and 5, in some embodiments between pH 5 and 7, and in some embodiments between pH 7 and 9.
- the multimer may be stable in an aqueous solution having a pH between pH 1 and 9, in some embodiments between pH 1 and 3, in some embodiments between pH 3 and 5, in some embodiments between pH 5 and 7, and in some embodiments between pH 7 and 9.
- the aqueous solution may have a physiologically acceptable pH.
- the ligand moiety may be capable of binding to a target and at least partially disrupting a biomolecule-biomolecule interaction (e.g., a protein-protein interaction). In some embodiments, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-nucleic acid interaction. In some cases, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-lipid interaction. In some cases, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-polysaccharide interaction. In some embodiments, the ligand moiety may be capable of at least partially stabilizing a biomolecule-biomolecule interaction. In certain embodiments, the ligand moiety may be capable of at least partially inhibiting a conformational change in a biomolecule target.
- a biomolecule-biomolecule interaction e.g., a protein-protein interaction
- the ligand moiety may be capable of binding to a target and at least partially disrupt
- the linker element may be capable of generating a signal.
- the linker element may be capable of fluorescing.
- the linker element may have greater fluorescence when the monomer to which it is attached is part of a multimer as compared to when the monomer to which it is attached is not part of a multimer.
- the fluorescent brightness of a linker element may increase by at least 2-fold, in some embodiments by at least 5-fold, in some embodiments by at least 10-fold, in some embodiments by at least 50-fold, in some embodiments by at least 100-fold, in some embodiments by at least 1000-fold, and in some embodiments by at least 10000-fold.
- a linker element in a multimer may have a peak fluorescence that is red-shifted relative to the peak fluorescence of the linker element in a monomer. In other embodiments, a linker element may have a peak fluorescence that is blue-shifted relative to the peak fluorescence of a linker element in a monomer.
- a first monomer may be capable of forming a biologically useful multimer when in contact with a second monomer in an aqueous media, for example, when the first and second monomer are different and form e.g. a heteromultimer in aqueous media.
- the first monomer can represented by the formula:
- X 1 is a first ligand moiety capable of binding to a first target biomolecule
- Y 1 is absent or is a connector moiety covalently bound to X 1 and Z 1 ;
- Z 1 is a first linker selected from the group consisting of:
- the second monomer has a boronic acid or oxaborole moiety capable of binding with the Z 1 moiety of Formula I to form the multimer.
- a 1 may be selected from the group consisting of C 1 -C 3 alkylene optionally substituted with one, two, or three halogens, or —C(O)—.
- Z 1 may be
- R 2 independently for each occurrence, is selected from H, C 1-4 alkyl, or two R 1 moities taken together form a 5- or 6-membered cycloalkyl or heterocyclic ring, wherein R 3 is H, or
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be a monosaccharide or a disaccharide.
- Z 1 may be selected from the group consisting of
- X is selected from O, S, CH, NR′, or when X is NR′, N may be covalently bonded to Y of formula I;
- R′ is selected from the group consisting of H and C 1-4 alkyl
- R 5 , R 6 , and R 7 are independently selected from the group consisting of H, C 1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C 1-4 alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or a mono- or bicyclic heterocyclic optionally substituted with amino, halo, hydroxyl, oxo, or cyano; and
- AA is a 5-6 membered heterocyclic ring optionally substituted by C 1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C 1-4 alkoxy; halogen; —OH; —CN; —COOH; —CONHR′, or —S—C 1-4 alkyl.
- Z 1 may be
- Z 1 may be
- X may be nitrogen.
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- Z 1 may be
- the second monomer may be X 2 —Y 2 —Z 2 (Formula II), wherein Z 2 is the boronic acid or oxaborale moiety, and wherein X 2 is a second ligand moiety capable of binding to a second target biomolecule, and Y 2 is absent or is a connector moiety covalently bound to X 2 and Z 2 .
- X 1 and X 2 may be the same. In other instances, X 1 and X 2 may be different.
- first target biomolecule and the second target biomolecule may be different. In other embodiments, the first target biomolecule and the second target biomolecule may be the same.
- Z 2 of the second monomer may be selected from the group consisting of:
- R 8 is selected from the group consisting of H, halogen, oxo, C 1-4 alkyl optionally substituted by hydroxyl, amino, halo or thio; C 2-4 alkenyl, C 1-4 alkoxy; —S—C 1-4 alkyl; —CN; —COOH; or —CONHR′;
- a 1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- Q is selected from the group consisting of substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- AA independently for each occurrence, is phenyl, aryl, or a 5-7 membered heterocyclic or heteroaryl ring having one, two, or three heteroatoms, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C 1-4 alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C 2-4 alkenyl; C 1-4 alkoxy; —S—C 1-4 alkyl; —CN; —NR 2 ′′′, wherein R′′′ is independently selected from the group consisting of H and C 1-4 alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
- R′ is H or C 1-4 alkyl.
- R 8 and the substituent comprising boronic acid may be ortho to each other, and R 8 may be —CH 2 NH 2 .
- Z 2 of the second monomer may be selected from the group consisting of:
- Z 2 of the second monomer may be selected from the group consisting of:
- Z 2 of the second monomer may be selected from the group consisting of:
- R 8 is selected from the group consisting of H, halogen, oxo, C 1-4 alkyl optionally substituted by hydroxyl, amino, halo or thio; C 2-4 alkenyl, C 1-4 alkoxy; —S—C 1-4 alkyl; —CN; —COOH; or —CONHR′;
- AA independently for each occurrence, is a 5-7 membered heterocyclic ring having one, two, or three heteroatoms, or phenyl, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halo, C 1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C 2-4 alkenyl; C 1-4 alkoxy; —S—C 1-4 alkyl; —CN; —NR 2 ′′′, wherein R′′′ is independently selected from the group consisting of H and C 1-4 alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
- R′ is H or C 1-4 alkyl.
- a first monomer may be capable of forming a biologically useful dimer or multimer when in contact with a second monomer in vivo, wherein the first and second linkers are the same (e.g. forming a homodimer or homomultimer) wherein the first monomer is represented by the formula:
- X 3 is a first ligand moiety capable of binding to a first target biomolecule
- Y 3 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- X 4 is a second ligand moiety capable of binding to a second target biomolecule
- Y 4 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- Z 3 is selected from the group consisting of:
- a first monomer may be capable of forming a biologically useful trimer when in contact with a second monomer and a third monomer in an aqueous media, wherein the first monomer is represented by the formula:
- X 2 is a first ligand moiety capable of binding to a first target biomolecule
- Y 2 is absent or is a connector moiety covalently bound to X 2 and Z 2 ;
- Z 2 is a first linker selected from the group consisting of:
- the second monomer and the third monomer each have a boronic acid moiety capable of binding with the Z 2 moiety of Formula II to form the trimer.
- R 8 and the substituent comprising boronic acid may be ortho to each other, and R 8 may be —CH 2 NH 2 .
- Z 2 of the first monomer may be selected from the group consisting of:
- Z 2 of the first monomer may be selected from the group consisting of:
- a monomer may be capable of reacting with one or more other monomers to form a multimer.
- a first monomer may react with a second monomer to form a dimer.
- a first monomer may react with a second monomer and a third monomer to form a trimer.
- a first monomer may react with a second monomer, a third monomer, and a fourth monomer to form a tetramer.
- each of the monomers that form a multimer may be essentially the same.
- each of the monomers that form a multimer may be substantially different.
- at least some of the monomers that form a multimer may be essentially the same or may be substantially different.
- the linker element of a first monomer and the linker element of a second monomer may be substantially different.
- the connector element of a first monomer and the connector element of a second monomer may be substantially different.
- the ligand moiety (e.g., a pharmacophore) of a first monomer and the ligand moiety (e.g., a pharmacophore) of the second monomer may be substantially different.
- formation of a multimer from a plurality of monomers may be irreversible. In some embodiments, formation of a multimer from a plurality of monomers may be reversible.
- the multimer may have an oligomer or dimer dissociation constant between 10 mM and 1 nM, in some embodiments between 1 mM and 100 nM, in some embodiments between 1 mM and 1 mM, and in some embodiments between 500 mM and 1 mM.
- the multimer may have a dissociation constant of less than 10 mM, in some embodiments less than 1 mM, in some embodiments less than 500 mM, in some embodiments less than 100 mM, in some embodiments less than 50 mM, in some embodiments less than 1 mM, in some embodiments less than 100 nM, and in some embodiments less than 1 nM.
- a first monomer and a second monomer may form a dimer in aqueous solution.
- the first monomer may form a biologically useful dimer with a second monomer in vivo.
- molecular self-assembly may be directed through noncovalent interactions, e.g., hydrogen bonding, metal coordination, hydrophobic forces, van der Waals forces, pi-pi interactions, electrostatic, and/or electromagnetic interactions.
- pi-pi and pi-cation interactions can be used to drive multimerization.
- van der Waals and electromagnetic forces are other interactions that can help to drive multimerization.
- acid/base pairs and donor-acceptor pairs e.g., amide and/or sulfonamide pairs, can be employed to help direct self-assembly.
- use of hydrophobic interactions can be used for multimerization targeting a membrane-bound protein.
- metal coordination might be used when the target itself incorporates the metal, but could also be used in other scenarios.
- a therapeutic multimer compound (e.g. a heteromultimer) may be formed from the multimerization in an aqueous media of a first monomer represented by:
- X 1 is a first ligand moiety capable of binding to a first target biomolecule
- Y 1 is absent or is a connector moiety covalently bound to X 1 and Z 1 ;
- Z 1 is a first linker selected from the group consisting of: a)
- a therapeutic dimerized compound may be formed from the dimerization in an aqueous media of a first monomer represented by:
- X 3 is a first ligand moiety capable of binding to a first target biomolecule
- Y 3 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- X 4 is a second ligand moiety capable of binding to a second target biomolecule
- Y 4 is absent or is a connector moiety covalently bound to X 4 and Z 3 ;
- Z 3 is selected from the group consisting of:
- a monomer may comprise a connector that joins the ligand moiety with the linker element.
- such connectors do not have significant binding or other affinity to an intended target.
- a connector may contribute to the affinity of a ligand moiety to a target.
- a connector element may be used to connect the linker element to the ligand moiety.
- the connector element may be used to adjust spacing between the linker element and the ligand moiety.
- the connector element may be used to adjust the orientation of the linker element and the ligand moiety.
- the spacing and/or orientation the linker element relative to the ligand moiety can affect the binding affinity of the ligand moiety (e.g., a pharmacophore) to a target.
- connectors with restricted degrees of freedom are preferred to reduce the entropic losses incurred upon the binding of a multimer to its target biomolecule.
- connectors with restricted degrees of freedom are preferred to promote cellular permeability of the monomer.
- the connector element may be used for modular assembly of monomers.
- a connector element may comprise a functional group formed from reaction of a first and second molecule.
- a series of ligand moieties may be provided, where each ligand moiety comprises a common functional group that can participate in a reaction with a compatible functional group on a linker element.
- the connector element may comprise a spacer having a first functional group that forms a bond with a ligand moiety and a second functional group that forms a bond with a linker element.
- Contemplated connecters may be any acceptable (e.g. pharmaceutically and/or chemically acceptable) bivalent linker that, for example, does not interfere with multimerization of the disclosed monomers.
- linkers may be substituted or unsubstituted C 1 -C 10 alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, acyl, sulfone, phosphate, ester, carbamate, or amide.
- Contemplated connectors may include polymeric connectors, such a polyethylene glycol or other pharmaceutically acceptable polymers.
- contemplated connectors may be a covalent bond or a bivalent C 1-10 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three or four methylene units of L are optionally and independently replaced by cyclopropylene, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, —SO 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C( ⁇ S)—, —C( ⁇ NR)—, phenyl, or a mono or bicyclic heterocycle ring.
- a connector may be from about 7 atoms to about 13 atoms in length, or about 8 atoms to about 12 atoms, or about 9 atoms to about 11 atoms in length.
- a connecter group is from about 6 ⁇ to about 15 ⁇ in length.
- contemplated monomers and multimers may be administered to a patient in need thereof.
- a method of administering a pharmaceutically effective amount of a multimeric compound to a patient in need thereof is provided.
- the method comprises administering to the patient thereof an amount of the first monomer and an amount of a boronic acid monomer in amounts effective such that the pharmaceutically effective amount of the resulting multimer is formed in vivo.
- a first monomer and a second monomer may be administered substantially sequentially. In other embodiments, the first monomer and the second monomer are administered substantially simultaneously. In some embodiments the monomers may be administered, sequentially or simultaneously, by different routes of administration. In still further embodiments, a first monomer and a second monomer may be administered after forming a multimer.
- a method of modulating two or more target biomolecule domains is provided.
- a first ligand moiety may bind to a first domain and a second ligand moiety may bind to a second domain.
- a multimer comprising the first and second ligand moieties may be form prior to binding the first and second domains. In other embodiments, the multimer may form after one and/or two of the monomers bind the first and second domains.
- the target biomolecule may be a protein. In other embodiments, the target biomolecule may be nucleic acid. In some cases, the ligand moiety may be a pharmacophore.
- a multimer may be used to inhibit or facilitate protein-protein interactions.
- a multimer may be capable of activating or inactivating a signaling pathway.
- a multimer may bind to a target protein and affect the conformation of the target protein such that the target protein is more biologically active as compared to when the multimer does not bind the target protein.
- monomers may be chosen such that a multimer formed from the monomers binds to at least two regions of a target molecule.
- protein-protein and protein-nucleic acid recognition often work through protein interaction domains, such as the SH2, SH3, and PDZ domains.
- protein interaction domains such as the SH2, SH3, and PDZ domains.
- SH2 domains are miniature receptors for protein regions containing a phosphorylated tyrosine.
- SH2 domains may be found in proteins that act as, or play a role in, for example, adaptors, scaffolds, kinases, phosphatases, ras signaling, transcription, ubiquitination, cytoskeletal regulation, signal regulation, and phospholipid second messenger signaling.
- SH3 domains bind peptide loops with the motif RXXK or PXXP.
- Many proteins have both SH2 and SH3 domains, which act as “receptors” to bind one or more protein partners.
- Coferons may be designed to inhibit binding of a phosphotyrosine protein to its cognate SH2 domain.
- monomers and multimers may be designed so one ligand moiety binds one motif (i.e. SH2), and a second ligand moiety binds a second motif (i.e. SH3), either on the same or different proteins.
- linker elements may be used to bring together two pharmacophores on the same target to: (i) bind the target with higher affinity; (ii) exhibit a stronger inhibition than either pharmacophore alone; (iii) exhibit greater activation than either pharmacophore alone; or (iv) create a binding entity covering a larger surface area of the target, making it harder for the organism/cell/virus to develop resistance to the drug via point mutations.
- a multimer may target a tryptase.
- a multimer may be used to treat conditions activated by a tryptase, such as mast cell mediated inflammatory conditions (e.g. asthma).
- mast cell mediated inflammatory conditions e.g. asthma
- Asthma is frequently characterized by progressive development of hyper-responsiveness of the trachea and bronchi to both immunospecific allergens and generalized chemical or physical stimuli, which lead to the onset of chronic inflammation.
- Leukocytes containing IgE receptors notably mast cells and basophils, are present in the epithelium and underlying smooth muscle tissues of bronchi. These leukocytes initially become activated by the binding of specific inhaled antigens to the IgE receptors and then release a number of chemical mediators. For example, degranulation of mast cells leads to the release of proteoglycans, peroxidase, arylsulfatase B, chymase, and tryptase,
- Human mast cell ⁇ -tryptase-II is a tetrameric serine protease that is concentrated in mast cell secretory granules.
- the enzyme is involved in IgE-induced mast cell degranulation in an allergic response and is potentially a target for the treatment of allergic asthma, rhinitis, conjunctivitis and dermatitis.
- Tryptase has also been implicated in the progression of renal, pulmonary, hepatic, testicular fibrosis, chronic obstructive pulmonary disease (COPD), and inflammatory conditions such as ulcerative colitis, inflammatory bowel disease, rheumatoid arthritis, and various other mast cell-related diseases.
- multimers may be used to treat such diseases.
- Tryptase is stored in the mast cell secretory granules and is the major protease of human mast cells. Tryptase has been implicated in a variety of biological processes, including degradation of vasodilatory and bronchodilatory neuropeptides and modulation of bronchial responsiveness to histamine.
- tryptase inhibitors may be useful as anti-inflammatory agents for treatment of inflammatory disease and may also be useful in treating or preventing allergic rhinitis, inflammatory bowel disease, psoriasis, ocular or vernal or ulcerative conjunctivitis, dermatological conditions (e.g., psoriasis, eczema, or atopic dermatitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis, hematoid arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or gouty arthritis), rheumatoid spondylitis, interstitial lung disease, chronic obstructive pulmonary disease, and diseases of joint cartilage destruction.
- dermatological conditions e.g., psoriasis, eczema, or atopic dermatitis
- arthritis e.g., rheumatoid arthritis, osteoarthritis, hema
- tryptase inhibitors may be useful in treating or preventing fibrotic conditions, for example, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hepatic fibrosis, renal fibrosis, testicular, and hypertrophic scars.
- tryptase inhibitors may be useful in treating or preventing myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture.
- tryptase has also been discovered to activate prostromelysin that in turn activates collagenase, thereby initiating the destruction of cartilage and periodontal connective tissue, respectively.
- tryptase inhibitors may be useful in the treatment or prevention of arthritis, periodontal disease, diabetic retinopathy, a condition relating to atherosclerotic plaque rupture, anaphylactic ulcerative colitis, and tumor growth.
- tryptase inhibitors may be useful in the treatment of anaphylaxis, multiple sclerosis, peptic ulcers, and syncytial viral infections.
- a variety of antibiotics elicit their antibacterial activity by binding to the bacterial ribosome and inhibiting protein synthesis. Many of these antibiotics bind the peptidyl transferase center of the ribosome (P site).
- a multimer may bind to two or more sites on the ribosome. For example, a first pharmacophore of a multimer may bind to the peptidyl transferase center of the ribosome (i.e., the P site) and a second multimer may bind to site adjacent to the P site.
- Linezolid an oxazolidinone antibiotic, is believed to bind adjacent to the binding site for Sparsomycin.
- target protein families are provided in Table 1 below. Also provided in Table 1 are endogenous ligands, agonists, and antagonists that bind to the protein families. Examples of detection assays are also provided in Table 1, which may be used in a screening assay to detect activation and/or inhibition of the target protein.
- Table 2 Provided in Table 2 are non-limiting examples of domains that can bind a ligand, proteins that contain the domains, known inhibitors, and K D values of binding partners (i.e., ligands). Examples of detection assays are also provided in Table 2, which may be used in a screening assay to find ligands for the domains.
- a pharmacophore is typically an arrangement of the substituents of a moiety that confers biochemical or pharmacological effects.
- identification of a pharmacophore may be facilitated by knowing the structure of the ligand in association with a target biomolecule.
- pharmacophores may be moieties derived from molecules previously known to bind to target biomolecules (e.g., proteins), fragments identified, for example, through NMR or crystallographic screening efforts, molecules that have been discovered to bind to target proteins after performing high-throughput screening of natural products libraries, previously synthesized commercial or non-commercial combinatorial compound libraries, or molecules that are discovered to bind to target proteins by screening of newly synthesized combinatorial libraries. Since most pre-existing combinatorial libraries are limited in the structural space and diversity that they encompass, newly synthesized combinatorial libraries may include molecules that are based on a variety of scaffolds.
- pharmacophores may be derived from traditional approaches such as fragment based drug design and structure based drug design.
- any pharmacophore including pre-existing pharmacophores such as approved drugs are amenable to be designed as monomers through the incorporation of the appropriate linker elements and connector elements.
- previously approved drugs that have poor efficacy due to a low affinity for a first macromolecular target may be utilized as a pharmacophore component of a first monomer which when combined with a pharmacophore of a second monomer that also binds the first macromolecular target or a second macromolecular target that interacts with the first macromolecular target results in enhanced binding and, in some cases, higher efficacy.
- previously approved drugs that have low efficacy as a result of size, molecular weight or other physicochemical attributes that reduce the cellular uptake of the drug may be amenable to being converted into one or more monomers that bear the appropriate pharmacophoric elements, such that each monomer has physicochemical attributes that allow for increased cellular uptake.
- a ligand moiety (e.g., a pharmacophore) may have a molecular weight between 50 Da and 2000 Da, in some embodiments between 50 Da and 1500 Da, in some embodiments, between 50 Da and 1000 Da, and in some embodiments, between 50 Da and 500 Da. In certain embodiments, a ligand moiety may have a molecular weight of less than 2000 Da, in some embodiments, less than 1000 Da, and in some embodiments less than 500 Da.
- the compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein.
- compositions may be administered to patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician.
- a compound may be administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. Parenteral administration may include subcutaneous injections, intravenous or intramuscular injections, or infusion techniques.
- Treatment can be continued for as long or as short a period as desired.
- the compositions may be administered on a regimen of, for example, one to four or more times per day.
- a suitable treatment period can be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely.
- a treatment period can terminate when a desired result, for example a partial or total alleviation of symptoms, is achieved.
- the present disclosure provides pharmaceutical compositions comprising monomers, dimers, and/or multimers as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
- disclosed compositions may be formulated as a unit dose, and/or may be formulated for oral or subcutaneous administration.
- Exemplary pharmaceutical compositions may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form, which contains one or more of the compounds, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral applications.
- the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
- the active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
- the principal active ingredient may be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound, or a non-toxic pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, di
- the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate
- Suspensions in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- compositions and compounds may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- a non-aqueous (e.g., fluorocarbon propellant) suspension could be used.
- Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions.
- an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers.
- the carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
- compositions suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate and cyclodextrins.
- Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants
- enteral pharmaceutical formulations including a disclosed pharmaceutical composition comprising monomers, dimers, and/or multimers, an enteric material; and a pharmaceutically acceptable carrier or excipient thereof are provided.
- Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs.
- the small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum.
- the pH of the duodenum is about 5.5
- the pH of the jejunum is about 6.5
- the pH of the distal ileum is about 7.5.
- enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10.0.
- Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleat, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins
- kits are provided containing one or more compositions each including the same or different monomers.
- Such kits include a suitable dosage form such as those described above and instructions describing the method of using such dosage form to treat a disease or condition. The instructions would direct the consumer or medical personnel to administer the dosage form according to administration modes known to those skilled in the art.
- Such kits could advantageously be packaged and sold in single or multiple kit units.
- An example of such a kit is a so-called blister pack.
- Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil.
- the recesses have the size and shape of the tablets or capsules to be packed.
- the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
- the tablets or capsules are sealed in the recesses between the plastic foil and the sheet.
- the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
- a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested.
- a memory aid is a calendar printed on the card, e.g., as follows “First Week, Monday, Tuesday, . . . etc. . . . Second Week, Monday, Tuesday, . . . ” etc.
- a “daily dose” can be a single tablet or capsule or several pills or capsules to be taken on a given day.
- a daily dose of a first compound can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa.
- the memory aid should reflect this.
- compositions that include a second active agent, or administering a second active agent.
- compositions that include a second active agent, or administering a second active agent.
- the compounds, as described herein may be substituted with any number of substituents or functional moieties.
- substituted whether preceded by the term “optionally” or not, and substituents contained in formulas, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
- the substituent when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.
- Non-limiting examples of substituents include acyl; aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO 2 ; —CN; —SCN; —SR x ; —CF 3 ; —CH 2 CF 3 ; —CHCl 2 ; —CH 2 OH; —CH 2 CH 2 OH; —CH 2 NH 2 ; —CH 2 SO 2 CH 3 ; —OR x , —C(O)R
- the compounds described herein are not intended to be limited in any manner by the permissible substituents of organic compounds. In some embodiments, combinations of substituents and variables described herein may be preferably those that result in the formation of stable compounds.
- stable refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
- acyl refers to a moiety that includes a carbonyl group.
- an acyl group may have a general formula selected from —C(O)R x ; —CO 2 (R x ); —C(O)N(R x ) 2 ; —OC(O)R x ; —OCO 2 R x ; and —OC(O)N(R x ) 2 ; wherein each occurrence of R x independently includes, but is not limited to, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents
- aliphatic includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups.
- aliphatic is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
- heteroaliphatic refers to aliphatic moieties that contain one or more oxygen, sulfur, nitrogen, phosphorus, or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc.
- heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to acyl; aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO 2 ; —CN; —SCN; —SR x ; —CF 3 ; —CH 2 CF 3 ; —CHCl 2 ; —CH 2 OH; —CH 2 CH 2 OH;
- aryl and “heteroaryl,” as used herein, refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted.
- Substituents include, but are not limited to, any of the previously mentioned substituents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound.
- aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like.
- heteroaryl refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from the group consisting of S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from the group consisting of S, O, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
- aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one, two, three, or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO 2 ; —CN; —CF 3 ; —CH 2 CF 3 ; —CHCl 2 ; —CH 2 OH; —CH
- heterocyclic refers to an aromatic or non-aromatic, partially unsaturated or fully saturated, 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size and bi- and tri-cyclic ring systems which may include aromatic five- or six-membered aryl or aromatic heterocyclic groups fused to a non-aromatic ring.
- heterocyclic rings include those having from one to three heteroatoms independently selected from the group consisting of oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- heterocyclic refers to a non-aromatic 5-, 6-, or 7-membered ring or a polycyclic group wherein at least one ring atom is a heteroatom selected from the group consisting of O, S, and N (wherein the nitrogen and sulfur heteroatoms may be optionally oxidized), including, but not limited to, a bi- or tri-cyclic group, comprising fused six-membered rings having between one and three heteroatoms independently selected from the group consisting of the oxygen, sulfur, and nitrogen, wherein (i) each 5-membered ring has 0 to 2 double bonds, each 6-membered ring has 0 to 2 double bonds, and each 7-membered ring has 0 to 3 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to an aryl or heteroaryl ring.
- alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein for example as C 2-6 alkenyl, and C 3-4 alkenyl, respectively.
- alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
- alkenyloxy refers to a straight or branched alkenyl group attached to an oxygen (alkenyl-O).
- alkenoxy groups include, but are not limited to, groups with an alkenyl group of 3-6 carbon atoms referred to herein as C 3-6 alkenyloxy.
- alkenyloxy groups include, but are not limited to allyloxy, butenyloxy, etc.
- alkoxy refers to a straight or branched alkyl group attached to an oxygen (alkyl-O—).
- exemplary alkoxy groups include, but are not limited to, groups with an alkyl group of 1-6 or 2-6 carbon atoms, referred to herein as C 1-6 alkoxy, and C 2 -C 6 alkoxy, respectively.
- exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
- alkoxycarbonyl refers to a straight or branched alkyl group attached to oxygen, attached to a carbonyl group (alkyl-O—C(O)—).
- exemplary alkoxycarbonyl groups include, but are not limited to, alkoxycarbonyl groups of 1-6 carbon atoms, referred to herein as C 1-6 alkoxycarbonyl.
- Exemplary alkoxycarbonyl groups include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, etc.
- alkynyloxy refers to a straight or branched alkynyl group attached to an oxygen (alkynyl-O)).
- exemplary alkynyloxy groups include, but are not limited to, propynyloxy.
- alkyl refers to a saturated straight or branched hydrocarbon, for example, such as a straight or branched group of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as C 1-6 alkyl, C 1-4 alkyl, and C 1-3 alkyl, respectively.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 3-methyl-2-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
- alkylcarbonyl refers to a straight or branched alkyl group attached to a carbonyl group (alkyl-C(O)—).
- exemplary alkylcarbonyl groups include, but are not limited to, alkylcarbonyl groups of 1-6 atoms, referred to herein as C 1-6 alkylcarbonyl groups.
- Exemplary alkylcarbonyl groups include, but are not limited to, acetyl, propanoyl, isopropanoyl, butanoyl, etc.
- alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-6, or 3-6 carbon atoms, referred to herein as C 2-6 alkynyl, and C 3-6 alkynyl, respectively.
- alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
- carbonyl refers to the radical —C(O)—.
- carboxylic acid refers to a group of formula —CO 2 H.
- cyano refers to the radical —CN.
- cycloalkoxy refers to a cycloalkyl group attached to an oxygen (cycloalkyl-O—).
- cycloalkyl refers to a monocyclic saturated or partially unsaturated hydrocarbon group of for example 3-6, or 4-6 carbons, referred to herein, e.g., as C 3-6 cycloalkyl or C 4-6 cycloalkyl and derived from a cycloalkane.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclohexenyl, cyclopentyl, cyclobutyl or, cyclopropyl.
- halo or halogen as used herein refer to F, Cl, Br, or I.
- heterocyclylalkoxy refers to a heterocyclyl-alkyl-O-group.
- heterocyclyloxyalkyl refers to a heterocyclyl-O-alkyl-group.
- heterocyclyloxy refers to a heterocyclyl-O— group.
- heteroaryloxy refers to a heteroaryl-O— group.
- hydroxy and “hydroxyl” as used herein refers to the radical —OH.
- oxo refers to the radical ⁇ O.
- connector refers to an atom or a collection of atoms optionally used to link interconnecting moieties, such as a disclosed linker and a pharmacophore.
- Contemplated connectors are generally hydrolytically stable.
- Treating includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
- “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or a human, as appropriate.
- preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.
- compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
- composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- the compounds can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- the mammal treated is desirably a mammal in which treatment of obesity, or weight loss is desired.
- “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
- the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by the researcher, veterinarian, medical doctor, or other clinician.
- the compounds are administered in therapeutically effective amounts to treat a disease.
- a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in weight loss.
- pharmaceutically acceptable salt(s) refers to salts of acidic or basic groups that may be present in compounds used in the present compositions.
- Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-
- Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids.
- the compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
- the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
- stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom. Various stereoisomers of these compounds and mixtures thereof are encompassed by this disclosure.
- Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated “( ⁇ )” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
- the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as geometric isomers, enantiomers or diastereomers.
- the enantiomers and diastereomers may be designated by the symbols “(+),” “( ⁇ ).” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
- Geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a cycloalkyl or heterocyclic ring, can also exist in the compounds.
- the symbol denotes a bond that may be a single, double or triple bond as described herein.
- Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
- the arrangement of substituents around a carbocyclic ring can also be designated as “cis” or “trans.”
- cis represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring.
- Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
- stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. Various stereoisomers of these compounds and mixtures thereof are encompassed by this disclosure.
- Individual enantiomers and diasteriomers of the compounds can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using steroselective chemical or enzymatic reagents.
- Racemic mixtures can also be resolved into their component enantiomers by well known methods, such as chiral-phase gas chromatography or crystallizing the compound in a chiral solvent.
- Stereoselective syntheses a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art.
- Stereoselective syntheses encompass both enantio- and diastereoselective transformations. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis , Wiley-VCH: Weinheim, 2009.
- the compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the compound is amorphous.
- the compound is a polymorph.
- the compound is in a crystalline form.
- isotopically labeled compounds which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into the compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 10 B, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- a compound may have one or more H atom replaced with deuterium.
- isotopically-labeled disclosed compounds are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- prodrug refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood, or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al, Nature Reviews Drug Discovery 2008, 7, 255).
- a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C 1-8 )alkyl, (C 2-12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4
- a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C 1-6 )alkanoyloxymethyl, 1-((C 1-6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1-6 )alkanoyloxy)ethyl (C 1-6 )alkoxycarbonyloxymethyl, N—(C 1-6 )alkoxycarbonylaminomethyl, succinoyl, (C 1-6 )alkanoyl, ⁇ -amino(C 1-4 )alkanoyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ -aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH) 2 , —P(O)(O(C 1 -C 6 )alkyl) 2 or
- a prodrug can be formed, for example, by creation of an amide or carbamate, an N-acyloxyakyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base, imine, or enamine.
- a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can be metabolically cleaved to generate a bioactive primary or secondary amine.
- the compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art.
- synthetic procedures known in the art.
- all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated.
- the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed.
- Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated.
- the starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.
- Lz-NA-19 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl)methyl)-3,4- dihydroxybenzamide 19.
- Lz-NA-20 (S)-2-(3,4-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin- 5-yl)methyl)acetamide 20.
- Lz-NA-21 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl)methyl)-2,3- dihydroxybenzamide 21.
- Lz-NA-22 (S)-2-(2,3-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin-5- yl)methyl)acetamide 22.
- Lz-NA-23 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin- 5-yl)methyl)-3-hydroxy-4- (hydroxymethyl)benzamide 23.
- Lz-NA-24 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin- 5-yl)methyl)-4-hydroxy-3- (hydroxymethyl)benzamide 24.
- Lz-NA-27 (S,E)-3-(3,4-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin-5- yl)methyl)acrylamide 25.
- Lz-NA-28 (S)-3-(3,4-dihydroxyphenyl)-N- ((3-(3-fluoro-4- morpholinophenyl)- 2-oxooxazolidin-5- yl)methyl)propanamide 26.
- Lz-NA-34 (S,E)-4-(3-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl) methylamino)-3-oxoprop- 1-enyl)-2- hydroxy-N-methoxybenzamide 27.
- Lz-NA-36 (S,E)-5-(3-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl) methylamino)-3-oxoprop-1- enyl)-2-hydroxybenzamide 28.
- Lz-NA-12 (S)-3-(3-fluoro-4- morpholinophenyl)-5-((2-oxo- 2,3-dihydro-1H-pyrrol-1- yl)methyl)oxazolidin-2-one Fluorfenicol analogues 29.
- NAFFLA- 19 N-((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)-3,4-dihydroxybenzamide 30.
- NAFFLA- 20 2-(3,4-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)acetamide 31.
- NAFFLA- 21 N-((1S)-3-fluoro-1-hydroxy- 1-(4-(methylsulfonyl) phenyl)propan-2-yl)- 2,3-dihydroxybenzamide 32.
- NAFFLA- 22 2-(2,3-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)acetamide 33.
- NAFFLA- 23 N-((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)propan-2-yl)-3- hydroxy-4-(hydroxymethyl) benzamide 34.
- NAFFLA- 27 (E)-3-(3,4-dihydroxyphenyl)-N- ((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)acrylamide 35.
- NAFFLA- 28 3-(3,4-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)propanamide 36.
- NAFFLA- 34 4-((E)-3-((1R,2S)-3-fluoro- 1-hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2-hydroxy-N- methoxybenzamide 37.
- NAFFLA- 35 4-((E)-3-((1R,2S)-3-fluoro-1- hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2- hydroxybenzamide 38.
- NAFFLA- 36 5-((E)-3-((1R,2S)-3-fluoro-1- hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2- hydroxybenzamide 39.
- NAFFLA- 37 N 1 -((1R,2S)-3-fluoro-1-hydroxy- 1-(4-(methylsulfonyl) phenyl)propan-2-yl)-4- hydroxy-N 3 - methoxyisophthalamide Tryptase targets Method-A 40.
- Target-31 ((2-(4-(3-(aminomethyl)phenyl) piperidine-1- carbonyl)-1H-indol-5- yl)(hydroxy)boryl)holmium 41.
- Target-62 3′-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl) biphenyl-2-ylboronic acid 42.
- Target-64 5-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 2-fluorophenylboronic acid 43.
- Target-35 3′-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)biphenyl- 3-ylboronic acid 44.
- Target-11F 8-(4-(5-(aminomethyl)-2- fluorophenyl)piperidine-1- carbonyl)naphthalen-2- ylboronic acid 45.
- Target-58 4-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 3-fluorophenylboronic acid 46.
- Target-57 3-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 4-fluorophenylboronic acid 47.
- Target-35F 3′-(4-(5-(aminomethyl)-2- fluorophenyl)piperidine-1- carbonyl)biphenyl-3-ylboronic acid 48.
- Target-33 (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-oxoprop- 1-enyl)phenylboronic acid 49.
- Target-34 (E)-3-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-oxoprop- 1-enyl)phenylboronic acid 50.
- Target-37 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl) benzo[b]thiophen-2-ylboronic acid 51.
- Target-31 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-4-ylboronic acid 52.
- Target-62 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-6-ylboronic acid 53.
- Target-64 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)benzo [b]thiophen-4-ylboronic acid Tryptase targets Method-B 54.
- Target-32 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-4-ylboronic acid 55.
- Target-59 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-6-ylboronic acid 56.
- Target-56 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)benzo [b]thiophen-4-ylboronic acid Tryptase targets Method-C 57.
- Target-28 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,3- dihydroxyphenyl)methanone 58.
- Target-27-F (4-(5-(aminomethyl)-2- fluorophenyl)piperidin-1-yl)(6,7- dihydroxynaphthalen-1- yl)methanone 59.
- Target-68 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,3,4- trihydroxyphenyl)methanone 60.
- Target-69 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3,4,5- trihydroxyphenyl)methanone 61.
- Target-77 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,4,5- trihydroxyphenyl)methanone 62.
- Target-78 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-chloro-4,5- dihydroxyphenyl)methanone 63.
- Target-43 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3,4,5- trihydroxyphenyl)prop-2-en-1- one 64.
- Target-70 N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2,3-dihydroxybenzamide 65.
- Target-71 N-(3-(4-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 3,4-dihydroxybenzamide 66.
- Target-97 4-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 6,7-dihydroxy-2H-chromen- 2-one 67.
- Target-100 3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-6,7- dihydroxy-2H-chromen-2-one 68.
- Target-102 3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-7,8- dihydroxy-2H-chromen-2-one Tryptase targets Method-D 69.
- Target-101 3-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)-7,8- dihydroxy-4-methyl-2H- chromen-2-one Tryptase targets Method-E 70.
- Target-74 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-hydroxy-4- (hydroxymethyl)phenyl) methanone 71.
- Target-65 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(4-hydroxy-3- (hydroxymethyl)phenyl) methanone 72.
- Target-40 (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(4-hydroxy-3- (hydroxymethyl)phenyl)prop- 2-en-1-one 73.
- Target-44 (4-(3- (aminomethyl)phenyl)piperidin- 1-yl)(7-hydroxy-6- (hydroxymethyl)naphthalen-1- yl)methanone Tryptase targets Method-F 74.
- Target-75 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2- hydroxybenzamide 75.
- Target-75a 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2-hydroxy- N-methoxybenzamide 76.
- Target-66 5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 2-hydroxybenzamide 77.
- Target-86 (E)-5-(3-(4-(3-(aminomethyl) phenyl)piperidine-1-yl)-3-oxoprop- 1-enyl)-2-hydroxybenzamide 78.
- Target-92 5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2- hydroxy-N-methoxybenzamide Tryptase targets Method-H 79.
- Target-72 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-hydroxy-2-methylpropanoic acid 80.
- Target-73 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-hydroxy-2-phenylpropanoic acid 81.
- Target-76 (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1- yl)-3-oxoprop-1-enyl)- 2-hydroxybenzamide 82.
- Target-76a (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)- 3-oxoprop-1-enyl)-2- hydroxy-N-methoxybenzamide 83.
- Target-81 3-(5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H-indol- 1-yl)-2-hydroxy-2- methylpropanoic acid 84.
- Target-82 3-(6-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- methylpropanoic acid 85.
- Target-83 3-(5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- phenylpropanoic acid 86.
- Target-84 3-(6-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- phenylpropanoic acid 87.
- Target-103 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-cyclopentyl-2- hydroxypropanoic acid Tryptase targets Method-I 88.
- Target-53 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)-3,4- dihydroxypyrrolidin-1- yl)propan-1-one 89.
- Target-29 2-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)- 3,4-dihydroxypyrrolidin-1- yl)ethanone 90.
- Target-30 2-(4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)-3,4- dihydroxypyrrolidin-1-yl) ethanone Tryptase targets Method-J 91.
- Target-78- Spiro (5-(aminomethyl)-2H- spiro[benzofuran-3,4′-piperidine]- 1′-yl) (3-chloro-4,5- dihydroxyphenyl)methanone 93.
- Target-2 Spiro (5-(aminomethyl)-2H-spiro [benzofuran-3,4′- piperidine]-1′-yl)(3,4- dihydroxyphenyl)methanone 94.
- Target-36 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(4-(1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5- yl)phenyl)methanone 97.
- Target-36- meta (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-(1-hydroxy-1,3- dihydrobenzo[c][1,2]oxoborol-5- yl)phenyl)methanone Tryptase targets 98.
- Target-21 N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2-(1-hydroxycyclobutyl)-2- oxoacetamide 99.
- Target- 21-diol N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2-hydroxy-2-(1- hydroxycyclobutyl)acetamide 100.
- Target-22 2-(3-(4-(3-(aminomethyl)phenyl) piperidine-1- carbonyl)phenoxy)-1-(1- hydroxycyclobutyl)ethanone 101.
- Target-42 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3- hydroxy-2-(hydroxymethyl) phenyl)prop-2-en-1-one 102.
- Target-14 (E)-3-(4-(3-(aminomethyl) phenyl)piperidine-1- carbonyl)styrylboronic acid 105.
- Target- 24 cis (Z)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3- (3,4-dihydroxyphenyl)prop-2- en-1-one 106.
- Target-25b (4-(3-(aminomethyl)phenyl) piperidin-1-yl) (3-((3S,4R)-3,4- dihydroxypyrrolidin-1- yl)phenyl)methanone 107.
- Target- 26 diol c is (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-((3R,4R)-3,4- dihydroxypyrrolidine-1- carbonyl)phenyl)methanone 108.
- Target-41 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3- hydroxy-4-(hydroxymethyl) phenyl)prop-2- en-1-one 109.
- Target-67 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-(3,4-dihydroxy- 3,4-dimethylpyrrolidin-1- yl)phenyl)methanone 110.
- Target-41 gem dimethyl (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(3-hydroxy- 4-(2-hydroxypropan-2- yl)phenyl)prop-2-en-1-one 111.
- CF1 4-(aminomethyl)-N-(4-(2- ((3S,4S)-3,4- dihydroxypyrrolidin-1-yl)-2- oxoethyl)benzyl)benzamide hydrochloride 112.
- CF5 (4-(3-(aminomethyl) phenyl)piperidin-1-yl)(3,4- dichlorophenyl)methanone 115.
- CF6 4-(aminomethyl)-N-(4-(2- ((3R,4R)-3,4- dihydroxypyrrolidin-1-yl)-2- oxoethoxy)benzyl)benzamide hydrochloride 116.
- CF7 (R)-4-(aminomethyl)-N-(4-(2-(3- hydroxy-4-oxopyrrolidin-1-yl)-2- oxoethoxy)benzyl)benzamide hydrochloride 117.
- CF10 (S)-4-(aminomethyl)-N-(4-(3-(3- hydroxy-4-oxopyrrolidin-1-yl)-3- oxopropoxy)benzyl)benzamide hydrochloride 118.
- CF13 N-(4-(aminomethyl)benzyl)-4-(2- (2,3-dihydroxypropanamido)acetyl) piperazine-1-carboxamide hydrochloride 120.
- CF15 (5-(aminomethyl)-2H- spiro[benzofuran-3,4′- piperidine]-1′-yl)(4-(2,3- dihydroxypropoxy)phenyl) methanone hydrochloride 121.
- CF17 1-(3-(4-(3-(aminomethyl) phenyl)piperidine-1-carbonyl) phenyl)-3-(3,3,3-trifluoro- 2-hydroxypropyl)urea hydrochloride 122.
- CF20 N-(4-(aminomethyl)benzyl)- 4-(2-(3-hydroxy-2- oxopropanamido)acetyl) piperazine-1- carboxamide
- Stock solutions of recominbant human tryptase, beta, from lung were made at 30 ⁇ M, in solution with 50 ⁇ M heparin sulfate and 1 M NaCl.
- Monomer tryptase inhibitor stock solutions were made at 50 mM in DMSO.
- Test substance plates were made at 1.2 ⁇ the final concentration in assay buffer (50 mM HEPES, 150 mM NaCl, 100 ⁇ M EDTA, pH 7.4, 0.02% Tween-20). A final concentration of 1 nM tryptase was used. When required, test substances were diluted in water immediately before use in 10-fold serial dilutions.
- the release of fluorescent AMC was immediately measured every 30 seconds over 15-30 minutes at an excitation wavelength of 367 nm, monitoring emission at 468 nm on a Spectramax M5 (Molecular Devices) microplate reader.
- the Softmax Pro (Molecular Devices) and Graphpad prism software were used to determine V max , and concentration-response curve IC 50 s, respectively.
- Combinations of monomeric test substances were typically tested in a 1:1 ratio initially, and those displaying IC 50 's>4 ⁇ lower than that of the most potent monomeric component were often retested with a range of ratios of manomeric concentrations.
- Monomers with the potential to form heterodimers were evaluated in an in vitro Transcription and Translation assay (TnT assay) using the commercially available E. coli S30 Extract System for Circular DNA kit (Promega Catalog #L1020) according to the manufacturers instructions with minor modifications. Monomers were tested independently to determine individual IC 50 values. Pairs of monomers with the potential to form heterodimers were assayed at concentrations that ranged about their individual IC25 values.
- Each reaction uses 2 ⁇ l (250 ng/ ⁇ l) of the pBESTlucTM DNA based circular luciferase plasmid (Promega Catalog #L492A), with 4 ⁇ l of complete amino acid mix (Promega Catalog #L4461), 13 ⁇ l of S30 Premix Without Amino Acids (Promega Catalog #L512A), 5 ⁇ l of S30 Extract (Promega Catalog #L464A), monomers at the appropriate concentration, and nuclease free water in a total volume of 35 ⁇ l. Assays were carried out in Costar 96 well white round bottom plates.
- Assay plates were setup with a master mix consisting of S30 extract and water, followed by the addition of compound, with the final addition of a master mix consisting of the plasmid, amino acid mix, and the S30 Premix. Plates were incubated at 37° C. for one hour followed by addition of 35 ⁇ l of the Bright-Glo Luciferase Reagent (Promega Catalog #E2620). After removal of 35 ⁇ l of the reaction mixture, the luminescence was recorded immediately in the Spectramax M5 plate reader (Molecular Devices). The data was plotted to generate dose-response curves using GraphPad Prism.
- IC 50 ranges are provided for various exemplary monomers against tryptase.
- the prefix “Target,” as used elsewhere in the Examples, has been shortened to “T.”
- “Target-14” has been shortened to “T14.”
- A” refers to an IC 50 range of 0.1 nM to 1 ⁇ M
- B refers to an IC 50 range of 1 ⁇ M to 10 ⁇ M
- C refers to an IC 50 range of 10 ⁇ M to 65 ⁇ M.
- T116SPIRO (1:10); T117; T131SPIRO; T56; T156; T35F; T10; T109SPIRO; T35SPAM; T35; T133SPIRO.
- T35SPIRO T107; T147; T107SPIRO; T155SPIRO; T132SPIRO; T31; T34; T32; T37; T154; T143; T59; T62; T54BASPIRO; T57; T64; T12; T144; T58; T33SPAM; T33; T11F; T54BA.
- T142EXOANTI T142ENDOSYN; T98; T100; T77; T9; T8
- IC 50 ratios are provided for various exemplary monomer pairs against tryptase.
- the IC 50 ratio is calculated by dividing the smallest monomer IC 50 value chosen from between monomer 1 and monomer 2 by the apparent IC 50 value for an essentially equimolar combination of monomer 1 and monomer 2.
- T the prefix “Target,” as used elsewhere in the Examples, has been shortened to “T.”
- T100 the prefix “Target,” as used elsewhere in the Examples, has been shortened to “T.”
- AA refers to an IC 50 ratio of 30 or greater
- BB refers to an IC 50 ratio of 10-30
- CC refers to an IC 50 ratio of 3-10.
- This compound was synthesized by oxidation of (S)—N-((3-(4-(2,5-dihydro-1H-pyrrol-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide by osmium tetroxide as in the reaction scheme below (see Scheme 3).
- Florfenicol amine was synthesized from commercially available florfenicol by the procedure reported in the literature (WO2005/85266). Coupling & subsequent demethylation reactions were carried out as per the general procedure described earlier for similar analogues of Linezolid.
- Boronate ester form step-2 was dissolved in mix of Water and solvents like THF/methanol/Acetone that are miscible in water. To this, lithium hydroxide was added and mixture was stirred at room temperature and monitored by TLC & LCMS till maximum starting was consumed (6-12 hrs required) THF was then concentrated and reaction mass was extracted with ethyl acetate and water. Organic layer was washed with water and combined aq. washings were acidified with 2N HCl and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulphate and concentrated in vacuum to get crude product. In most of the cases products were sufficient pure to be used for the next step. The details of compounds synthesized by above method are as below.
- TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- Non commercial aryl/hetero aryl carboxy boronic acids were synthesized from corresponding aryl halo carboxylic acids by reaction with LDA & Tri alkyl borate followed by hydrolysis as per method described in the literature (US-patent application 2008/306082; 2008 example 20B)
- TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- Desired halo aryl carboxylic acids were first coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate and coupled products were reacted with bis pinacolato diborane to get boronate esters which were hydrolyzed to corresponding boronic acids.
- step-1 was converted boronate ester by reacting with Bis Pinacolato Borane in presence of Potassium acetate DPPF-PdCl 2 .DCM by heating in 1,4-dioxane/Dimethyl sulfoxide for 12 hrs. R.M was then concentrated in vacuum and residue was purified by column chromatography.
- step-2 Products of step-2 were stirred with trifluoro acetic acid in dichloromethane at room temp. Reaction mass was then concentrated in vacuum and used for next step without purification.
- the details of compounds synthesized are as below in Table 19.
- Desired dimethoxy analogues of carboxylic acids were first coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate and coupled products were de-methylated using boron tribromide.
- 6,7-dimethoxy-2-oxo-2H-chromene-3-carboxylic acid & 7,8-dimethoxy-2-oxo-2H-chromene-3-carboxylic acid required for target—100 & 102 were prepared by the reaction of Meldrums acid with 2-hydroxy-4,5-dimethoxybenzaldehyde or 2-hydroxy-3,4-dimethoxybenzaldehyde in water at 75° C. for 2 hrs. Precipitated products were sufficient pure to be used for the next step.
- Required aldehydes for this were prepared from corresponding trimethoxy benzaldehydes by demethylation using AlCl 3 in benzene ( JOC, 54, 4112, 1989)
- Target-69 BBr 3 (3 eq) DCM (85 vol), R.T. 2 hrs, 23.6% Mol. Wt:- 342.38 M.I.
- Desired carboxylic acid (A) was coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate followed by deprotection of Boc functionality.
- step-4 Products were purified by column chromatography over silica gel using methanol (0-5%) in Chloroform.
- Boc deprotection of the products from step-1 was carried out by stirring it with hydrochloric acid in presence of co-solvent like methanol or dioxane at room temperature. Solvents were then evaporated and residue was purified by reverse phase preparative HPLC. Products were isolated as TFA salts. Details of the compounds synthesized are as below in Table 26.
- step-1 products Protection of step-1 products was carried out using 2,2-dimethoxy propane by refluxing in acetone in presence of catalytic p-toluene sulfonic acid. Reaction was monitored by LCMS and after completion of reaction solvents were distilled and crude product obtained was purified by column chromatography using ethyl acetate (0-10%) in hexane. The details of compounds synthesized are as below in Table 27.
- step-2 products were carried out as per procedure described in Method-A (step-3).
- step-3 hydrolysis of corresponding cyano compound (G-44) was carried out using ethanolic potassium hydroxide under reflux to get mixture of acid and corresponding amide. This mixture was used for next step without purification.
- the details of compounds synthesized are as below in Table 28.
- Boc and isopropylidine deprotection of the compounds was carried out by stirring with Methanolic HCl or Trifluoro acetic acid in dichloromethane at room temperature. Reactions were monitored by LCMS and after reaction completion, reaction mass was concentrated and residue was purified by reverse phase preparative HPLC. Products were isolated as TFA salts. The details of compounds synthesized are as below in Table 30.
- Desired Carbmethoxy hydroxy benzaldehyde was dissolved in Acetonitrile and aq solution of di-sodium hydrogen phosphate & 30% hydrogen peroxide was then added and reaction mass cooled to 0° C. Aq. solution of Sodium chlorite was added to the reaction mass drop wise and reaction mass was allowed to warm to room temperature. Stirring continued at room temperature and reaction was monitored by LCMS till maximum starting was consumed. Reaction mass was then concentrated, residue was acidified with aq. HCl and product extracted in ethyl acetate. Ethyl acetate extract dried over sodium sulfate and concentrated to get the crude product which was sufficient pure for the use in next step. The details of the compounds synthesized are as below in Table 31.
- step-1 Products from step-1 were converted to desired amides either by conversion to acid chloride and subsequent reaction with ammonia/desired amine or by coupling reaction using EDCI-HOBT in DMF followed by usual work-up as described in method-A (step-4.) Crude products were purified by column chromatography over silica gel using methanol (0-30%) in chloroform.
- step-2 Hydrolysis of step-2 products was carried out as per general procedure followed in method-A (step-3) crude products were used for next step unless specified.
- step-3 products Coupling reactions of step-3 products with tert-butyl 3-(piperidin-4-yl)benzylcarbamate were carried out as per general procedure followed in method-A (step-4) Crude products
- Step-4 products Boc deprotection of Step-4 products was carried out by stirring with Aq. hydrochloric acid-methanol or methanolic HCl at room temperature. Crude products were purified by reverse phase preparative HPLC and isolated as TFA salts.
- Alfa hydroxy carboxylic acids were synthesized by reacting desired epoxide with tert-butyl 3-(1-(3-hydroxybenzoyl)piperidin-4-yl)benzyl carbamate in presence of base to yield Alfa hydroxy carboxylic esters that were hydrolyzed and de-protected to get the title compounds (Scheme-1).
- Hydroxy ester from step-2 was hydrolyzed to acid following general procedure in method-A, step3.
- Compounds were purified by column chromatography over silica gel using methanol (1-15%) in chloroform. The details of the compounds synthesized are as below in Table 38.
- Boc deprotection of the step-3 products was carried out by stirring with methanolic HCl at room temperature. Reactions were monitored by LCMS and after reaction completion, solvents were evaporated in vacuum and residue was purified by reverse phase preparative HPLC to get the products as TFA salts.
- the details of the compounds synthesized are as below in Table 39.
- Meta/para hydroxy benzoic acid was coupled with tert-butyl 3-(1-(3-hydroxybenzoyl)piperidin-4-yl)benzylcarbamate. Coupled product was reacted with ethyl bromo acetate/methyl acrylate in presence of base to yield corresponding O-Alky product with aliphatic ester functionality which was hydrolyzed and coupled with cis-pyrrolidine diol (e.g. as shown in EP1961750 & WO2009/61879) the coupled products were de-protected to yield the title compounds.
- step-1 Product from step-1 was dissolved in methyl acrylate. To this catalytic hydroquinone was added as polymerization inhibitor followed by sodium metal. Reaction mass was then refluxed for 48 hrs and monitored by LCMS. After consumption of maximum starting, the reaction mass was concentrated and the residue was purified by column chromatography over neutral alumina using Methanol (0-10%) in dichloromethane.
- Spiro key intermediate (E) was synthesized from 2H-spiro[benzofuran-3,4′-piperidine]-5-carbonitrile (US 2009/0163527, & B.org. Med. Chem. Lett. 2008, 18, 2114-2121.) through the reaction sequence described in the scheme below.
- Residue was diluted with water ( ⁇ 20 volumes) and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulphate and concentrated to get the crude product which was purified by column chromatography over silica gel using ethyl acetate (0-40%) in hexane to get the pure product.
- step-1 & 2 Procedure described in method-C, step-1 & 2 was followed for Target-78-spiro & and Procedure as per method-A, step-4 & 9 was followed for Target-2 spiro.
- Target-2 Spiro 1) tert-butyl ((2H-spiro [benzofuran-3,4′-piperidin]- 5-yl)methyl)carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DMF (10 vol), RT, 12 h, Yield - 60% 2) TFA (3 eq) DCM (25 vol), R.T. 4 hrs, Yield - 51% Mol. Wt:- 354.40 M.I.
- step-3 product Dibenzoyl peroxide & N-bromo succinamide were added.
- the resulting mixture was heated to 75° C. and reaction was monitored by LCMS. After consumption of maximum starting the reaction mixture was diluted with water and extracted with dichloromethane. Organic phase was again washed with water followed by brine, and dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the crude product.
- the crude product was purified by column chromatography over silica gel using 1-5% ethyl acetate in hexane. The details of the compounds synthesized are as below in Table 52.
- Step-4 product To a stirred solution of Step-4 product in acetonitrile, trifluoro acetic acid and water were added and mixture was heated to 91° C. and monitored by LCMS. After maximum starting was consumed, The reaction mixture was concentrated and residue obtained was diluted with water and extracted with ethyl acetate. Concentration of ethyl acetate layer yielded crude product which was purified by column chromatography over silica gel using 10-35% ethyl acetate in hexane.
- step-5 product lithium hydroxide, THF & water was heated to 60° C. Reaction was monitored by LCMS till maximum starting was consumed. The reaction mixture was concentrated and diluted with water. pH of the reaction mass was then adjusted to ⁇ 2 using Conc. HCl. Precipitated product was filtered, washed with water and dried in vacuum oven. The details of the compounds synthesized are as below in Table 54.
- Step 3 Synthesis of benzyl 3-(1-(3-aminobenzoyl)piperidin-4-yl)benzylcarbamate
- Step 4 Synthesis of benzyl 3-(1-(3-(2-cyclobutylideneacetamido)benzoyl)piperidin-4-yl)benzylcarbamate
- Step 5 Synthesis of benzyl 3-(1-(3-(2-hydroxy-2-(1-hydroxycyclobutyl)acetamido)benzoyl)piperidin-4-yl)benzylcarbamate
- Reaction mixture was quenched with 10% aqueous sodium bisulphite solution and stirred for ⁇ 1 h at room temperature. Aqueous layer was extracted with ethyl acetate, dried over sodium sulphate. Crude product obtained was purified by column chromatography (silica 60-120 mesh, ethyl acetate/n-hexane) afforded semi solid.
- Step 7 Synthesis of N-(3-(4-(3-(aminomethyl)phenyl)piperidine-1-carbonyl)phenyl)-2-(1-hydroxycyclobutyl)-2-oxoacetamide
- triphenyl phosphine (0.56 g, 2.25 mmol) was allowed to stir at ⁇ 20° C.
- DIAD (0.45 g, 0.44 mL, 2.25 mmol) was added. Yellow precipitate was observed in the reaction mixture.
- Methyl 3-hydroxybenzoate (0.26 g, 1.73 mmol) in 3 mL THF was added dropwise to the reaction mixture and stirred for 10-15 min.
- Step 4 Synthesis of tert-butyl 3-(1-(3-(2-cyclobutylidene ethoxy)benzoyl)piperidin-4-yl)benzylcarbamate
- Step 5 Synthesis of tert-butyl 3-(1-(3-(2-cyclobutylideneethoxy)benzoyl)piperidin-4-yl)benzylcarbamate
- Step 4 product (0.23 g, 0.47 mmol), OsO 4 (4% aqueous solution, 0.012 mL, 18.5 ⁇ mol) was added and stirred for 10 min at room temperature. Then NMO (50% aqueous solution, 0.13 mL, 0.56 mmol) was added and allowed to stir at room temperature overnight.
- OsO 4 4% aqueous solution, 0.012 mL, 18.5 ⁇ mol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 61/473,093, filed Apr. 7, 2011, which is hereby incorporated by reference in its entirety.
- Current drug design and drug therapies have not addressed the urgent need for therapies that interact with extended areas or multiple domains of biomolecules such as proteins. For example, there is an urgent need for therapies that are capable of, e.g., modulating protein-protein interactions, e.g., by modulating, simultaneously, domains on a single protein or both a domain on one protein and a domain on another protein. There is also an urgent need for such therapies that modulate fusion proteins, such as those that occur in cancer.
- For example, signaling pathways are used by cells to generate biological responses to external or internal stimuli. A few thousand gene products control both ontogeny/development of higher organisms and sophisticated behavior by their many different cell types. These gene products can work in different combinations to achieve their goals and often do so through protein-protein interactions. Such proteins possess modular protein domains that recognize, bind, and/or modify certain motifs. Protein-protein and protein-nucleic acid recognition often function through protein interactions domains, for example, such as the SH2, SH3, and PDZ domains. These protein-interaction domains may represent a meaningful area for developing targeted therapies. Other macromolecular interactions that may serve as potential targets for effective therapies include protein-nucleic acid interactions, protein-carbohydrate interactions, and protein-lipid interactions.
- Current drug design and drug therapy approaches do not address this urgent need to find drugs that interfere with intracellular protein-protein interactions or protein signaling. Although antibodies and other biological therapeutic agents may have sufficient specificity to distinguish among closely related protein surfaces, factors such as their high molecular weight prevent oral administration and uptake of the antibodies. Conversly, orally active pharmaceuticals are generally too small to disrupt protein-protein surface interactions, which can be much larger than the orally active pharmaceuticals. Further, previous attempts to link, e.g., two pharmacophores that each interact with e.g. different protein domains have focused on large covalently linked compounds assembled in organic solvents. These assemblies typically have a molecular weight too large for oral administration or effective cellular and tissue permeation.
- Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety (e.g. a pharmacophore for the target biomolecule), a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
- In one aspect, a first monomer capable of forming a biologically useful multimer when in contact with a second monomer in an aqueous media is provided. The first monomer is represented by the formula:
-
X1—Y1—Z1 (Formula I) - and pharmaceutically acceptable salts, stereoisomers, metabolites, and hydrates thereof, wherein
-
- X1 is a first ligand moiety capable of binding to a first target biomolecule;
- Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
- Z1 is a first linker as shown below; and
- the second monomer has a boronic acid or oxaborole moiety capable of binding with the Z1 moiety of Formula I to form the multimer.
- In another aspect, a method of administering a pharmaceutically effective amount of a multimeric compound to a patient in need thereof is provided. The method comprises administering to the patient thereof an amount of a first monomer as described above and an amount of a boronic acid or oxaborole monomer in amounts effective such that the pharmaceutically effective amount of the resulting multimer is formed in vivo.
- In yet another aspect, a therapeutic multimer compound formed from the multimerization in an aqueous media of a first monomer is provided. The multimer is represented by the formula:
-
X1—Y1—Z1 (Formula I) - and a second monomer represented by
-
X2—Y2—Z2 (Formula II), - wherein
-
- X1 is a first ligand moiety capable of binding to a first target biomolecule;
- Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
- Z1 is a first linker as shown below;
wherein - X2 is a second ligand moiety capable of binding to a second target biomolecule;
- Y2 is absent or is a connector moiety covalently bound to X2 and Z2; and
- Z2 is a boronic acid or oxaborale moiety capable of binding with the Z1 moiety of Formula I to form the multimer; and
- pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof.
- In still another aspect, a method of modulating two or more target biomolecule domains substantially simultaneously is provided. The method comprises contacting an aqueous composition comprising said biomolecule domains with a first monomer represented by:
-
X1—Y1—Z1 (Formula I) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof, wherein
-
- X1 is a first ligand moiety capable of binding to a first target biomolecule domain; and
a second monomer represented by:
- X1 is a first ligand moiety capable of binding to a first target biomolecule domain; and
-
X2—Y2—Z2 (Formula II), - wherein
-
- X2 is a ligand moiety capable of binding to a second target biomolecule domain;
- wherein upon contact with the aqueous composition, said first monomer and said second monomer forms a dimer that binds to the first target biomolecule domain and the second target biomolecule domain.
- In yet another aspect, a method of treating a disease associated with two or more target biomolecule domains in a patient in need thereof is provided. The method comprises administering to said patient a first monomer represented by:
-
X1—Y1—Z1 (Formula I) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof, wherein
-
- X1 is a first ligand moiety capable of binding to a first target biomolecule domain; and
- administering to said patient a second monomer represented by:
-
X2—Y2—Z2 (Formula II), - wherein
- X2 is a second ligand moiety capable of binding to a second target biomolecule domain, wherein upon administration, said first monomer and said second monomer forms a dimer in vivo that binds to the first target biomolecule domain and the second target biomolecule domain.
- In still another aspect, a first monomer capable of forming a biologically useful dimer when in contact with a second monomer in vivo is provided. The first monomer is represented by the formula:
-
X3—Y3—Z3 (Formula IV); - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
- and the second monomer is represented by:
-
X4—Y4—Z3 (Formula V) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
wherein -
- X3 is a first ligand moiety capable of binding to a first target biomolecule;
- Y3 is absent or is a connector moiety covalently bound to X4 and Z3;
- X4 is a second ligand moiety capable of binding to a second target biomolecule;
- Y4 is absent or is a connector moiety covalently bound to X4 and Z3;
- Z3 is as shown below.
- In yet another aspect, a therapeutic dimerized compound formed from the dimerization in an aqueous media of a first monomer is provided. The first monomer is represented by:
-
X3—Y3—Z3 (Formula IV); - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
- and a second monomer is represented by:
-
X4—Y4—Z3 (Formula V) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
wherein - X3 is a first ligand moiety capable of binding to a first target biomolecule;
- Y3 is absent or is a connector moiety covalently bound to X4 and Z3;
- X4 is a second ligand moiety capable of binding to a second target biomolecule;
- Y4 is absent or is a connector moiety covalently bound to X4 and Z3;
- Z3 is as shown below.
- In still another aspect, a method of treating a disease associated with two or more target biomolecule domains in a patient in need thereof is provided. The method comprises administering to said patient two or more monomers each independently selected from the group represented by:
-
X3—Y3—Z3 (Formula IV); - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
and a second monomer is represented by: -
X4—Y4—Z3 (Formula V) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
wherein - X3 is a first ligand moiety capable of binding to a first target biomolecule;
- Y3 is absent or is a connector moiety covalently bound to X4 and Z3;
- X4 is a second ligand moiety capable of binding to a second target biomolecule;
- Y4 is absent or is a connector moiety covalently bound to X4 and Z3;
- Z3 is as shown below, wherein upon administration, said first monomer and said second monomer forms a dimer in vivo that binds to the first target biomolecule domain and the second target biomolecule domain.
- In yet another aspect, a first monomer capable of forming a biologically useful trimer when in contact with a second monomer and a third monomer in an aqueous media is provided. The first monomer is represented by the formula:
-
X2—Y2—Z2 (Formula II) - and pharmaceutically acceptable salts, stereoisomers, metabolites, and hydrates thereof, wherein
-
- X2 is a first ligand moiety capable of binding to a first target biomolecule;
- Y2 is absent or is a connector moiety covalently bound to X2 and Z2;
- Z2 is a first linker as shown below, and the second monomer and the third monomer each have a boronic acid moiety capable of binding with the Z2 moiety of Formula II to form the trimer.
-
FIG. 1A shows an x-ray co-crystal structure of a multimer bound to adjacent subunits of mast cell beta-tryptase-II, according to an embodiment. The cationic aminomethyl-phenyl-piperidine moieties of the multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the linker elements are joined by a cyclic tetrahedral sp3 boronate diester linkage; -
FIG. 1B shows the chemical structure of the multimer bound to tryptase inFIG. 1A , according to an embodiment; -
FIG. 2A shows dose response curves for T2 & T35 monomers and for T2 and T35 combined in a 1:1 ratio of T2:T35, according to an embodiment; -
FIG. 2B shows a reaction scheme for the formation of the 1:1 multimer inFIG. 2A , according to an embodiment; -
FIG. 3 shows the tryptase-bound state of the 1:1 multimer of T2:T35 shown inFIG. 1A , according to an embodiment; -
FIG. 4A shows an x-ray co crystal structure of a multimer bound to adjacent subunits of mast cell beta-tryptase, according to an embodiment. The cationic aminomethyl-phenyl-piperidine moieties of a 1:1 T27:T10 multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the multimer is joined by a cyclic planar sp2 boronic acid diester linkage; -
FIG. 4B shows a reaction scheme for the formation of the 1:1 multimer inFIG. 4A , according to an embodiment; -
FIG. 5A shows an x-ray co-crystal structure of a T92+T35 heterodimer at pH5.5 and pH6.5 bound to tryptase, according to an embodiment. The structure confirms the sp3 state of the phenolic-hydroxamate/boronate complex bound to tryptase under both conditions; -
FIG. 5B shows a reaction scheme for the formation of the 1:1 multimer inFIG. 5A , according to an embodiment; -
FIG. 6A shows an x-ray co-crystal structure of a T55 homodimer bound to tryptase, according to an embodiment. The cationic aminomethyl-phenyl-piperidine moieties of the multimer are bound in the pharmacophoric pockets of the tryptase subunits, and the monomers are joined by a covalent spiroketal linkage; and -
FIG. 6B shows a reaction scheme for the formation of the 1:1 multimer inFIG. 6A , according to an embodiment. - Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety (e.g. a pharmacophore moiety), a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins. For example, contemplated monomers may be separate or separatable in a solid or in an aqueous media under one set of conditions, and when placed in an aqueous media having one or more biomolecules, with another (e.g., under a different set of conditions), can 1) form a multimer through the linker on each monomer; and either: 2a) bind to the biomolecule in two or more locations (e.g. protein domains) through each ligand moiety of the respective monomer or 2b) bind to two or more biomolecules through each ligand moiety of the respective monomer. In an exemplary embodiment, disclosed monomers may interact with another appropriate monomer (i.e. a monomeric pair) in an aqueous media (e.g., in vivo) to form a multimer (e.g. a dimer) that can bind to two separate target biomolecule domains (e.g. protein domains).
- The ligand moiety of a contemplated monomer, in some cases, may be a pharmacophore or a ligand moiety that is e.g., capable of binding to a biomolecule, such as for example, a protein, e.g. a specific protein domain, a component of a biological cell such as ribosome (composed of proteins and nucleic acids), or an enzyme active site (e.g. a protease, such as tryptase). In some embodiments, the linker element comprises a functional group capable of forming a chemical bond with another linker element. In some embodiments, the linker moiety may also serve as a signaling entity or “reporter,” and in some instances the assembly of two or more linkers can produce a fluorescent entity or fluorophore with properties distinct from the individual linker moiety. In another aspect, a plurality of monomers, each comprising a linker element, may react to form a multimer connected by the linker elements. In some embodiments, the multimer may be formed in vivo. In some instances, the multimer may have enhanced properties relative to the monomers that form the multimer. For example, in certain embodiments, the multimer may bind to a target with greater affinity than any of the monomers that form the multimer. Also described are methods of making the compositions and methods of administering the compositions.
- In some embodiments, a plurality of monomers may assemble to form a multimer. The multimer may be used for a variety of purposes. For example, in some instances, the multimer may be used to perturb a biological system. As described in more detail below, in some embodiments, the multimer may bind to a target biomolecule, such as a protein, nucleic acid, or polysaccharide. In certain embodiments, the multimer may be used as a pharmaceutical.
- Advantageously, in some embodiments, the multimer may form in vivo upon administration of suitable monomers to a subject. Also advantageously, the multimer may be capable of interacting with a relatively large target site as compared to the individual monomers that form the multimer. For example, a target may comprise, in some embodiments, two protein domains separated by a distance such that a multimer, but not a monomer, may be capable of binding to both domains essentially simultaneously. In some embodiments, contemplated multimers may bind to a target with greater affinity as compared to a monomer binding affinity alone.
- In some embodiments, a contemplated multimer may advantageously exhibit enhanced properties relative to the monomers that form the multimer. As discussed above, a multimer may have improved binding properties as compared to the monomers alone. In some embodiments, a multimer may have improved signaling properties. For example, in some cases, the fluorescent properties of a multimer may be different as compared to a monomer. As discussed in more detail below, in some embodiments the fluorescent brightness of a multimer at a particular wavelength may be greater than the fluorescent brightness at the same wavelength of the monomers that form the multimer. Advantageously, in some embodiments, a difference in signaling properties between the multimer and the monomers that form the multimer may be used to detect formation of the multimer. In some embodiments, detection of the formation of the multimer may be used to screen monomers, as discussed in more detail below. Also as discussed in more detail below, in some embodiments, the multimers may be used for imaging or as diagnostic agents.
- It should be understood that a multimer, as used herein, may be a homomultimer (i.e., a multimer formed from two or more essentially identical monomers) or may be a heteromultimer (i.e., a multimer formed from two or more substantially different monomers). In some embodiments, a contemplated multimer may comprise 2 to about 10 monomers, for example, a multimer may be a dimer, a trimer, a tetramer, or a pentamer.
- In some embodiments, a monomer may comprise a ligand moiety, a linker element, and a connector element that associates the ligand moiety with the linker element. In some embodiments, the linker element of a first monomer may combine with the linker element of a second monomer. In some cases, the linker element may comprise a functional group that can react with a functional group of another linker element to form a bond linking the monomers. In some embodiments, the linker element of a first monomer may be substantially the same as the linker element of a second monomer. In some embodiments, the linker element of a first monomer may be substantially different than the linker element of a second monomer.
- In some cases, the ligand moiety may be a pharmacophore. In some embodiments, the ligand moiety (e.g., a pharmacophore) may bind to a target molecule with a dissociation constant of less than 1 mM, in some embodiments less than 500 microM, in some embodiments less than 300 microM, in some embodiments less than 100 microM, in some embodiments less than 10 microM, in some embodiments less than 1 microM, in some embodiments less than 100 nM, in some embodiments less than 10 nM, and in some embodiments less than 1 nM.
- In some embodiments, the IC50 of the first monomer against a first target biomolecule and the IC50 of the second monomer against a second target biomolecule may be greater than the apparent IC50 of a combination of the monomers against the first target biomolecule and the second target biomolecule. The combination of monomers may be any suitable ratio. For example, the ratio of the first monomer to the second monomer may be between 10:1 to 1:10, in some embodiments between 5:1 and 1:5, and in some embodiments between 2:1 and 1:2. In some cases, the ratio of the first monomer to the second monomer may be essentially 1:1. In some instances, the ratio of the smaller of the IC50 of the first monomer and the second monomer to the apparent IC50 of the multimer may be at least 3.0. In other instances, the ratio of the smaller IC50 of the first monomer or the second monomer to the apparent IC50 of the multimer may be at least 10.0. In some embodiments, the ratio of the smaller IC50 of the first monomer or the second monomer to the apparent IC50 of the multimer may be at least 30.0.
- For example, for disclosed monomers forming a heteromultimer, the apparent IC50 resulting from an essentially equimolar combination of monomers against the first target biomolecule and the second target biomolecule is at least about 3 to 10 fold lower, at least about 10 to 30 fold lower, at least about 30 fold lower, or at least about 40 to 50 fold lower than the lowest of the IC50 of the second monomer against the second target biomolecule or the IC50 of the first monomer against the first target biomolecule.
- It will be appreciated that for monomers forming homodimers (or homo-oligomeric or homomultimeric, as described below), in aqueous solution, there may an equilibrium between the monomeric and dimeric (or oligomeric) states with higher concentrations favoring greater extent of dimer formation. As the binding of monomers to the target biomolecule increases their proximity and effectively increases their local concentration on the target, the rate and extent of dimerization (oligomerization) is promoted when geometries are favorable. As a result, the occupancy of the target by favorable monomers maybe nearly completely in the homodimeric (or oligomeric) state. In this manner the target for example, may serve as a template for the dimerization of the monomers, significantly enhancing the extent and rate of dimerization.
- While the affinity of the multimer for its target biomolecule(s) often cannot be measured directly due to the dynamic reversible equilibrium with its monomers in an aqueous or biological milieu, it may be possible to extract an apparent multimer-target dissociation constant from a series of experimental determinations. Exploring the effects of a matrix of monomer concentrations, monomer ratios, along with changes in concentration(s) in the target biomolecule(s), coupled with determinations of multimer-monomer dissociation constants, and in some cases additional binding competition, kinetic and biophysical methods, one can extract an estimate of the affinity of the multimeric assembly for its target(s). Through such approaches, one can demonstrate that in some embodiments, the affinity of the multimer for the target biomolecule(s) are less than 1 μM, in some embodiments less than 1 nM, in some embodiments less than 1 μM, in some embodiments less than 1 fM, and in some embodiments less than 1 aM, and in some embodiments less than 1 zM.
- Affinities of heterodimerizing monomers for the target biomolecule can be assessed through the testing of the respective monomers in appropriate assays for the target activity or biology because they do not typically self-associate. In contrast, the testing of homodimerizing monomers may not, in some embodiments, afford an affinity for the monomeric or dimeric state, but rather the observed effect (e.g. IC50) is a result of the monomer-dimer dynamics and equilibrium, with the apparent binding affinity (or IC50) being e.g., a weighted measure of the monomer and dimeric inhibitory effects upon the target.
- In some cases, the pH of the aqueous fluid in which the multimer forms may be between
pH pH pH pH pH pH pH pH pH pH - In some embodiments, the ligand moiety may be capable of binding to a target and at least partially disrupting a biomolecule-biomolecule interaction (e.g., a protein-protein interaction). In some embodiments, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-nucleic acid interaction. In some cases, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-lipid interaction. In some cases, the ligand moiety may be capable of binding to a target and at least partially disrupting a protein-polysaccharide interaction. In some embodiments, the ligand moiety may be capable of at least partially stabilizing a biomolecule-biomolecule interaction. In certain embodiments, the ligand moiety may be capable of at least partially inhibiting a conformational change in a biomolecule target.
- In some instances, the linker element may be capable of generating a signal. For example, in some embodiments, the linker element may be capable of fluorescing. In some cases, the linker element may have greater fluorescence when the monomer to which it is attached is part of a multimer as compared to when the monomer to which it is attached is not part of a multimer. In some embodiments, upon multimer formation, the fluorescent brightness of a linker element may increase by at least 2-fold, in some embodiments by at least 5-fold, in some embodiments by at least 10-fold, in some embodiments by at least 50-fold, in some embodiments by at least 100-fold, in some embodiments by at least 1000-fold, and in some embodiments by at least 10000-fold. In some embodiments, a linker element in a multimer may have a peak fluorescence that is red-shifted relative to the peak fluorescence of the linker element in a monomer. In other embodiments, a linker element may have a peak fluorescence that is blue-shifted relative to the peak fluorescence of a linker element in a monomer.
- In certain embodiments, a first monomer may be capable of forming a biologically useful multimer when in contact with a second monomer in an aqueous media, for example, when the first and second monomer are different and form e.g. a heteromultimer in aqueous media. For example, the first monomer can represented by the formula:
-
X1—Y1—Z1 (Formula I) - and pharmaceutically acceptable salts, stereoisomers, metabolites, and hydrates thereof, wherein
- X1 is a first ligand moiety capable of binding to a first target biomolecule;
- Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
- Z1 is a first linker selected from the group consisting of:
- a)
-
- wherein
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- A2, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of —N—, acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, provided that at least one of A1 and A2 is present; or
- A1 and A2, together with the atoms to which they are attached, form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
- A3 is selected from the group consisting of —NHR′, —SH, or —OH;
- W is CR′ or N;
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- m is 1-6;
- represents a single or double bond; and
- R1 is (a) absent; or (b) selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- Q1 is (a) absent; or (b) selected from the group consisting of substituted or unsubstituted aliphatic or substituted or unsubstituted heteroaliphatic; or
- R1 and Q1 together with the atoms to which they are attached form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
- wherein
- b)
-
- wherein
- BB, independently for each occurrence, is a 4-8 membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl moiety is optionally substituted with one or more groups represented by R2, wherein the two substituents comprising —OH have a 1,2 or 1,3 configuration;
- each R2 is independently selected from hydrogen, halogen, oxo, sulfonate, —NO2, —CN, —OH, —NH2, —SH, —COOH, —CON(R′)2, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, or two R2 together with the atoms to which they are attached form a fused substituted or unsubstituted 4-6 membered cycloalkyl or heterocyclic bicyclic ring system;
- A1, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- R′ is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- wherein
- c)
-
- wherein
- BB is a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety;
- A3, independently for each occurrence, is selected from the group consisting of —NHR′, —OH, or —O—C1-4alkyl;
- R3 and R4 are independently selected from the group consisting of H, C1-4alkyl, phenyl, or R3 and R4 taken together from a 3-6 membered ring;
- R5 and R6 are independently selected from the group consisting of H, C1-4 alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together form phenyl or a 4-6 membered heterocycle; and
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- wherein
- d)
-
- wherein
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- A3, independently for each occurrence, is selected from the group consisting of —NHR′ or —OH;
- AR is a fused phenyl or 4-7 membered aromatic or partially aromatic heterocyclic ring, wherein AR is optionally substituted by oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; —S—C1-4 alkyl; halogen; —OH; —CN; —COOH; —CONHR′; wherein the two substituents comprising —OH are ortho to each other;
- R5 and R6 are independently selected from the group consisting of H, C1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; CONHR′; and
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- wherein
- e)
-
- wherein
- Q1 is selected from the group consisting of C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; or phenyl;
- Q2, independently for each occurrence, is selected from the group consisting of H, C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; phenyl; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
- A3, independently for each occurrence, is selected from the group consisting of —NH2 or —OH;
- A4, independently for each occurrence, is selected from the group consisting of —NH—NH2; —NHOH, —NH—OR″, or —OH;
- wherein
- f)
-
- wherein
- A5 is selected from the group consisting of —OH, —NH2, —SH, —NHR′″; R′″ is selected from —NH2; —OH; —O-phenyl; and C1-4alkoxy;
- R5 and R6 are independently selected from the group consisting of H, C1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together may form a 5-6 membered ring; and
- wherein
- the second monomer has a boronic acid or oxaborole moiety capable of binding with the Z1 moiety of Formula I to form the multimer.
- In some embodiments, A1 may be selected from the group consisting of C1-C3alkylene optionally substituted with one, two, or three halogens, or —C(O)—.
- In other embodiments, Z1 may be
- wherein R2, independently for each occurrence, is selected from H, C1-4 alkyl, or two R1 moities taken together form a 5- or 6-membered cycloalkyl or heterocyclic ring, wherein R3 is H, or
- In certain embodiments, Z1 may be
- In some cases, Z1 may be
- For example, in some instances, Z1 may be
- In some embodiments, Z1 may be a monosaccharide or a disaccharide.
- In some cases, Z1 may be selected from the group consisting of
- wherein
- X is selected from O, S, CH, NR′, or when X is NR′, N may be covalently bonded to Y of formula I;
- R′ is selected from the group consisting of H and C1-4alkyl;
- R5, R6, and R7 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or a mono- or bicyclic heterocyclic optionally substituted with amino, halo, hydroxyl, oxo, or cyano; and
- AA is a 5-6 membered heterocyclic ring optionally substituted by C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′, or —S—C1-4alkyl. For example, in some embodiments, Z1 may be
- In some instances, Z1 may be
- In certain cases, X may be nitrogen.
- In some embodiments, Z1 may be
- In other embodiments, Z1 may be
- For example, in some cases, Z1 may be
- In other instances, Z1 may be
- In some embodiments, Z1 may be
- In some cases, Z1 may be
- For example, Z1 may be
- In other embodiments, Z1 may be
- In some cases, Z1 may be
- In some embodiments, Z1 may be
- In some embodiments, Z1 may be
- For example, Z1 may be
- In certain embodiments, Z1 may be
- In other embodiments, Z1 may be
- In some embodiments, the second monomer may be X2—Y2—Z2 (Formula II), wherein Z2 is the boronic acid or oxaborale moiety, and wherein X2 is a second ligand moiety capable of binding to a second target biomolecule, and Y2 is absent or is a connector moiety covalently bound to X2 and Z2. In some instances, X1 and X2 may be the same. In other instances, X1 and X2 may be different.
- In some cases, the first target biomolecule and the second target biomolecule may be different. In other embodiments, the first target biomolecule and the second target biomolecule may be the same.
- In some embodiments, Z2 of the second monomer may be selected from the group consisting of:
- wherein
- R8 is selected from the group consisting of H, halogen, oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —COOH; or —CONHR′;
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- Q is selected from the group consisting of substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- AA, independently for each occurrence, is phenyl, aryl, or a 5-7 membered heterocyclic or heteroaryl ring having one, two, or three heteroatoms, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C1-4alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C2-4alkenyl; C1-4alkoxy; —S—C1-4 alkyl; —CN; —NR2′″, wherein R′″ is independently selected from the group consisting of H and C1-4alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
- R′ is H or C1-4alkyl.
- In certain embodiments, R8 and the substituent comprising boronic acid may be ortho to each other, and R8 may be —CH2NH2. In some cases, Z2 of the second monomer may be selected from the group consisting of:
- In some embodiments, Z2 of the second monomer may be selected from the group consisting of:
- In some cases, Z2 of the second monomer may be selected from the group consisting of:
- wherein
- R8 is selected from the group consisting of H, halogen, oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —COOH; or —CONHR′;
- AA, independently for each occurrence, is a 5-7 membered heterocyclic ring having one, two, or three heteroatoms, or phenyl, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C2-4alkenyl; C1-4alkoxy; —S—C1-4alkyl; —CN; —NR2′″, wherein R′″ is independently selected from the group consisting of H and C1-4alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
- R′ is H or C1-4alkyl.
- In some embodiments, a first monomer may be capable of forming a biologically useful dimer or multimer when in contact with a second monomer in vivo, wherein the first and second linkers are the same (e.g. forming a homodimer or homomultimer) wherein the first monomer is represented by the formula:
-
X3—Y3—Z3 (Formula IV); - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
- and the second monomer is represented by:
-
X4—Y4—Z3 (Formula V) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
wherein - X3 is a first ligand moiety capable of binding to a first target biomolecule;
- Y3 is absent or is a connector moiety covalently bound to X4 and Z3;
- X4 is a second ligand moiety capable of binding to a second target biomolecule;
- Y4 is absent or is a connector moiety covalently bound to X4 and Z3;
- Z3 is selected from the group consisting of:
- a)
- wherein
-
- A3 is —OH, —SH, or —NHR′;
- R3 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl;
- R4 is selected from the group consisting of H, halo, C1-4alkyl, C3-6cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl; or
- R3 and R4 taken together from a 3-6 membered ring; and
- b)
- wherein
-
- R′ is selected from C1-4alkyl optionally substituted with hydroxyl; —NH2; —OH; and C1-4alkoxy;
- R3 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl;
- R4 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl; or
- R3 and R4 taken together from a 3-6 membered ring.
- In some embodiments, a first monomer may be capable of forming a biologically useful trimer when in contact with a second monomer and a third monomer in an aqueous media, wherein the first monomer is represented by the formula:
-
X2—Y2—Z2 (Formula II) -
- and pharmaceutically acceptable salts, stereoisomers, metabolites, and hydrates thereof, wherein
- X2 is a first ligand moiety capable of binding to a first target biomolecule;
- Y2 is absent or is a connector moiety covalently bound to X2 and Z2;
- Z2 is a first linker selected from the group consisting of:
- wherein
-
- R8 is selected from the group consisting of H, halogen, oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C2-4alkenyl, C1-4alkoxy; —S—C1-4alkyl; —CN; —COOH; or —CONHR′;
- R′ is H or C1-4alkyl;
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- Q is selected from the group consisting of substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- AA, independently for each occurrence, is phenyl, aryl, or a 5-7 membered heterocyclic or heteroaryl ring having one, two, or three heteroatoms, wherein AA is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C1-4alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C2-4alkenyl; C1-4alkoxy; —S—C1-4alkyl; —CN; —NR2′″, wherein R′″ is independently selected from the group consisting of H and C1-4alkyl; —COOH; —CONHR′; or two substituents together with the atoms to which they are attached form a fused 4-6 membered cycloalkyl or heterocyclic bicyclic ring system; and
- the second monomer and the third monomer each have a boronic acid moiety capable of binding with the Z2 moiety of Formula II to form the trimer.
- In some embodiments, R8 and the substituent comprising boronic acid may be ortho to each other, and R8 may be —CH2NH2.
- In some instances, Z2 of the first monomer may be selected from the group consisting of:
- In certain instances, Z2 of the first monomer may be selected from the group consisting of:
- As discussed above, a monomer may be capable of reacting with one or more other monomers to form a multimer. In some embodiments, a first monomer may react with a second monomer to form a dimer. In other embodiments, a first monomer may react with a second monomer and a third monomer to form a trimer. In still other embodiments, a first monomer may react with a second monomer, a third monomer, and a fourth monomer to form a tetramer. In some embodiments, each of the monomers that form a multimer may be essentially the same. In some embodiments, each of the monomers that form a multimer may be substantially different. In certain embodiments, at least some of the monomers that form a multimer may be essentially the same or may be substantially different.
- In some embodiments, the linker element of a first monomer and the linker element of a second monomer may be substantially different. In other embodiments, the connector element of a first monomer and the connector element of a second monomer may be substantially different. In still other embodiments, the ligand moiety (e.g., a pharmacophore) of a first monomer and the ligand moiety (e.g., a pharmacophore) of the second monomer may be substantially different.
- In some cases, formation of a multimer from a plurality of monomers may be irreversible. In some embodiments, formation of a multimer from a plurality of monomers may be reversible. For example, in some embodiments, the multimer may have an oligomer or dimer dissociation constant between 10 mM and 1 nM, in some embodiments between 1 mM and 100 nM, in some embodiments between 1 mM and 1 mM, and in some embodiments between 500 mM and 1 mM. In certain embodiments, the multimer may have a dissociation constant of less than 10 mM, in some embodiments less than 1 mM, in some embodiments less than 500 mM, in some embodiments less than 100 mM, in some embodiments less than 50 mM, in some embodiments less than 1 mM, in some embodiments less than 100 nM, and in some embodiments less than 1 nM.
- In some embodiments, a first monomer and a second monomer may form a dimer in aqueous solution. For example, in some instances, the first monomer may form a biologically useful dimer with a second monomer in vivo.
- Without wishing to be bound by any theory, it is believed that molecular self-assembly may be directed through noncovalent interactions, e.g., hydrogen bonding, metal coordination, hydrophobic forces, van der Waals forces, pi-pi interactions, electrostatic, and/or electromagnetic interactions.
- Without wishing to be bound by any theory, pi-pi and pi-cation interactions can be used to drive multimerization. In addition, van der Waals and electromagnetic forces are other interactions that can help to drive multimerization. Alternatively, acid/base pairs and donor-acceptor pairs, e.g., amide and/or sulfonamide pairs, can be employed to help direct self-assembly. In other cases, use of hydrophobic interactions can be used for multimerization targeting a membrane-bound protein. Additionally, metal coordination might be used when the target itself incorporates the metal, but could also be used in other scenarios.
- In some embodiments, a therapeutic multimer compound (e.g. a heteromultimer) may be formed from the multimerization in an aqueous media of a first monomer represented by:
-
X1—Y1—Z1 (Formula I) - and a second monomer represented by
-
X2—Y2—Z2 (Formula II), - wherein
- X1 is a first ligand moiety capable of binding to a first target biomolecule;
- Y1 is absent or is a connector moiety covalently bound to X1 and Z1;
- Z1 is a first linker selected from the group consisting of: a)
- wherein
-
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- A2, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of —N—, acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, provided that at least one of A1 and A2 is present; or
- A1 and A2, together with the atoms to which they are attached, form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
- A3 is selected from the group consisting of —NHR′, —SH, or —OH;
- W is CR′ or N;
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- m is 1-6;
- represents a single or double bond; and
- R1 is (a) absent; or (b) selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- Q1 is (a) absent; or (b) selected from the group consisting of substituted or unsubstituted aliphatic or substituted or unsubstituted heteroaliphatic; or
- R1 and Q1 together with the atoms to which they are attached form a substituted or unsubstituted 4-8 membered cycloalkyl or heterocyclic ring;
- b)
- wherein
-
- BB, independently for each occurrence, is a 4-8 membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl moiety is optionally substituted with one or more groups represented by R2, wherein the two substituents comprising —OH have a 1,2 or 1,3 configuration;
- each R2 is independently selected from hydrogen, halogen, oxo, sulfonate, —NO2, —CN, —OH, —NH2, —SH, —COOH, —CON(R′)2, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, or two R2 together with the atoms to which they are attached form a fused substituted or unsubstituted 4-6 membered cycloalkyl or heterocyclic bicyclic ring system;
- A1, independently for each occurrence, is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- R′ is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- c)
- wherein
-
- BB is a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocyclic, aryl, or heteroaryl moiety;
- A3, independently for each occurrence, is selected from the group consisting of —NHR′, —OH, or —O—C1-4alkyl;
- R3 and R4 are independently selected from the group consisting of H, C1-4 alkyl, phenyl, or R3 and R4 taken together from a 3-6 membered ring;
- R5 and R6 are independently selected from the group consisting of H, C1-4 alkyl optionally substituted by hydroxyl, amino, halogen, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together form phenyl or a 4-6 membered heterocycle; and
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- d)
-
- wherein
- A1 is (a) absent; or (b) selected from the group consisting of acyl, substituted or unsubstituted aliphatic, or substituted or unsubstituted heteroaliphatic;
- A3, independently for each occurrence, is selected from the group consisting of —NHR′ or —OH;
- AR is a fused phenyl or 4-7 membered aromatic or partially aromatic heterocyclic ring, wherein AR is optionally substituted by oxo, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; —S—C1-4alkyl; halogen; —OH; —CN; —COOH; —CONHR′; wherein the two hydroxyl moieties are ortho to each other;
- R5 and R6 are independently selected from the group consisting of H, C1-4alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; CONHR′; and
- R′ is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —NH2, —NO2, —SH, or —OH;
- wherein
- e)
-
- wherein
- Q1 is selected from the group consisting of C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; or phenyl;
- Q2, independently for each occurrence, is selected from the group consisting of H, C1-4alkyl, alkylene, or a bond; C1-6cycloalkyl; a 5-6 membered heterocyclic ring; phenyl; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
- A3, independently for each occurrence, is selected from the group consisting of —NH2 or —OH;
- A4, independently for each occurrence, is selected from the group consisting of —NH—NH2; —NHOH, —NH—OR″, or —OH;
- R″ is selected from the group consisting of H or C1-4alkyl; and
- wherein
- f)
-
- wherein
- A5 is selected from the group consisting of —OH, —NH2, —SH, —NHR′″; R′″ is selected from C1-4alkyl optionally substituted with hydroxyl; —NH2; —OH; —O-phenyl; and C1-4alkoxy;
- R5 and R6 are independently selected from the group consisting of H, C1-4 alkyl optionally substituted by hydroxyl, amino, halo, or thio; C1-4alkoxy; halogen; —OH; —CN; —COOH; —CONHR′; or R5 and R6 taken together may form a 5-6 membered ring;
wherein
- X2 is a second ligand moiety capable of binding to a second target biomolecule;
- Y2 is absent or is a connector moiety covalently bound to X2 and Z2; and
- Z2 is a boronic acid or oxaborale moiety capable of binding with the Z1 moiety of Formula I to form the multimer; and
- pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof.
- wherein
- In some embodiments, a therapeutic dimerized compound may be formed from the dimerization in an aqueous media of a first monomer represented by:
-
X3—Y3—Z3 (Formula IV); - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
- and a second monomer is represented by:
-
X4—Y4—Z3 (Formula V) - and pharmaceutically acceptable salts, stereoisomers, metabolites and hydrates thereof,
wherein - X3 is a first ligand moiety capable of binding to a first target biomolecule;
- Y3 is absent or is a connector moiety covalently bound to X4 and Z3;
- X4 is a second ligand moiety capable of binding to a second target biomolecule;
- Y4 is absent or is a connector moiety covalently bound to X4 and Z3;
- Z3 is selected from the group consisting of:
- a)
- wherein
-
- A3 is —OH, —SH, or —NHR′;
- R3 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl;
- R4 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl; and
- b)
- wherein
-
- R′ is selected from C1-4alkyl optionally substituted with hydroxyl; —NH2; —OH; and C1-4alkoxy;
- R3 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl;
- R4 is selected from the group consisting of H, halo, C1-4alkyl, C3-6 cycloalkyl, and heterocycle, wherein C1-4alkyl, C3-6cycloalkyl, or heterocycle may be optionally substituted by one, two, or three substituents selected from the group consisting of halo, cyano, amino, or hydroxyl.
- Connectors
- In some embodiments, a monomer may comprise a connector that joins the ligand moiety with the linker element. In some instances, such connectors do not have significant binding or other affinity to an intended target. However, in certain embodiments, a connector may contribute to the affinity of a ligand moiety to a target.
- In some embodiments, a connector element may be used to connect the linker element to the ligand moiety. In some instances, the connector element may be used to adjust spacing between the linker element and the ligand moiety. In some cases, the connector element may be used to adjust the orientation of the linker element and the ligand moiety. In certain embodiments, the spacing and/or orientation the linker element relative to the ligand moiety can affect the binding affinity of the ligand moiety (e.g., a pharmacophore) to a target. In some cases, connectors with restricted degrees of freedom are preferred to reduce the entropic losses incurred upon the binding of a multimer to its target biomolecule. In some embodiments, connectors with restricted degrees of freedom are preferred to promote cellular permeability of the monomer.
- In some embodiments, the connector element may be used for modular assembly of monomers. For example, in some instances, a connector element may comprise a functional group formed from reaction of a first and second molecule. In some cases, a series of ligand moieties may be provided, where each ligand moiety comprises a common functional group that can participate in a reaction with a compatible functional group on a linker element. In some embodiments, the connector element may comprise a spacer having a first functional group that forms a bond with a ligand moiety and a second functional group that forms a bond with a linker element.
- Contemplated connecters may be any acceptable (e.g. pharmaceutically and/or chemically acceptable) bivalent linker that, for example, does not interfere with multimerization of the disclosed monomers. For instance, such linkers may be substituted or unsubstituted C1-C10 alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, acyl, sulfone, phosphate, ester, carbamate, or amide. Contemplated connectors may include polymeric connectors, such a polyethylene glycol or other pharmaceutically acceptable polymers. For example, contemplated connectors may be a covalent bond or a bivalent C1-10 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three or four methylene units of L are optionally and independently replaced by cyclopropylene, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, —SO2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO2—, —C(═S)—, —C(═NR)—, phenyl, or a mono or bicyclic heterocycle ring. In some embodiments, a connector may be from about 7 atoms to about 13 atoms in length, or about 8 atoms to about 12 atoms, or about 9 atoms to about 11 atoms in length. For purposes of counting connector length when a ring is present in the connector group, the ring is counted as three atoms from one end to the other. In another embodiment, a connecter group is from about 6 Å to about 15 Å in length.
- In some embodiments, contemplated monomers and multimers may be administered to a patient in need thereof. In some embodiments, a method of administering a pharmaceutically effective amount of a multimeric compound to a patient in need thereof is provided. In some cases, the method comprises administering to the patient thereof an amount of the first monomer and an amount of a boronic acid monomer in amounts effective such that the pharmaceutically effective amount of the resulting multimer is formed in vivo.
- In some embodiments, a first monomer and a second monomer may be administered substantially sequentially. In other embodiments, the first monomer and the second monomer are administered substantially simultaneously. In some embodiments the monomers may be administered, sequentially or simultaneously, by different routes of administration. In still further embodiments, a first monomer and a second monomer may be administered after forming a multimer.
- In some instances, a method of modulating two or more target biomolecule domains is provided. In some embodiments, a first ligand moiety may bind to a first domain and a second ligand moiety may bind to a second domain. In certain embodiments, a multimer comprising the first and second ligand moieties may be form prior to binding the first and second domains. In other embodiments, the multimer may form after one and/or two of the monomers bind the first and second domains.
- In some embodiments, the target biomolecule may be a protein. In other embodiments, the target biomolecule may be nucleic acid. In some cases, the ligand moiety may be a pharmacophore.
- In some embodiments, a multimer may be used to inhibit or facilitate protein-protein interactions. For example, in some cases, a multimer may be capable of activating or inactivating a signaling pathway. Without wishing to be bound by any theory, a multimer may bind to a target protein and affect the conformation of the target protein such that the target protein is more biologically active as compared to when the multimer does not bind the target protein. In some embodiments monomers may be chosen such that a multimer formed from the monomers binds to at least two regions of a target molecule.
- Without wishing to be bound by any theory, protein-protein and protein-nucleic acid recognition often work through protein interaction domains, such as the SH2, SH3, and PDZ domains. Currently, there are over 75 such motifs reported in the literature (Hunter, et al., Cell 100:113-127 (2000); Pawson et al., Genes & Development 14:1027-1047 (2000)). For example, SH2 domains are miniature receptors for protein regions containing a phosphorylated tyrosine. SH2 domains may be found in proteins that act as, or play a role in, for example, adaptors, scaffolds, kinases, phosphatases, ras signaling, transcription, ubiquitination, cytoskeletal regulation, signal regulation, and phospholipid second messenger signaling. As another non-limiting example, SH3 domains bind peptide loops with the motif RXXK or PXXP. Many proteins have both SH2 and SH3 domains, which act as “receptors” to bind one or more protein partners. Coferons may be designed to inhibit binding of a phosphotyrosine protein to its cognate SH2 domain. Alternatively, monomers and multimers may be designed so one ligand moiety binds one motif (i.e. SH2), and a second ligand moiety binds a second motif (i.e. SH3), either on the same or different proteins.
- Many large proteins or macromolecular complexes (e.g., ribosomes) have multiple binding sites with known drug inhibitors. In some embodiments, linker elements may be used to bring together two pharmacophores on the same target to: (i) bind the target with higher affinity; (ii) exhibit a stronger inhibition than either pharmacophore alone; (iii) exhibit greater activation than either pharmacophore alone; or (iv) create a binding entity covering a larger surface area of the target, making it harder for the organism/cell/virus to develop resistance to the drug via point mutations.
- In some embodiments, a multimer may target a tryptase. For example, a multimer may be used to treat conditions activated by a tryptase, such as mast cell mediated inflammatory conditions (e.g. asthma). Asthma is frequently characterized by progressive development of hyper-responsiveness of the trachea and bronchi to both immunospecific allergens and generalized chemical or physical stimuli, which lead to the onset of chronic inflammation. Leukocytes containing IgE receptors, notably mast cells and basophils, are present in the epithelium and underlying smooth muscle tissues of bronchi. These leukocytes initially become activated by the binding of specific inhaled antigens to the IgE receptors and then release a number of chemical mediators. For example, degranulation of mast cells leads to the release of proteoglycans, peroxidase, arylsulfatase B, chymase, and tryptase, which results in bronchiole constriction.
- Human mast cell β-tryptase-II is a tetrameric serine protease that is concentrated in mast cell secretory granules. The enzyme is involved in IgE-induced mast cell degranulation in an allergic response and is potentially a target for the treatment of allergic asthma, rhinitis, conjunctivitis and dermatitis. Tryptase has also been implicated in the progression of renal, pulmonary, hepatic, testicular fibrosis, chronic obstructive pulmonary disease (COPD), and inflammatory conditions such as ulcerative colitis, inflammatory bowel disease, rheumatoid arthritis, and various other mast cell-related diseases. In some embodiments, multimers may be used to treat such diseases.
- Tryptase is stored in the mast cell secretory granules and is the major protease of human mast cells. Tryptase has been implicated in a variety of biological processes, including degradation of vasodilatory and bronchodilatory neuropeptides and modulation of bronchial responsiveness to histamine. As a result, tryptase inhibitors may be useful as anti-inflammatory agents for treatment of inflammatory disease and may also be useful in treating or preventing allergic rhinitis, inflammatory bowel disease, psoriasis, ocular or vernal or ulcerative conjunctivitis, dermatological conditions (e.g., psoriasis, eczema, or atopic dermatitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis, hematoid arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, or gouty arthritis), rheumatoid spondylitis, interstitial lung disease, chronic obstructive pulmonary disease, and diseases of joint cartilage destruction.
- In addition, tryptase has been shown to be a potent mitogen for fibroblasts, suggesting its involvement in the pulmonary fibrosis in asthma and interstitial lung diseases. Therefore, in some embodiments, tryptase inhibitors may be useful in treating or preventing fibrotic conditions, for example, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hepatic fibrosis, renal fibrosis, testicular, and hypertrophic scars.
- Additionally, tryptase inhibitors may be useful in treating or preventing myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture.
- Tryptase has also been discovered to activate prostromelysin that in turn activates collagenase, thereby initiating the destruction of cartilage and periodontal connective tissue, respectively. In some embodiments, tryptase inhibitors may be useful in the treatment or prevention of arthritis, periodontal disease, diabetic retinopathy, a condition relating to atherosclerotic plaque rupture, anaphylactic ulcerative colitis, and tumor growth. Also, tryptase inhibitors may be useful in the treatment of anaphylaxis, multiple sclerosis, peptic ulcers, and syncytial viral infections.
- A variety of antibiotics elicit their antibacterial activity by binding to the bacterial ribosome and inhibiting protein synthesis. Many of these antibiotics bind the peptidyl transferase center of the ribosome (P site). In some embodiments, a multimer may bind to two or more sites on the ribosome. For example, a first pharmacophore of a multimer may bind to the peptidyl transferase center of the ribosome (i.e., the P site) and a second multimer may bind to site adjacent to the P site. As a non-limiting, illustrative example, Linezolid, an oxazolidinone antibiotic, is believed to bind adjacent to the binding site for Sparsomycin. The close juxtaposition of the linezolid binding site with the sparosmycin binding site presents a possible scenario for developing monomers based on linezolid and sparsomycin that can dimerize on binding to the ribosome, thereby creating a high affinity and high specificity inhibitor of bacterial protein synthesis.
- Other non-limiting examples of target protein families are provided in Table 1 below. Also provided in Table 1 are endogenous ligands, agonists, and antagonists that bind to the protein families. Examples of detection assays are also provided in Table 1, which may be used in a screening assay to detect activation and/or inhibition of the target protein.
- Provided in Table 2 are non-limiting examples of domains that can bind a ligand, proteins that contain the domains, known inhibitors, and KD values of binding partners (i.e., ligands). Examples of detection assays are also provided in Table 2, which may be used in a screening assay to find ligands for the domains.
-
TABLE 1 Examples of Protein Families and Their Pharmacological Targets EXAMPLES OF EXAMPLES OF ENDOGENOUS CURRENT CURRENT EXAMPLES OF TARGET TARGET LIGAND AGONISTS ANTAGONISTS DETECTION FAMILY EXAMPLE (MODULATORS) (ACTIVATORS) (INHIBITORS) ASSAYS G-PROTEIN β2 adrenergic epinephrine, albuterol, propranolol, HitHunter, PathHunter COUPLED receptors norepinephrine salbutamol, butoxamine (DiscoverX), cAMP RECEPTORS terbutaline, assay, Intracellular salmeterol calcium flux, TANGO, GeneBlazer, ELISA, binding assays G-PROTEIN Muscarinic Acetylcholine Acetylcholine, Scopolamine, HitHunter, PathHunter COUPLED receptors Pilocarpine atropine, (DiscoverX), cAMP RECEPTORS ipratropium, assay, Intracellular caproctamine calcium flux, TANGO, GeneBlazer, ELISA, binding assays G-PROTEIN H1 histamine histamine Histamine diphenhydramine, HitHunter, PathHunter COUPLED receptor doxylamine, (DiscoverX), cAMP RECEPTORS pyrilamine, assay, Intracellular brompheniramine, calcium flux, TANGO, chlorpheniramine, GeneBlazer, ELISA, Loratadine, binding assays Fexofenadine, Cetrizine, Desoratadine NUCLEAR Estrogen Estriol, estrone, 17-beta-estradiol, Tamoxifen, ICI Hit-hunter RECEPTORS receptor estradiol Chlorotrianisene, 164, 384, (Discoverx), reporter Dienestrol, Keoxifene, assays, TANGO, Fosfestrol, Mepitiostane GeneBlazer, ELISA, Diethylstilbestrol, ligand binding assays, Zeranol VOLTAGE voltage-gated veratridine, tetrodotoxin, Intracellular ion flux GATED ION sodium aconitine saxitoxin, assays CHANNELS channels VOLTAGE voltage-gated BAY K 8644, ω-conotoxin, ω- Intracellular ion flux GATED ION calcium CGP 28392 agatoxins, assays CHANNELS channels dihydropyridine, nifedipine LIGAND kainate glutamate kainic acid, CNQX, HitHunter, PathHunter GATED ION receptor domoic acid, LY293558, (DiscoverX), cAMP CHANNELS LY339434, LY294486 assay, Intracellular ion ATPA, flux, TANGO, iodowillardiine, GeneBlazer, ELISA, (2S,4R)-4- ligand binding assays, methylglutamic acid RECEPTOR epidermal epidermal growth EGF, TGFa, PD153035, anti- reporter assays, kinase TYROSINE growth factor factor amphiregulin EGFR antibody assays, CO-IP, BRET, KINASES receptor betacellulin, C225, FRET, TANGO, (EGFR) epiregulin, aeroplysinin-1, GeneBlazer, neuregulins AG18, AG82, HitHunter, PathHunter AG99, AG112, (DiscoverX), ELISA AG213, AG490, AG494, AG527, AG555, AG556 GROWTH Vascular VEGFR Ranibizumab, Hit-hunter FACTORS endothelial bevacizumab, (Discoverx), reporter growth factor sunitinib, assays, TANGO, sorafenib, GeneBlazer, ELISA, axitinib, ligand binding assays, pazopanib, Naphthamides PROTEASES Caspase granzyme B; Granzyme B, Z-VAD(OMe)- caspase assays, caspase caspase FMK, Z-VAD- apoptosis assays, CHO mitochondrial Dy, CO- IP, BRET, FRET, TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), ELISA PHOSPHATASES PP1 phosphoserine/threonine calyculin A, protein tyrosine residues nodularin, phosphatase assay, tautomycin CO-IP, BRET, FRET, TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), ELISA PROTEIN ERK MEK AG126, kinase assay, CO-IP, KINASES apigenin, Ste- BRET, FRET, MPKKKPTPIQL reporter assays, NP-NH2, H- TANGO, GeneBlazer, GYGRKKRRQR HitHunter, PathHunter RR-G- (DiscoverX) MPKKKPTPIQL NP-NH2, PD98059, U0126, MISC Adenylate G proteins, bordetella NKY80, 2′,3′- BRET, FRET, calcium ENZYMES cyclase calcium pertussis, Dideoxyadenosine, flux assays, cAMP cholera toxin, 2′,5′- assays, TANGO, forskolin Dideoxyadenosine, GeneBlazer, SQ22536, HitHunter, PathHunter MDL-12330A (DiscoverX) MISC Acetylcholine Caproctamine, Acetylcholinesterase ENZYMES sterase Metrifonate, Assay, Amplex Red, Physostigmine, Ellman method, HPLC Galantamine, Dyflos, Neostigmine BIOACTIVE Ceramide sphingomyelin TNF□. Fas fumonisin B TLC lipid charring, LIPIDS ligand, 1,25 diacylglycerol kinase dihydroxy labeling in vitro vitamin D, {tilde over (□)}interferon CYTOKINES IL2 IL2R BAY 50-4798, daclizumab, TANGO, GeneBlazer, P1-30, SP4206 basiliximab, HitHunter, PathHunter SP4206 (DiscoverX), IL2 dependent mouse CTLL cell line, ELISA MISC BCLXL BAD BH3I-1, A- TANGO, GeneBlazer, PROTEINS 371191, ABT- HitHunter, PathHunter 737 (DiscoverX), CO-IP, BRET, FRET, ELISA MISC p53 MDM2, JNK1-3, PRIMA-1, Pifithrin-α caspase assays, PROTEINS ERK1-2, p38 MIRA-1, RITA, apoptosis assays, MAPK, ATR, mitochondrial Dy, CO- ATM, Chk1, IP, BRET, FRET, Chk2, DNA-PK, TANGO, GeneBlazer, CAK HitHunter, PathHunter (DiscoverX), ELISA MISC Tubulin tubulin ALB109564, kinase assay, CO-IP, PROTEINS ABT-751, BRET, FRET, D24851, reporter assays, D64131, TANGO, GeneBlazer, benomyl, □-arrestin(DiscoverX estramustine, LY290181 MISC □-amyloid L1,10- Stagnant Amyloid PROTEINS phenanthroline Fibril Formation derivatives, Assay, amyloid KLVFF, LVFFA, fibrillization assay Memoquin, SLF- CR MISC thymidylate raltitrexed, caspase assays, PROTEINS synthase pemetrexed, apoptosis assays, nolatrexed, mitochondrial Dy, CO- ZD9331, IP, BRET, FRET, GS7904L, TANGO, GeneBlazer, fluorouracil HitHunter, PathHunter (DiscoverX), ELISA UBIQUITIN MDM2 p53 trans-4-Iodo, 4′- TANGO, GeneBlazer, LIGASES boranyl- HitHunter, PathHunter chalcone, (DiscoverX), CO-IP, Nutlins, MI-219, BRET, FRET, ELISA, MI-63, RITA, reporter assay HLI98 VIRAL HPV E2 HPV E1 indandiones, E2 displacement assay, REGULATORS podophyllotoxin TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), CO-IP, BRET, FRET, ELISA, reporter assay BACTERIAL ZipA FtsZ substituted 3-(2- TANGO, GeneBlazer, CELL indolyl)piperidines, HitHunter, PathHunter DIVISION 2-phenyl (DiscoverX), CO-IP, PROTEINS indoles BRET, FRET, ELISA, reporter assay, polarization competition assay, CYTOKINES TNF TNFR infliximab, TANGO, GeneBlazer, adalimumab, HitHunter, PathHunter etanercept (DiscoverX), CO-IP, BRET, FRET, ELISA, SCAFFOLD JIP1 JNK BI-78D3, TIJIP TANGO, GeneBlazer, PROTEINS HitHunter, PathHunter (DiscoverX), CO-IP, BRET, FRET, ELISA, kinase assay DNA REPAIR PARP INO-1001, TANGO, GeneBlazer, AG014699, BS- HitHunter, PathHunter 201, AZD2281, (DiscoverX), CO-IP, BS-401 BRET, FRET, ELISA, RIBOSOMES Antibiotics ribosomes tetracyclins, cell death assay, macrolides, lincosamides, streptogramins HISTONE HDAC1 suberoylanilide TANGO, GeneBlazer, DEACETYLASES hydroxamic acid, HitHunter, PathHunter trichostatin A, (DiscoverX), CO-IP, LBH589 BRET, FRET, ELISA, APOPTOSIS XIAP SMAC/DIABLO, SM102-SM130 CO-IP, BRET, FRET, REGULATORS caspase 3, caspase reporter assays, 7, caspase 9 TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), cell death assays CHAPERONE Hsp90 Cdc37, survivin Celastrol, CO-IP, BRET, FRET, PROTEINS shepherdin reporter assays, TANGO, GeneBlazer, HitHunter, PathHunter DiscoverX), SERINE/THREONINE mTOR Raptor, Rapamycin, kinase assay, CO-IP, PROTEIN mLST8/GβL caffeine, BRET, FRET, KINASES farnesylthiosalicylic reporter assays, acid, TANGO, GeneBlazer, curcumin, HitHunter, PathHunter temsirolimus, (DiscoverX) everolimus SERINE/THREONINE- B-raf & B-raf K-ras PLX4720 kinase assay, CO-IP, PROTEIN V600E BRET, FRET, KINASES reporter assays, TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), CYCLIN CDK2 Cyclin A, cyclin E Variolin, kinase assay, CO-IP, DEPENDENT Meriolin BRET, FRET, KINASES reporter assays, TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), GROWTH IGF-1R IGFII PQIP CO-IP, BRET, FRET, FACTOR reporter assays, RECEPTORS TANGO, GeneBlazer, HitHunter, PathHunter (DiscoverX), PROTEASOME 20S 19S Bortezomib, CO-IP, BRET, FRET, salinosporamide cell viability A, -
TABLE 2 Examples of Protein Domains EXAMPLE OF EXAMPLES APPROXIMATE PROTEIN EXAMPLES OF OF KD OF CONTAINING KNOWN DETECTION BINDING DOMAIN PARTNER DOMAIN INHIBITORS ASSAYS PARTNERS SH2 Phospho-tyrosine Grb2 Fmoc-Glu-Tyr-Aib- Surface 0.2-11 μM residues Asn-NH2; Ac- plasmon SpYVNVQ-NH2, resonance macrocycles, (SPR) STATTIC technology, FHA Phospho-threonine KIF13B 1-100 μM and phospho- tyrosine residues 14-3-3 Phospho-serine 14-3-3 R18 7 nM-20 μM residues WW ligands containing Pm1 Zn(II) 6 μM-190 μM PpxY, Proline-rich Dipicolylamine- sequences based artificial receptors WD40 Apaf-1 1 μM MH2 phospho-serine SMAD2 240 nM residues BROMO acetylated lysine CBP 1 μM-4 mM residues UBA mono-, di-, tri-, and HHR23A 6 μM-2.35 mM tetra-ubiquitin PTB Phospho-tyrosine IRS-1 LSNPTX-NH2, PTB domain 160 nM-10 μM residues, Asn-Pro-X- LYASSNOAX- binding Tyr motifs NH2, assays LYASSNPAX-NH2 SH3 Proline-rich peptides Grb2 Peptidimer-c, 1-500 μM with consensus Pro- VPPPVPPRRR, X-X-Pro, (VPPPVPPRRR)2K) EVH1 FPxΦP motifs, ActA 10-50 μM PPxxF motifs GYF proline-rich CDBP2 10-160 μM sequences, VHS TOM1 11-50 μM PDZ PDZ, Val-COOH MNT1 NSC668036, FJ9 1-500 μM PUF RNA PUM1 10-100 nM TUBBY DNA, TULP1 phosphotidylinositol SAM CNK 71 nM-1 μM DD DD FADD CARD CARD Apaf-1 1.4 μM PyD PyD Pyrin 4 μM PB1 PB1 Bem1 4-500 nM BRCT BRCT BRCA1 113 nM-6 μM pH phosphatidylinositol- AKT1 NSC 348900, 1.76 nM-350 μM 4,5-bisphosphate, perifosine, SH5, PI-3, 4-P2 or PI- SH23, SH24, SH25, 3,4,5-P3 ml14, ml15, ml16 FYVE Phosphatidylinositol SARA 50 nM-140 μM 3-phosphate, zinc C1 phorbol esters, PKC isoforms 0.58-800 nM diacylglycerol FERM PI(3)P, PI(4)P, PTLP1 200 nM-30 μM PI(5)P, IP3, C2 Calcium, acidic Nedd4 250 nM-94 μM phospholipids PX PI(3,4)P2, PI(3)P, CISK 1.8 nM-50 μM PI(3,5)P2, PI(4)P, PI(5)P, PI(3,4,5)P3, PI(4,5)P2 ENTH PtdIns(4,5)P2, Epsin1 98 nM-1 μM PtdIns(1,4,5)P3, PI(3,4)P2; PI(3,5)P2 - A pharmacophore is typically an arrangement of the substituents of a moiety that confers biochemical or pharmacological effects. In some embodiments, identification of a pharmacophore may be facilitated by knowing the structure of the ligand in association with a target biomolecule. In some cases, pharmacophores may be moieties derived from molecules previously known to bind to target biomolecules (e.g., proteins), fragments identified, for example, through NMR or crystallographic screening efforts, molecules that have been discovered to bind to target proteins after performing high-throughput screening of natural products libraries, previously synthesized commercial or non-commercial combinatorial compound libraries, or molecules that are discovered to bind to target proteins by screening of newly synthesized combinatorial libraries. Since most pre-existing combinatorial libraries are limited in the structural space and diversity that they encompass, newly synthesized combinatorial libraries may include molecules that are based on a variety of scaffolds.
- Additionally pharmacophores may be derived from traditional approaches such as fragment based drug design and structure based drug design. Those skilled in the art will recognize that any pharmacophore including pre-existing pharmacophores such as approved drugs are amenable to be designed as monomers through the incorporation of the appropriate linker elements and connector elements. For example, previously approved drugs that have poor efficacy due to a low affinity for a first macromolecular target may be utilized as a pharmacophore component of a first monomer which when combined with a pharmacophore of a second monomer that also binds the first macromolecular target or a second macromolecular target that interacts with the first macromolecular target results in enhanced binding and, in some cases, higher efficacy. Likewise, previously approved drugs that have low efficacy as a result of size, molecular weight or other physicochemical attributes that reduce the cellular uptake of the drug may be amenable to being converted into one or more monomers that bear the appropriate pharmacophoric elements, such that each monomer has physicochemical attributes that allow for increased cellular uptake.
- In some embodiments, a ligand moiety (e.g., a pharmacophore) may have a molecular weight between 50 Da and 2000 Da, in some embodiments between 50 Da and 1500 Da, in some embodiments, between 50 Da and 1000 Da, and in some embodiments, between 50 Da and 500 Da. In certain embodiments, a ligand moiety may have a molecular weight of less than 2000 Da, in some embodiments, less than 1000 Da, and in some embodiments less than 500 Da.
- In certain embodiments, the compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein.
- Disclosed compositions may be administered to patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician. For treating clinical conditions and diseases noted above, a compound may be administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. Parenteral administration may include subcutaneous injections, intravenous or intramuscular injections, or infusion techniques.
- Treatment can be continued for as long or as short a period as desired. The compositions may be administered on a regimen of, for example, one to four or more times per day. A suitable treatment period can be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely. A treatment period can terminate when a desired result, for example a partial or total alleviation of symptoms, is achieved.
- In another aspect, pharmaceutical compositions comprising monomers, dimers, and/or multimers as disclosed herein formulated together with a pharmaceutically acceptable carrier provided. In particular, the present disclosure provides pharmaceutical compositions comprising monomers, dimers, and/or multimers as disclosed herein formulated together with one or more pharmaceutically acceptable carriers. These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used. For example, disclosed compositions may be formulated as a unit dose, and/or may be formulated for oral or subcutaneous administration.
- Exemplary pharmaceutical compositions may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form, which contains one or more of the compounds, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
- For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
- Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof.
- Suspensions, in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- Dosage forms for transdermal administration of a subject composition includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- The ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Compositions and compounds may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
- Pharmaceutical compositions suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants
- In another aspect, enteral pharmaceutical formulations including a disclosed pharmaceutical composition comprising monomers, dimers, and/or multimers, an enteric material; and a pharmaceutically acceptable carrier or excipient thereof are provided. Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs. The small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5 and the pH of the distal ileum is about 7.5. Accordingly, enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10.0. Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleat, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac and copal collophorium, and several commercially available enteric dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above materials is either known or is readily determinable in vitro. The foregoing is a list of possible materials, but one of skill in the art with the benefit of the disclosure would recognize that it is not comprehensive and that there are other enteric materials that may be used.
- Advantageously, kits are provided containing one or more compositions each including the same or different monomers. Such kits include a suitable dosage form such as those described above and instructions describing the method of using such dosage form to treat a disease or condition. The instructions would direct the consumer or medical personnel to administer the dosage form according to administration modes known to those skilled in the art. Such kits could advantageously be packaged and sold in single or multiple kit units. An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
- It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., as follows “First Week, Monday, Tuesday, . . . etc. . . . Second Week, Monday, Tuesday, . . . ” etc. Other variations of memory aids will be readily apparent. A “daily dose” can be a single tablet or capsule or several pills or capsules to be taken on a given day. Also, a daily dose of a first compound can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa. The memory aid should reflect this.
- Also contemplated herein are methods and compositions that include a second active agent, or administering a second active agent.
- Also contemplated herein are methods and compositions that include a second active agent, or administering a second active agent.
- Certain terms employed in the specification, examples, and appended claims are collected here. These definitions should be read in light of the entirety of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
- In some embodiments, the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term “substituted” whether preceded by the term “optionally” or not, and substituents contained in formulas, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
- In some instances, when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. In some embodiments, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Non-limiting examples of substituents include acyl; aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO2; —CN; —SCN; —SRx; —CF3; —CH2CF3; —CHCl2; —CH2OH; —CH2CH2OH; —CH2NH2; —CH2SO2CH3; —ORx, —C(O)Rx; —CO2(Rx); —C(O)N(Rx)2; —OC(O)Rx; —OCO2Rx; —OC(O)N(Rx)2; —N(Rx)2; —SORx; —S(O)2Rx; —NRxC(O)Rx; or —C(Rx)3; wherein each occurrence of Rx independently includes, but is not limited to, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Furthermore, the compounds described herein are not intended to be limited in any manner by the permissible substituents of organic compounds. In some embodiments, combinations of substituents and variables described herein may be preferably those that result in the formation of stable compounds. The term “stable,” as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
- The term “acyl,” as used herein, refers to a moiety that includes a carbonyl group. In some embodiments, an acyl group may have a general formula selected from —C(O)Rx; —CO2(Rx); —C(O)N(Rx)2; —OC(O)Rx; —OCO2Rx; and —OC(O)N(Rx)2; wherein each occurrence of Rx independently includes, but is not limited to, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted.
- The term “aliphatic,” as used herein, includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, “aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties. The term “heteroaliphatic,” as used herein, refers to aliphatic moieties that contain one or more oxygen, sulfur, nitrogen, phosphorus, or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc. In certain embodiments, heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to acyl; aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO2; —CN; —SCN; —SRx; —CF3; —CH2CF3; —CHCl2; —CH2OH; —CH2CH2OH; —CH2NH2; —CH2SO2CH3; —ORx, —C(O)Rx; —CO2(Rx); —C(O)N(Rx)2; —OC(O)Rx; —OCO2Rx; —OC(O)N(Rx)2; —N(Rx)2; —SORx; —S(O)2Rx; —NRxC(O)Rx; or —C(Rx)3; wherein each occurrence of Rx independently includes, but is not limited to, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted.
- In general, the terms “aryl” and “heteroaryl,” as used herein, refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted. Substituents include, but are not limited to, any of the previously mentioned substituents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. In certain embodiments, aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. In certain embodiments, the term heteroaryl, as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from the group consisting of S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from the group consisting of S, O, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
- It will be appreciated that aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one, two, three, or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; cycloalkoxy; heterocyclylalkoxy; heterocyclyloxy; heterocyclyloxyalkyl; alkenyloxy; alkynyloxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; oxo; —F; —Cl; —Br; —I; —OH; —NO2; —CN; —CF3; —CH2CF3; —CHCl2; —CH2OH; —CH2CH2OH; —CH2NH2; —CH2SO2CH3; —C(O)Rx; —CO2(Rx); —CON(Rx)2; —OC(O)Rx; —OCO2Rx; —OCON(Rx)2; —N(Rx)2; —S(O)2Rx; —NRx(CO)Rx, wherein each occurrence of Rx independently includes, but is not limited to, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
- The term “heterocyclic,” as used herein, refers to an aromatic or non-aromatic, partially unsaturated or fully saturated, 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size and bi- and tri-cyclic ring systems which may include aromatic five- or six-membered aryl or aromatic heterocyclic groups fused to a non-aromatic ring. These heterocyclic rings include those having from one to three heteroatoms independently selected from the group consisting of oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. In certain embodiments, the term heterocyclic refers to a non-aromatic 5-, 6-, or 7-membered ring or a polycyclic group wherein at least one ring atom is a heteroatom selected from the group consisting of O, S, and N (wherein the nitrogen and sulfur heteroatoms may be optionally oxidized), including, but not limited to, a bi- or tri-cyclic group, comprising fused six-membered rings having between one and three heteroatoms independently selected from the group consisting of the oxygen, sulfur, and nitrogen, wherein (i) each 5-membered ring has 0 to 2 double bonds, each 6-membered ring has 0 to 2 double bonds, and each 7-membered ring has 0 to 3 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to an aryl or heteroaryl ring.
- The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein for example as C2-6alkenyl, and C3-4alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
- The term “alkenyloxy” used herein refers to a straight or branched alkenyl group attached to an oxygen (alkenyl-O). Exemplary alkenoxy groups include, but are not limited to, groups with an alkenyl group of 3-6 carbon atoms referred to herein as C3-6alkenyloxy. Exemplary “alkenyloxy” groups include, but are not limited to allyloxy, butenyloxy, etc.
- The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to an oxygen (alkyl-O—). Exemplary alkoxy groups include, but are not limited to, groups with an alkyl group of 1-6 or 2-6 carbon atoms, referred to herein as C1-6alkoxy, and C2-C6alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
- The term “alkoxycarbonyl” as used herein refers to a straight or branched alkyl group attached to oxygen, attached to a carbonyl group (alkyl-O—C(O)—). Exemplary alkoxycarbonyl groups include, but are not limited to, alkoxycarbonyl groups of 1-6 carbon atoms, referred to herein as C1-6alkoxycarbonyl. Exemplary alkoxycarbonyl groups include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, etc.
- The term “alkynyloxy” used herein refers to a straight or branched alkynyl group attached to an oxygen (alkynyl-O)). Exemplary alkynyloxy groups include, but are not limited to, propynyloxy.
- The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon, for example, such as a straight or branched group of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as C1-6alkyl, C1-4alkyl, and C1-3alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 3-methyl-2-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
- The term “alkylcarbonyl” as used herein refers to a straight or branched alkyl group attached to a carbonyl group (alkyl-C(O)—). Exemplary alkylcarbonyl groups include, but are not limited to, alkylcarbonyl groups of 1-6 atoms, referred to herein as C1-6alkylcarbonyl groups. Exemplary alkylcarbonyl groups include, but are not limited to, acetyl, propanoyl, isopropanoyl, butanoyl, etc.
- The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-6, or 3-6 carbon atoms, referred to herein as C2-6alkynyl, and C3-6alkynyl, respectively.
- Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
- The term “carbonyl” as used herein refers to the radical —C(O)—.
- The term “carboxylic acid” as used herein refers to a group of formula —CO2H.
- The term “cyano” as used herein refers to the radical —CN.
- The term “cycloalkoxy” as used herein refers to a cycloalkyl group attached to an oxygen (cycloalkyl-O—).
- The term “cycloalkyl” as used herein refers to a monocyclic saturated or partially unsaturated hydrocarbon group of for example 3-6, or 4-6 carbons, referred to herein, e.g., as C3-6cycloalkyl or C4-6cycloalkyl and derived from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclohexenyl, cyclopentyl, cyclobutyl or, cyclopropyl.
- The terms “halo” or “halogen” as used herein refer to F, Cl, Br, or I.
- The term “heterocyclylalkoxy” as used herein refers to a heterocyclyl-alkyl-O-group.
- The term “heterocyclyloxyalkyl” refers to a heterocyclyl-O-alkyl-group.
- The term “heterocyclyloxy” refers to a heterocyclyl-O— group.
- The term “heteroaryloxy” refers to a heteroaryl-O— group.
- The terms “hydroxy” and “hydroxyl” as used herein refers to the radical —OH.
- The term “oxo” as used herein refers to the radical ═O.
- The term “connector” as used herein to refers to an atom or a collection of atoms optionally used to link interconnecting moieties, such as a disclosed linker and a pharmacophore. Contemplated connectors are generally hydrolytically stable.
- “Treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
- “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.
- The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
- The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). The mammal treated is desirably a mammal in which treatment of obesity, or weight loss is desired. “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
- In the present specification, the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by the researcher, veterinarian, medical doctor, or other clinician. The compounds are administered in therapeutically effective amounts to treat a disease. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in weight loss.
- The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in compounds used in the present compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
- The compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom. Various stereoisomers of these compounds and mixtures thereof are encompassed by this disclosure. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
- The compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as geometric isomers, enantiomers or diastereomers. The enantiomers and diastereomers may be designated by the symbols “(+),” “(−).” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. Geometric isomers, resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a cycloalkyl or heterocyclic ring, can also exist in the compounds. The symbol denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring can also be designated as “cis” or “trans.” The term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
- The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. Various stereoisomers of these compounds and mixtures thereof are encompassed by this disclosure.
- Individual enantiomers and diasteriomers of the compounds can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using steroselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well known methods, such as chiral-phase gas chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantio- and diastereoselective transformations. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
- The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In one embodiment, the compound is amorphous. In one embodiment, the compound is a polymorph. In another embodiment, the compound is in a crystalline form.
- Also embraced are isotopically labeled compounds which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 10B, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. For example, a compound may have one or more H atom replaced with deuterium.
- Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- The term “prodrug” refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood, or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al, Nature
Reviews Drug Discovery 2008, 7, 255). For example, if a compound or a pharmaceutically acceptable salt, hydrate, or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C1-8)alkyl, (C2-12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl. - Similarly, if a compound contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C1-6)alkanoyloxymethyl, 1-((C1-6)alkanoyloxy)ethyl, 1-methyl-1-((C1-6)alkanoyloxy)ethyl (C1-6)alkoxycarbonyloxymethyl, N—(C1-6)alkoxycarbonylaminomethyl, succinoyl, (C1-6)alkanoyl, α-amino(C1-4)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
- If a compound incorporates an amine functional group, a prodrug can be formed, for example, by creation of an amide or carbamate, an N-acyloxyakyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base, imine, or enamine. In addition, a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can be metabolically cleaved to generate a bioactive primary or secondary amine. For examples, see Simplício, et al.,
Molecules 2008, 13, 519 and references therein. - All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
- The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.
- At least some of the compounds identified as “Intermediates” herein are contemplated as active ingredients.
- For ease of reading, intermediates are provided in Table 3. At least some of the compounds identified as “Intermediates” herein are contemplated as compounds of the invention. Example compounds are provided in Table 4.
-
TABLE 3 INTERMEDIATES INDEX Sr. No. Structure Compound Name Cmpd. Code Sparsomycin analogues 1. (E)-N-(3,4-dimethoxybenzyl)-3-(5- methyl-2,6-dioxo-1,2,3,6- tetrahydropyrimidin-4-yl)acrylamide SPARSO- 10a 2. (E)-N-benzyl-3-(5-methyl-2,6- dioxo-1,2,3,6- tetrahydropyrimidin-4- yl)acrylamide SPARSO-17 3. (E)-N-(3-hydroxypropyl)-3-(5- methyl-2,6-dioxo-1,2,3,6- tetrahydropyrimidin-4-yl)acrylamide SPARSO-18 4. (E)-3-(5-methyl-2,6-dioxo- 1,2,3,6-tetrahydropyrimidin-4- yl)-N-propylacrylamide SPARSO-19 Tryptase targets Method- D 5. (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(4-hydroxy- 3-methoxyphenyl)prop-2-en- 1-one T-24 mono methoxy 6. (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(5-hydroxy-1H- indol-2-yl)methanone Target- 31a 7. (4-(3-(aminomethyl) phenyl)piperidin-1-yl) (2- bromobenzo[b]thiophen-4- yl)methanone Target- 37a 8. (4-(3- (aminomethyl)phenyl)piperidin-1-yl) (benzofuran-4-yl)methanone Target- 38H 9. 1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-(3-fluoro- 4-hydroxyphenyl)ethanone Target- 54a 10. (4-(3-(aminomethyl)phenyl) piperidin-1-yl) (4- bromobenzo[b]thiophen-2- yl)methanone Target-56a 11. (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(3,4,5- trimethoxyphenyl)prop-2-en-1- one Target- 43a 12. 8-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 6H-[1,3]dioxolo[4,5- g]chromen-6-one Target-97a Tryptase targets Method- I 13. (4-(3-(aminomethyl)phenyl)piperidin-1- yl)(3-hydroxyphenyl)methanone Target-53b Tryptase targets 14. (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-((3S,4R)- 3,4-dihydroxypyrrolidine-1- carbonyl)phenyl)methanone Target-26 diol trans 15. (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(4- cyclopropyl-3-hydroxyphenyl) prop-2-en-1-one Target-41- Cyclopropyl -
TABLE 4 EXAMPLES INDEX Sr. No. Cmpd. Code Structure Compound Name Sparsomycin analogues 16. SPARSO- 10 (E)-N-(3,4-dihydroxybenzyl)-3-(5- methyl-2,6-dioxo-1,2,3,6- tetrahydropyrimidin-4-yl)acrylamide Linezolid analogues 17. LZD-2 N-(((5S)-3-(4-(3,4- dihydroxypyrrolidin-1-yl)- 3-fluorophenyl)-2-oxooxazolidin-5- yl)methyl) acetamide 18. Lz-NA-19 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl)methyl)-3,4- dihydroxybenzamide 19. Lz-NA-20 (S)-2-(3,4-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin- 5-yl)methyl) acetamide 20. Lz-NA-21 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl)methyl)-2,3- dihydroxybenzamide 21. Lz-NA-22 (S)-2-(2,3-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin-5- yl)methyl) acetamide 22. Lz-NA-23 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin- 5-yl)methyl)-3-hydroxy-4- (hydroxymethyl) benzamide 23. Lz-NA-24 (S)-N-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin- 5-yl)methyl)-4-hydroxy-3- (hydroxymethyl) benzamide 24. Lz-NA-27 (S,E)-3-(3,4-dihydroxyphenyl)- N-((3-(3-fluoro-4-morpholino- phenyl)-2-oxooxazolidin-5- yl)methyl) acrylamide 25. Lz-NA-28 (S)-3-(3,4-dihydroxyphenyl)-N- ((3-(3-fluoro-4- morpholinophenyl)- 2-oxooxazolidin-5- yl)methyl) propanamide 26. Lz-NA-34 (S,E)-4-(3-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl) methylamino)-3-oxoprop- 1-enyl)-2- hydroxy-N- methoxybenzamide 27. Lz-NA-36 (S,E)-5-(3-((3-(3-fluoro-4- morpholinophenyl)-2- oxooxazolidin-5-yl) methylamino)-3-oxoprop-1- enyl)-2- hydroxybenzamide 28. Lz-NA-12 (S)-3-(3-fluoro-4- morpholinophenyl)-5-((2-oxo- 2,3-dihydro-1H-pyrrol-1- yl)methyl)oxazolidin-2- one Fluorfenicol analogues 29. NAFFLA- 19 N-((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl)-3,4- dihydroxybenzamide 30. NAFFLA- 20 2-(3,4-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl) acetamide 31. NAFFLA- 21 N-((1S)-3-fluoro-1-hydroxy- 1-(4-(methylsulfonyl) phenyl)propan-2-yl)- 2,3- dihydroxybenzamide 32. NAFFLA- 22 2-(2,3-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl) acetamide 33. NAFFLA- 23 N-((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)propan-2-yl)-3- hydroxy-4-(hydroxymethyl) benzamide 34. NAFFLA- 27 (E)-3-(3,4-dihydroxyphenyl)-N- ((1S)-3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl) acrylamide 35. NAFFLA- 28 3-(3,4-dihydroxyphenyl)-N-((1S)- 3-fluoro-1-hydroxy-1-(4- (methylsulfonyl)phenyl)propan-2- yl) propanamide 36. NAFFLA- 34 4-((E)-3-((1R,2S)-3-fluoro- 1-hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2-hydroxy-N- methoxybenzamide 37. NAFFLA- 35 4-((E)-3-((1R,2S)-3-fluoro-1- hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2- hydroxybenzamide 38. NAFFLA- 36 5-((E)-3-((1R,2S)-3-fluoro-1- hydroxy-1-(4-(methylsulfonyl) phenyl)propan-2-ylamino)-3- oxoprop-1-enyl)-2- hydroxybenzamide 39. NAFFLA- 37 N1-((1R,2S)-3-fluoro-1-hydroxy- 1-(4-(methylsulfonyl) phenyl)propan-2-yl)-4- hydroxy-N3- methoxyisophthalamide Tryptase targets Method- A 40. Target-31 ((2-(4-(3-(aminomethyl)phenyl) piperidine-1- carbonyl)-1H-indol-5- yl)(hydroxy)boryl) holmium 41. Target-62 3′-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl) biphenyl-2- ylboronic acid 42. Target-64 5-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 2- fluorophenylboronic acid 43. Target-35 3′-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)biphenyl- 3- ylboronic acid 44. Target-11F 8-(4-(5-(aminomethyl)-2- fluorophenyl)piperidine-1- carbonyl)naphthalen-2- ylboronic acid 45. Target-58 4-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 3- fluorophenylboronic acid 46. Target-57 3-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 4- fluorophenylboronic acid 47. Target-35F 3′-(4-(5-(aminomethyl)-2- fluorophenyl)piperidine-1- carbonyl)biphenyl-3- ylboronic acid 48. Target-33 (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-oxoprop- 1-enyl) phenylboronic acid 49. Target-34 (E)-3-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-oxoprop- 1-enyl) phenylboronic acid 50. Target-37 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl) benzo[b]thiophen-2- ylboronic acid 51. Target-31 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-4-ylboronic acid 52. Target-62 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-6- ylboronic acid 53. Target-64 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)benzo [b]thiophen-4-ylboronic acid Tryptase targets Method- B 54. Target-32 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-4-ylboronic acid 55. Target-59 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 1H-indol-6- ylboronic acid 56. Target-56 2-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)benzo [b]thiophen-4-ylboronic acid Tryptase targets Method-C 57. Target-28 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,3- dihydroxyphenyl) methanone 58. Target-27-F (4-(5-(aminomethyl)-2- fluorophenyl)piperidin-1-yl)(6,7- dihydroxynaphthalen-1- yl) methanone 59. Target-68 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,3,4- trihydroxyphenyl)methanone 60. Target-69 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3,4,5- trihydroxyphenyl)methanone 61. Target-77 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(2,4,5- trihydroxyphenyl)methanone 62. Target-78 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-chloro-4,5- dihydroxyphenyl)methanone 63. Target-43 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3,4,5- trihydroxyphenyl)prop-2-en-1- one 64. Target-70 N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2,3-dihydroxybenzamide 65. Target-71 N-(3-(4-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 3,4-dihydroxybenzamide 66. Target-97 4-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)- 6,7-dihydroxy-2H-chromen- 2-one 67. Target-100 3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-6,7- dihydroxy-2H-chromen-2-one 68. Target-102 3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-7,8- dihydroxy-2H-chromen-2-one Tryptase targets Method-D 69. Target-101 3-(2-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-2-oxoethyl)-7,8- dihydroxy-4-methyl-2H- chromen-2-one Tryptase targets Method-E 70. Target-74 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-hydroxy-4- (hydroxymethyl)phenyl) methanone 71. Target-65 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(4-hydroxy-3- (hydroxymethyl)phenyl) methanone 72. Target-40 (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(4-hydroxy-3- (hydroxymethyl)phenyl)prop- 2-en-1-one 73. Target-44 (4-(3- (aminomethyl)phenyl)piperidin- 1-yl)(7-hydroxy-6- (hydroxymethyl)naphthalen-1- yl)methanone Tryptase targets Method-F 74. Target-75 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2- hydroxybenzamide 75. Target-75a 4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2-hydroxy- N-methoxybenzamide 76. Target-66 5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)- 2-hydroxybenzamide 77. Target-86 (E)-5-(3-(4-(3-(aminomethyl) phenyl)piperidine-1-yl)-3-oxoprop- 1-enyl)-2-hydroxybenzamide 78. Target-92 5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-2- hydroxy-N-methoxybenzamide Tryptase targets Method-H 79. Target-72 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-hydroxy-2-methylpropanoic acid 80. Target-73 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-hydroxy-2-phenylpropanoic acid 81. Target-76 (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1- yl)-3-oxoprop-1-enyl)- 2-hydroxybenzamide 82. Target-76a (E)-4-(3-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)- 3-oxoprop-1-enyl)-2- hydroxy-N-methoxybenzamide 83. Target-81 3-(5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H-indol- 1-yl)-2-hydroxy-2- methylpropanoic acid 84. Target-82 3-(6-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- methylpropanoic acid 85. Target-83 3-(5-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- phenylpropanoic acid 86. Target-84 3-(6-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)-1H- indol-1-yl)-2-hydroxy-2- phenylpropanoic acid 87. Target-103 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 2-cyclopentyl-2- hydroxypropanoic acid Tryptase targets Method-I 88. Target-53 3-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)-3,4- dihydroxypyrrolidin-1- yl)propan-1-one 89. Target-29 2-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)- 3,4-dihydroxypyrrolidin-1- yl)ethanone 90. Target-30 2-(4-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenoxy)- 1-((3S,4R)-3,4- dihydroxypyrrolidin-1-yl) ethanone Tryptase targets Method-J 91. Target-35- Spiro 3′-(5-(aminomethyl)-2H-spiro [benzofuran-3,4′-piperidine]- 1′-ylcarbonyl)biphenyl-3- ylboronic acid 92. Target-78- Spiro (5-(aminomethyl)-2H- spiro[benzofuran-3,4′-piperidine]- 1′-yl) (3-chloro-4,5- dihydroxyphenyl)methanone 93. Target-2 Spiro (5-(aminomethyl)-2H-spiro [benzofuran-3,4′- piperidine]-1′-yl)(3,4- dihydroxyphenyl)methanone 94. Target-35- Spiro amidine 3′-(5-carbamimidoyl-2H-spiro [benzofuran-3,4′-piperidine]- 1′-ylcarbonyl)biphenyl-3- ylboronic acid 95. T-33 spiro amidine (E)-4-(3-(5-carbamimidoyl-2H- spiro[benzofuran-3,4′-piperidine]- 1′-yl)-3-oxoprop- 1-enyl)phenylboronic acid Tryptase targets-Method-K 96. Target-36 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(4-(1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5- yl)phenyl)methanone 97. Target-36- meta (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-(1-hydroxy-1,3- dihydrobenzo[c][1,2]oxoborol-5- yl)phenyl)methanone Tryptase targets 98. Target-21 N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2-(1-hydroxycyclobutyl)-2- oxoacetamide 99. Target- 21-diol N-(3-(4-(3-(aminomethyl)phenyl) piperidine-1-carbonyl)phenyl)- 2-hydroxy-2-(1- hydroxycyclobutyl)acetamide 100. Target-22 2-(3-(4-(3-(aminomethyl)phenyl) piperidine-1- carbonyl)phenoxy)-1-(1- hydroxycyclobutyl)ethanone 101. Target-42 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3- hydroxy-2-(hydroxymethyl) phenyl)prop-2-en-1-one 102. Target-55 tert-butyl 3-(1-(3-(3-hydroxy- 3-methyl-2-oxobutanamido) benzoyl)piperidin-4-yl) benzylcarbamate 103. Target- 55-diol tert-butyl 3-(1-(3-(2,3- dihydroxy-3-methylbutanamido) benzoyl)piperidin-4-yl) benzylcarbamate 104. Target-14 (E)-3-(4-(3-(aminomethyl) phenyl)piperidine-1- carbonyl)styrylboronic acid 105. Target- 24 cis (Z)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3- (3,4-dihydroxyphenyl)prop-2- en-1-one 106. Target-25b (4-(3-(aminomethyl)phenyl) piperidin-1-yl) (3-((3S,4R)-3,4- dihydroxypyrrolidin-1- yl)phenyl)methanone 107. Target- 26 diol cis (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-((3R,4R)-3,4- dihydroxypyrrolidine-1- carbonyl)phenyl)methanone 108. Target-41 (E)-1-(4-(3-(aminomethyl) phenyl)piperidin-1-yl)-3-(3- hydroxy-4-(hydroxymethyl) phenyl)prop-2- en-1-one 109. Target-67 (4-(3-(aminomethyl)phenyl) piperidin-1-yl)(3-(3,4-dihydroxy- 3,4-dimethylpyrrolidin-1- yl)phenyl)methanone 110. Target-41 gem dimethyl (E)-1-(4-(3-(aminomethyl)phenyl) piperidin-1-yl)-3-(3-hydroxy- 4-(2-hydroxypropan-2- yl)phenyl)prop-2-en-1-one 111. CF1 4-(aminomethyl)-N-(4-(2- ((3S,4S)-3,4- dihydroxypyrrolidin-1-yl)-2- oxoethyl)benzyl)benzamide hydrochloride 112. CF2 (S)-4-(aminomethyl)-N-(4- (2-(3-hydroxy-4- oxopyrrolidin-1-yl)-2- oxoethoxy)benzyl)benzamide hydrochloride 113. CF4 3-(1-(3,4- dichlorobenzoyl)piperidin-4- yl)benzimidamide hydrochloride 114. CF5 (4-(3-(aminomethyl) phenyl)piperidin-1-yl)(3,4- dichlorophenyl)methanone 115. CF6 4-(aminomethyl)-N-(4-(2- ((3R,4R)-3,4- dihydroxypyrrolidin-1-yl)-2- oxoethoxy)benzyl)benzamide hydrochloride 116. CF7 (R)-4-(aminomethyl)-N-(4-(2-(3- hydroxy-4-oxopyrrolidin-1-yl)-2- oxoethoxy)benzyl)benzamide hydrochloride 117. CF10 (S)-4-(aminomethyl)-N-(4-(3-(3- hydroxy-4-oxopyrrolidin-1-yl)-3- oxopropoxy)benzyl)benzamide hydrochloride 118. CF12 (R)-4-(aminomethyl)-N-(4-(3-(3- hydroxy-4-oxopyrrolidin-1-yl)-3- oxopropoxy)benzyl)benzamide hydrochloride 119. CF13 N-(4-(aminomethyl)benzyl)-4-(2- (2,3-dihydroxypropanamido)acetyl) piperazine-1-carboxamide hydrochloride 120. CF15 (5-(aminomethyl)-2H- spiro[benzofuran-3,4′- piperidine]-1′-yl)(4-(2,3- dihydroxypropoxy)phenyl) methanone hydrochloride 121. CF17 1-(3-(4-(3-(aminomethyl) phenyl)piperidine-1-carbonyl) phenyl)-3-(3,3,3-trifluoro- 2-hydroxypropyl)urea hydrochloride 122. CF20 N-(4-(aminomethyl)benzyl)- 4-(2-(3-hydroxy-2- oxopropanamido)acetyl) piperazine-1- carboxamide - Stock solutions of recominbant human tryptase, beta, from lung (Promega: catalog number G5631, or Enzo Life Sciences: catalog number BML-SE418) were made at 30 μM, in solution with 50 μM heparin sulfate and 1 M NaCl. Monomer tryptase inhibitor stock solutions were made at 50 mM in DMSO. Test substance plates were made at 1.2× the final concentration in assay buffer (50 mM HEPES, 150 mM NaCl, 100 μM EDTA, pH 7.4, 0.02% Tween-20). A final concentration of 1 nM tryptase was used. When required, test substances were diluted in water immediately before use in 10-fold serial dilutions. After the indicated incubation time, the test substance-tryptase solution at 1.2× concentration, was diluted into assay buffer containing a final concentration of 200 μM N-tert-butoxycarbonyl-Gln-Ala-Arg-AMC HBr [AMC=7-amino-4-methylcoumarin] (Boc-Gln-Ala-Arg-AMC; Enzo Life Sciences: catalog number BML-P237) to a final volume of 50 μl in black opaque round bottom 96 well plates (Corning, catalog number 3792). The release of fluorescent AMC was immediately measured every 30 seconds over 15-30 minutes at an excitation wavelength of 367 nm, monitoring emission at 468 nm on a Spectramax M5 (Molecular Devices) microplate reader. The Softmax Pro (Molecular Devices) and Graphpad prism software were used to determine Vmax, and concentration-response curve IC50s, respectively. Combinations of monomeric test substances were typically tested in a 1:1 ratio initially, and those displaying IC50's>4× lower than that of the most potent monomeric component were often retested with a range of ratios of manomeric concentrations.
- Monomers with the potential to form heterodimers were evaluated in an in vitro Transcription and Translation assay (TnT assay) using the commercially available E. coli S30 Extract System for Circular DNA kit (Promega Catalog #L1020) according to the manufacturers instructions with minor modifications. Monomers were tested independently to determine individual IC50 values. Pairs of monomers with the potential to form heterodimers were assayed at concentrations that ranged about their individual IC25 values. Each reaction uses 2 μl (250 ng/μl) of the pBESTluc™ DNA based circular luciferase plasmid (Promega Catalog #L492A), with 4 μl of complete amino acid mix (Promega Catalog #L4461), 13 μl of S30 Premix Without Amino Acids (Promega Catalog #L512A), 5 μl of S30 Extract (Promega Catalog #L464A), monomers at the appropriate concentration, and nuclease free water in a total volume of 35 μl. Assays were carried out in Costar 96 well white round bottom plates. Assay plates were setup with a master mix consisting of S30 extract and water, followed by the addition of compound, with the final addition of a master mix consisting of the plasmid, amino acid mix, and the S30 Premix. Plates were incubated at 37° C. for one hour followed by addition of 35 μl of the Bright-Glo Luciferase Reagent (Promega Catalog #E2620). After removal of 35 μl of the reaction mixture, the luminescence was recorded immediately in the Spectramax M5 plate reader (Molecular Devices). The data was plotted to generate dose-response curves using GraphPad Prism.
- In Table 5 below, IC50 ranges are provided for various exemplary monomers against tryptase. For the names of the monomers, the prefix “Target,” as used elsewhere in the Examples, has been shortened to “T.” For example, “Target-14” has been shortened to “T14.” “A” refers to an IC50 range of 0.1 nM to 1 μM, “B” refers to an IC50 range of 1 μM to 10 μM, and “C” refers to an IC50 range of 10 μM to 65 μM.
-
TABLE 5 MONOMER IC50 VALUES Monomers Monomer IC50 range T14 A T55 A T84 A T21 A T82 A T4 A T46 A T103 A CMI17 A T130 A CMI21 A T25B A T74 A T55D A T81 A T102 A T67 A T75A A T14A A T22 A T21D A T70 A T56 A T3 A T56A A T36M A T76A A T78SPIRO A T31A A T27 A T43 A T65 A CF17 A T41 A T71 A T78 A CF5 A T129A A T101 A T53 A T66 A T72 A T2 A T35F A T2SPIRO A T10 A T83 A T41CYCLO A T41GEM A T76 A T35AM A CF20 A T35 A T73 A T42 B T35SPIRO B CF14 B T24DI B T26DTRANS B T31 B T34 B T32 B T37 B T44i3 B CF12 B T1 B T69 B T86 B T24CIS B T24MON B T44 B T130A B T59 B T30 B T36 B T24 B T62 B T68 B T27F B T37A B T13A B CF15 B T26DCIS B T57 B T64 B T75 B T5 B T92 B T97 B T12 B T22D B T58 B T28 B T53B B T33AM B T54A B T33 B CF13 B T11F B CF7 B T10A B T29 B T40 B T12A B T27A B T11 C CF10 C CF2 C T13 C CF1 C T100 C CF6 C T77 C T9 C - T75APSPIRO; T75AP (1:10); T84 (1:10); T82 (1:10); T103 (1:10); CMI9317 (1:10); T75ASPIRO 1:10; CMI9321 (1:10); T25b (1:10); T85A (1:10); T74 (1:10); T55D (1:10); T81 (1:10); T102 (1:10); T67; T75A; T114-Spiro; T92OTB (1:10); T70; T21 (Diol); T3; T76A; T78SPIRO; T78SPIRO; T27; T113SPIRO; T43; T65; T41; T71; T78; T75AOTBSPIRO; T101; T53; T66; T142ENDOANTI; T72; T2; T141ENDOANTI; T2-spiro; T92SPIRO; T83 (1:10); T74SPIRO; T41GEM; T76; T73; T136A; T104; T104SPIRO.
- T42; T126; T24Dihydro; T26diol trans; T920PH; T92PHSPIRO; T1; T86; T69; T24cis; T141EXOANTI; T44; T141EXOSYN; T139RACEENDO; T30; T24; T68; T27F; T99; T26diol cis; T75; T5; T92; T127; T97; T920TBSPIRO; T22_diol; T75AOTB; T28; T140RACEENDO; T40; T96.
- In Table 6 below, IC50 ratios are provided for various exemplary monomer pairs against tryptase. The IC50 ratio is calculated by dividing the smallest monomer IC50 value chosen from between
monomer 1 andmonomer 2 by the apparent IC50 value for an essentially equimolar combination ofmonomer 1 andmonomer 2. For the names of the monomers, the prefix “Target,” as used elsewhere in the Examples, has been shortened to “T.” For example, “Target-100” has been shortened to “T100.” “AA” refers to an IC50 ratio of 30 or greater, “BB” refers to an IC50 ratio of 10-30, and “CC” refers to an IC50 ratio of 3-10. -
TABLE 6 IC50 RANGES FOR 1:1 COMBINATIONS OF MONOMERS Monomer 1 Monomer 2 Ratio IC50 range T100 T11 AA T27F T64 AA T28 T33 AA T28 T35SPIRO AA T2SPIRO T35SPAM AA T2SPIRO T35SPIRO AA T42 T10 AA T68 T35SPAM AA T69 T35SPAM AA T69 T35SPIRO AA T78 T35 AA T78 T35F AA T78 T35SPAM AA T78 T35SPIRO AA T78SPIRO T35 AA T78SPIRO T35F AA T78SPIRO T35SPAM AA T78SPIRO T35SPIRO AA T92 T10 AA T92 T11 AA T92 T11F AA T92 T35 AA T92 T35SPAM AA T92 T35SPIRO AA T100 T11F BB T100 T13 BB T100 T33 BB T100 T37 BB T100 T64 BB T2 T35 BB T2 T35F BB T2 T35SPAM BB T2 T35SPIRO BB T24 T11F BB T26diol cis T33 BB T27F T11 BB T27F T12 BB T27F T13 BB T27F T32 BB T27F T34 BB T27F T35 BB T27F T35F BB T27F T35SPAM BB T27F T35SPIRO BB T27F T37 BB T27F T57 BB T27F T58 BB T28 T35 BB T28 T35F BB T28 T35SPAM BB T2spiro T35 BB T2spiro T35F BB T40 T11F BB T42 T11F BB T42 T35SPIRO BB T42 T37 BB T68 T33 BB T68 T35 BB T68 T35F BB T68 T35SPIRO BB T68 T58 BB T69 T35 BB T69 T35F BB T74 T35SPAM BB T92 T35F BB T92 T37 BB T97 T10 BB T97 T11 BB T97 T11F BB T97 T33 BB T97 T37 BB T97 T58 BB T97 T64 BB T1 T11F CC T1 T35SPIRO CC T1 T37 CC T1 T64 CC T100 T10 CC T100 T12 CC T100 T32 CC T100 T35SPAM CC T100 T56 CC T100 T58 CC T100 T59 CC T101 T56 CC T2 T11F CC T21 (Diol) T56 CC T22_diol T33SPAM CC T22_diol T57 CC T22_diol T58 CC T22_diol T64 CC T24 T11 CC T24 T32 CC T24 T33 CC T24 T34 CC T24 T35 CC T24 T35SPAM CC T24 T35SPIRO CC T24 T37 CC T24 T57 CC T24 T58 CC T24 T59 CC T24 T64 CC T24cis T11 CC T24cis T12 CC T24cis T13 CC T24cis T32 CC T24cis T37 CC T24cis T56 CC T24cis T57 CC T24cis T58 CC T24cis T59 CC T24Dihydro T32 CC T24Dihydro T35SPAM CC T24Dihydro T37 CC T24Dihydro T58 CC T24Dihydro T59 CC T25B T36 CC T26diol cis T11F CC T26diol cis T32 CC T26diol cis T64 CC T26diol trans T36 CC T27 T34 CC T27 T35 CC T27 T35F CC T27 T35SPAM CC T27 T64 CC T27F T10 CC T27F T11F CC T27F T31 CC T27F T33SPAM CC T27F T36 CC T27F T59 CC T27F T62 CC T28 T11 CC T28 T11F CC T28 T31 CC T28 T33SPAM CC T28 T34 CC T28 T36 CC T28 T58 CC T28 T59 CC T29 T11F CC T30 T59 CC T40 T33SPAM CC T40 T35SPAM CC T40 T58 CC T42 T32 CC T42 T34 CC T42 T35 CC T42 T35F CC T42 T35SPAM CC T42 T58 CC T42 T59 CC T43 T32 CC T43 T34 CC T43 T36 CC T43 T37 CC T43 T56 CC T44 T12 CC T44 T64 CC T5 T32 CC T5 T64 CC T65 T35F CC T65 T35SPAM CC T65 T35SPIRO CC T68 T11 CC T68 T11F CC T68 T33SPAM CC T68 T34 CC T68 T36 CC T68 T37 CC T68 T57 CC T68 T59 CC T69 T11F CC T69 T37 CC T69 T58 CC T69 T64 CC T71 T32 CC T73 T32 CC T75 T34 CC T75 T35F CC T75 T58 CC T75 T59 CC T75A T35 CC T75A T35F CC T75A T35SPAM CC T75A T35SPIRO CC T76 T10 CC T76 T31 CC T76 T35SPAM CC T76 T59 CC T77 T11 CC T77 T13 CC T77 T35F CC T77 T35SPIRO CC T78 T34 CC T78 T37 CC T86 T35SPIRO CC T92 T12 CC T92 T13 CC T92 T58 CC T97 T12 CC T97 T13 CC T97 T35 CC T97 T35SPAM CC T97 T35SPIRO CC T97 T36 CC T97 T57 CC T97 T59 CC T97 T62 CC - T104SPIRO+T35SPIRO; T104+T133SPIRO; T104SPIRO+T35SPAM; T104SPIRO+T133SPIRO; T104+T35SPAM; T78+T133SPIRO; T104+T35SPIRO; T78+T35; T74SPIRO+T133SPIRO; T27F+T133SPIRO; T92+T133SPIRO; T78+T35SPAM; T92+T132SPIRO; T92+T35SPAM; T104+T132SPIRO; T104SPIRO+T132SPIRO; T74SPIRO+T112SPIRO; T27F+T51; T104SPIRO+T35; T78+T35F; T78SPIRO+T35SPAM; T78+T35SPIRO; T74SPIRO+T35SPAM; T28+T133SPIRO; T78SPIRO+T133SPIRO; T104+T35; T28+T107SPIRO; T104+T112SPIRO; T78SPIRO+T35; T78+T132SPIRO; T74SPIRO+T35SPIRO; T104SPIRO+T35F; T2Spiro+T35SPAM; T78SPIRO+T35SPIRO; T28+T147; T28+T35SPIRO; T27F+T64; T78SPIRO+T35F; T68+T133SPIRO; T27F+T132SPIRO; T113SPIRO+T133SPIRO; T68+T147; T92+T112SPIRO; T2Spiro+T133SPIRO; T74SPIRO+T132SPIRO; T42+T112SPIRO; T69+T132SPIRO; T28+T132SPIRO; T28+T107; T92PHSPIRO+T35SPIRO; T104SPIRO+T112SPIRO; T92+T35SPIRO; T104+T35F; T69+T133SPIRO; T27F+T107SPIRO; T78SPIRO+T132SPIRO; T27F+T54BA; T92PHSPIRO+T133SPIRO; T28+T33; T27F+T109SPIRO; T68+T132SPIRO; T92PHSPIRO+T132SPIRO; T27F+T107; T92+T11F; T92PHSPIRO+T35SPAM; T78+T112SPIRO; T96+T11; T92SPIRO+T133SPIRO; T2+T133SPIRO; T68+T107SPIRO; T92+T11; T2SPIRO+T35SPIRO; T69+T35SPAM; T96+T11F; T92PHSPIRO+T109SPIRO; T92+T35; T92SPIRO+T35SPAM; T100+T11; T2Spiro+T132SPIRO; T69+T35SPIRO; T78+T131SPIRO; T28+T109SPIRO; T74SPIRO+T35F; T74SPIRO+T35; T68+T107; T27+T133SPIRO; T139RACEENDO+T32; T78SPIRO+T112SPIRO; T2+T131SPIRO; T69+T131SPIRO; T104+T131SPIRO.
- T2Spiro+T35F; T27F+T58; T78SPIRO+T131SPIRO; T69+T112SPIRO; T27F+T12; T92PHSPIRO+T35; T27F+T35; T42+T37; T92+T35F; T27F+T34; T27F+T35SPAM; T92SPIRO+T35SPIRO; T126+T112SPIRO; T920PH+T35SPIRO; T92SPIRO+T132SPIRO; T92+T37; T2+T35SPAM; T28+T155SPIRO; T27F+T35SPIRO; T2Spiro+T131SPIRO; T100+T11F; T28+T146; T28+T35; T74SPIRO+T131SPIRO; T68+T109SPIRO; T920PH+T35SPAM; T68+T146; T42+T10; T92+T109SPIRO; T92PHSPIRO+T112SPIRO; T27F+T112SPIRO; T92PHSPIRO+T35F; T26diol cis+T33; T2+T132SPIRO; T27F+T57; T28+T35F; T68+T33; T68+T35; T92SPIRO+T35F; T97+T133SPIRO; T920PH+T35; T27F+T32; T92OPH+T133SPIRO; T92OPH+T132SPIRO; T2Spiro+T35; T113SPIRO+T35SPAM; T2+T35F; T27F+T54BASPIRO; T99+T32; T68+T35SPIRO; T27F+T147; T27F+T155SPIRO; T96+T56; T98+T11; T141EXOSYN+T32; T2+T35; T96+T37; T104SPIRO+T131SPIRO; T74+T112SPIRO; T27F+T37; T68+T35F; T24+T11F; T2Spiro+T112SPIRO; T69+T35; T96+T132SPIRO; T92SPIRO+T35; T2+T35SPIRO; T96+T54BA; T42+T35SPIRO; T28+T35SPAM; T113SPIRO+T35SPIRO; T97+T11F; T27F+T13; T104SPIRO+T109SPIRO; T69+T35F; T96+T133SPIRO; T920PH+T35F; T97+T11; T2+T112SPIRO; T68+T58; T920PH+T37; T92PHSPIRO+T131SPIRO; T77+T132SPIRO; T96+T32; T27F+T35F; T127+T147; T97+T33; T40+T11F; T141EXOSYN+T62; T78+T109SPIRO; T100+T37; T97+T64; T100+T51; T100+T13; T92OPH+T109SPIRO; T42+T133SPIRO; T97+T58; T98+T11F; T92OPH+T112SPIRO; T140RACEENDO+T54BA; T97+T37; T92+T131SPIRO; T28+T54BA; T42+T11F; T27F+T11; T96+T51; T65+T133SPIRO; T100+T133SPIRO; T92PHSPIRO+T107SPIRO; T74SPIRO+T109SPIRO; T74+T35SPAM; T127+T33; T100+T64.
Additional 1:1 Combinations Belonging to Group CC: T69+T109SPIRO; T68+T35SPAM; T100+T155SPIRO; T24+T11; T75A+T35F; T40+T58; T28+T59; T27+T51; T92+T54BASPIRO; T75+T112SPIRO; T28+T33SPAM; T140RACEENDO+T59; T29+T11F; T42+T35SPAM; T96+T35SPIRO; T78SPIRO+T109SPIRO; T24cis+T37; T68+T36; T68+T112SPIRO; T101+T56; T42+T132SPIRO; T139RACEENDO+T62; T113SPIRO+T132SPIRO; T92+T64; T104+T109SPIRO; T97+T132SPIRO; T24+T59; T127+T132SPIRO; T1+T133SPIRO; T27F+T146; T68+T155SPIRO; T142EXOANTI+T146; T24+T58; T28+T58; T75+T133SPIRO; T24+T133SPIRO; T140RACEENDO+T33; T27F+T131SPIRO; T27+T109SPIRO; T92+T54BA; T24cis+T132SPIRO; T99+T56; T74 +T35SPAM; T27+T132SPIRO; T42+T11; T1+T37; T24+T37; T43+T56; T75+T35SPIRO; T75A+T35SPIRO; T75+T132SPIRO; T92+T58; T920TB+T51; T92SPIRO+T131SPIRO; T100+T56; T96+T13; T96+T64; T77+T35SPAM; T27F+T59; T98+T32; T127+T107SPIRO; T26diol cis+T32; T77+T11; T26diol cis+T11; T100+T54BA; T96+T109SPIRO; T27F+T10; T100+T32; T97+T59; T1+T11F; T127+T35SPIRO; T97+T32; T126+T35SPAM; T139RACEENDO+T117METHYLSPIRO; T140RACEENDO+T13; T27F+T36; T75A+T131SPIRO; T75A+T35SPAM; T24+T54BASPIRO; T100+T146; T66+T133SPIRO; T92+T107SPIRO; T44+T64; T75A+T112SPIRO; T27F+T33; T97+T54BA; T96+T58; T24cis+T13; T28+T51; T113SPIRO+T35F; T126+T155SPIRO; T97+T51; T22_diol+T51; T114SPIRO+T156; T127+T146; T24cis+T32; T82+T117; T126+T109SPIRO; T92+T57; T74+T133SPIRO; T114SPIRO+T131SPIRO; T127+T133SPIRO; T74+T35SPIRO; T24+T132SPIRO; T100+T132SPIRO; T68+T131SPIRO; T96+T54BASPIRO; T100+T35SPAM; T5+T32; T27F+T11F; T43+T64; T68+T37; T69+T11F; T69+T37; T126+T35SPIRO; T96+T35SPAM; T27+T107SPIRO; T24+T54BA; T75+T35SPAM; T69+T107SPIRO; T24+T64; T97+T35SPIRO; T92PHSPIRO+T155SPIRO; T26diol cis+T155SPIRO; T104+T107; T75A+T132SPIRO; T97+T34; T92+T107; T97+T12; T92+T13; T27+T107; T24+T32; T100+T35SPIRO; T75A+T133SPIRO; T68+T11; T75+T59; T114SPIRO+T35SPAM; T2+T11F; T140RACEENDO+T58; T2Spiro+T109SPIRO; T28+T112SPIRO; T96+T146; T77+T131SPIRO; T42+T54BASPIRO; T29+T11; T114SPIRO+T133SPIRO; T24+T34; T27+T35F; T24+T33; T92OPH+T107SPIRO; T86+T34; T92+T10; T22_diol+T58; T96+T12; T24cis+T54BASPIRO; T139RaceEndo+T154; T28+T154; T28+T34; T100+T12; T27+T131SPIRO; T114SPIRO+T35SPIRO; T69+T11; T68+T54BASPIRO; T98+T13; T83+T132SPIRO; T24cis+T12; T97+T35SPAM; T104+T107SPIRO; T126+T107SPIRO; T77+T35SPIRO; T24Dihydro+T11F; T75AOTB+T51; T68+T34; T71+T32; T98+T51; T75A+T35; T40+T57; T76+T31; T2+T109SPIRO; T127+T07; T69+T107; T24cis+T59; T24cis+T133SPIRO; T27F+T62; T73+T34; T24Dihydro+T133SPIRO; T27+T35SPAM; T75AOTB+T144; T92OPH+T131SPIRO; T24+T57; T42+T34; T104+T155SPIRO; T100+T34; T42+T59; T99+T37; T65+T132SPIRO; T140RaceEndo+T51; T100+T109SPIRO; T113SPIRO+T35; T1+T112SPIRO; T24cis+T58; T43+T36; T40+T133SPIRO; T98+T54BA; T68+T54BA; T92OTBSPIRO+T12; T97+T109SPIRO; T29+T37; T78+T155SPIRO; T27+T35; T24Dihydro+T132SPIRO; T97+T13; T75+T34; T83+T133SPIRO; T1+T35SPAM; T5+T64; T24Dihydro+T32; T24Dihydro+T59; T114SPIRO+T35F; T75+T35; T92+T12; T104SPIRO+T107SPIRO; T141EXOANTI+T32; T92PHSPIRO+T37; T96+T131SPIRO; T99+T34; T126+T133SPIRO; T78+T34; T77+T112SPIRO; T920TBSPIRO+T64; T98+T64; T43+T133SPIRO; T43+T37; T97+T56; T104Spiro+T07; T24cis+T11; T96+T112SPIRO; T104SPIRO+T155SPIRO; T99+T64; T92SPIRO+T112SPIRO; T100+T58; T114SPIRO+T155SPIRO; T76+T112SPIRO; T24+T35SPAM; T8+T35SPAM; T24cis+T54BA; T74SPIRO+T107SPIRO; T99+T54BASPIRO; T141EXOSYN+T147; T42+T58; T127+T35SPAM; T141EXOANTI+T155SPIRO; T141EXOSYN+T155SPIRO; T40+T132SPIRO; T24Dihydro+T37; T42+T35; T75+T58; T920PH+T54BASPIRO; T78+T107; T114SPIRO+T132SPIRO; T100+T57; T97+T62; T68+T11F; T96+T35; T28+T31; T126+T51; T139RACEENDO+T64; T70+T56; T27+T64; T28+T11F; T22_diol+T54BA; T22_diol+T146; T97+T57; T22_diol+T144; T44+T132SPIRO; T100+T107SPIRO; T24Dihydro+T11; T24+T35; T68+T59; T24+T35SPIRO; T92OPH+T11; T142EXOANTI+T154; T126+T107; T42+T36; T98+T132SPIRO; T42+T54BA; T28+T143; T98+T12; T28+T11; T98+T133SPIRO; T139RACEENDO+T12; T97+T54BASPIRO; T126+T132SPIRO; T73+T32; T42+T35F; T77+T133SPIRO; T127+T154; T104+T37; T74SPIRO+T107; T77+T11F; T127+T58; T26diol cis+T11F; T43+T34; T92+T155SPIRO; T142EXOANTI+T107; T65+T35SPIRO; T69+T36; T73+T155SPIRO; T76+T35SPAM; T24Dihydro+T58; T69+T54BASPIRO; T75APSPIRO+T33SPAM; T1+T35SPIRO; T75A+T109SPIRO; T1+T107SPIRO; T24cis+T64; T43+T32; T92PHSPIRO+T11F; T22_diol+T64; T40+T33SPAM; T127+T35; T66+T132SPIRO; T92OTBSPIRO+T132SPIRO; T71+T34; T26diol trans+T36; T113SPIRO+T131SPIRO; T97+T36; T92SPIRO+T109SPIRO; T86+T133SPIRO; T40+T35SPAM; T75AP+T54BASPIRO; T142EXOANTI+T107SPIRO; T24+T33SPAM; T113SPIRO+T146; T22_diol+T33SPAM; T86+T35SPIRO; T65+T35SPAM; T27+T54BA; T92+T36; T24Dihydro+T54BASPIRO; T42+T109SPIRO; T70+T131SPIRO; T98+T35SPIRO; T103+T56; T24Dihydro+T35SPAM; T69+T58; T41GEM+T112SPIRO; T99+T12; T42+T155SPIRO; T29+T54BA; T141EXOANTI+T37; T28+T36; T44+T133SPIRO; T139RaceEndo+T51; T24cis+T35SPAM; T30+T59; T21 (Diol)+T56; T40+T146; T127+T109SPIRO; T40+T51; T1+T64; T142EXOANTI+T147; T2+T107; T75+T36; T78+T37; T76+T10; T75AP+T54BA; T77+T13; T40+T54BA; T100+T59; T96+T35F; T98+T58; T127+T155SPIRO; T104SPIRO+T34; T78+T10; T65+T35F; T5+T107; T99+T58; T78+T107SPIRO; T24+T51; T75+T109SPIRO; T98+T109SPIRO; T22_diol+T57; T126+T35; T44+T12; T96+T57; T140RACEENDO+T155SPIRO; T113SPIRO+T156; T1+T54BASPIRO; T99+T62; T114SPIRO+T35; T98+T146; T74+T35F; T1+T107; T141EXOANTI+T12; T27+T112SPIRO; T92OPH+T107; T92+T56; T139RACEENDO+T146; T27+T34; T97+T112SPIRO; T27F+T31; T24cis+T57; T28+T64; T74SPIRO+T36; T97+T107SPIRO; T139RaceEndo+T143; T25B+T36; T104+T11F; T42+T32; T140RACEENDO+T34; T75+T35F; T104+T11; T75AOTBSPIRO+T10; T92+T144; T75A+T59; T99+T11F; T99+T54BA; T141EXOSYN+T34; T22_diol+T155SPIRO; T69+T155SPIRO; T136A+T109SPIRO; T140RACEENDO+T37; T24cis+T56; T40+T144; T68+T33SPAM; T75AP+T37; T69+T64; T22_diol+T109SPIRO; T24Dihydro+T112SPIRO; T140RACEENDO+T146; T127+T12; T29+T33; T140RACEENDO+T36; T100+T54BASPIRO; T27F+T144; T76+T59; T139RACEENDO+T147; T97+T35; T98+T34; T69+T54BA; T78SPIRO+T155SPIRO; T27F+T33SPAM; T75APSPIRO+T117METHYLSPIRO; T104+T36; T75AOTB+T143; T26diol cis+T64; T75AP+T64; T98+T35SPAM; T92PHSPIRO+T36; T68+T57; T24Dihydro+T10; T24cis+T10; T75AOTB+T12; T77+T35F; T44+T107SPIRO. - Synthesis of 3-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid was carried out as shown in the scheme below and described in the literature.
-
- 100 mg (0.510 mmol) 3-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylic acid, desired amine (1.5 eq.), N-Ethoxycarbonyl-2-ethoxy-1,2-Dihydroquinoline (
EEDQ 2 eq.) in dimethyl formamide (DMF, 5 mL) were heated to 100° C. and monitored by TLC & LCMS. After consumption of starting material the crude product was isolated either by diluting reaction mass by ethyl acetate followed by filtration of precipitated crude product, or concentrating the DMF in GeneVac® to obtain the crude product. - Dihydroxy compound (Sparso-10) was synthesized by de-methylation of corresponding dimethoxy compound (Sparso-10a) by boron tribromide in dichloromethane at room temperature.
- Crude products were purified by preparative HPLC.
- Analytical data of the coupled product synthesized is tabulated below in Table 7.
-
TABLE 7 ANALYTICAL DATA Sr. No Code Structure Analytical data 2 SPARSO-10 Mol. Wt:- 317.29 M.I. Peak observed: 318.20 HPLC Purity:- 99.37% 1H NMR DMSO-d6:- 2.25 (s, 3H), 4.15- 4.16 (d, 2H), 6.48-6.50 (d, 1H), 6.62- 6.64 (d, 2H), 7.06-7.10 (d, 1H), 7.20- 7.24 (d, 1H), 8.43 (t, 1H), 8.68 (s, 1H), 8.82 (s, 1H), 11.21 (bs, 2H). - This compound was synthesized by oxidation of (S)—N-((3-(4-(2,5-dihydro-1H-pyrrol-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide by osmium tetroxide as in the reaction scheme below (see Scheme 3).
- These reactions were carried out as per literature method (J. Med. Chem. 1996, 39, 673-679) described for synthesis of Linezolid. 2,5-dihydro-1H-pyrrole was used instead of morpholine in step-1.
-
- To a solution of (S)—N-((3-(4-(2,5-dihydro-1H-pyrrol-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (0.4 g, 1.25 mmol) in acetone (10 mL) and water (3 mL), Osmium tetroxide (3.1 mg, 0.012 mmol), was added at room temperature. The reaction mixture was stirred for 15 min. N-methyl morpholine oxide (161 mg, 1.3 mmol) was added and the reaction mixture was allowed to stir at room temperature overnight. TLC (Mobile phase 60% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.7) and product formation (Rf 0.25). 10% sodium bisulphite solution (40 mL) was added and the reaction mixture was stirred for 10 min. The compound was extracted in ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. The compound was purified by column chromatography using Hexane:ethyl acetate as eluent to give the desired product as white solid. (0.07 g, 15.9%)
- Mol. Wt: −353.34, M.I. Peak observed: −354.20, HPLC Purity: −99.09%
- 1H NMR DMSO-d6: −1.83 (s, 3H), 3.16-3.19 (m, 2H), 3.38 (t, 2H), 3.47-3.49 (m, 2H), 3.64-3.68 (q, 1H), 4.01-4.08 (m, 3H), 4.65-4.68 (m, 2H), 4.84-4.85 (d, 1H), 6.65 (t, 1H), 7.05-7.07 (dd, 1H), 7.33-7.38 (dd, 1H), 8.23 (t, 1H). LCMS: (M+1) 354.2
-
- De-methylated Linezolid was synthesized and acylated with desired carboxylic acids by the procedure described earlier. Demethylation of the compounds obtained after acylation with dimethoxy aryl carboxylic acids to get desired diol was carried out as per general procedure below. (Step-3 in the
Scheme 4, above) - Dimethoxy intermediates were dissolved in dichloromethane (10-50 vol depending on solubility) the reaction mass was cooled to 0° C., Boron tribromide (3 eq) was added and reaction mass was gradually warmed to room temperature. Stirring was continued at room temperature and reaction was monitored by LCMS till maximum starting was consumed (˜1-8 hrs required). Reaction mass was then concentrated and excess BBr3 was removed by multiple strippings of methanol to get the products as hydrobromide salts.
- The (o-hydroxy amido) aryl analogues were synthesized by coupling of corresponding suitably substituted carboxylic acid with de-acetyl Linezolid (Step-6 in the above reaction scheme) as per the general procedure described earlier.
- Analogues with o-hydroxy methyl phenol group were synthesized by coupling desired aryl carboxylic acid with 2-(hydroxymethyl)phenol functionality that was protected with isopropylidine group and subsequent deprotection of coupled product in methanolic HCl at room temperature (
Step 4 & 5 inreaction Scheme 4.) - All the crude products were purified by reverse phase preparative HPLC. Pure products were isolated as TFA salts. Analytical data of the compounds synthesized is as below in Table 8.
-
TABLE 8 ANALYTICAL DATA Sr. No. Code Structure Analytical data 7 Lz-NA- 19 Mol. Wt:- 431.41 M.I. Peak observed: 432.30 HPLC Purity:- 99.40% 1H NMR DMSO-d6:- 2.95 (t, 4H), 3.51-3.57 (m, 2H), 3.73 (t, 4H), 3.80-3.84 (m, 2H), 4.09-4.14 (m, 2H), 4.78-4.80-(m, 1H), 6.73- 6.76 (d, 1H), 7.06 (t, 1H), 7.17-7.19 (d, 2H), 7.27 (s, 1H), 7.46- 7.50 (1H), 8.49 (t, 1H). 8 Lz-NA- 20 Mol. Wt:- 445.41 M.I. Peak observed: 446.30 HPLC Purity:- 9927% 1H NMR DMSO-d6:- 2.96 (t, 4H), 3.22 (s, 3H), 3.39 (t, 2H), 3.65-3.67 (m, 1H), 3.73 (t, 4H), 4.05 (t, 1H), 4.66-4.73 (m, 2H), 6.41- 6.43 (d 1H), 6.54-6.56 (d, 1H), 6.63 (s, 1H), 7.04- 7.14 (m, 2H), 7.45-7.49 (dd, 1H), 8.35 (t, 1H). 9 Lz-NA- 21 Mol. Wt:- 431.14 M.I. Peak observed: 432.30 HPLC Purity:- 99.18% 1H NMR DMSO-d6:- 2.95 (t, 4H), 3.65 (t, 2H), 3.73 (t, 4H), 3.83 (t, 1H), 4.15 (t, 2H), 4.85-4.88 (m, 1H), 6.71 (t, 1H), 6.91-6.93 (d, 1H), 7.05 (t, 1H), 7.07- 7.13 (d, 1H), 7.17-7.20 (d, 1H), 7.28-7.30 (d, 1H), 7.45- 7.49 (d, 1H), 9.04 (t, 1H). 10 Lz-NA- 22 Mol. Wt:- 445.44 M.I. Peak observed: 446.00 HPLC Purity:- 97.59% 1H NMR DMSO-d6:- 2.96 (t, 4H), 3.41-3.45 (m, 4H), 3.68- 3.74 (m, 5H), 4.07 (t, 1H), 4.70-4.74 (m, 1H), 6.46- 6.47 (m, 2H), 6.61-6.63 (m, 1H), 7.06 (t, 1H), 7.15-7.17 (d, 1H), 7.44-7.49 (dd, 1H), 8.37 (t, 1H). 11 Lz-NA- 23 Mol. Wt:- 445.41 M.I. Peak observed: 446.10 HPLC Purity:- 99.92% 1H NMR DMSO-d6:- 2.95 (t, 4H), 3.55-3.59 (m, 2H), 3.72 (t, 4H), 3.81-3.84 (m, 1H), 4.13 (t, 1H), 4.49 (s, 2H), 4.81-4.84 (m, 1H), 7.05 (t, 1H), 7.17-7.19 (d, 1H), 7.24-7.28 (t, 2H), 7.33- 7.35 (d, 1H), 7.46-7.50 (dd, 1H), 8.66 (t, 1H), 9.63 (s, 1H). 12 Lz-NA- 24 Mol. Wt:- 445.44 M.I. Peak observed: 446.35 HPLC Purity:- 94.37% 1H NMR DMSO-d6:- 2.95 (t, 4H), 3.52-3.61 (m, 3H), 3.73 (t, 4H), 3.81-3.85 (m, 1H), 4.10-4.14 (m, 1H), 4.47 (s, 2H), 4.80-4.83-(m, 1H), 6.78-6.80 (d 1H), 7.05 (t, 1H), 7.17-7.19 (d, 1H), 7.46-7.50 (dd, 1H), 7.58-7.61 (dd, 1H), 7.87 (s, 1H), 8.56 (t, 1H), 10.00 (bs, 1H). 13 Lz-NA- 27 Mol. Wt:- 457.45 M.I. Peak observed:- 458.40 HPLC Purity:- 95.46% 1H NMR DMSO-d6:- 2.94 (t, 4H), 3.52-3.55 (m, 3H), 3.72-3.77 (m, 5H), 4.11 (t, 1H), 4.75-4.79 (m, 1H), 6.35- 6.39 (d, 1H), 6.72-6.74 (d, 1H), 6.81-6.84 (dd, 1H), 6.93 (s, 1H), 7.07 (t, 1H), 7.16- 7.19 (dd, 1H), 7.23-7.27 (d, 1H), 7.46-7.51 (dd, 1H), 8.36 (t, 1H), 9.25 (bs, 1H). 14 Lz-NA- 28 Mol. Wt:- 459.47 M.I. Peak observed: 460.30 HPLC Purity:- 99.42% 1H NMR DMSO-d6:- 2.30 (t, 2H), 2.57 (t, 2H), 2.95 (t, 4H), 3.36-3.46 (m, 3H), 3.64- 3.68 (m, 1H), 3.73 (t, 4H), 4.03 (t, 1H), 4.65-4.70 (m, 1H), 6.37-6.39 (d, 1H), 6.53 (s, 1H), 6.57-6.59 (d, 1H), 7.06 (t, 1H), 7.13-7.15 (d, 1H), 7.46-7.50 (d, 1H), 8.20 (t, 1H), 8.7 (bs, 1H). 15 Lz-NA- 34 Mol. Wt:- 514.50 M.I. Peak observed: 515.15 HPLC Purity:- 98.69% 1H NMR DMSO-d6:- 2.94 (t, 4H), 3.56 (t, 4H), 3.72 (t, 6H), 4.11 (t, 1H), 4.79 (m, 1H), 6.69-6.73 (d, 1H, , J = 15.6 Hz), 7.02-7.07 (m, 3H), 7.16-7.18 (d, 1H, , J = 8.8 Hz), 7.34-7.38 (d, 1H, , J = 16 Hz), 7.46-7.50 (d, 1H, , J = 15.2 Hz), 7.64-7.66 (d, 1H, , J = 8 Hz), 8.55 (t, 1H0, 11.81 (bs, 1H). 16 Lz-NA- 36 Mol. Wt:- 484.47 M.I. Peak observed: 484.95 HPLC Purity:- 96.2% -
- Florfenicol amine was synthesized from commercially available florfenicol by the procedure reported in the literature (WO2005/85266). Coupling & subsequent demethylation reactions were carried out as per the general procedure described earlier for similar analogues of Linezolid.
-
TABLE 9 ANALYTICAL DATA Sr. No. Code Structure Analytical data 1 NAFFLA-19 Mol. Wt:- 383.39 M.I. Peak observed: 384.15 HPLC Purity:- 99.38% 1H NMR DMSO-d6:- 3.22 (s, 3H), 3.60 (m, 1H), 4.3-4.72 (m, 3H), 4.98 (s, 1H), 6.71- 6.73 (d, 1H), 7.11-7.13 (d, 1H), 7.17 (s, 1H), 7.59-7.60 (d, 2H), 7.80-7.85 (m, 3H), 9.11 (s, 1H), 9.46 (s, 1H). 2 NAFFLA-20 Mol. Wt:- 397.42 M.I. Peak observed: 398.25 HPLC Purity:- 99.87% 1H NMR DMSO-d6:- 3.15 (s, 3H), 3.20- 3.23 (m, 2H), 4.19-4.61 (m, 3H), 4.88 (s, 1H), 6.32-6.34 (d, 1H), 6.55 (s, 1H, J = 8 Hz), 6.58-6.60 (d, 1H, J = 8 Hz,), 7.49-7.51 (d, 2H, J = 8 Hz), 7.77-7.79 (d, 2H, J = 8 Hz) 3 NAFFLA-21 Mol. Wt:- 383.39 M.I. Peak observed: 384.15 HPLC Purity:- 98.60% 1H NMR DMSO-d6:- 3.16 (s, 3H), 4.52-4.70 (m, 3H), 5.03 (s, 1H), 6.11-6.12 (d, 1H), 6.67 (t, 1H), 6.89- 6.91 (d, 1H, J = 7.2 Hz), 6.727- 6.29 (d, 1H, J = 8 Hz, ), 7.63-7.65 (d, 2H, J = 8 Hz), 7.83-7.85 (d, 2H, J = 8.4 Hz), 8.67-8.69 (d, 1H), 9.43 (bs, 1H), 11.30 (bs, 1H). 4 NAFFLA-22 Mol. Wt:- 397.42 M.I. Peak observed: 398.00 HPLC Purity:- 94.48% 1H NMR DMSO-d6:- 3.14 (s, 3H), 3.21-3.41 (m, 3H), 4.19-4.26 (m, 1H), 4.37 (t, 1H), 4.49-4.65 (m, 1H), 4.90 (s, 1H), 6.32-6.34 (d, 1H), 6.51 (t, 1H), 6.63-6.66 (d, 1H), 7.50-7.52 (d, 2H), 7.74-7.76 (d, 2H), 7.86-7.88 (d, 1H), 8.7 (bs, 1H), 9.12 (bs, 1H). 5 NAFFLA-23 Mol. Wt:- 397.42 M.I. Peak observed: 398.00 HPLC Purity:- 96.44% 1H NMR DMSO-d6:- 3.16 (s, 3H), 4.36 (t, 1H), 4.48 (s, 2H), 4.59-4.74 (m, 2H), 4.99-5.00 (d, 1H), 7.13 (s, 1H), 7.20-7.22 (d, 1H, , J = 8.8 Hz), 7.32-7.34 (d, 1H, , J = 7.6 Hz), 7.60-7.62 (d, 2H, , J = 8 Hz), 7.83- 7.85 (d, 2H, , J = 8 Hz), 8.024-8.045 (d, 1H, , J = 8.4 Hz), 9.62 (bs, 1H), 6 NAFFLA-27 Mol. Wt:- 409-42 M.I. Peak observed:- 410.20 HPLC Purity:- 96.02% 1H NMR DMSO-d6:- 3.17 (s, 3H), 4.28 (t, 1H), 4.37-4.40 (m, 1H), 4.55-4.65 (m, 1H), 4.96 (s, 1H), 6.06-6.07 (d, 1H), 6.45-6.49 (d, 1H, , J = 15.6 Hz), 6.70-6.72 (d, 1H), 6.77-6.79 (d, 1H), 6.89 (s, 1H), 7.09-7.13 (d, 1H, , J = 15.6 Hz), 7.61-7.63 (d, 2H), 7.84- 7.86 (d, 2H), 7.96-7.98 (d, 1H), 9.10 (bs, 1H), 9.36 (bs, 1H). 7 NAFFLA-28 Mol. Wt:- 411.44 M.I. Peak observed:- 412.25 HPLC Purity:- 98.12% 1H NMR CD3OD:- 2.37 (t, 2H), 2.61 (t, 2H), 3.09 (s, 3H), 4.20-4.59 (m, 3H), 4.97 (s, 1H), 6.46-6.48 (d, 1H), 6.59 (s, 1H), 6.64-6.66 (d, 1H), 7.51- 7.54 (d, 2H), 7.86-7.88 (d, 2H). 8 NAFFLA-34 Mol. Wt:- 466.48 M.I. Peak observed:- 467.00 HPLC Purity:- 97.56% 1H NMR DMSO-d6:- 3.17 (s, 3H), 3.72 (s, 3H), 4.28-4.67 (m, 3H), 4.98 (s, 1H), 6.12 (bs, 1H), 6.81-6.85 (d, 1H, J = 16 Hz), 7.03 (s, 2H), 7.20-7.24 (d, 1H, J = 15.6 Hz), 7.63-7.65 (d, 3H), 7.85-7.87 (d, 2H), 8.16- 8.18 (d, 1H), 11.82 (bs, 2H). 9 NAFFLA-35 Mol. Wt:- 436.45 M.I. Peak observed:- 437.00 HPLC Purity:- 98.36% 1H NMR DMSO-d6:- 3.17 (s, 3H), 4.29 (t, 1H), 4.42 (m, 1H), 4.56 (t, 1H), 4.98 (bs, 1H), 6.11 (s, 1H), 6.83-6.87 (d, 1H, J = 15.6 Hz), 6.99 (s, 2H), 7.21-7.24 (d, 1H, J = 15.6 Hz), 7.63-7.65 (d, 2H), 7.85-7.87 (t, 4H), 7.96 (bs, 1H), 8.14- 8.16 (d, 1H), 8.41 (bs, 1H), 13.09 (s, 1H). 10 NAFFLA-36 Mol. Wt:- 436.45 M.I. Peak observed:- 437.05 HPLC Purity:- 98.78% 1H NMR DMSO-d6:- 3.1 (s, 3H), 4.29- 4.31 (t, 1H), 4.42 (m, 1H), 4.53-4.55 (m, 1H), 4.63 (bs, 1H), 4.98 (s, 1H), 6.61-6.65 (d, 1H, J = 15.6 Hz), 6.91-6.93 (d, 1H), 7.20-7.24 (d, 1H, J = 15.6 Hz), 7.57-7.60 (m, 3H), 7.85-8.02 (m, 5H), 8.41 (bs, 1H). 11 NAFFLA-37 Mol. Wt:- 440.44 M.I. Peak observed:- 441.15 HPLC Purity:- 97.02% 1H NMR DMSO-d6:- 3.16 (s, 3H), 3.72 (s, 3H), 4.34-4.75 (m, 3H), 4.49-4.50 (d, 1H), 6.1 (bs, 1H), 6.93-6.95 (d, 1H), 7.60- 7.62 (d, 2H), 7.73-7.87 (m, 3H), 8.11 (s, 1H), 11.74 (bs, 1H), 11.92 (bs, 1H). - These compounds were synthesized by either of the two methods (Method A & Method B) as below. Required aryl halo carboxylic acids in step-1 of both the methods were either procured commercially or synthesized in house by known methods in the literature.
- Required aryl pinacolato boronate esters/boronic acids with carboxylic acid groups were synthesized and coupled with desired tert-butyl 3-(piperidin-4-yl)benzylcarbamate. Later boronate ester functionality was hydrolyzed to boronic acid in acidic media.
- Required aryl halo/hydroxy carboxylic acids were esterified by refluxing with excess methanol/ethanol in presence of catalytic sulfuric acid or refluxing the required aryl halo/hydroxy carboxylic acid with thionyl chloride-Methanol/ethanol followed by standard work up involving distillation of excess alcohol and subsequent treatment of residue with aq. sodium bicarbonate followed by extraction with dichloromethane/ethyl acetate. Purification was carried out by column chromatography over 100-200 mesh silica gel using hexane-ethyl acetate.
- O-triflate derivatives of hydroxy esters were synthesized as per procedure described in the literature. (J. Med. Chem. 53(5), 2010-2037, 2010)
- The details of compounds synthesized are as below in Table 10.
-
TABLE 10 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data B-31 1) Thionyl chloride (1.5 eq.), Methanol (25 vol), 4 h, 65° C., 93% 2) As per J. Med. Chem. 53(5), 2010- 2037, 2010, 81% Ionization not observed in LCMS 1H NMR (400 MHz, CDCL3): δ 9.10 bs, 1H), 7.62 (d, J = 4.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.28-7.20 (m, 2H), 3.97 (S, 3H) B-62 Analogously as per Angew. Chem, Int. Edn. 43(40), 5331-5335, 2004. Mol. Wt:- 305.17 M.I. Peak observed: 306 1H NMR (400 MHz, CDCl3): δ 1.40 (t, J = 7 Hz, 3H), 4.35- 4.50 (q, J = 7 Hz, 2H), 7.20-7.44 (m, 3H), 7.46-7.56 (m, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 8.04-8.10 (m, 2H). B-64 Thionyl chloride (1.5 eq.), Methanol (25 vol), 4 h, 65° C., 96% Mol. Wt:- 247.06 M.I. Peak observed: 247, 249.20 [MH+] B-35 Thionyl chloride (1.5 eq.), Methanol (25 vol), 4 h, 65° C., 92% 1H NMR (400 MHz, CDCl3):- 3.9 (s, 1H), 7.3 (t, 1H), 7.48 (m, 3H), 7.68 (d, 2H), 8.05 (d, 1H), 8.21 (s, 1H). B11-F Synthesized using Lit. Procedures (Helvetica Chimica Acta, 1938, 21, 1519-1520; USP4391816, Bull. Chem. Soc. Japan. 1975, 48, 3356-3366; WO2008/ 100480 A1 1H NMR (400 MHz, CDCl3): 4 (s, 3H), 7.66 (t, 1H), 7.65 (d, 1H), 7.8 (d, 1H), 8.02 (d, 1H), 8.23 (d, 1H), 9.03 (s, 1H). B-58 Thionyl chloride (2 eq.), Methanol (10 vol), 4 h, 65° C., 94% 1HNMR (400 MHz, CDCl3):- 3.62 (s, 2H), 3.72 (s, 3H), 7.18 (t, 1H), 7.25 (d, 2H). B-57 Thionyl chloride (2 eq.), Methanol (10 vol), 4 h, 65° C., 95% Mol. Wt:- 247.06 M.I. Peak observed: 247.95, 249 [MH+] - A solution of aryl halo/O-trifluoromethyl sulfonyl carboxylate in common solvents like toluene, dimethyl sulfoxide, dioxane etc was degassed with Argon, to this solution (bis-pinacolato)diboron, Potassium acetate, and Pd(dppf)2Cl2 were added at room temperature and the mixture was heated at 80-100° C. and monitored by TLC & LCMS till starting was consumed to maximum extent. The reaction mixture was then diluted with water and extracted with ethyl acetate, and ethyl acetate extract was evaporated under vacuum to give the crude products that were purified by column chromatography over silica gel (Gradient: −0-10% ethyl acetate in hexane) The details of compounds synthesized by above method are as below in Table 11.
-
TABLE 11 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data C-31 bispinacolato diboron (1.5 eq.), PdCl2 (dppf) (3 mol %), dppf (3 mol %), Potassium acetate (3.0 eq.), dioxane, 20 hr, 100° C., Yield 54%Ionization not observed in LCMS, 1H NMR (400 MHz, CDCl3): δ 8.97 (bs, 1H), 8.23 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.26-7.22 (m, 1H), 3.95 (s, 3H), 1.37 (s, 12H) C-62 Ethyl 2′-bromo-[1,1′-biphenyl]- 3-carboxylate (1 eq), potassium acetate (3 eq) bispinacolato diboron (10 eq) PdCl2 (dppf). DCM adduct (0.03 eq) DMSO (46 V) 110° C. for 5 h. inorganics removed by column Chromatography & carried forward to next stepIonization not observed in LCMS, 1H NMR (400 MHz, CDCl3): δ 1.19 (s, 12H), 1.38 (t, J = 7.2 Hz, 3H), 4.33-4.42 (q, J = 7.1 Hz, 2H), 7.30-7.65 (m, 5H), 7.78 (d, J = 7.2 Hz, 1H), 8.00-8.10 (m, 2H). C-64 KOAc (3 eq), Bis Pin. Borane (3 eq), DPPF-PdCl2•DCM (6 mol %), Toluene (100 vol), Reflux, 3 hrs. Crude product carried forward to next step without purification as it was sufficient pure. Mol. Wt:- 294.13 M.I. Peak observed: 295.1 C-35 KOAc (3 eq), Bis Pin. Borane (10 eq), DPPF-PdCl2•DCM (6 Mol %), DMSO (12.5 vol), 80° C., 4 hrs. 65%. Ionization not observed in LCMS. Crude product carried forward for next step C-11F KOAc (3 eq), Bis Pin. Borane (10 eq), DPPF-PdCl2•DCM (3 Mol %), DMSO (10 vol), 80° C., 5 hrs. 57.8%. Ionization not observed in LCMS, 1H NMR (400 MHz; CDCl3):- δ 1.39 (s, 12H), 4.02 (s, 3H, 7.52 (t 1H), 7.85-7.93 (m, 2H), 8.00 (d, 1H, J = 8), 8.13- 8.14 (d 1H, J = 6.8), 9.32 (s 1H) C-58 KOAc (3 eq), Bis Pin. Borane (10 eq.), DPPF-PdCl2•DCM (6 Mol %), DMSO (12.5 vol), 80° C., 3 hrs, 61%, Ionization not observed in LCMS. Crude product carried forward for next step. C-57 KOAc (3 eq), Bis Pin. Borane (10 eq), DPPF-PdCl2•DCM (6%), DMSO (12.5 vol), 80° C., 4 hrs. 65%. Ionization not observed in LCMS 1H NMR (400 MHz, CDCl3):- 1.32 (s, 12H), 3.70 (m, 5H), 7.05 (t, 1H), 7.70 (m, 2H). - Boronate ester form step-2 was dissolved in mix of Water and solvents like THF/methanol/Acetone that are miscible in water. To this, lithium hydroxide was added and mixture was stirred at room temperature and monitored by TLC & LCMS till maximum starting was consumed (6-12 hrs required) THF was then concentrated and reaction mass was extracted with ethyl acetate and water. Organic layer was washed with water and combined aq. washings were acidified with 2N HCl and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulphate and concentrated in vacuum to get crude product. In most of the cases products were sufficient pure to be used for the next step. The details of compounds synthesized by above method are as below.
- The details of compounds synthesized are as below in Table 12.
-
TABLE 12 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data D-31 LiOH (2.0 eq.), THF:H2O (2:1), RT, 90%. Ionization not observed in LCMS. Crude product used for next step D-62 LiOH (3.0 eq.), THF:H2O (1:1), RT, 25%. Ionization not observed in LCMS, 1H NMR (400 MHz, CDCl3): δ 1.12 (s, 12H), 7.24-7.46 (m, 4H), 7.55 (d, J = 7.2 Hz, 1H), 7.71 (d, J = 7.2 Hz, 1H), 8.00 (d, J = 7.6 Hz, 1H), 8.06 (s, 1H). D-64 LiOH (3.0 eq.), THF:H2O (1:1), RT, 4 h, 65%. Mol. Wt:- 280.10 M.I. Peak observed ESMS (-Ve mode):- 279 D-35 LiOH (3.0 eq.), THF:H2O (1:1), RT, 4 h, 80%. Mol. Wt:- 324.18 M.I. Peak observed ESMS (-Ve mode):- 323.52 D-11F LiOH (3.0 eq.), THF:H2O (1:1), RT, 8 h, 84% . . . Purified by column chromatography over silica gel using 0-20% ethyl acetate in n-hexane Mol. Wt:- 298.14 M.I. Peak observed ESMS (-Ve mode):- 297.48 D-58 LiOH (3.0 eq.), THF:H2O (1:1), RT, 8 h, 84%. Ionization not observed in LCMS 1HNMR (400 MHz, DMSO-d6):- 1.35 (s, 14H), 3.62 (s, 2H) 7.29- 7.42 (m, 2H) 7.98 (s, 1H) D-57 LiOH (3.0 eq.), THF:H2O (1:1), RT, 8 h, 78.8%. Ionization not observed in LCMS, 1HNMR (400 MHz, DMSO-d6):- 1.35 (d, 14H), 3.70 (d, 2H), 6.91 (t, 1H) 7.40 (m, 1H), 7.79 (m, 1H) - To a stirred solution of carboxylic acid from step-3 in DCM or DMF was added and EDCI, HOBT (in some cases) & DMAP or DIPEA. The solution was stirred for 15 min. at 0° C. followed by addition of desired tert-butyl 3-(piperidin-4-yl)benzylcarbamate. Stirring was continued at room temperature and reaction was monitored by LCMS till maximum, starting materials were consumed. Reaction mixture was then quenched with Water and aq. layer was extracted with dichloromethane and combined organic layers were dried over sodium sulphate and concentrated under vacuum to afford the product which was used for next step without purification. The details of compounds synthesized by above method are as below in Table 13.
-
TABLE 13 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data E-31 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.0 eq.), EDCI (1.5 eq.), HOBT (1.5 eq.), DIPEA (2.5 eq.), DMF, RT, 15 h, 57% Mol. Wt:- 559.50 M.I. Peak observed: 582 (M + Na) 1H NMR (400 MHz, CD3OD): δ 8.10 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.30- 7.20 (m, 4H), 6.88 (s, 1H), 4.80-4.66 (m, 2H), 4.26-4.15 (m, 2H), 2.96-2.86 (m, 2H), 2.00-1.92 (m, 2H), 1.86-1.72 (m, 2H), 1.45 (s, 9H), 1.36 (s, 12H) E-62 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), DCM (125 vol), RT, 24 h, 48%. Mol. Wt:- 596.56 M.I. Peak observed: 619.15 (M + Na) E-64 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 4 h, 81% Mol. Wt:- 552.48 M.I. Peak observed: 575.15 (M + Na) E-35 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 4 h, 90%, Crude product used for next step Mol. Wt:- 596.56 M.I. Peak observed: 597.45 E-11F tert-butyl 4- fluoro-3- (piperidin-4-yl) benzyl carbamate (1.3 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 4 h, 86% Crude product used for next step Mol. Wt:- 588.52 M.I. Peak observed: 589.40 E-58 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.2 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 4 h, 81.6%, Crude product used for next step Mol. Wt:- 552.48 M.I. Peak observed: 575.25 (M + Na) E-57 tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1.3 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 4 h, 98%, Crude product used for next step Mol. Wt:- 552.48 M.I. Peak observed: 553.55 E-35F tert-butyl 4- fluoro-3- (piperidin-4-yl) benzylcarbamate (1.2 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT 4 h, 92%, Crude product used for next step. Mol. Wt:- 614.55 M.I. Peak observed: 615.45 - Products from step-4 were stirred with aq. hydrochloric acid or trifluoracetic acid (TFA) in a co-solvent like Acetonitrile, methanol, THF, DCM etc. Reaction was monitored by LCMS till maximum, starting materials were consumed. Reaction mass was then concentrated in vacuum to remove the solvents and residue obtained was purified by reverse phase preparative HPLC. The pure fraction of mobile phase was lyophilized to get the products as TFA salts.
- TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- Sometimes only Boc deprotection observed to be taking place with boronate ester functionality intact. In such cases further hydrolysis of isolated Boc de-protected boronate esters was carried out followed by purification using preparative HPLC.
- The details of compounds synthesized are as below in Table 14.
-
TABLE 14 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target- 31 Conc. HCl (8.0 eq.), MeOH, 15 h, RT, followed by prep HPLC. Isolated as TFA salt of boronate ester, 50% Converted to hydrochloride by aq. HCl (4.0 eq.), 4 h, RT and lyophilization, 60% Mol. Wt:- 377.24 LCMS (m/z): 378 [M + 1] HPLC Purity: 93.98% 1H NMR (400 MHz, D2O): δ 8.22- 8.12 (m, 1H), 7.54-7.28 (m, 6H), 7.04-6.96 (m, 1H), 4.66-4.52 (m, 2H), 4.24- 4.10 (m, 2H), 3.50-3.34 (m, 1H), 3.20-2.94 (m, 2H), 2.10- 1.70 (m, 4H) Target- 62 HCl (5.7 v), MeOH (85 V), 24 h, RT, followed by prep HPLC. Isolated as TFA salt, 26%. Mol. Wt:- 414.3 M.I. Peak observed: 415.4 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.50-1.95 (br, 4H), 2.80-2.90 (m, 1H), 3.20-3.40 (m, 4H), 3.84 (brs, 1H), 3.95-4.10 (m, 2H), 4.65 (brs, 1H), 7.25-7.55 (m, 10H), 8.00 (s, 2H), 8.10 (brs, 2H) Target- 64 TFA (10 eq) DCM (65 vol), R.T. 12 hrs, 58% Mol. Wt:- 370.22 M.I. Peak observed: 371.00 HPLC Purity:- 99.09% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.36- 1.50 (m, 2H), 1.71-1.77 (m, 2H), 2.60-2.79 (m, 2H), 3.06- 3.13 (m, 1H), 3.72 (s, 2H), 3.98- 4.08 (m, 3H), 4.54-4.57 (d, 1H), 7.03 (t, 1H), 7.21-7.43 (m, 6H), 8.29 (bs, 2H). Target- 35 Conc. HCl (10 vol), THF (66 vol), 15 h, RT, 14.4% Mol. Wt:- 414.30 M.I. Peak observed: 415.05 HPLC Purity:- 94.79% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.64- 1.86 (m, 4H), 2.84-2.87 (m, 2H), 3.23 (m, 2H) 3.65-3.73 (m, 1H), 3.99-4.01 (d, 2H), 4.69 (bs, 1H), 7.29-7.57 (m, 7H), 7.70-7.80 (m, 4H), 8.15 (bs, 1H), 8.24 (bs, 1H). Target- 11F Conc. HCl (4 vol), THF (66 vol), 15 h, RT, 12.7% Mol. Wt:- 406.26 M.I. Peak observed: 407.30 HPLC Purity:- 96.62% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.15- 1.91 (m, 4H), 2.97-3.47 (m, 3H), 3.64 (t, 1H) 4.01 (bs, 2H), 4.84- 4.87 (m, 1H), 7.21 (t, 1H) 7.37- 7.61 (m, 4H), 7.93- 7.95 (m, 3H), 8.19-8.34 (m, 4H D2O exchangable). Target- 58 Conc. HCl (3.75 vol), THF (25 vol), 16 h, RT, 19.2% Mol. Wt:- 370.23 M.I. Peak observed: 371.30 HPLC Purity:- 95.81% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.46- 1.79 (m, 4H), 2.64-3.20 (m, 4H), 3.97-4.02 (m, 2H), 4.07- 4.10 (m, 1H), 4.52- 4.55 (d, 2H), 7.21- 7.37 (m, 5H), 7.47-7.55 (m, 2H), 8.29 (bs, 4H). Target- 57 Conc. HCl (5.7 vol), THF (25 vol), 16 h, RT, 26% Mol. Wt:- 370.22 M.I. Peak observed: 371.30 HPLC Purity:- 95.77% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.48- 1.54 (m, 2H), 1.77-1.80 (d, 2H) 2.67 (t, 1H), 2.80 (t, 1H), 3.17 (t, 1H), 3.75 (s, 2H), 3.99- 4.01 (q, 2H), 4.08-4.12 (d, 1H), 4.55-4.58 (d, 1H), 7.11 (t, 1H), 7.24-7.36 (m, 4H), 7.67- 7.27 (m, 2H), 8.26 (bs, 2H). Target- 35F Conc. HCl (8 vol), THF (25 vol), 16 h, RT, 25.7% Mol. Wt:- 432.29 M.I. Peak observed: 433.40 HPLC Purity:- 98.83% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.69- 1.84 (m, 4H), 2.93- 3.19 (m, 3H), 3.74 (bs, 1H), 3.99- 4.01 (q, 2H), 4.67 (bs, 1H), 7.21 (t, 1H), 7.34-7.47 (m, 3H), 7.54-7.58 (m, 2H), 7.69- 7.80 (m, 4H), 8.15 (bs, 2H), 8.21 (bs, 2H). - Non commercial aryl/hetero aryl carboxy boronic acids were synthesized from corresponding aryl halo carboxylic acids by reaction with LDA & Tri alkyl borate followed by hydrolysis as per method described in the literature (US-patent application 2008/306082; 2008 example 20B)
- Coupling reaction of aryl boronic acids were carried out as per general procedure described in Step-4 above. The details of compounds synthesized are as below in Table 15.
-
TABLE 15 ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data H-33 tert-butyl 3-(piperidin-4-yl) benzylcarbamate. (1.0 eq.), EDCI (1.5 eq.), HOBT (1.1 eq.), DMAP (1.1 eq.), DCM (100 vol), DMF (2 vol) RT, 2 h, 88%. Crude product was used for next step Mol. Wt:- 464.36 M.I. Peak observed: 465.65 H-34 tert-butyl 3-(piperidin-4-yl) benzylcarbamate. (1.0 eq.), EDCI (1.5 eq.), HOBT (1.1 eq.), DMAP (1.1 eq.), DCM (100 vol), DMF (2 vol) RT, 2 h, 88%, Crude product was used for next step Wt:- 464.36 M.I. Peak observed: 464.85 H-37 tert-butyl 3-(piperidin-4-yl) benzylcarbamate. (1.1 eq.), EDCI (1.3 eq.), DMAP (2 eq.), DCM (50 vol), RT, 2 h, 50%, Crude product was used for next step Mol. Wt:- 494.41 M.I. Peak observed: 518.75 (M + Na) - Products from step-8 were stirred with Trifluoro acetic acid in dichoromethane at room temperature and reactions were monitored by TLC & LCMS till maximum, starting materials were consumed. Reaction mass was concentrated in vacuum to remove excess trifluoro acetic acid and dichloromethane. Crude products obtained were purified by reverse phase preparative HPLC. The pure fraction of mobile phase was lyophilized to get the products as TFA salts.
- TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- The details of compounds synthesized are as below in Table 16.
-
TABLE 16 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-33 TFA (1.5 eq) DCM (66 vol), R.T. 14 hrs 12%Mol. Wt:- 364.24 M.I. Peak observed: 364.90 HPLC Purity:- 97.22% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.53-1.59 (m, 2H), 1.83 (t, 2H), 2.69-2.88 (m, 2H), 3.20- 3.23 (m, 1H), 3.97-4.01 (q, 2H), 4.42-4.47 (d, 1H), 4.64-4.67 (d, 1H), 7.27-7.39 (m, 4H), 7.48-7.52 (d, 2H), 7.67-7.69 (d, 2H), 7.80- 7.82 (d, 2H), 8.23 (bs, 4H). Target-34 TFA (1.5 eq) DCM (66 vol), R.T. 14 hrs 12%Mol. Wt:- 364.25 M.I. Peak observed: 364.90 HPLC Purity:- 95.01% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.57-1.84 (m, 4H), 2.67-2.88 (m, 2H), 3.20-3.23 (m, 1H), 3.99-4.01 (q, 2H), 4.41-4.44 (d, 1H), 4.65-4.68 (d, 1H), 7.27-7.39 (m, 6H), 7.48-7.52 (d, 2H), 7.76 (t, 2H), 8.08 (bs, 2H), 8.21 (bs, 2H). Target-37 HCl (10 vol) THF (50 vol), R.T. 5 hrs 40%Mol. Wt:- 394.29 M.I. Peak observed: 395.00 HPLC Purity:- 97.24% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.49-1.91 (m, 4H), 2.81-3.19 (m, 4H), 3.42-3.55 (m, 2H), 3.99-4.00 (d, 2H), 4.78-4.80 (d, 1H), 7.30-7.46 (m, 6H), 8.04-8.06 (d, 2H), 8.34 (bs, 2H). - Desired halo aryl carboxylic acids were first coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate and coupled products were reacted with bis pinacolato diborane to get boronate esters which were hydrolyzed to corresponding boronic acids.
- tert-butyl 3-(piperidin-4-yl)benzylcarbamate & desired aryl halo carboxylic acids were stirred with PyBop & Diisopropyl ethyl amine in DMF for 24 hrs at room temperature. Reaction mixture was then quenched with water and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulfate and concentrated to get the crude product which was purified by column chromatography.
- The details of compounds synthesized are as below in Table 17.
-
TABLE 17 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data A-32 tert-butyl 3-(piperidin-4- yl) benzyl carbamate (1 eq.) Py Bop (2 eq) in DMF (30 vol) & DIPEA (2.5 eq), 24 h. RT, Yield 93% Mol. Wt:- 512.4 M.I. Peak observed: 512, 514 [MH+] 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.38 (s, 9H), 1.60-1.95 (m, 4H), 2.80-2.91 (m, 1H), 2.95-3.05 (m, 2H), 4.11 (d, J = 5.6 Hz, 2H), 4.55 (br, 2H), 6.80 (s, 1H), 7.00- 7.20 (m, 4H), 7.20-7.40 (m, 3H), 7.44 (d, J = 8.4 Hz, 1H), 12.0 (s, 1H). A-59 tert-butyl 3-(piperidin-4- yl) benzyl carbamate (1 eq) Py Bop (2 eq) in DMF (30 vol) & DIPEA (2.5 eq), 24 h. RT, Yield 71% Mol. Wt:- 512.4 M.I. Peak observed: 536 (MH+ + Na) 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.46 (s, 9H), 1.70-1.90 (m, 2H), 1.95-2.05 (m, 2H), 2.80-2.90 (m, 1H), 3.0-3.4 (brm, 2H), 4.31 (brd, 2H), 4.84 (brd, 2H), 6.78 (s, 1H), 7.10-7.19 (m, 3H), 7.20-7.32 (m, 2H), 7.50 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 9.50 (brs, 1H). A-56 tert-butyl 3-(piperidin-4- yl) benzyl carbamate (1 eq) Py Bop (2 eq) in DMF (10 vol) & DIPEA (2.5 eq), 24 h. RT, Yield 65% Mol. Wt:- 529.5 M.I. Peak observed: 529.35, 531 [MH+] 1H NMR CDCl3:- 1HNMR (400 MHz, CDCl3) 1.43 (s, 1H), 1.70-2.00 (m, 4H), 2.75-2.92 (m, 1H), 3.00-3.40 (br, 2H), 4.30 (d, 2H), 4.40-5.00 (br, 2H), 7.00-7.40 (m, 5H), 7.55 (d, 1H), 7.60 (s, 1H), 7.80 (d, 1H). - Product of step-1, was converted boronate ester by reacting with Bis Pinacolato Borane in presence of Potassium acetate DPPF-PdCl2.DCM by heating in 1,4-dioxane/Dimethyl sulfoxide for 12 hrs. R.M was then concentrated in vacuum and residue was purified by column chromatography.
- The details of compounds synthesized are as below in Table 18.
-
TABLE 18 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-32 KOAc (3 eq.), Bis Pin. Borane (10 eq.), DPPF-PdCl2•DCM (Mol. 6%), Dioxane (40 vol), Reflux, 12 hrs. inorganics removed by column Chromatography & carried forward to next step Mol. Wt:- 559.5 M.I. Peak observed: 560 B-59 KOAc (3 eq.), Bis Pin. Borane (10 eq.), DPPF-PdCl2•DCM (Mol. 3%), DMSO (35 vol), 80° C. deg, 12 hrs. purified Column Chromatography, Yield 59%Mol. Wt:- 559.5 M.I. Peak observed: 560 1H NMR CDCl3:- 1HNMR (400 MHz, CDCl3) 1.37 (s, 12H), 1.46 (s, 9H), 1.71-1.85 (m, 2H), 1.95-2.05 (m, 2H), 2.80-2.91 (m, 1H), 3.01-3.30 (brm, 2H), 4.30 (brd, 2H), 4.84 (brd, 2H), 6.80 (s, 1H), 7.10-7.20 (m, 3H), 7.27-7.32 (m, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.92 (s, 1H), 9.11 (brs, 1H). C-56 KOAc (3 eq), Bis Pin. Borane (10 eq), DPPF-PdCl2•DCM ( Mol 3%), Dioxane (200 vol), 110° C. deg, 12 hrs. purified by Column Chromatography, Yield 74%Mol. Wt:- 576.6 M.I. Peak observed: 599.15 (M + Na) 1H NMR CDCl3:- 1HNMR (400 MHz, CDCl3) 1.23 (s, 12H), 1.38 (s, 9H), 1.70-2.00 (m, 4H), 2.77-2.90 (m, 1H), 2.91-3.50 (br, 2H), 4.31 (brs, 2H), 4.50-5.20 (br, 2H), 7.10-7.45 (m, 5H), 7.50-7.70 (m, 1H), 7.85- 8.00 (m, 1H), 8.23 (s, 1H). - Products of step-2 were stirred with trifluoro acetic acid in dichloromethane at room temp. Reaction mass was then concentrated in vacuum and used for next step without purification. The details of compounds synthesized are as below in Table 19.
-
TABLE 19 ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data C-32 TFA (3 vol) DCM (100 vol), R.T. 24 hrs subjected to next step without purification Mol. Wt:- 459.4 M.I. Peak observed: 460 C-59 TFA (2 Vol) DCM (200 vol), R.T. 24 hrs subjected to next step without purification Mol. Wt:- 459.4 M.I. Peak observed: 460 C-56 TFA (7.5 Vol) DCM (100 vol), R.T. 24 hrs subjected to next step without purification Mol. Wt:- 476.6 M.I. Peak observed: 477 - Products of step-3 were stirred with conc. HCl, acetonitrile & water for about 5 hrs under nitrogen atmosphere. There after reaction mass was concentrated in vacuum and crude boronic acid was purified by preparative HPLC. Products were isolated either as TFA salts or acetate salts depending on the buffer used during purification by prep HPLC. The details of compounds synthesized are as below in Table 20.
-
TABLE 20 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-32 Conc. HCl (3 eq) ACN:Water 1:1 200 vol. R.T. 5 hrs. and prep purification isolated as acetate salt, Yield, 41% Mol. Wt:- 377.2 M.I. Peak observed: 378 HPLC Purity:- 96.55% (220 nm) 1H NMR CD3CN + D2O:- 1HNMR (400 MHz, CD3CN + D2O) 1.80-1.91 (m, 2H), 1.94 (s, 3H, acetate), 2.05- 2.15 (m, 2H), 3.00-3.10 (m, 1H), 3.20-3.50 (brm, 2H), 4.15 (s, 2H), 4.80 (brd, 2H), 7.35-7.52 (m, 6H), 7.65 (d, J = 6.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H). Target-59 Conc. HCl (3 eq) ACN:Water 1:1 200 vol. R.T. 5 hrs. and prep purification isolated as acetate salt, Yield 17%Mol. Wt:- 377.2 M.I. Peak observed: 378 HPLC Purity:- 97.3% (220 nm) 1H NMR CD3CN + D2O:- 1HNMR (400 MHz, CD3CN + D2O) 1.80-1.90 (m, 2H), 1.94 (s, 3H, acetate), 2.05- 2.15 (m, 2H), 3.00-3.10 (m, 1H), 3.20-3.50 (brm, 2H), 4.17 (s, 2H), 4.75 (brd, 2H), 6.97 (s, 1H), 7.35-7.52 (m, 4H), 7.61 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 8.06 (s, 1H) Target-56 Conc. HCl (3 eq) ACN:Water 1:1 200 vol. R.T. 5 hrs. and prep purification isolated as TFA salt, Yield 15%Mol. Wt:- 394.3 M.I. Peak observed: 395 HPLC Purity:- 97.37% (220 nm) 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.60-1.95 (br, 4H), 2.85-2.95 (m, 1H), 3.25- 3.40 (br, 4H), 3.95-4.10 (m, 2H), 4.30-4.70 (br, 2H), 7.22-7.48 (m, 5H), 7.83 (d, J = 6.8 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 8.15 (s, 1H), 8.41 (br, 2H). - Desired dimethoxy analogues of carboxylic acids were first coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate and coupled products were de-methylated using boron tribromide.
- 2-(6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-8-yl)acetic acid, required for targets 97 was synthesized by Pechmann reaction of Sesamol & diethyl 3-oxopentanedioate using toluene as a solvent and following the procedure described in the literature for analogous substrate (Chemistry Letters, 2, 110-111, 2001)
- 6,7-dimethoxy-2-oxo-2H-chromene-3-carboxylic acid & 7,8-dimethoxy-2-oxo-2H-chromene-3-carboxylic acid required for target—100 & 102 were prepared by the reaction of Meldrums acid with 2-hydroxy-4,5-dimethoxybenzaldehyde or 2-hydroxy-3,4-dimethoxybenzaldehyde in water at 75° C. for 2 hrs. Precipitated products were sufficient pure to be used for the next step. Required aldehydes for this were prepared from corresponding trimethoxy benzaldehydes by demethylation using AlCl3 in benzene (JOC, 54, 4112, 1989)
- These reactions were performed as per general procedure described in method-A (step-4) or method-B (step-1). The details of compounds synthesized are as below in Table 20.
- Crude products were used for next step without purification.
-
TABLE 20 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-28 Common core (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 42% Mol. Wt:- 454.56 M.I. Peak observed:- 455.40 Crude product used for next step B-27-F Common core (1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 89% Mol. Wt:- 522.61 M.I. Peak observed:- 545.10 (M + Na) Crude product used for next step B-68 Common core (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 93% Mol. Wt:- 484.28 M.I. Peak observed:- 485.40 Crude product used for next step B-69 Common core (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 96% Mol. Wt:- 484.28 M.I. Peak observed:- 485.40 Crude product used for next step B-77 Common core (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 89.4% Mol. Wt:- 484.58 M.I. Peak observed:- 485.00 Crude product used for next step B-78 Common core (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 89.5% Mol. Wt:- 489.00 M.I. Peak observed:- 512 (M + Na) Crude product used for next step B-43 (E)-3-(3, 4, 5-trimethoxy phenyl) acrylic acid (1 eq.), tert-butyl 3-(piperidin-4- yl) benzylcarbamate (1 eq.), PyBop (2 eq.), DIPEA (2.5 eq.), DMF (5 V), 24 h, RT, 63%. Mol. Wt:- 510.62 M.I. Peak observed:- 533 (M + Na) 1H NMR (400 MHz, CDCl3): □ 1.46 (s, 9H), 1.65-1.80 (m, 2H), 1.90- 2.05 (m, 2H), 2.72-2.85 (m, 1H), 3.10-3.50 (br, 2H), 3.88 (s, 3H), 3.90 (s, 6H), 4.30 (d, J = 5.2 Hz, 2H), 4.75-5.00 (br, 2H), 6.75 (s, 2H), 6.82 (d, J = 15 Hz, 1H), 7.09-7.20 (m, 3H), 7.26-7.32 (m, 1H), 7.60 (d, J = 15 Hz, 1H). B-97 2-(6-oxo-6H-[1,3]dioxolo [4,5-g]chromen-8-yl)acetic acid (1 eq) tert-butyl 3- (piperidin-4-yl) benzylcarbamate (1 eq.), EDCI (2 eq.), DMAP (0.5 eq.), DCM (20 V), 12 h, RT, 86%. Mol. Wt:- 520.57 M.I. Peak observed:- 543 (M + Na) B-100 6,7-dimethoxy-2-oxo-2H- chromene-3-carboxylic acid (1 eq) tert-butyl 3- (piperidin-4-yl) benzylcarbamate (1 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), DCM (100 V), 12 h, RT, 80%. Mol. Wt:- 522.59 M.I. Peak observed:- 523 B-102 7,8-dimethoxy-2-oxo-2H- chromene-3-carboxylic acid (1 eq) tert-butyl 3- (piperidin-4-yl) benzylcarbamate (1.2 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), DCM (66 vol), 12 h, RT, 80.6%. Mol. Wt:- 522.59 M.I. Peak observed:- 523 1H NMR (400 MHz, DMSO-d6): 1.39 (s, 9H), 1.50-1.90 (m, 4H), 2.60-2.90 (m, 2H), 3.10-3.25 (m, 1H), 3.84 (s, 3H), 3.92 (s, 3H), 4.09 (s, 2H), 4.29 (brd, 1H), 4.59 (brd, 1H), 7.00-7.55 (m, 6H), 8.02 (s, 1H), 8.13 (s, 1H). - Product from step-1 was dissolved in dichloromethane and the solution was cooled to 0° C. Boron tribromide (3 eq) was added and reaction mass was gradually warmed to room temperature. Stirring was continued at room temperature and reaction was monitored by TLC & LCMS till maximum starting was consumed (1-8 hrs required). Reaction mass was then concentrated and excess BBr3 was removed by multiple strippings of methanol. Residue containing crude product as hydrobromide was purified by reverse phase preparative HPLC. Pure product isolated as TFA salts were converted to hydrochloride by dissolving in 2N hydrochloric acid followed by lyophilization to get the title compounds as hydrochloride salts.
- The details of compounds synthesized are as below in Table 21.
-
TABLE 21 ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data Target-28 BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 42% Mol. Wt:- 326.39 M.I. Peak observed:- 327.25 HPLC Purity:- 99.42 1H NMR DMSO-d6:- 1.53- 1.75 (m, 4H), 2.76-2.82 (m, 4H), 3.9-4.0 (q, 2H), 6.56 (d, 1H), 6.67 (t, 1H), 6.80 (d, 1H), 7.24- 7.38 (m, 4H), 8.32 (bs, 2H-D2O exchangable). Target-27-F BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 16% Mol. Wt:- 394.43 M.I. Peak observed: 395.30 HPLC Purity:- 96.75 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO) 1.53-1.88 (m, 4H), 2.91- 3.33 (m, 4H), 4.0 (bs, 2H), 4.82 (m, 1H), 6.99 (s, 1H), 7.15- 7.36 (m, 5H), 7.59-7.64 (m, 2H), 7.82-7.84 (d, 1H-D2O exchangable), 8.34-8.43 (m, 2H- D2O exchangable). Target-68 BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 22% Mol. Wt:- 342.38 M.I. Peak observed:- 343.20 HPLC Purity:- 97.94 1H NMR CD3OD:- 1.75- 1.94 (m, 4H), 2.90-3.31 (m, 4H), 4.10 (s, 2H), 4.35 (bs, 1H), 6.43 (d, 1H, J = 8.4 Hz), 6.66 (d, 1H, J = 8.4 Hz), 7.29- 7.41 (m, 4H). Target-69 BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 23.6% Mol. Wt:- 342.38 M.I. Peak observed:- 343.25 HPLC Purity: - 97.41 1H NMR CD3OD:- 1.75- 1.94 (m, 4H), 2.90-3.31 (m, 4H), 4.10 (s, 2H), 6.47 (s, 2H), 7.03-7.38 (m, 4H). Target-77 BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 22.7% Mol. Wt:- 342.38 M.I. Peak observed:- 343.25 HPLC Purity:- 99.73 1H NMR DMSO-d6:- 1.54-1.60 (m, 2H), 1.74-1.77 (d, 4H), 2.75-2.96 (m, 4H), 3.96-4.14 (m, 2H), 6.34 (s, 1H), 6.54 (s, 1H), 7.24-7.39 (4H), 8.34 (bs, 3H). Target-78 BBr3 (3 eq) DCM (85 vol), R.T. 2 hrs, 34% Mol. Wt:- 360.83 M.I. Peak observed:- 361.20 HPLC Purity:- 99.91 1H NMR DMSO-d6:- 1.57-1.79 (m, 4H), 2.78-2.84 (m, 4H), 3.98- 4.02 (q, 3H), 6.85 (s, 2H), 7.28-7.42 (m, 4H), 8.28 (bs, 3H), 9.57 (bs, 1H), 10.14 (bs, 1H). Target-43 BBr3 (1M in DCM, 5 eq.), DCM (100 Vol), 24 h, RT, 15%. Mol. Wt:- 368.43 M.I. Peak observed:- 369 HPLC Purity:- 99.49% 1H NMR (400 MHz, DMSO- d6): δ 1.55 (brs, 2H), 1.80 (brs, 2H), 2.79-2.88 (m, 1H), 3.10-3.40 (br, 2H), 3.95-4.20 (m, 2H), 4.30-4.70 (br, 2H), 6.62 (s, 2H), 6.89 (d, J = 15.2 Hz, 1H), 7.20- 7.40 (m, 5H), 8.11 (brs, 2H), 8.64 (brs, 1H), 8.97 (brs, 2H). Target-97 BBr3 (1M in DCM, 4 eq.), DCM (66 Vol), 12 h, RT, 15%. Isolated as TFA salt, Yield:- 20% Mol. Wt:- 408.45 M.I. Peak observed:- 409 HPLC: 98.37% (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.60-2.0 (m, 4H), 2.78-3.0 (m, 2H), 3.30-3.45 (brm, 1H, merged in solvent peak), 3.90-4.10 (m, 2H), 4.11 (s, 2H), 4.12 (br, 1H), 4.60- 4.80 (brd, 1H), 6.14 (s, 1H), 6.78 (s, 1H), 7.04 (s, 1H), 7.28-7.50 (m, 4H). Target-100 BBr3 (1M in DCM, 4 eq.), DCM (100 Vol), 12 hr, RT, Isolated as TFA salt, Yield:- 19.4% Mol. Wt:- 394.42 M.I. Peak observed:- 395.25 HPLC: 98.83% (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.70-2.00 (m, 4H), 2.85-3.00 (m, 2H), 3.75-3.85 (brd, 1H), 4.10 (s, 2H), 4.70-4.80 (brd, 2H), 6.80 (s, 1H), 7.02 (s, 1H), 7.26-7.44 (m, 4H), 7.95 (s, 1H). Target-102 BBr3 (1M in DCM, 4 eq.), DCM (80 Vol), 12 hr, RT, Isolated as TFA salt, Yield:- 25% Mol. Wt:- 394.42 M.I. Peak observed:- 395.25 HPLC: 99.27% (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.77-1.99 (m, 4H), 2.92- 2.98 (m, 2H), 3.31 (brs, 1H merged in solvent peak), 3.81-3.85 (m, 1H), 4.11 (brs, 2H), 4.76 (brs, 1H, merged in solvent water peak), 6.87 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 7.29-7.42 (m, 4H), 7.98 (brs, 1H) - Reaction was performed as per General procedure described in method-A (step-4)
- Reaction details and analytical data is as below in Table 22.
-
TABLE 22 ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data C tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 99% Step-3:- Mol. Wt:- 409.24 M.I. Peak observed:- 432.05 (M + Na) Crude product used for next step - These reactions were performed as per General procedure described in Step-4 (method A); the details of compounds synthesized are as below in Table 23.
-
TABLE 23 ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data D-70 Step-4:- 2,3- dimethoxy benzoic acid (1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 79.5% Step-4:- Mol. Wt:- 573.68 M.I. Peak observed:- 574.50 Crude product used for next step D-71 Step-4:- 3,4- dimethoxy benzoic acid (1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 81.6% Step-4:- Mol. Wt:- 573.68 M.I. Peak observed:- 596.15 (M + Na) Crude product used for next step - These reactions were performed as per General procedure described in Step-2 above. The details of compounds synthesized are as below in Table 24.
-
TABLE 24 ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data Target-70 BBr3 (3 eq) DCM (85 vol), R.T., 2 hrs, Compound purified by prep HPLC yield:- 21% Mol. Wt:- 445.51 M.I. Peak observed:- 446.40 HPLC Purity:- 99.41 1H NMR DMSO- d6:- 1.63-1.86 (m, 4H), 2.82-3.29 (m, 3H), 3.78 (bs, 1H), 4.00-4.01 (q, 2H), 4.63 (bs, 1H), 6.77 (t, 1H), 6.98-7.00 (d, 1H, J = 7.2 Hz), 7.18-7.20 (d, 1H,, J = 7.6 Hz), 7.31- 7.47 (m, 5H), 7.71-7.73 (d, 1H), 7.84 (s, 2H), 8.23 (bs, 2H), 9.47 (bs, 1H), 10.47 (bs, 1H), 11.42 (s, 1H). Target-71 BBr3 (3 eq) DCM (85 vol), R.T., 2 hrs, Compound purified by prep HPLC yield:- 16.7% Mol. Wt:- 445.51 M.I. Peak observed:- 446.35 HPLC Purity:- 98.41 1H NMR DMSO-d6:- 1.61-1.86 (m, 4H), 2.82-3.19 (m, 3H), 3.75 (s, 1H), 3.98-4.02 (q, 2H), 4.63 (bs, 1H), 6.82-6.84 (d, 1H, J = 8.4 Hz), 7.09-7.11 (d, 1H,, J = 7.6 Hz), 7.28-7.42 (m, 7H), 7.76-7.78 (d, 1H), 7.90 (s, 1H), 8.26 (bs, 2H), 9.27 (bs, 1H), 9.69 (bs, 1H), 10.09 (s, 1H). - Desired carboxylic acid (A) was coupled with tert-butyl 3-(piperidin-4-yl)benzylcarbamate followed by deprotection of Boc functionality.
- 2-(7,8-dihydroxy-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid required for Target-101 was synthesized Pechmann reaction of Pyrogallol & Diethyl acetyl succinate using toluene as a solvent and following the procedure described in the literature for analogous substrate i.e. resorcinol (Chemistry Letters, 2, 110-111, 2001)
- Some halo analogues of the Boronic acids in method-A were also synthesized by this approach.
- These reactions were carried out as per general procedure in method-A (step-4) Products were purified by column chromatography over silica gel using methanol (0-5%) in Chloroform.
-
TABLE 25 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-101 2-(7,8-dihydroxy- 4-methyl-2-oxo-2H- chromen-3-yl)acetic acid (1 eq) tert-butyl 3-(piperidin-4-yl) benzyl carbamate (1.2 eq.), EDCI (1.2 eq.), HOBT (1.5 eq.), DIPEA (1.5 eq.), DMF (50 vol), RT, 12 h, Yield:- 30% Mol. Wt.: 522.59 Peak observed in LCMS:- 523.2 1H NMR (400 MHz, DMSO-d6): δ 1.39 (s, 9H), 1.46- 1.90 (m, 4H), 2.28 (s, 3H), 2.60-2.90 (m, 2H), 3.12-3.30 (m, 1H), 3.60-3.80 (m, 2H), 4.11 (d, J = 5.2 Hz, 1H), 4.19 (brd, 1H), 4.49 (brd, 1H), 6.81 (d, J = 8.8 Hz, 1H), 7.00- 7.40 (m, 5H), 9.23 (s, 1H), 9.92 (s, 1H) - Boc deprotection of the products from step-1 was carried out by stirring it with hydrochloric acid in presence of co-solvent like methanol or dioxane at room temperature. Solvents were then evaporated and residue was purified by reverse phase preparative HPLC. Products were isolated as TFA salts. Details of the compounds synthesized are as below in Table 26.
-
TABLE 26 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-101 conc. HCl (10 V), Methanol (100 V), 24 h, RT, Isolated as hydrochloride in pure form after work-up Yield:- 81.3% Mol. Wt.: 422.47 LCMS: (M + 1) 423.2 HPLC Purity:- 95.30% 1H NMR (400 MHz, DMSO-d6): δ 1.40- 1.90 (m, 4H), 2.28 (s, 3H), 2.60-2.89 (m, 2H), 3.16-3.27 (m, 1H), 4.00 (d, 2H), 4.05 (s, 2H), 4.21 (brd, 1H), 4.51 (brd, 1H), 6.84 (d, J = 8.8 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.25-7.43 (m, 4H), 8.36 (br, 2H) - Ortho hydroxy aromatic aldehyde with carbethoxy/methoxy functionality at suitable position was reduced to get o-hydroxy methyl phenols which were then protected and ester functionality hydrolyzed to get required protected carboxylic acid, which upon coupling with tert-butyl 3-(piperidin-4-yl) benzylcarbamate and subsequent deprotection in acidic media afforded the title compounds.
- In case of napthyl derivative, corresponding cyano derivative instead of carbethoxy/methoxy derivative analogue was synthesized by the route described in scheme-2 and used during step-3.
- Required ortho hydroxy aromatic aldehydes with carbethoxy/methoxy functionality were synthesized either by esterification of corresponding carboxylic acid available commercially using reaction conditions described in method-A step-1 (for 4-formyl-3-hydroxy methyl benzoate) or synthesized as per methods in the literature (JACS, 131, 15608-15609, 2009 for methyl 3-formyl-4-hydroxybenzoate; Syn. Comm, 29, 2061-2068,1999. for 3-formyl-4-hydroxy ethyl cinnamate). (E)-ethyl 3-(3-formyl-4-hydroxyphenyl)acrylate was synthesized as per methods in the literature (Syn. Comm. 30 1003-1008 2000). Aldehyde functionality was reduced either by catalytic hydrogenation or using sodium borohydride in methanol. The details of compounds synthesized are as below in Table 27.
-
TABLE 27 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data A-74 10% Pd/C (10% w/w.), Hydrogen (balloon pressure), Methanol (50 vol), 4 h, RT, 79% Mol. Wt:- 182.17 M.I. Peak observed (ESMS):- 181.40 (-Ve mode) 1H NMR DMSO-d6:- 3.79 (s, 1H), 4.5 (s, 2H), 7.3 (m, 3H). A-65 MeOH (80 V) at 0° C. NaBH4 (1 eq) 0°C. 1 h. 70% Mol. Wt:- 182.17 LCMS: (M + 1) 182.8 1H NMR (400 MHz, DMSO-d6): δ 3.78 (s, 3H), 4.48 (s, 2H), 6.84 (d, J = 8.4 Hz, 1H), 7.68-7.72 (dd, J = 2.4 and 8.4 Hz, 1H), 7.97 (s, 1H), 10.31 (s, 1H) A-40 EtOH (30 V) at 0° C. NaBH4 (1 eq) 0° C. 30 min. Crude taken for next step Mol. Wt:- 222.24 LCMS: (M + 1) 223 1H NMR (400 MHz, CDCl3): δ 1.32 (t, J = 7.0 Hz, 3H), 4.20-4.27 (q, J = 7.0 Hz, 2H), 4.88 (s, 2H), 6.25 (d, J = 16 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 7.20 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 16 Hz, 1H), 8.0 (brs, 1H). - Protection of step-1 products was carried out using 2,2-dimethoxy propane by refluxing in acetone in presence of catalytic p-toluene sulfonic acid. Reaction was monitored by LCMS and after completion of reaction solvents were distilled and crude product obtained was purified by column chromatography using ethyl acetate (0-10%) in hexane. The details of compounds synthesized are as below in Table 27.
-
TABLE 27 ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-74 2,2-dimethoxy propane (4 eq.), acetone (50 vol), PTSA (catalytic), 3 h, RT, Yield:- 59% 1H NMR CDCl3:- 1.48 (s, 6H), 3.95 (s, 3H), 4.86 (s, 2H), 7.1 (d, 1H), 7.45 (s, 1H), 7.5 (d, 1H). B-65 Acetone (72 V) 2,2- dimethoxy propane (3 eq) and PPTS (0.1 eq) RT overnight. Yield:- 59% Mol. Wt:- 222.24 LCMS: (M + 1) 222.75 1H NMR (400 MHz, CDCl3): δ 1.52 (s, 6H), 3.85 (s, 3H), 4.84 (s, 2H), 6.81 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 1.2 Hz, 1H), 7.82 (dd, J = 1.2 and 8.6 Hz, 1H) B-40 Acetone (250 V), 2,2 dimethoxy propane (3 eq) PPTS (0.1 eq) RT overnight. Yield:- 65% Mol. Wt:- 262.30 LCMS: (M + 1) 262.9 1H NMR (400 MHz, CDCl3): δ 1.33 (t, J = 7 Hz, 3H), 1.55 (s, 6H), 4.22-4.27 (m, 2H), 4.85 (s, 2H), 6.29 (d, J = 16.4 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 7.15 (s, 1H), 7.35-7.37 (m, 1H), 7.60 (d, J = 15.6 Hz, 1H). - Hydrolysis of step-2 products was carried out as per procedure described in Method-A (step-3). In case of C-44, hydrolysis of corresponding cyano compound (G-44) was carried out using ethanolic potassium hydroxide under reflux to get mixture of acid and corresponding amide. This mixture was used for next step without purification. The details of compounds synthesized are as below in Table 28.
-
TABLE 28 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data C-74 LiOH (3.0 eq.), THF:H2O (1:1), RT, 4 h, 62%. Ionisation not observed in LCMS. HPLC purity - 90%. Used as such for next step. C-65 THF:H2O:MeOH (50:50:10 V) LiOH•H2O (1.5 eq) RT overnight. 93% LCMS: Ionization was not observed 1H NMR (400 MHz, DMSO-d6): δ 1.49 (s, 6H), 4.88 (s, 2H), 6.86 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 7.73 (d, J = 8.8 Hz, 1H). C-40 THF:H2O:MeOH (17:17:5 V), LiOH•H2O (1.5 eq) RT overnight. 92% Mol. Wt:- 234.25 LCMS: (M + Na) 256.8 1H NMR (400 MHz, DMSO-d6) δ 1.47 (s, 6H), 4.83 (s, 2H), 6.35 (d, J = 16 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 7.43-7.52 (m, 3H). C-44 EtOH (8 V) 30% solution of KOH (8 V mL) 80° C. 24 h. 2:1 mix of acid: amide obtained used as such for next step. LCMS: Ionization was not observed - Coupling reactions of protected carboxylic acids from step-3 were carried out as per general procedure described in Method-A (Step-4). The details of compounds synthesized are as below in Table 29.
-
TABLE 29 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data D-74 tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, 89% Mol. Wt:- 480.60 M.I. Peak observed:- 503.25 (M + Na) D-65 tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1 eq) DCM (100 V), DMAP (0.5 eq), EDCI (1.5 eq) RT overnight. 79% Mol. Wt:- 480.60 LCMS: (M + 1) 481.5 D-40 tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DCM (66 V), DMAP (0.5 eq) EDCI (1.5 eq) RT overnight. 50% Mol. Wt:- 506.63 LCMS: (M + Na) 529.2 D-44 tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DCM (66 V), DMAP (0.5 eq), EDCI (1.5 eq), RT overnight. 40% LCMS: (M + Na) 553.15 1H NMR (400 MHz, CDCl3): δ 1.47 (s, 9H), 1.63 (s, 6H), 1.60-2.00 (m, 4H), 2.70-2.81 (m, 1H), 2.85-3.20 (m, 2H), 3.45-3.65 (m, 1H), 4.30 (s, 2H), 4.82 (br, 1H), 5.00-5.25 (m, 2H), 7.00-7.22 (m, 3H), 7.28-7.43 (m 4H), 7.50 (s, 1H), 7.74 (d, J = 7.6 Hz, 1H). - Boc and isopropylidine deprotection of the compounds was carried out by stirring with Methanolic HCl or Trifluoro acetic acid in dichloromethane at room temperature. Reactions were monitored by LCMS and after reaction completion, reaction mass was concentrated and residue was purified by reverse phase preparative HPLC. Products were isolated as TFA salts. The details of compounds synthesized are as below in Table 30.
-
TABLE 30 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-74 Methanolic HCl (25 vol), 4 h, RT, Prep purification Isolated as TFA Salt Yield:- 17.2% Mol. Wt:- 340.41 M.I. Peak observed:- 340.95 HPLC Purity:- 99.14 1H NMR DMSO-d6:- 1.59-1.77 (m, 4H), 2.80- 2.86 (m, 4H), 4.00-4.04 (q, 2H), 4.49 (s, 2H), 6.79 (s, 1H), 6.82-6.84 (d, 1H), 7.27-7.38 (m, 5H), 8.13 (bs, 3H), 9.64 (bs, 1H) Target-65 DCM (100 V), TFA (3 eq) RT overnight Prep purification. Isolated as TFA Salt Yield:- 32% Mol. Wt:- 340.42 LCMS: (M + 1) 341 HPLC: 99.56 % (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.60-2.10 (br, 4H), 2.88-3.00 (m, 1H), 3.30 (br, 4H, merged in solvent peak), 4.10 (s, 2H), 4.67 (s, 2 H), 6.84 (d, J = 8.4 Hz, 1H), 7.22-7.45 (m, 6H). Target-40 DCM (100 V) TFA (3 eq) RT 2 h. Prep purification. Isolated as TFA Salt Yield:- 30.5% Mol. Wt:- 366.45 LCMS: (M + Na) 389 HPLC: 92 % trans 7% cis (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.55-1.81 (m, 2H), 1.90-2.10 (m, 2H), 2.80-3.00 (m, 1H), 3.31 (br, 4H, merged in solvent peak), 4.10 (s, 2H), 4.66 (s, 2H), 6.80 (d, J = 8.4 Hz, 1H), 7.00 (s, J = 15.2 Hz, 1H), 7.20-7.50 (m, 5H), 7.56 (d, J = 15.2 Hz, 1H), 7.60 (s, 1H).Target-44 DCM (100 V) TFA (3 eq) 0° C. 2 h. Prep purification. Isolated as TFA Salt Yield:- 42% Mol. Wt:- 390.47 LCMS: (M + Na) 413 HPLC: 99.07% (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.50-2.10 (m, 4H), 2.82-3.00 (m, 1H), 3.00-3.29 (m, 2H); 3.40-3.60 (br, 2H), 4.10 (s, 2H), 4.80 (s, 2H), 7.01 (s, 1H), 7.20 (s, 1H), 7.23-7.42 (m, 5H), 7.80-7.90 (m, 2H). - To a solution of 3,5 dihydroxy-2-napthoic acid (5 g, 24.5 mmol) in THF dry (100 mL), DMS-Borane (7 mL, 73.5 mmol) was added drop wise at room temperature. The reaction mixture was then allowed to reflux for 4 h. TLC (
Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.2) and product formation (Rf-0.4) The reaction mixture was cooled and quenched with saturated solution of ammonium chloride. The compound was extracted in ethyl acetate. The organic layer was dried over sodium sulphate, concentrated and purified by column chromatography using ethyl acetate (0-20%) in hexane afford 6-(hydroxymethyl)naphthalene-1,7-diol as an off white solid. Yield: (3.9 g, 83.8%). - LCMS: Ionization not observed; 1H NMR (400 MHz, DMSO-d6): δ 4.61 (d, J=5.2 Hz, 2H), 5.11 (t, J=5.8 Hz, 1H, —OH), 6.71 (d, J=7.6 Hz, 1H), 7.02 (t, J=7.8 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 7.36 (s, 1H), 7.70 (s, 1H), 9.64 (bs, 1H), 9.71 (bs, 1H).
- To a solution of 6-(hydroxymethyl)naphthalene-1,7-diol (1 g, 5.26 mmol) in acetone (120 mL), pyridinium-p-toluenesulfonate (0.13 g, 0.52 mmol) followed by 2,2 dimethoxy propane (0.77 mL, 6.31 mmol) were added at room temperature. The reaction mixture was then allowed to stir at room temperature overnight. TLC (
Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.4) and product formation (Rf-0.7) The reaction mixture was concentrated to dryness and purified by column chromatography using neutral 60-120 mesh silica to give 2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxin-9-ol. NMR is in agreement with the structure. Yield: (1.2 g, 99%) - LCMS: Ionization not observed; 1H NMR (400 MHz, CDCl3): δ 1.60 (s, 6H) 5.06 (s, 2H), 5.39 (bs, 1H, —OH), 6.74 (d, J=7.2 Hz, 1H), 7.14 (t, J=7.8 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.44 (s, 1H), 7.54 (s, 1H).
- To a solution of 2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxin-9-ol (1.2 g, 5.21 mmol) in DCM (130 mL) triethylamine (2.2 mL, 15.6 mmol) was added and the reaction mixture was cooled to 0° C. Triflic anhydride (1.3 mL, 7.82 mmol) was added drop wise during which the reaction mixture became black in color. The reaction mixture was allowed to stir as such for 2 h. TLC (
Mobile phase 10% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.3) and product formation (Rf-0.6). The reaction mixture was diluted with water. The organic layer was separated dried over sodium sulphate concentrated to give 2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxin-9-yl trifluoromethanesulfonate. The product was used as such for further reaction without purification. Yield: (1.88 g, Crude) - LCMS: Ionization not observed; 1H NMR (400 MHz, CDCl3): δ 1.62 (s, 6H), 5.08 (s, 2H), 7.30 (t, J=8 Hz, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.42 (s, 1H), 7.55 (s, 1H), 7.73 (d, J=8.4 Hz, 1H).
- To a solution of 2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxin-9-yl trifluoromethanesulfonate (0.37 g, 1.02 mmol) in degassed DMF (5 mL) zinc cyanide (0.23 g, 2.04 mmol) was added and the reaction mixture was further degassed for 15 min. Palladium tetrakis (0.23 g, 0.2 mmol) was added and the reaction mixture was degassed for 15 min. The reaction mixture was then heated in a bottle at 80° C. for 3 h. TLC (
Mobile phase 10% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.6) and product formation (Rf-0.4). The reaction mixture was cooled and filtered through a celite pad. The compound was extracted in ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulphate concentrated and purified by column chromatography using Hexane ethyl acetate as eluent (60-120 mesh neutral silica) to give 2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxine-9-carbonitrile. Yield: (0.13 g, 54%). - LCMS: Ionization not observed; 1H NMR (400 MHz, CDCl3): δ 1.62 (s, 6H), 5.09 (s, 2H), 7.34 (t, J=7.8 Hz, 1H), 7.56 (s, 1H), 7.62 (s, 1H), 7.82 (d, J=7.2 Hz, 1H), 7.93 (d, J=8.4 Hz, 1H).
- Ortho hydroxy aromatic aldehydes, with carbethoxy or methoxy functionality at suitable position were oxidized to get o-carboxy phenols which were then converted to amide by reaction either with ammonia/o-Methyl hydroxylamine. Ester functionality was then hydrolyzed to get required o-Hydroxy amido carboxylic acid, which upon coupling with tert-butyl 3-(piperidin-4-yl)benzylcarbamate and subsequent deprotection in acidic media afforded the title compounds.
- Desired Carbmethoxy hydroxy benzaldehyde was dissolved in Acetonitrile and aq solution of di-sodium hydrogen phosphate & 30% hydrogen peroxide was then added and reaction mass cooled to 0° C. Aq. solution of Sodium chlorite was added to the reaction mass drop wise and reaction mass was allowed to warm to room temperature. Stirring continued at room temperature and reaction was monitored by LCMS till maximum starting was consumed. Reaction mass was then concentrated, residue was acidified with aq. HCl and product extracted in ethyl acetate. Ethyl acetate extract dried over sodium sulfate and concentrated to get the crude product which was sufficient pure for the use in next step. The details of the compounds synthesized are as below in Table 31.
-
TABLE 31 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-75 4-Formyl, 3-Hydroxy methyl benzoate, (1 eq) ACN (65 V), NaH2PO4•2H2O (0.32 eq in 11 V water), H2O2 30% solution (5 eq) NaClO2 (1.4 eq in 10 V of water) RT 2 h. Yield - 35.46%Ionization not observed in LCMS 1H NMR DMSO-d6:- 3.91 (s, 3 h) 7.42 (d, 1H) 7.60 s (1H) 7.78 (d, 1H) 10.19 (s, 1H), 11.1 (s, 1H) B-66 3-Formyl, 4-Hydroxy methyl benzoate ACN (37.5 V), NaH2PO4•2H2O (0.32 eq in 11 V water), H2O2 30% solution (5 eq) NaClO2 (1.4 eq in 10 V of water) RT 2 h. Yield - 53.4%Ionization not observed in LCMS 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 7.06 (d, J = 8.8 Hz, 1H), 8.02-8.07 (dd, J = 1.6 and 8.6 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H). - Products from step-1 were converted to desired amides either by conversion to acid chloride and subsequent reaction with ammonia/desired amine or by coupling reaction using EDCI-HOBT in DMF followed by usual work-up as described in method-A (step-4.) Crude products were purified by column chromatography over silica gel using methanol (0-30%) in chloroform.
- Intermediates C-76 & D-76 were synthesized by Heck reaction of the desired o-Hydroxy-4-bromo benzamides (Synthesized form 4-bromo-2-hydroxybenzoic acid as per general procedure described earlier) using ethyl acrylate and following the procedure described in the literature for analogous compounds (Bull. Korean Chem. Soc. 1999, Vol. 20, 232-236)
- Intermediate C-86 was synthesized by the procedure described in the literature (J. Med. Chem. 43, 1670-1683, 2000)
- The details of compounds synthesized are as below in Table 32.
-
TABLE 32 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data C-75 EDCI (1.1 eq.), HOBT (1.1 eq.), aq ammonia (4 eq.), DMF (60 vol), RT, 14 h, purified by column chromatography (0- 30% Methanol-chloroform), Yield - 10%, Mol. Wt:- 195.17 M.I. Peak observed:- 196 C-75a B-75 (1 eq), DCM (75 Vol), TEA (1.5 eq) Thionyl chloride (1.5 eq) 0° C. 1 h. NH2OMe•HCl (1.5 eq) DCM (32 vol), TEA (2 eq) was added and stirred for 2 h. purified by column chromatography (0-30% Methanol-chloroform), Yield - 64%, Mol. Wt:- 225.20 M.I. Peak observed:- 225.75 C-66 DMF (35 Vol), EDCI (1.2 eq) HOBt (1.2 eq) Aq NH3 (1 Vol) RT overnight. 91% Mol. Wt:- 195.17 M.I. Peak observed:- 195.75 1H NMR (400 MHz, DMSO-d6): δ 3.82 (s, 3H), 6.98 (d, J = 8.8 Hz, 1H), 7.25 (brs, 2H), 7.95-7.98 (dd, J = 2 and 8.6 Hz, 1H), 8.54 (d, J = 2 Hz, 1H). C-92 B-66 (1 eq), DCM (100 Vol), TEA (3 eq) Thionyl chloride (1.5 eq) 0° C. 1 h. NH2OMe•HCl (1 eq) DCM (32 vol), TEA (2 eq) was added and stirred for 2 h. Yield - 52.6% Mol. Wt:- 225.20 M.I. Peak observed:- 225.7 1H NMR (400 MHz, CDCl3): δ 3.91 (s, 3H), 3.92 (s, 3H), 7.03 (d, J = 8.8 Hz, 1H), 8.05-8.09 (dd, J = 1.8 and 8.6 Hz, 1H), 8.16 (s, 1H), 9.48 (s, 1H), 12.2 (s, 1H) C-76 Bull. Korean Chem. Soc. 1999, Vol. 20, 232-236 White solid; Yield:- 60% Mol. Wt.: 235.24 M.I. Peak observed:- 236 C-76a As above White solid; Yield:- 93% Mol. Wt.: 265.26 M.I. Peak observed:- 266 C-86 J. Med. Chem. 43, 1670- 1683, 2000 Yield:- 71.4% Mol. Wt.: 235.24 M.I. Peak observed:- 277 (M + ACN) 1H NMR (400 MHz, DMSO-d6): δ 1.25 (t, J = 7.0 Hz, 3H), 4.10-4.23 (q, J = 7 Hz, 2H), 6.57 (d, J = 16 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 16 Hz, 1H), 7.74-7.80 (dd, J = 2.0 and 8.6 Hz, 1H), 8.06 (s, 1H), 8.28 (d, J = 2 Hz, 1H), 8.50 (s, 1H), 13.5 (s, 1H). - Hydrolysis of step-2 products was carried out as per general procedure followed in method-A (step-3) crude products were used for next step unless specified.
- The details of compounds synthesized are as below in Table 33.
-
TABLE 33 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data D-75 LiOH (3.0 eq.), THF:H2O (1:1), RT, 4 h, Yield:- 60%. Ionization not observed in LCMS Crude product subjected to next step. D-75a LiOH (3.0 eq.), THF:H2O (1:1), RT, 4 h, Yield:- 86%. Mol. Wt: 211.17 M.I. Peak observed:- 212 D-66 Acetone (25 V) 1N NaOH (25 V) RT 12 hrs Yield:- 60%Mol. Wt:- 181.15 M.I. Peak observed:- 181.7 1H NMR (400 MHz, DMSO-d6): δ 6.94- 6.97 (m, 1H), 7.94-7.96 (m, 1H), 8.01 (br, 1H), 8.52 (d, J = 2 Hz, 1H), 8.64 (br, 1H), 12.76 (br, 1H), 13.67 (s, 1H). D-92 Acetone (25 Vol) 1N NaOH (25 Vol) RT stir 12 hrs. Crude product contaminated with Sodium chloride was used for next step without purification.Mol. Wt:- 211.17 M.I. Peak observed:- 211.8 1H NMR (400 MHz, DMSO-d6): δ 3.70 (s, 3H), 7.05 (d, J = 8.4 Hz, 1H), 7.89- 7.93 (dd, J = 1.4 and 8.6 Hz, 1H), 8.26 (s, 1H). D-76 LiOH (4.0 eq.), MeOH:H2O (4:1), RT, 4 h, Acidified with aq. Citric acid instead of HCl during work-up. Yield:- 75%. Mol. Wt.: 207.18 M.I. Peak observed:- 208 [M + 1] D-76a LiOH (4.0 eq.), MeOH:H2O (4:1), RT, 4 h, Acidified with aq. Citric acid instead of HCl during work-up. Yield:- 70%. Mol. Wt.: 237.21 M.I. Peak observed:- 238 [M + 1] D-86 Acetone (25 Vol) 1N NaOH (25 Vol) RT stir 12 hrs. Crude product was taken for further step.Mol. Wt:- 207.18 M.I. Peak observed:- 208 - Coupling reactions of step-3 products with tert-butyl 3-(piperidin-4-yl)benzylcarbamate were carried out as per general procedure followed in method-A (step-4) Crude products
- The details of compounds synthesized are as below in Table 34. Unless specified crude products ere used for next step without further purification.
-
TABLE 34 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data E-75 tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, yield:- 40%, Mol. Wt:- 453.53 M.I. Peak observed:- 476.15 (M + Na) E-75a tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (85 vol), RT, 4 h, yield:- 61%, Mol. Wt:- 483.56 M.I. Peak observed:- 484.10 E-66 tert-butyl-3-(piperidin-4- yl)benzyl carbamate (1.2 eq) DCM (100 Vol), DMAP (0.5 eq), EDCI (1.5 eq) RT overnight. 50% Mol. Wt:- 453.53 M.I. Peak observed:- 454.3 1H NMR (400 MHz, DMSO-d6): δ 1.38 (s, 9H), 1.50-1.90 (m, 4H), 2.70-2.85 (m, 1H), 2.90-3.20 (br, 1H), 3.60-4.00 (br, 1H), 4.00-4.15 (brm, 2H), 4.20- 4.80 (br, 2H), 6.90-7.51 (m, 6H), 7.99 (s, 1H), 8.01 (brs, 1H), 8.51 (brs, 1H), 13.3 (s, 1H). E-92 tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DCM (100 Vol), DMAP (0.5 eq), EDCI (1.5 eq) RT 12 hrs, Purified by column chromatography on silica gel using methanol (0-10%) in chloroform. Yield:- 61%Mol. Wt:- 483.56 M.I. Peak observed:- 506 (M + Na) 1H NMR (400 MHz, CDCl3): δ 1.46 (s, 9H), 1.64-2.00 (m, 4H), 2.70-2.82 (m, 1H), 2.90-3.40 (br, 2H), 4.29 (s, 2H), 4.50-5.00 (br, 2H), 6.97 (d, J = 8.4 Hz, 1H), 7.00-7.20 (m, 4H), 7.26-7.30 (m, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 10.7 (s, 1H), 12.1 (s, 1H). E-76 tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DMF (10 Vol), HOBT (1.5 eq), EDCI (1.5 eq) DIEA (2.5 eq) RT 12 hrs, Yield:- 71%Mol. Wt.: 479.57 M.I. Peak observed:- 480 [M + 1] E-76a tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DMF (10 Vol), HOBT (1.5 eq), EDCI (1.5 eq) DIEA (2.5 eq) RT 12 hrs, Yield:- 36%Mol. Wt: 509.59 M.I. Peak observed:- 532.25 [M + Na] E-86 tert-butyl-3-(piperidin-4-yl) benzylcarbamate (1.2 eq) DCM (60 Vol), DMAP (0.5 eq), EDCI (1.5 eq) RT 12 hrs, Purified by column chromatography on silica gel using methanol (0-10%) in chloroform. Yield:- 45%Mol. Wt:- 479.57 M.I. Peak observed:- 480 1H NMR (400 MHz, DMSO-d6): δ 1.37 (s, 9H), 1.53 (br, 2H), 1.83 (br, 2H), 2.60-2.90 (m, 2H), 3.10-3.30 (m, 1H), 4.10 (d, J = 5.6 Hz, 2H), 4.40 (br, 1H), 4.63 (br, 1H), 6.91 (d, J = 8.4 Hz, 1H), 7.00-7.40 (m, 6H), 7.44 (d, J = 15.2 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 8.07 (brs, 1H), 8.20 (s, 1H), 8.48 (brs, 1H), 13.5 (s, 1H). - Boc deprotection of Step-4 products was carried out by stirring with Aq. hydrochloric acid-methanol or methanolic HCl at room temperature. Crude products were purified by reverse phase preparative HPLC and isolated as TFA salts.
- The details of compounds synthesized are as below in Table 35.
-
TABLE 35 REACTION CONDITIONS & ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data Target-75 Methanolic HCl (25 vol), 4 h, RT Purified by prep. HPLC, isolated as TFA Salt, Yield:- 20% Mol. Wt:- 353.41 M.I. Peak observed:- 354.05 HPLC Purity:- 96.79 1H NMR DMSO-d6:- 1.61- 1.83 (m, 4H), 2.80-2.85 (m, 2H), 3.16 (m, 1H), 3.61-3.64 (d, 1H), 4.00- 4.04 (q, 2H), 4.60-4.63 (d, 1H), 6.87 (s, 2H), 7.27-7.39 (m, 4H), 7.90- 7.92 (d, 1H), 8.03 (bs, 1H), 8.13 (bs, 2H), 8.48 (bs, 1H), 13.20 (bs, 1H). Target-75a Methanolic HCl (25 vol), 4 h, RT Purified by prep. HPLC, isolated as TFA Salt, Yield:- 11% Mol. Wt:- 383.44 M.I. Peak observed:- 384.20 HPLC Purity:- 97.05 1H NMR DMSO-d6:- 1.61- 1.83 (m, 4H), 2.08 (m, 2H), 3.15- 3.16 (m, 2H), 3.76 (s, 1H), 4.00 (s, 2H), 4.58 (m, 1H), 6.89-6.92 (m, 2H), 7.26- 7.36 (m, 4H), 7.67-7.69 (d, 1H). Target-66 Methanol (100 V), concentrated HCl (10 V) RT overnight. 70% HCl salt Mol. Wt:- 353.41 M.I. Peak observed:- 353.66 HPLC: 96% (220 nm). 1H NMR (400 MHz, DMSO-d6): δ 1.50- 1.85 (m, 4H), 2.79-2.90 (m, 1H), 3.20- 3.45 (br, 4H), 3.95-4.05 (m, 2H), 6.94 (d, J = 8.4 Hz, 1H), 7.20-7.60 (m, 5H), 8.00 (s, 1H), 8.02 (s, 1H), 8.22 (brs, 2H), 8.51 (brs, 1H), 13.30 (brs, 1H). Target-92 Methanol (100 V), concentrated HCl (10 V) RT 12 hrs. Purified by prep. HPLC isolated as TFA Salt. Yield:- 70%Mol. Wt:- 383.44 M.I. Peak observed:- 384.2 HPLC: 99.5% (220 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.50- 1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91- 3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). Target-76 Methanol (30 Vol), concentrated HCl (1 Vol) RT 3 hrs. Isolated as hydrochloride salt in pure form after work-up. Yield:- 45%Mol. Wt.: 379.45 M.I. Peak observed:- 380 [M + 1] HPLC Purity: 95.60% 1H NMR (400 MHz, CD3OD): 7.80 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 15.6 Hz, 1H), 7.45-7.30 (m, 4H), 7.26 (d, J = 15.6 Hz, 1H), 7.20-7.12 (m, 2H), 4.82-4.74 (m, 1H), 4.48-4.36 (m, 1H), 4.10 (s, 2H), 3.00-2.82 (m, 2H), 2.04-1.90 (m, 2H), 1.80-1.62 (m, 2H) Target-76a Methanol (30 Vol), concentrated HCl (1 Vol) RT 3 hrs. Isolated as hydrochloride salt in pure form after work-up. Yield:- 72%.Mol. Wt.: 409.48 M.I. Peak observed:- 410 [M + 1] HPLC Purity: 96.93% 1H NMR (400 MHz, CD3OD): 7.69 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 15.2 Hz, 1H) 7.43-7.18 (m, 6H), 7.16 (s, 1H), 4.82-4.74 (m, 1H), 4.46-4.36 (m, 1H), 4.10 (s, 2H), 3.83 (s, 3H), 3.02- 2.84 (m, 2H), 2.06-1.90 (m, 2H), 1.80-1.64 (m, 2H). Target-86 Methanol (100 V), concentrated HCl (10 V) RT 12 hrs. Isolated as hydrochloride salt in pure form after work-up. Yield:- 92.30%Mol. Wt:- 379.45 M.I. Peak observed:- 380.2 HPLC: 94.8% (220 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.40- 1.70 (br, 2H), 1.84 (br, 2H), 2.60-2.91 (m, 2H), 3.10-3.30 (m, 1H), 3.98 (d, J = 5.6 Hz, 2H), 4.40-4.70 (br, 2H), 6.91 (d, J = 8.4 Hz, 1H), 7.20-7.50 (m, 6H), 7.78 (d, J = 8.8 Hz, 1H), 8.07 (br, 1H), 8.32 (br, 2H), 8.37 (br, 2H), 8.65 (br, 1H). - Alfa hydroxy carboxylic acids were synthesized by reacting desired epoxide with tert-butyl 3-(1-(3-hydroxybenzoyl)piperidin-4-yl)benzyl carbamate in presence of base to yield Alfa hydroxy carboxylic esters that were hydrolyzed and de-protected to get the title compounds (Scheme-1).
- Similarly
indole 5/6 carboxylic acids were coupled with tert-butyl 3-(piperidin-4-yl)benzyl carbamate and resulting coupled products were treated with desired epoxides. Alfa hydroxy ester formed in the reaction gets hydrolyzed during the work-up to yield alpha hydroxy acids which were subjected to Boc De-protection to get the title compounds (SCHEME 12, part Scheme-2). - Coupling of desired carboxylic acid was carried out with tert-butyl 3-(piperidin-4-yl)benzylcarbamate as per general procedure described in Method-A step-4 was followed. The details of compounds synthesized are as below in Table 36.
-
TABLE 36 REACTION CONDITIONS & ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data A tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1.0 eq.), EDCI (1.5 eq.), HOBT (1.5 eq.), DIPEA (2.5 eq.), DMF, RT, 24 h, Yield:- 87% Mol. Wt:- 410.51 M.I. Peak observed:- 433.55 (M + Na) D-81/83 Indole-5-carboxylic acid (1 eq), tert-butyl 3-(piperidin-4-yl) benzyl carbamate (1.3 eq.), EDCI (1.2 eq.), DMAP (2.0 eq.), DMF, DCM, RT, 3 h, Yield:- 75% Mol. Wt:- 433.54 M.I. Peak observed:- 434.05 D-82/84 Indole-6-carboxylic acid (1 eq), tert-butyl 3-(piperidin-4-yl) benzyl carbamate (1.3 eq.), EDCI (1.2 eq.), DMAP (2.0 eq.), DMF, DCM, RT, 3 h, Yield:- 73% Mol. Wt:- 433.54 M.I. Peak observed:- 434.10 - Stirred suspension of Product from step-1 (intermediate A) in dimethyl formamide was added using potassium carbonate followed by desired epoxide. Reaction mass was heated to 100° C. and reaction monitored by LCMS till maximum starting was consumed. There after reaction mass was cooled to room temperature and diluted with water and extracted with ethyl acetate. Ethyl acetate extract was washed with water, dried over sodium sulfate and concentrated in vacuum to get the crude product which was purified by column chromatography over silica gel using 0-25% ethyl acetate in hexane. Epoxide required for Synthesis of target-103 was synthesized by the procedure described in the literature (J. Am. Chem. Soc. 113, 3096-3106, 1991)
- Details of the compounds synthesized are as below in Table 37.
-
TABLE 37 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-72 K2CO3 (4.0 eq.), DMF, 100° C., 5 h, 79% Mol. Wt: 540.65 M.I. Peak observed:- 563.40 (M + Na in ESMS) B-73 K2CO3 (4.0 eq.), DMF, 100° C., 5 h, 68% Mol. Wt: 602.72 M.I. Peak observed:- 603 (ESMS) B-103 K2CO3 (4.0 eq.), DMF, 100° C., 5 h, 80% Mol. Wt: 594.33 ESMS (m/z): 617 [M + Na] - Hydroxy ester from step-2 was hydrolyzed to acid following general procedure in method-A, step3. Compounds were purified by column chromatography over silica gel using methanol (1-15%) in chloroform. The details of the compounds synthesized are as below in Table 38.
-
TABLE 38 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data C-72 LiOH (2.0 eq.), THF:H2O (1:1), RT, Yield:- 79%. Mol. Wt: 512.59 LCMS (m/z): 535.15 [M + 1] C-73 LiOH (2.0 eq.), THF:H2O (1:1), RT, Yield:- 70%. Mol. Wt: 574.66 LCMS (m/z): 597 [M + Na] C-103 KOH (10.0 eq.), EtOH:H2O (1:1), RT, Yield:- 75%. Mol. Wt: 566.69 LCMS (m/z): 567.20 [M + Na] - Boc deprotection of the step-3 products was carried out by stirring with methanolic HCl at room temperature. Reactions were monitored by LCMS and after reaction completion, solvents were evaporated in vacuum and residue was purified by reverse phase preparative HPLC to get the products as TFA salts. The details of the compounds synthesized are as below in Table 39.
-
TABLE 39 REACTION CONDITIONS & ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data Target-72 Conc. HCl (8.0 eq.), MeOH, 15 h, RT, 62% isolated as TFA salt from prep HPLC and later converted to hydrochloride. Mol. Wt: 412.48 M.I. Peak observed:- 413.10 [M + 1] HPLC Purity: 98.83% 1H NMR (400 MHz, DMSO):- 7.45-7.25 (m, 5H), 7.12-7.00 (m, 2H), 6.92- 6.82 (m, 1H), 4.84-4.74 (m, 1H), 4.25 (d, J = 9.4 Hz, 1H), 4.10 (s, 2H), 4.03 (d, J = 9.4 Hz, 1H), 3.94-3.82 (m, 1H), 3.28-3.20 (m, 1H), 3.00-2.86 (m, 2H) , 2.02-1.92 (m, 1H), 1.88- 1.60 (m, 3H), 1.48 (s, 3H) Target-73 Cone. HCl (8.0 eq.), MeOH, 15 h, RT, Prep HPLC. isolated as TFA salt Yield:- 36% Mol. Wt: 474.55 M.I. Peak observed:- 475 [M + 1] HPLC Purity: 98.44% 1H NMR (400 MHz, CD3OD): δ 7.73- 7.70 (m, 2H), 7.42-7.28 (m, 8H), 7.12-7.08 (m, 1H), 7.05-7.00 (m, 2H), 4.82-4.75 (m, 1H), 4.71 (d, J = 9.4 Hz, 1H), 4.22 (d, J = 9.4 Hz, 1H), 4.10 (s, 2H), 3.92-3.84 (m, 1H), 3.28- 3.20 (m, 1H), 3.00-2.88 (m, 2H), 2.03-1.92 (m, 1H), 1.85-1.60 (m, 3H) Target-103 DCM (20 Vol), TFA (10 Vol), 2 h, RT, 50% isolated as TFA salt from prep HPLC and later converted to hydrochloride. Mol. Wt: 466.57 M.I. Peak observed:- 467.10 HPLC Purity: 97.58% 1H NMR (400 MHz, DMSO):- δ 1.47- 1.83 (m, 11H), 2.21 (t, 1H), 2.82-2.84 (m, 2H), 3.16 (bs, 1H), 3.94-4.00 (m, 3H), 4.18-4.20 (d, 1H), 4.62 (bs, 1H), 6.93- 7.00 (m, 4H), 7.30-7.36 (m, 4H). - Stirred suspension of coupled product form step-1 in THF was added sodium hydride. Stirring continued for 30 min and desired epoxy ester was added to it. Stirring continued at room temp and reaction monitored by LCMS. LCMS indicated peak of corresponding carboxylic acid instead of ester. After completion of reaction, Reaction mass was concentrated in vacuum and quenched with ice. pH of the reaction mass was then adjusted to 3-4 by potassium hydrogen sulfate and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulfate and concentrated in vacuum to get the crude product which was used for next step without purification.
-
TABLE 40 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data E-81 NaH (10 eq),THF (20 Vol), Methyl-2-methyloxirane-2- carboxylate (4.0 eq), R.T. Yield:- 70% Mol. Wt:- 535.63 M.I. Peak observed:- 558.10 (Na+) E-82 NaH (10 eq), THF (20 Vol), Methyl-2-methyloxirane-2- carboxylate (4.0 eq) Yield:- 65% Mol. Wt:- 535.63 M.I. Peak observed:- 536.00 E-83 NaH (10 eq),THF (20 Vol), Methyl-2-phenyloxirane- 2-carboxylate (4.0 eq) Yield:- 72.63% Mol. Wt:- 597.70 M.I. Peak observed:- 598.15 E-84 NaH (10 eq), THF (20 Vol) Methyl-2-phenyloxirane- 2-carboxylate (4.0 eq) Yield:- 77.48% Mol. Wt:- 597.70 M.I. Peak observed: 598.45 - Boc de-protection of Product from step-6 was carried out as per general procedure described in method-A, step-9.
-
TABLE 41 REACTION CONDITIONS & ANALYTICAL DATA Brief Reaction Comp. No. Structure conditions Analytical data Target-81 TFA (10 Vol), DCM (20 Vol), 4 Hrs, Isolated as TFA Salt by prep. HPLC. Yield:- 20%. Mol. Wt:- 435.52 M.I. peak observed:- 436.15 HPLC Purity:- 97.17% 1H NMR DMSO-d6:- 1.266 (s, 3H), 1.63- 1.722 (m, 4H, 2.835-2.913 (m, 4H), 4.029-4.015 (d, 2H, 4.294-4.331 (d, 1H, J = 14.4 Hz), 4.402-4.438 (d, 1H, J = 14.8 Hz), 6.492 (s, 1H), 7.166- 7.187 (d, 1H, J = 8.4 Hz), 7.291-7.398 (m, 5H), 7.607 (s, 1H), 7.557-7.578 (d, 1H, J = 8.4 Hz), 8.132 (s, 3H). Target-82 TFA (10 Vol), DCM (20 Vol), 4 Hrs, Isolated as TFA Salt by prep. HPLC. Yield:- 10%. Mol. Wt:- 435.52 M.I. peak observed:- 436.05 HPLC Purity:- 97.79% 1H NMR DMSO-d6:- 1.265 (s, 3H), 1.615- 1.751 (m, 4H), 2.871-2.812 (m, 4H),, 4.004-4.033 (d, 2H), 4.305- 4.342 (d, 1H, J = 14.8 Hz), 4.452-4.416 (d, 1H, J = 14.4 Hz), 5.538 (m, 1H), 6.472- 6.479 (d, 1H), 7.059-7.081 (d, 1H),7.550- 7.571 (d, 1H), 7.277-7.406 (m, 2H), 7.626 (s, 1H), 6.902-6.934 (t, 1H), 8.135 (s, 3H), 12.9 (s, 1H). Target-83 TFA (20 Vol), DCM (40 Vol), 4 Hrs, Isolated as TFA Salt by prep. HPLC and converted to hydrochloride Yield:- 30% Mol. Wt:- 497.58 M.I. peak observed:- 498 HPLC Purity:- 99.85% 1H NMR DMSO-d6:- 1.586-1.768 (m, 4H), 2.796-2.855 (m, 2H), 3.427- 3.523 (m, 2H), 3.055- 2.988 (m, 1H), 4.022-3.972 (d, 2H), 4.503- 4.539 (d, 1HJ = 14.4 Hz), 4.875-4.911 (d, 1H, J = 14.4 Hz), 6.418-6.424 (d, 1H), 7.101-7.105 (dd, 1H, J = 1.6 Hz), 7.256- 7.368 (m, 7H), 7.446 (s, 1H), 7.512 (s, 1H), 7.629-7.625 (dd, 1H, J = 1.6 Hz), 7.446-7.560 (m, 2H), 8.371 (bs, 2H),. Target-84 TFA (20 Vol), DCM (40 Vol), 4 Hrs, Isolated as TFA Salt by prep. HPLC and converted to hydrochloride Yield:- 30% Mol. Wt:- 497.58 M.I. peak observed:- 498.40 HPLC Purity:- 98.03% 1H NMR DMSO-d6:- 1.633-1.799 (m, 4H), 2.820-2.879 (m, 2H), 3.988- 4.015 (d, 2H), 4.493-4.532 (d, 1H, J = 15.6 Hz), 4.838- 4.924 (d, 1H, J = 14.4 Hz), 6.397-6.405 (d, 1H), 7.033-7.053 (d, 1H, J = 8 Hz), 7.442 (s, 1H), 7.448-7.518 (d, 1H, J = 8 Hz), 7.632-7.613 (d, 3H), 8.326 (bs, 3H) - Meta/para hydroxy benzoic acid was coupled with tert-butyl 3-(1-(3-hydroxybenzoyl)piperidin-4-yl)benzylcarbamate. Coupled product was reacted with ethyl bromo acetate/methyl acrylate in presence of base to yield corresponding O-Alky product with aliphatic ester functionality which was hydrolyzed and coupled with cis-pyrrolidine diol (e.g. as shown in EP1961750 & WO2009/61879) the coupled products were de-protected to yield the title compounds.
- This reaction was performed as per the general procedure described for step-4 in method “A” using meta or para-hydroxy benzoic acid.
- The details of compounds synthesized are as below in Table 42.
- Product from step-1 was dissolved in methyl acrylate. To this catalytic hydroquinone was added as polymerization inhibitor followed by sodium metal. Reaction mass was then refluxed for 48 hrs and monitored by LCMS. After consumption of maximum starting, the reaction mass was concentrated and the residue was purified by column chromatography over neutral alumina using Methanol (0-10%) in dichloromethane.
- Product from step-1 was added to suspension of potassium carbonate in acetone at room temperature. Ethyl bromo acetate was then added to this and refluxed and reaction was monitored by LCMS. After maximum starting was consumed, Reaction mass was concentrated and residue was diluted with dichloromethane and washed with water. Organic layer was filtered, dried over a=sodium sulfate and concentrated to get the crude product which was used for next step without further purification.
-
TABLE 42 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data B-53 Methyl acrylate (20 vol), Na metal (10 eq), hydroqunone (catalytic), 48 h, 75° C., Yield:- 82.9% Mol. Wt:- 496.60 M.I. Peak observed:- 519.45 (M + Na) Purity:- 83% B-29 Ethyl bromo acetate (1 eq.), K2CO3 (3 eq), acetone (100 vol), reflux temp, 3 h, Yield:- 100%, Crude product carried forward Mol. Wt:- 496.60 M.I. Peak observed:- 519.35 (M + Na) Crude product used for next step B-30 Ethyl bromo acetate (1 eq.), K2CO3 (3 eq), acetone (100 vol), reflux temp, 3 h, 98%, Crude product carried forward for next step. - These reactions were performed as per general procedure followed for step-3 of method A. In some cases sodium hydroxide was used instead of lithium hydroxide as reactions were unsuccessful with lithium hydroxide
- The details of compounds synthesized are as below in Table 43.
-
TABLE 43 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data C-53 LiOH (2.0 eq.), THF:H2O (1:1), RT, 12, h, Yield:- 77%. Mol. Wt:- 482.57 M.I. Peak observed:- 505.45 (M + Na) Crude product used for next step C-29 NaOH (3.0 eq.), THF:H2O (1:1), RT, Yield:- 74%. Mol. Wt:- 468.54 M.I. Peak observed:- 491.20 (M + Na) Crude product used for next step C-30 NaOH (3.0 eq.), THF:H2O (1:1), RT, Yield:- 70%. Mol. Wt:- 468.54 M.I. Peak observed:- 491.20 (M + Na) Crude product used for next step - Protected cis-pyrrolidine diol required was synthesized as per procedure described in the literature (EP1961750 & WO2009/61879). Coupling reactions were carried out as per the general procedure described in method-A (step-4).
- The details of compounds synthesized are as below in Table 44.
-
TABLE 44 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data D-53 protected cis pyrrolidine diol (1.1 eq) EDCI (1.5 eq), DMAP (1.2 eq), DCM (100 vol), RT, 3 h, Yield:- 82.2% Mol. Wt:- 607.74 M.I. Peak observed:- 630.15 (M + Na) Crude product used for next step D-29 protected cis pyrrolidine diol (1.3 eq) EDCI (1.5 eq), DMAP (1.2 eq), DCM (100 vol), RT, 3 h, Yield:- 44.6% Mol. Wt:- 593.71 M.I. Peak observed:- 594.41 Crude product used for next step D-30 protected cis pyrrolidine diol (1.3 eq) EDCI (1.5 eq), DMAP (1.2 eq), DCM (100 vol), RT, 3 h, Yield:- 40% Mol. Wt:- 593.71 M.I. Peak observed:- 594.48 Crude product used for next step - Products form step-4 were deprotected as per procedure described in method A (Step-5) the details of compounds synthesized are as below in Table 45.
-
TABLE 45 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-53 Methanolic HCl (25 vol), 4 h, RT, 89%. Isolated by prep HPLC As TFA salt and converted to hydro- chloride Mol. Wt:- 467.56 M.I. Peak observed:- 468.10 HPLC Purity:- 95.41 1H NMR DMSO-d6:- 1.62-1.83 (m, 4H) 2.69 (t, 2H), 2.79- 2.85 (m, 2H), 3.16- 3.50 (m, 7H), 3.99 (t, 2H), 4.04-4.08 (m, 2H), 4.21 (t, 2H), 4.65 (bs, 1H), 6.93-7.05 (m, 3H), 7.18 (s,1H), 7.29- 7.42 (m, 4H), 8.26 (bs, 2H). Target-29 TFA (6 eq) DCM (100 vol), R.T., 7 hrs, Isolated by prep HPLC As TFA salt 33%. Mol. Wt:- 453.53 M.I. Peak observed:- 454.50 HPLC Purity:- 98.79 1H NMR DMSO-d6:- 1.60-1.83 (m, 4H), 2.83 (t, 2H), 3.18- 3.33 (m, 5H), 3.62- 3.66 (m, 2H), 3.97- 4.07 (m, 4H), 4.62 (bs, 1H), 4.74 (s, 2H), 6.92-6.99 (m, 3H), 7.27-7.39 (m, 5H), 8.12 (bs, 2H). Target-30 TFA (6 eq) DCM (100 vol), R.T., 7 hrs, Isolated by prep HPLC As TFA salt 21%. Mol. Wt:- 453.53 M.I. Peak observed:- 454.40 HPLC Purity:- 95.34 1H NMR DMSO-d6:- 1.59-1.77 (m, 4H), 2.83 (t, 2H), 3.16- 3.40 (m, 5H), 3.62- 3.66 (m, 2H), 4.00- 4.08 (m, 4H), 4.76 (s, 2H), 6.94-6.96 (d, 2H), 7.27-7.37 (m, 6H), 8.12 (bs, 2H). - Spiro key intermediate (E) was synthesized from 2H-spiro[benzofuran-3,4′-piperidine]-5-carbonitrile (US 2009/0163527, & B.org. Med. Chem. Lett. 2008, 18, 2114-2121.) through the reaction sequence described in the scheme below.
- Boronic acids or hydroxy compounds were synthesized form it through the identical reaction sequence followed earlier (Method A & C). Spiro amidines were synthesized as per the reaction sequence mentioned in
steps 7 & 8. - To a stirred solution of 2H-spiro[benzofuran-3,4′-piperidine]-5-carbonitrile (5 g, 0.023 mol) in THF (10 vol) and aq. solution of sodium bicarbonate (10 vol) was added benzyl chloroformate (1.3 eq 0.030 mol) at 0-5° C. and the reaction mixture was stirred for 3 hrs at same temperature. There after it was warmed to room temperature and stirring continued for additional 2 hrs. Solvents were then evaporated under reduced pressure and aq layer was extracted with ethyl acetate. Ethyl acetate extracts were dried over sodium sulphate and concentrated to get the Crude product which purified by column chromatography over silica gel using ethyl acetate (0-20%) in hexane to get the pure product.
- Yield: 60%
- Mol. Wt: −348.40
- M.I peak observed: −348.95
- To a stirred solution of benzyl-5-cyano-2H-spiro[benzofuran-3,4′-piperidine]-1′-carboxylate (4 g, 0.011 mol) in methanol (10 vol) was added Boc anhydride (5.01 g, 2.0 eq 0.022 mol)& NiCl2 (0.372 g, 0.25 eq, 0.0028 mol) at 0-5° C. Sodium borohydride (0.869 g, 2.0 eq, 0.22 mol) was then added portion wise maintaining the temperature. Reaction mixture was allowed to warm to room temperature and stirring continued for 3 hrs there after. Solvents were evaporated under reduced pressure. Residue was diluted with water (˜20 volumes) and extracted with ethyl acetate. Ethyl acetate extract was dried over sodium sulphate and concentrated to get the crude product which was purified by column chromatography over silica gel using ethyl acetate (0-40%) in hexane to get the pure product.
- Yield: 3.2 g (62.7%)
- Mol. Wt: −438.52
- M.I peak observed: −475.55 (M+Na)
- To a stirred solution of benzyl5-((tert-butoxycarbonyl)amino)-2H-spiro[benzofuran-3,4′-piperidine]-1′-carboxylate (3 g, 0.0066 mol) in methanol (15 vol) was added 10% Pd/C (500 mg) at room temperature under nitrogen atmosphere. The mixture was then stirred under hydrogen pressure (˜10 Kg) at room temperature in an autoclave till no more hydrogen was consumed & LCMS there after indicated formation of product and absence of starting material (˜4 hrs required). Vessel was depressurized and the reaction mass was filtered through celite; solvent was evaporated in vacuum, and the residue was purified by column chromatography get pure product which was characterized by LCMS. Yield: 63%
- Mol. Wt: −(318.41)
- M.I peak observed: −(319.05)
- Procedure described in method-A step-4 & 5 was followed.
-
TABLE 46 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-35- Spiro 1) tert-butyl ((2H- spiro[benzofuran-3,4′- piperidin]-5-yl)methyl) carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 12 h, 81% 2) TFA (10 eq) Acetonitrile (65 vol), R.T. 12 hrs, 57% Mol. Wt:-442.31 M.I. Peak observed: 443.40 HPLC Purity:- 95.81% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO):- 1.67- 1.79 (m, 4H), 3.16-3.29 (m, 2H), 3.92-3.93 (q, 4H), 4.50 (s, 3H), 6.81-6.83 (d, 1H), 7.23- 7.25 (d, 1H), 7.40-7.58 (m, 4H), 7.71-7.81 (m, 4H), 8.15 (s, 1H), 8.25 (bs, 2H). - Procedure described in method-C, step-1 & 2 was followed for Target-78-spiro & and Procedure as per method-A, step-4 & 9 was followed for Target-2 spiro.
-
TABLE 47 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target-78- Spiro 1) tert-butyl ((2H- spiro[benzofuran-3,4′-piperidin]- 5-yl)methyl)carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 12 h, Yield - 90% 2) BBr3 (3 eq) DCM (85 vol), R.T. 1 hrs, Yield - 74% Mol. Wt:- 388.84 M.I. Peak observed: 411.00 (M + Na) HPLC Purity:- 99.60% 1H NMR DMSO-d6:- 1HNMR (400 MHz, DMSO):- 1.72 (m, 4H), 3.14 (m, 4H), 3.94- 3.95 (q, 2H), 4.49 (s, 2H), 6.80-6.86 (m, 3H), 7.20- 7.23 (d, 1H), 7.41 (s, 1H), 8.02 (bs, 2H), 9.59 (bd, 1H), 10.11 (bs, 1H). Target-2 Spiro 1) tert-butyl ((2H-spiro [benzofuran-3,4′-piperidin]- 5-yl)methyl)carbamate (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DMF (10 vol), RT, 12 h, Yield - 60% 2) TFA (3 eq) DCM (25 vol), R.T. 4 hrs, Yield - 51% Mol. Wt:- 354.40 M.I. Peak observed: 377.00 (M + Na) HPLC Purity:- 99.33% 1H NMR CD3OD:- 1.814- 1.930 (m, 4H), 3.14 (m, 4H), 4.04 (s, 2H), 4.56 (s, 2H), 6.90 (s, 1H), 6.18-6.83 (m, 3H), 7.31 (s, 1H), 7.224-7.244 (dd, 1H). - These reactions were carried out as per procedure described in method-A (step-4 or step-8).
-
TABLE 48 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data F-35-Spiro amidine 2H-spiro[benzofuran-3,4′- piperidine]-5-carbonitrile (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 12 h, purified by column chromatography, over silica gel using 0-40% ethyl acetate in hexane. Yield - 75% Mol. Wt:- 520.43 M.I. Peak observed: 543.22 (M + Na) F-33 spiro amidine 2H-spiro[benzofuran-3,4′- piperidine]-5-carbonitrile (1.1 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM (100 vol), RT, 12 h, column chromatography, over silica gel using 0-40% ethyl acetate in hexane, Yield - 52% Mol. Wt:- 388.22 M.I. Peak observed: 389.35 - Products from step-7 were treated Ethanolic HCl at ambient temperature followed by methanolic ammonia in a sealed bottle to get the title compounds which were isolated by prep. HPLC as TFA salts which were later converted to hydrochloride salts by stirring with 2N HCl for 30 min and subsequent lyophilization.
-
TABLE 49 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data Target-35- Spiro amidine 1) Ethanolic HCl (5 vol) RT, 4 H, purified by column chromatography, over silica gel using 0-40% methanol in chloroform Yield - 75% 2) Methanolic ammonia (10 vol), heating in sealed tube, 12 h, purified by prep HPLC, isolated as TFA salt, converted to HCl salt. Yield - 43% Mol. Wt:- 455.31 M.I. peak observed:- 456.20 HPLC Purity:- 98.66% 1H NMR DMSO-d6:- 1.703-1.847 (m, 4H), 3.057 (m, 2H), 3.657 (m, 2H), 4.657 (s, 2H), 7.038-7.018 (d, 1H), 7.413-7.457 (m, 2H), 7.570 (t, 1H), 7.790 (t, 1H), 7.866 (s, 1H), 8.142 (s, 1H), 7.675- 7.746 (m, 4H), 8.746 (bs, 2H), 9.079 (s, 2H), 8.142 (s, 1H), T-33 spiro amidine 1) Ethanolic HCl (5 vol) RT, 4 H, purified by column chromatography, over silica gel using 0-40% methanol in chloroform Yield-61% 2) Methanolic ammonia (10 vol), heating in sealed tube, 12 h, purified by prep HPLC, isolated as TFA salt, converted to HCl salt. Yield - 13% Mol. Wt:- 405.25 M.I. peak observed:- 406.10 HPLC Purity:- 98.36% 1H NMR DMSO-d6:- 1.784-1.815 (m, 4H), 2.900 (m, 1H), 4.340-4.493 (m, 2H), 4.862 (s, 2H), 7.029- 7.050 (d, 1H), 7.364-7.403 (d, 1H J = 15.6 Hz), 7.513- 7.551 (d, 1H, J = 15.2 Hz), 7.689-7.822 (d, 5H), 7.804 (s, 1H), 9.050 (bsa, 2H), 8.710 (bs, 2H), 8.134 (bs, 2H). - These targets were synthesized by reaction sequence below in
Scheme 15. - 1-bromo-4-iodo-2-methylbenzene was synthesized as per procedures available in the literature (Bioorganic and Medicinal Chemistry, 16, 6764-6777, 2008; J. Am. Chem. Soc., 122, 6871-6883, 2000.)
- Suzuki coupling of Step-1 product with meta/para carbethoxy/methoxy phenyl boronic acid was carried out in presence of Palladium (0) Tetrakis (Triphenyl phosphene) in dioxane and sodium carbonate as base. After completion of reaction, the reaction mixture was filtered through celite pad and filtrate was concentrated under reduced pressure residue was diluted with water and extracted with ethyl acetate to get crude product. Crude products obtained were purified by column chromatography over silica gel using 5-10% ethyl acetate in hexane. The details of the intermediates synthesized are as below in Table 50.
-
TABLE 50 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data B-36 Boronic acid (1.2 eq.), Water (5 vol) Dioxane (20 vol), Pd-Tetrakis (10 mol %), Sodium carbonate (2 eq.), 80° C., 15 hrs. Yield 64.8% 1H NMR CDCl3:- 2.447 (s, 3H), 3.942 (s, 3H), 7.260 (s, 1H), 7.308-7.327 (d, 1H, J = 7.6 Hz), 7.452-7.472 (d, 1H, J = 8 Hz), 7.608- 7.628 (d, 2H, J = 8 Hz), 7.802 (s, 1H), 8.086-8.106 (d, 2H, J = 8 Hz). B-36- meta Same as above Yield:- 60% Mol. Wt:- 319.19 M.I. Peak observed:- 362.25 ACN adduct. - Stirred suspension of step-2 products in toluene was degassed with argon and to this were added potassium acetate, PdCl2-DPPF-CH2Cl2 and Bis(Pinacolato)Diborane. Reaction mass was heated to reflux & monitored by LCMS till maximum starting material was consumed. The mixture was the filtered through celite pad and filtrate was concentrated under reduced pressure to yield the crude product. The crude product was purified by column chromatography over silica gel using 1-5% ethyl acetate in hexane. The details of the compounds synthesized are as below in Table 51.
-
TABLE 51 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data C-36 Bispinacolato diborane (2.5 eq.), PdCl2 (dppf) (5 mol %), dppf (3 mol %), Potassium acetate (3.0 eq.), Toluene (30 vol), Reflux, 5 hrs., Yield 50%1H NMR CDCl3:- 1.362 (s, 12H), 2.586 (s, 3H), 3.936 (s, 3H), 7.257-7.275 (d, 1H, J = 7.2 Hz), 7.570- 7.589 (d, 1H, J = 7.6 Hz), 7.667-7.688 (d, 2H, J = 8.4 Hz), 8.023 (s, 1H), 8.070- 8.091 (d, 2H, J = 8.4 Hz). C-36- meta Same as above Yield:- 75% Mol. Wt:- 366.26 M.I. Peak observed:- 367.20 - To a stirred solution of step-3 product in Carbon tetrachloride, Dibenzoyl peroxide & N-bromo succinamide were added. The resulting mixture was heated to 75° C. and reaction was monitored by LCMS. After consumption of maximum starting the reaction mixture was diluted with water and extracted with dichloromethane. Organic phase was again washed with water followed by brine, and dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography over silica gel using 1-5% ethyl acetate in hexane. The details of the compounds synthesized are as below in Table 52.
-
TABLE 52 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data D-36 Benzoyl peroxide (0.2 eq.), NBS (1.2 eq.) CCl4 (20 vol), 75° C. for 3 hrs. Yield:- 60% 1H NMR CDCl3:- 1.392 (s, 12H), 3.943 (s, 3H), 4.967 (s, 3H), 7.479-7.499 (d, 1H, J = 8 Hz),7.644-7.650 (d, 1H), 7.692-7.671 (d, 2H, J = 8.4 Hz), 8.071 (s, 1H), 8.108-8.088 (d, 2H, J = 8 Hz). D-36- meta Same as above Yield:- 65% Mol. Wt:- 445.15 M.I. Peak observed:- 446.20 - To a stirred solution of Step-4 product in acetonitrile, trifluoro acetic acid and water were added and mixture was heated to 91° C. and monitored by LCMS. After maximum starting was consumed, The reaction mixture was concentrated and residue obtained was diluted with water and extracted with ethyl acetate. Concentration of ethyl acetate layer yielded crude product which was purified by column chromatography over silica gel using 10-35% ethyl acetate in hexane.
- The details of the compounds synthesized are as below in Table 53.
-
TABLE 53 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data E-36 Acetonitrile (30 vol) TFA (10 vol) Water (5 Vol), 91° C. 14 hrs, Yield:- 50% 1H NMR DMSO-d6:- 3.881 (s, 3H), 5.055 (s, 2H), 7.536-7.556 (d, 1H, J = 8 Hz), 7.778-7.855 (m, 3H), 8.032- 8.073 (m, 3H), 9.286 (s, 1H). E-36- meta Same as above Yield:- 50% Mol. Wt:- 282.10 M.I. Peak observed:- 283.25 - A mixture of step-5 product, lithium hydroxide, THF & water was heated to 60° C. Reaction was monitored by LCMS till maximum starting was consumed. The reaction mixture was concentrated and diluted with water. pH of the reaction mass was then adjusted to ˜2 using Conc. HCl. Precipitated product was filtered, washed with water and dried in vacuum oven. The details of the compounds synthesized are as below in Table 54.
-
TABLE 54 REACTION CONDITIONS & ANALYTICAL DATA Comp. No. Structure Brief Reaction conditions Analytical data F-36 LiOH (10 eq), THF (10 vol), Water (20 Vol), 60° C., 2 hrs. Yield:- 60% 1H NMR DMSO-d6:- 5.054 (s, 2H), 7.141- 7.165 (d, 1H, J = 9.6 Hz), 7.531-7.551 (d, 1H, J = 8 Hz), 7.778- 7.846 (m, 2H), 7.992- 8.058 (m, 2H), 7.084 (s, 1H). F-36- meta Same as above Yield:- 75% 1H NMR DMSO-d6:- 5.051 (s, 2H), 7.523- 7.543 (d, 1H, J = 8 Hz), 7.618- (t, 1H), 7.812-7.832 (d, 1H), 7.922-7.955 (d, 2H), 8.076 (s, 1H), 8.216 (s, 1H), 9.275 (S, 1H), 13.10 (s, 1H) - These reactions were carried out as per general procedure described in method-A, Step-4. DMF was used as co-solvent. pH of the reaction mass was adjusted to ˜5 by adding dilute HCl prior to the extraction. The details of the compounds synthesized are as below in Table 55.
-
TABLE 55 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data G-36 tert-butyl 3-(piperidin- 4-yl) benzyl carbamate (1.3 eq.), EDCI•HCl (1.5 eq.), DMAP (2 eq.), DCM (20 vol), DMF (10 vol), RT, 4 h, Yield:- 50%, Mol. Wt:- 526.43 M.I. peak observed:- 527.5 G-36- meta Same as above Yield: 70% Mol. Wt:- 526.43 M.I. peak observed:- 549.05 (M + Na) - Boc de-protection of Product from step-6 was carried out as per general procedure described in method-A, step-9.
-
TABLE 56 REACTION CONDITIONS & ANALYTICAL DATA Comp. Brief Reaction No. Structure conditions Analytical data Target- 36 TFA (20 eq.), Dichloromethane (20 vol), R.T. 4 hr. Prep HPLC. isolated as TFA salt converted to hydrochloride Yield:- 12.76% Mol. Wt:- 426.32 M.I. peak observed:- 427.05 HPLC Purity:- 99.10% 1H NMR DMSO-d6:- 1.646- 1.769 (m, 4H), 4.653-4.681 (m, 1H), 2.822-2.881 (m, 2H), 3.104- 3.218 (m, 2H), 3.997-4.011 (d, 2H), 5.047 (s, 2H), 7.458 (s, 1H), 8.055 (s, 1H), 7.535-7.554 (m, 2H), 7.298-7.375 (m, 3H), 7.726-7.746 (d, 2H, J = 8 Hz), 7.816-7.796 (d, 2H, J = 8 Hz) 8.372 (s, 3H). Target- 36- meta Same as above isolated as TFA salt & converted to hydrochloride Yield:- 50% Mol. Wt:- 426.32 M.I. peak observed:- 427.06 HPLC Purity:- 99.47% 1H NMR DMSO-d6:- 1.670- 2.070 (m, 4H), 2.813-2.873 (m, 2H), 3.166-3.230 (m, 1H), 3.989- 4.003 (d, 2H), 3.578-3.558 (m, 1H), 5.046 (s, 2H), 7.469 (s, 1H), 7.669, (s, 1H), 8.095 (s, 1H), 7.288- 7.340 (m, 3H), 7.819-7.816 (d, 1H, J = 8 Hz), 7.757-7.737 (d, 1H, J = 8 Hz), 7.433-7.414 (d, 1H, J = 7.6 Hz), 7.512-7.532, (d, 1H, J = 8 Hz), 8.406 (s, 3H) - Synthesis of the N-(3-(4-(3-(aminomethyl)phenyl)piperidine-1-carbonyl)phenyl)-2-(1-hydroxycyclobutyl)-2-oxoacetamide was carried out as shown in the scheme below.
-
- Detailed experimental procedure and analytical data is as follows.
-
- In 1:1:0.5 THF/water/Methanol (10:10:5 mL each), ethyl 2-cyclobutylideneacetate (1.2 g, 8.57 mmol) and lithium hydroxide monohydrate (2.15 g, 51.4 mmol) was added at room temperature. Reaction mixture was allowed to stir at room temperature for 16 h. TLC showed absence of starting material (Rf=0.4, 30% ethyl acetate/n-hexane). THF and Methanol was removed under reduced pressure. Aqueous layer was acidified with citric acid and extracted with ethyl acetate. Crude product was purified by column chromatography (silica gel 60-120 mesh ethyl acetate/n-hexane as eluent) to afford white solid.
- Yield: 0.6 g (62%)
- 1H NMR (400 MHz, CDCl3): δ 2.02-2.20 (m, 2H). 2.86 (t, J=7.8 Hz, 2H), 3.14 (t, J=7.8 Hz, 2H), 5.59 (t, J=2 Hz, 1H).
-
- To a solution of 3-aminobenzoic acid (6 g, 0.043 mmol), Triethyl amine (12.1 mL, 87.6 mmol), water (50 mL) in 1-4 Dioxane (100 mL) was added Boc anhydride (15 mL, 65.7 mmol) at room temperature. Reaction mixture was allowed to stir for 16 h at room temperature. TLC showed absence of starting material (Rf=0.7, 70% ethyl acetate/n-hexane). 1-4 Dioxane was removed under reduced pressure and 3N HCl solutions (60 mL) was added drop wise in the reaction mixture. White precipitate obtained was filter out, washed with hexane and dried.
- Yield: 10 g (97%)
- 1H NMR (400 MHz, CDCl3): δ 1.47 (s, 9H), 7.35 (t, J=8 Hz, 1H), 7.53 (d, J=8 Hz, 1H), 7.61 (d, J=8 Hz, 1H), 8.14 (s, 1H), 9.53 (s, 1H), 12.9 (br, 1H).
-
- To a solution of 3-((tert-butoxycarbonyl)amino)benzoic acid (2.19 g, 9.24 mmol) in acetonitrile (30 mL), benzyl 3-(piperidin-4-yl)benzylcarbamate (3 g, 9.24 mmol), EDCI (1.9 g, 10.2 mmol), HOBt (2.5 g, 18.5 mmol), DIPEA (4 mL, 23.1 mmol) were added and the reaction mixture was allowed to stir at room temperature overnight under nitrogen atmosphere. TLC showed absence of starting material (Rf=0.67, 60% ethyl acetate/n-hexane). Acetonitrile was removed under reduced pressure; the reaction mixture was washed with water. The organic layer was separated, dried over sodium sulphate, concentrated and purified by column chromatography (Silica gel 100-200 mesh using 0-80% ethyl acetate in hexane as eluent) to give the desired product as brown semi solid. This was used as such for the next step.
- Yield: 1.6 g (32%)
- LCMS: m/z (M+Na) 566
- 1H NMR (400 MHz, CDCl3): δ 1.51 (s, 9H), 1.60-2.00 (br, 4H), 2.70-2.80 (m, 1H), 2.90-3.30 (br, 2H), 3.80-4.00 (br, 1H), 4.38 (d, J=5.6 Hz, 2H), 4.84 (br, 1H), 5.14 (s, 2H), 6.64 (s, 1H), 7.00-7.50 (m, 12H).
-
- In 16 mL of methanol, product from step 2 (1.6 g, 2.94 mmol) and 6.4 mL of conc. HCl was allowed to stir at room temperature for 16 h. Methanol was removed under reduced pressure. Water (20 ml) was added in reaction mixture and basified by 2 N NaOH solution. Aqueous layer was extracted with ethyl acetate. Organic layer was washed with brine and water. Further organic layer was dried over sodium sulphate and evaporated under reduced pressure. Crude compound was purified by column chromatography (Silica gel 60-120 mesh using 0-80% ethyl acetate in hexane as eluent) to give the desired product as white solid.
- Yield: 1.1 g (84%)
- LCMS: m/z (M+23) 466
- 1H NMR (400 MHz, CDCl3): δ 1.70-2.00 (br, 4H), 2.70-2.81 (m, 1H), 2.82-3.20 (br, 1H), 3.92 (br, 1H), 4.38 (d, J=5.6 Hz, 2H), 4.70-5.10 (br, 2H), 5.15 (s, 2H), 6.70-6.82 (m, 3H), 7.00-7.50 (m, 11H).
-
- To a solution of 2-cyclobutylideneacetic acid (0.27 g, 2.41 mmol) in DMF (8 mL), 3-(1-(3-aminobenzoyl)piperidin-4-yl)benzylcarbamate (1.09 g, 2.41 mmol), Pybop (2.5 g, 4.82 mmol), DIPEA (1.1 mL, 6.02 mmol) were added and the reaction mixture was allowed to stir at room temperature for overnight under nitrogen atmosphere. TLC showed absence of starting material (Rf=0.37, 80% ethyl acetate/n-hexane). Reaction mixture was quenched with water, extracted by ethyl acetate, organic layer washed with water and brine. Organic layer was dried over sodium sulphate and evaporated under reduced pressure. Crude compound was purified by column chromatography (Silica gel 100-200 mesh using 0-80% ethyl acetate in hexane as eluent) to give the desired product as white solid.
- Yield: 0.84 g (65%)
- LCMS: m/z (M+Na) 560
- 1H NMR (400 MHz, DMSO-d6): δ 1.40-1.92 (br, 4H), 2.0-2.15 (m, 2H), 2.70-2.90 (m, 4H), 3.00-3.20 (m, 3H), 3.70 (br, 1H), 4.19 (d, J=6 Hz, 2H), 4.62 (brs, 1H), 5.05 (s, 2H), 5.80 (s, 1H), 7.00-7.50 (m, 10H), 7.61 (d, J=8 Hz, 1H), 7.73 (s, 1H), 7.77-7.83 (m, 1H), 9.92 (s, 1H).
-
- In 2 mL acetone and 0.3 mL of water benzyl 3-(1-(3-(2-cyclobutylideneacetamido)benzoyl)piperidin-4-yl)benzylcarbamate (0.012 g, 22 μmol), OsO4 (4% aqueous solution, 6 μL, 0.9 μmol) was added and stirred for 10 min at room temperature. Then NMO (50% aqueous solution, 6 μL, 26 μmol) was added and allowed to stir at room temperature overnight. TLC showed absence of starting material (Rf=0.2, 80% ethyl acetate/n-hexane). Reaction mixture was quenched with 10% aqueous sodium bisulphite solution and stirred for ˜1 h at room temperature. Aqueous layer was extracted with ethyl acetate, dried over sodium sulphate. Crude product obtained was purified by column chromatography (silica 60-120 mesh, ethyl acetate/n-hexane) afforded semi solid.
- Yield: 0.011 g (91%)
- LCMS: m/z (M+Na) 594
- 1H NMR (400 MHz, CDCl3): δ 1.50-2.30 (m, 9H), 2.50-2.70 (br, 2H), 2.72-3.00 (br, 2H), 3.12 (br, 2H), 3.75-3.95 (m, 2H), 4.36 (d, J=5.6 Hz, 2H), 4.84 (br, 1H), 5.14 (s, 2H), 7.00-7.50 (m, 12H), 7.72 (s, 1H), 8.86 (s, 1H).
-
- To a solution of benzyl 3-(1-(3-(2-hydroxy-2-(1-hydroxycyclobutyl)acetamido)-benzoyl)piperidin-4-yl)benzylcarbamate (0.011 g, 0.019 mmol), DCM (10 mL), Dess Martin periodinane (0.24 g, 0.57 mmol) was added at room temperature. Reaction mixture was stirred under nitrogen atmosphere for 2 h. TLC showed absence of starting material (Rf=0.4, 100% ethyl acetate). Reaction mixture was quenched with carbonate resin, filter through cotton. DCM was evaporated under reduced pressure. Further crude compound was purified by preparative TLC and taken ahead as such for the next step.
- Yield: 0.01 g (9%)
- LCMS: m/z (M+1) 570
-
- To a solution of intermediate-6 (0.009 g. 0.016 mmol), CHCl3 (5 mL), TMSI (1 drop) was added at room temperature. Reaction mixture was stirred under nitrogen atmosphere for 16 h. LCMS showed 46% starting material. In reaction mixture TMSI (2 drops) was added at room temperature. Further reaction mixture was stirred for 6 h. TLC showed absence of starting material (Rf=0.2, 100% ethyl acetate). Reaction mixture was quenched with aq. ammonium formate solution (3 mL), DCM layer was separated out, aq layer lyophilized and further purified by Prep. HPLC to isolate the compound as a TFA salt.
- Yield: 0.0047 g (47%, TFA salt)
- LCMS: m/z (M+1) 436
- HPLC: 85.13% (220 nm)
- 1H NMR (400 MHz, CD3OD): δ 1.55-2.00 (m, 4H), 2.02-2.20 (m, 2H), 2.35-2.65 (m, 3H), 2.80-3.20 (m, 2H), 3.10-3.30 (br, 3H, merged in the solvent peak), 3.87 (br, 1H), 4.10 (s, 2H), 7.18-7.50 (m, 6H), 7.62 (d, J=8.0 Hz, 1H), 7.85 (s, 1H).
- Title compound was synthesized as shown in
Scheme 17 below. - Detailed experimental procedure and analytical data is as follows.
-
- In 40 mL of dry DCM ethyl 2-cyclobutylideneacetate (0.85 g, 6.07 mmol) was allowed to cool to −78° C. under nitrogen atmosphere. To this solution DIBAL-H (1M in toluene) (1.72 g, 12.1 mL, 12.1 mmol) was added dropwise. Reaction was monitored by TLC. When the starting material was consumed completely the reaction mixture was quenched with MeOH/H2O (1:1) (Rf=0.28, 20% ethyl acetate/n-hexane). DCM layer was separated and dried over sodium sulphate. DCM was removed under reduced pressure. Crude product was purified by column chromatography (silica gel 60-120 mesh, 0-20% ethyl acetate and n-hexane as eluent) afforded colorless oil.
- Yield: 0.5 g (84%)
- 1H NMR (400 MHz, CDCl3): δ 1.61 (br, 1H), 1.91-2.05 (m, 2H), 2.65-2.74 (m, 4H), 4.02 (d, J=7.2 Hz, 2H), 5.30-5.36 (m, 1H).
-
- In 10 mL of dry THF, triphenyl phosphine (0.56 g, 2.25 mmol) was allowed to stir at −20° C. To this solution, DIAD (0.45 g, 0.44 mL, 2.25 mmol) was added. Yellow precipitate was observed in the reaction mixture. Methyl 3-hydroxybenzoate (0.26 g, 1.73 mmol) in 3 mL THF was added dropwise to the reaction mixture and stirred for 10-15 min. 2-cyclobutylideneethanol (0.17 g, 1.73 mmol) in 3 mL of dry THF was added dropwise (after complete addition clear yellow solution was observed) and resulting reaction mixture was stirred at RT overnight (Rf=0.62, 20% ethyl acetate/n-Hexane). Water was added to the reaction mixture. Aqueous layer was washed with diethyl ether. Crude product was purified by column chromatography (silica gel 60-120 mesh, ethyl acetate and n-hexane) to afford light yellow oil.
- Yield: 0.2 g (50%)
- LCMS: m/z (M+1) 233
- 1H NMR (400 MHz, CDCl3): δ 1.95-2.06 (m, 2H), 2.70-2.81 (m, 4H), 3.91 (s, 3H), 4.44 (d, J=7.2 Hz, 2H), 5.38-5.46 (m, 1H), 7.06-7.14 (dd, J=2.4 and 8.4 Hz, 1H), 7.32 (t, J=8.0 Hz, 1H), 7.57 (t, J=2.4 Hz, 1H), 7.62 (d, J=7.6 Hz, 1H).
-
- In 1:1 THF/water (5 mL each) product from step 2 (0.2 g, 0.86 mmol) and lithium hydroxide monohydrate (0.1 g, 2.58 mmol) was allowed to stir at room temperature. After 2 h TLC showed desired product and starting material, 3 eq. of lithium hydroxide monohydrate (0.1 g, 2.58 mmol) was added and stirred for ˜2 h. TLC showed complete consumption of starting material (Rf=0.35 in 50% ethyl acetate/n-hexane). THF was removed under reduced pressure. Aqueous layer was acidified with citric acid and extracted with ethyl acetate. Crude product was purified by column chromatography (silica gel 60-120 mesh ethyl acetate/n-hexane as eluent) to afford colorless oil.
- Yield: 0.14 g (77%)
- 1H NMR (400 MHz, CDCl3): δ 1.96-2.07 (m, 2H), 2.72-2.82 (m, 4H), 4.46 (d, J=6.8 Hz, 2H), 5.38-5.47 (m, 1H), 7.12-7.18 (dd, J=2.4 and 8.0 Hz, 1H), 7.37 (t, J=8.0 Hz, 1H), 7.62 (s, 1H), 7.70 (d, J=7.6 Hz, 1H).
-
-
Sr. Mol. Molar No. Chemical Wt. Quantity mmol Ratio 1 3-(2-cyclobutylidene- 218 0.14 g 0.64 1 ethoxy) benzoic acid 2 tert-butyl 3-(piperidin- 290 0.18 g 0.64 1 4-yl)benzyl carbamate (Int-E, Boc) 3 EDCI 191 0.14 g 0.70 1.1 4 HOBT 135 0.17 g 1.28 2.0 5 DIPEA 129 0.2 g 1.6 2.5 6 Dichloromethane — 10 mL — — - To a solution of
Step 3 product (0.14 g, 0.64 mmol) in dry dichloromethane (10 mL), Int-E (Boc protected) (0.18 g, 0.64 mmol), EDCI (0.14 g, 0.70 mmol), HOBt (0.17 g, 1.28 mmol), DIPEA (0.27 mL, 1.6 mmol) were added and the reaction mixture was allowed to stir at RT overnight under nitrogen atmosphere. TLC showed absence of starting material (Rf=0.75, 30% ethyl acetate/n-hexane). The reaction mixture was washed with sat. NaHCO3 solution. The organic layer was separated, dried over sodium sulphate, concentrated and purified by column chromatography (Silica gel 60-120 mesh using 0-40% ethyl acetate in hexane as eluent) to give the desired product as colorless oil. - Yield: 0.23 g (73%)
- LCMS: m/z (M+1) 491
- 1H NMR (400 MHz, CDCl3): δ 1.46 (s, 11H), 1.95-2.0 (m, 2H), 2.71-2.84 (m, 7H), 3.09 (br, 1H), 3.91 (br, 1H), 4.30 (br, 2H), 4.41 (d, J=6.8 Hz, 2H), 4.82 (br, 2H), 5.40-5.45 (m, 1H), 6.90-7.00 (m, 3H), 7.10-7.20 (m, 3H), 7.26-7.33 (m, 2H).
-
-
Sr. Mol. Molar No. Chemical Wt. Quantity mmol Ratio 1 tert-butyl 3-(1-(3-(2- 490 0.23 g 0.47 1 cyclobutylideneethoxy) benzoyl)piperidin-4- yl)benzylcarbamate 2 OsO4 (4% aq.) 254 0.0047 g 18.5 0.04 μmol 3 N-Methylmorpholine 117 0.066 g 0.56 1.2 oxide [NMO] (50% aq.) 4 Acetone — 7 mL — — 5 Water — 1.5 mL — — - In 7 mL acetone and 1.5 mL of
water Step 4 product (0.23 g, 0.47 mmol), OsO4 (4% aqueous solution, 0.012 mL, 18.5 μmol) was added and stirred for 10 min at room temperature. Then NMO (50% aqueous solution, 0.13 mL, 0.56 mmol) was added and allowed to stir at room temperature overnight. - Reaction mixture was quenched with 10% aqueous sodium bisulphite solution and stirred for ˜1 h at room temperature. Aqueous layer was extracted with ethyl acetate, dried over sodium sulphate. Crude product obtained was purified by column chromatography (silica 60-120 mesh, ethyl acetate/n-hexane; Rf=0.14, 50% ethyl acetate/n-hexane) afforded colorless oil.
- Yield: 0.18 g (73%)
- LCMS: m/z (M+1) 525
- 1H NMR (400 MHz, CDCl3): δ 1.47 (s, 9H), 1.61-1.76 (m, 4H), 2.05-2.16 (m, 4H), 2.35-2.40 (m, 1H), 2.70-2.90 (m, 4H), 3.11 (br, 1H), 3.86 (br, 1H), 4.05-4.20 (m, 3H), 4.30 (br, 2H), 4.85 (s, 2H), 6.93-7.06 (m, 3H), 7.11-7.17 (m, 3H), 7.26-7.35 (m, 2H).
-
-
Sr. Mol. Molar No. Chemical Wt. Quantity mmol Ratio 1 tert-butyl 3-(1-(3-(2-hydroxy- 524 0.1 g 0.19 1 2-(1-hydroxycyclobutyl) ethoxy)benzoyl)piperidin-4- yl)benzylcarbamate 2 Oxalyl chloride 127 0.032 mL 0.38 2 3 DMSO 78 0.028 mL 0.40 2.1 4 Triethyl amine 101 0.2 mL 1.52 8 5 Dichloromethane — 8 mL — — - A solution of DMSO (0.028 mL, 0.40 mmol) in DCM (5 mL) was cooled to −78° C. To this solution oxalyl chloride (0.032 mL, 0.38 mmol) in 1 mL DCM was added dropwise. Then step 5 product (0.1 g, 0.19 mmol) in 2 mL of DCM was added. Resulting reaction mixture was allowed to stir at −78° C. for 1 h under nitrogen. To this solution triethyl amine (0.2 mL, 1.52 mmol) was added and reaction mixture was allowed to warm to room temperature and stir overnight. Reaction mixture was quenched with sat. NH4Cl solution, aq. layer washed with DCM, dried over sodium sulphate. Crude reaction mixture was purified by column chromatography (60-120 mesh, ethyl acetate/n-hexane)
- Yield: 0.028 g, 28%.
- LCMS: (M+Na) 545
- 1H NMR (400 MHz, CDCl3): δ 1.47 (s, 9H), 1.60-1.80 (br, 4H), 1.90-2.10 (m, 4H), 2.30-2.50 (m, 2H), 2.70-3.20 (m, 4H), 3.85 (br, 1H), 4.03 (s, 2H), 4.30 (d, J=4.8 Hz, 2H), 4.84 (br, 1H), 6.90-7.04 (m, 3H), 7.10-7.20 (m, 3H), 7.28-7.34 (m, 2H).
-
- In 9:1 TFA/water (3/0.3 mL) product from step 6 (0.020 g, 0.038 mmol) allowed to stir at RT for ˜2 h. As TLC showed complete consumption of starting material reaction mixture was concentrated under vacuum. Compound was purified by preparative HPLC.
- Yield: 8.31 mg (41.5%, TFA salt).
- LCMS: (M+1) 423
- HPLC purity: 92.5% (220 nm)
- 1H NMR (400 mHz, CD3OD): δ 1.60-1.90 (m, 3H), 1.90-2.10 (m, 4H), 2.25-2.50 (m, 3H), 2.85-3.00 (m, 2H), 3.20-3.30 (m, 1H), 3.84 (br, 1H), 3.95-4.15 (m, 4H), 4.80 (br, 1H), 6.90-7.10 (m, 3H), 7.22-7.44 (m, 5H).
-
- Detailed experimental procedure and analytical data is as follows.
-
- To a cold solution of 2-bromo-6-methoxybenzoic acid (4.0 g, 17.3 mmol) in THF (80 mL), BH3:DMS (34.6 mL, 34.6 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 10 h. The reaction mixture was slowly poured onto ice and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to afford (2-bromo-6-methoxyphenyl)methanol as a white solid.
- Yield: 3.4 g, (91%)
- Mol. Wt.: 217.06
- LCMS (m/z): 240 [M+Na]
-
- To a solution of (2-bromo-6-methoxyphenyl)methanol (2.45 g, 11.4 mmol) in DCM (50 mL), DMAP (0.14 g, 1.14 mmol) and Et3N (4.0 mL, 28.5 mmol) was added. The reaction mixture was stirred at room temperature for 10 min followed by addition of TBDMS-Cl (5.16 g, 34.2 mmol). The reaction mixture was stirred at room temperature for 6 h and was concentrated under reduced pressure and purified by column chromatography (0-10% EtOAc in hexane) to yield ((2-bromo-6-methoxybenzyl)oxy)(tert-butyl)dimethylsilane.
- Yellow liquid; Yield: 3.0 g, (80%)
- Mol. Wt.: 331.32
- 1H NMR (400 MHz, CDCl3): δ 7.15 (d, J=8.0 Hz, 1H), 7.09 (t, J=8.0 Hz, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.85 (s, 2H), 3.82 (s, 3H), 0.91 (s, 9H), 0.09 (s, 6H).
- Step-3: Synthesis of (E)-ethyl 3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxyphenyl)acrylate
-
Sr. Molar No. Chemical Mol. Wt. Quantity mmol Ratio 1 ((2-bromo-6- 331.32 1.0 g 3.02 1.0 methoxybenzyl)oxy)(tert- butyl) dimethylsilane 2 Ethyl acrylate 100.11 1.32 mL 12.0 4.0 3 Tri-O-Tolylphosphine 304.37 0.23 g 0.75 0.25 4 Pd(OAc)2 224.5 0.17 g 0.75 0.25 5 Et3N 101.19 1.68 mL 12.0 4.0 6 Acetonitrile — 25 mL — — - A solution of ((2-bromo-6-methoxybenzyl)oxy)(tert-butyl)dimethylsilane (1.0 g, 3.02 mmol), ethyl acrylate (1.32 mL, 12.0 mmol), triethyl amine (1.68 mL, 12.0 mmol), tri-o-tolyl phosphine (0.23 g, 0.75 mmol) in acetonitrile (25 mL) was degassed with argon for 10 min. Palladium acetate (0.17 g, 0.75 mmol) was added and degassed with argon for 10 min. The reaction mixture was refluxed at 80° C. for 4 h. The reaction mixture was concentrated under vacuo, diluted with ethyl acetate, filtered over celite and purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield (E)-ethyl 3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxyphenyl)acrylate as white solid.
- Yield: 0.9 g, (86%)
- Mol. Wt.: 350.19
- LCMS (m/z): 391 [M+K].
-
- To a solution of methyl (E)-ethyl 3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxyphenyl)acrylate (0.5 g, 1.42 mmol) in THF:H2O (15 mL) was added LiOH (0.12 g, 2.85 mmol), the resulting solution was stirred at room temperature for 5 h. The organic solvent was concentrated, residue acidified with 10% citric acid solution, extracted with EtOAc. The combined organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure and triturated with diethyl ether to yield the (E)-3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxyphenyl)acrylic acid as a white solid.
- Yield: 0.33 g, (72%)
- Mol. Wt.: 322.47.
-
-
Sr. No. Chemical Mol. Wt. Quantity mmol Molar Ratio 1 (E)-3-(2-(((tert-butyldimethylsilyl) 322.47 0.33 g 1.02 1.0 oxy)methyl)-3-methoxyphenyl) acrylic acid 2 tert-butyl 3-(piperidin-4-yl)benzylcarbamate 290.4 0.29 g 1.02 1.0 3 EDCI 191.7 0.29 g 1.53 1.5 4 HOBt 135.1 0.21 g 1.53 1.5 5 DIEA 129.25 0.35 mL 2.04 2.0 6 DMF — 10 mL — — - To a solution of (E)-3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxyphenyl)acrylic acid (0.33 g, 1.02 mmol) in anhydrous DMF (10 mL) at 0° C., was added HOBt (0.21 g, 1.53 mmol). The reaction mixture was stirred for 10 minutes and EDCI (0.29 g, 1.53 mmol), tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.29 g, 1.02 mmol) and DIEA (0.35 mL, 2.04 mmol) were added. The resulting solution was allowed to stir at RT for 15 h. The reaction mixture was diluted with EtOAc and washed with H2O, dried (Na2SO4) and evaporated under vacuo. The crude product was purified by silica gel column chromatography (5-10% MeOH in CHCl3) to afford (E)-tert-butyl 3-(1-(3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxyphenyl)acryloyl)piperidin-4-yl)benzylcarbamate as a yellow solid.
- Yield: 0.35 g, (55%)
- Mol. Wt.: 594.35
- LCMS (m/z): 617 [M+Na].
-
- To a stirred solution of (E)-tert-butyl 3-(1-(3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxyphenyl)acryloyl)piperidin-4-yl) benzylcarbamate (0.1 g, 0.17 mmol) in DCM (5 mL) was added BBr3 (0.68 mL, 1 M in DCM) at 0° C. The resulting solution was stirred at 0° C. for 2 h and the reaction was monitored by LCMS. The reaction mixture was evaporated under vacuo and purified by prep-HPLC to afford (E)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3-hydroxy-2-(hydroxymethyl)phenyl)prop-2-en-1-one as a TFA salt.
- Yield: 0.028 g, (46%)
- Mol. Wt.: 366.45
- LCMS (m/z): 367 [M+1]
- HPLC Purity: 99.78%
- 1H NMR (400 MHz, CD3OD): δ 7.99 (d, J=15.2 Hz, 1H), 7.44-7.26 (m, 4H), 7.22-7.12 (m, 2H), 7.07 (d, J=15.2 Hz, 1H), 6.85 (d, J=7.6 Hz, 1H), 4.80-4.72 (m, 1H), 4.46-4.34 (m, 1H), 4.10 (s, 2H), 3.00-2.80 (m, 2H), 2.02-1.90 (m, 2H), 1.80-1.64 (m, 2H).
- Synthesis of the N-(3-(4-(3-(aminomethyl)phenyl)piperidine-1-carbonyl)phenyl)-3-hydroxy-3-methyl-2-oxobutanamide was carried out as shown in the scheme below.
- Detailed experimental procedure and analytical data is as follows.
-
- To a solution of 3-methylbut-2-enoic acid (2.5 g, 25 mmol) in DCM (30 mL), methyl 3-aminobenzoate (4.5 g, 30 mmol), EDCI (7.2 g, 37.5 mmol), DMAP (1.5 g, 12.5 mmol) were added and the reaction mixture was allowed to stir at room temperature for overnight under nitrogen atmosphere. TLC showed absence of starting material (Rf=0.5, 30% ethyl acetate/n-hexane). The reaction mixture was washed with water and 2N HCl. The organic layer was separated, dried over sodium sulphate, concentrated. Solid was washed with diethyl ether three times get off white solid.
- Yield: 4.5 g (77%)
- LCMS: m/z (M+1) 234
- 1H NMR (400 MHz, CDCl3): δ 1.89 (s, 3H), 2.23 (s, 3H), 3.90 (s, 3H), 5.73 (s, 1H), 7.31-7.50 (m, 2H), 7.75 (d, J=7.2 Hz, 1H), 7.92 (br, 1H), 8.06 (s, 1H).
-
- A solution of methyl 3-(3-methylbut-2-enamido)benzoate (4.5 g, 19.3 mmol), Lithium hydroxide monohydrate (2.43 g, 58 mmol) in THF (10 mL), H2O (10 mL), MeOH (5 mL) allowed to stir for 16 h at room temperature. TLC showed absence of starting material (Rf=0.3, 50% ethyl acetate/n-hexane). Solvent was removed under reduced pressure. Reaction mixture was acidified with 10% citric acid solution; white precipitate obtained was filtered out and washed with hexane and dried under vacuum.
- Yield: 4 g (95%)
- LCMS: m/z (M+1) 219.9
- 1H NMR (400 MHz, DMSO-d6): δ 1.86 (s, 3H), 2.15 (s, 3H), 5.86 (s, 1H), 7.40 (t, J=7.6 Hz, 1H), 7.59 (d, J=7.6 Hz, 1H), 7.82 (d, J=7.6 Hz, 1H), 8.27 (s, 1H), 10.0 (s, 1H), 12.8 (br, 1H).
-
- To a solution of 3-(3-methylbut-2-enamido)benzoic acid (0.03 g, 0.136 mmol) in DCM (2 mL), tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.047 g, 0.16 mmol), EDCI (0.039 g, 0.2 mmol), DMAP (0.008 g, 0.07 mmol) were added and the reaction mixture was allowed to stir at room temperature for overnight under nitrogen atmosphere. TLC showed absence of starting material (Rf=0.53, 80% ethyl acetate/n-hexane). The reaction mixture was washed with water, 2N HCl, followed by brine. The organic layer was separated, dried over sodium sulphate concentrated under reduced pressure. Compound was used as it is for next step.
- Yield: 0.027 g (40%)
- LCMS: m/z (M+Na) 514.4
- 1H NMR (400 MHz, CDCl3): δ 1.46 (s, 9H), 1.66-1.90 (br, 4H), 1.91 (s, 3H), 2.22 (s, 3H), 2.70-2.90 (m, 1H), 3.13 (br, 1H), 3.90 (br, 1H), 4.30 (d, J=4.8 Hz, 2H), 4.87 (br, 2H), 5.74 (s, 1H), 7.00-7.40 (m, 7H), 7.50-7.70 (m, 3H).
-
-
Sr. Mol. Molar No. Chemical Wt. Quantity Mmol Ratio 1 tert-butyl 3-(1-(3-(3- 491 0.027 g 55 μmol 1 methylbut-2-enamido) benzoyl)piperidin-4-yl) benzylcarbamate. 2 OsO4 (4% aq.) 254 13 μL 2.2 μmol 0.04 3 N-Methylmorpholine oxide 117 15 μL 66 μmol 1.2 [NMO] (50% aq.) 4 Acetone — 2 mL — — 5 Water — 0.3 mL — — - In 2 mL acetone and 0.3 mL of water tert-butyl 3-(1-(3-(3-methylbut-2-enamido)benzoyl)piperidin-4-yl)benzylcarbamate (0.027 g, 55 μmol), OsO4 (4% aqueous solution, 13 μL, 2.2 μmol) was added and stirred for 10 min at room temperature. Then NMO (50% aqueous solution, 15 μL, 66 μmol) was added and allowed to stir at room temperature overnight. TLC showed absence of starting material (Rf=0.4, 100% ethyl acetate). Reaction mixture was quenched with 10% aqueous sodium bisulphite solution and stirred for ˜1 h at room temperature. Aqueous layer was extracted with ethyl acetate, dried over sodium sulphate. Crude product obtained was purified by column chromatography (100-200 mesh, ethyl acetate/n-hexane) afforded off white solid.
- Yield: 0.017 g (60%)
- LCMS: m/z (M+Na) 548.15
- 1H NMR (400 MHz, CDCl3): δ 1.20 (s, 3H), 1.34 (s, 3H), 1.46 (s, 9H), 1.70-2.00 (br, 4H), 2.70-3.25 (br, 3H), 3.76 (s, 1H), 3.90 (br, 1H), 4.31 (s, 2H), 4.50-5.00 (br, 2H), 7.10-7.50 (m, 8H), 7.69 (bs, 1H), 8.90 (bs, 1H).
-
- To a solution of Intermediate 4 (0.01 g, 0.019 mmol), DCM (5 mL), Dess Martin periodinane (0.24 g, 0.57 mmol) was added at room temperature. Reaction mixture was stirred under nitrogen atmosphere for 2 h. TLC showed absence of starting material (Rf=0.4, 100% ethyl acetate). Reaction mixture was quenched with carbonate resin, filter through cotton. DCM was evaporated under reduced pressure. Crude compound was purified by preparative TLC (100% ethyl acetate as a mobile phase).
- Yield: 0.018 g (18%)
- LCMS: m/z (M+Na) 546.
-
- To a solution of tert-butyl 3-(1-(3-(3-hydroxy-3-methyl-2-oxobutanamido)benzoyl)piperidin-4-yl)benzylcarbamate (0.01 g, 0.019 mmol), methanol (2.5 mL), Conc. HCl (0.12 mL) was added at room temperature. Reaction mixture was stirred for 16 h. Methanol was evaporated under reduced pressure. Crude compound was purified by Preparative HPLC.
- Yield: 4.8 mg (60%, TFA salt)
- LCMS: m/z (M+MeOH) 446
- 1H NMR (400 MHz, CD3OD): δ 1.24 (s, 3H), 1.29 (s, 3H), 1.65-2.10 (br, 4H), 2.88-3.10 (m, 2H), 3.20-3.30 (br, 2H), 3.90 (br, 1H), 4.11 (s, 2H), 7.20-7.50 (m, 6H), 7.61 (d, J=8.0 Hz, 1H), 7.90 (s, 1H).
-
- Detailed experimental procedure and analytical data is as follows.
- Methyl 3-bromobenzoate was synthesized from 3-bromobenzoic acid by esterification with thionyl chloride in methanol. Further Sonogashira coupling was carried out with ethynyl(trimethyl)silane to afford methyl 3-((trimethylsilyl)ethynyl)benzoate, which upon hydrolysis with lithium hydroxide in methanol yielded 3-ethynylbenzoic acid as per known procedures.
-
- To a cold solution of 3-ethynylbenzoic acid (0.2 g, 1.37 mmol) in anhydrous
- THF (10 mL), was added catechol borane (0.15 mL, 1.37 mmol). The reaction mixture was stirred at room temperature for 2 h. The resulting solution was poured into cold water and extracted with EtOAc. The organic layer was washed with H2O, dried over Na2SO4 and evaporated under vacuo. The crude product was purified by silica gel column chromatography (0-20%, EtOAc in hexane) to afford (E)-3-(2-(benzo[d][1,3,2]dioxaborol-2-yl)vinyl)benzoic acid as a white solid.
- Yield: 0.27 g (75%)
- 1H NMR (400 MHz, Acetone-d6): δ 8.18-8.12 (m, 1H), 7.95 (d, J=7.2 Hz, 1H), 7.92-7.86 (m, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.51 (t, J=7.2 Hz, 1H), 7.43 (d, J=18.2 Hz, 1H), 7.12-7.02 (m, 1H), 6.84-6.76 (m, 1H), 6.70-6.62 (m, 1H), 6.32 (d, J=18.2 Hz, 1H).
-
-
Sr. No. Chemical Mol. Wt. Quantity mmol Molar Ratio 1 (E)-3-(2-(benzo[d][1,3,2] 266.06 0.1 g 0.38 1.0 dioxaborol-2-yl)vinyl) benzoic acid 2 tert-butyl 3-(piperidin-4-yl) 290.35 0.11 g 0.38 1.2 benzylcarbamate 3 EDCi 191.7 0.11 g 0.57 1.5 4 HOBt 135.12 0.077 g 0.57 1.5 5 DIEA 129.25 0.13 mL 0.76 2.0 6 DMF — 5 mL — — - To a solution of (E)-3-(2-(benzo[d][1,3,2]dioxaborol-2-yl)vinyl)benzoic acid (0.1 g, 0.38 mmol) in anhydrous DMF (5 mL) at 0° C., was added HOBt (0.077 g, 0.57 mmol). The reaction mixture was stirred for 10 minutes and EDCI (0.11 g, 0.57 mmol), tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.11 g, 0.38 mmol) and DIEA (0.13 mL, 0.76 mmol) were added. The resulting solution was allowed to stir at room temperature for overnight. The reaction mixture was then diluted with EtOAc and was washed with H2O. The organic layer was dried over Na2SO4 and evaporated under vacuo. The crude product was purified by silica gel column chromatography (0-15%, EtOAc in hexane) to afford (E)-(3-(4-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)piperidine-1-carbonyl)styryl)boronic acid.
- White solid; Yield: 0.06 g (35%)
- Mol. Wt.: 464.36
- LCMS (m/z): 465 [M+1].
-
- To a stirred solution of (E)-(3-(4-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)piperidine-1-carbonyl)styryl)boronic acid (0.05 g, 0.09 mmol) in MeOH (3 mL) was added 2 N HCl (0.05 mL) at room temperature. The resulting solution was stirred at room temperature for 5 h. The reaction mixture was evaporated under vacuo and the resultant residue was triturated with diethyl ether to afford (E)-(3-(4-(3-(aminomethyl)phenyl)piperidine-1-carbonyl)styryl)boronic acid hydrochloride as a white solid.
- Yield: 0.02 g (64%)
- Mol. Wt.: 364.25
- LCMS (m/z): 365 [M+1], 387 [M+Na]
- HPLC Purity: 94.17%
- 1H NMR (400 MHz, CD3OD): δ 7.62-7.54 (m, H), 7.52-7.46 (m, 1H), 7.42-7.18 (m, 7H), 6.37 (d, J=18.0 Hz, 1H), 4.02 (s, 3H), 3.82-3.70 (m, 1H), 3.20-3.10 (m, 1H), 2.95-2.76 (m, 2H), 1.95-1.82 (m, 1H), 1.80-1.52 (m, 3H).
-
- Detailed experimental procedure and analytical data is as follows.
-
- (E)-1-(4-(3-(Aminomethyl)phenyl)piperidin-1-yl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one hydrochloride was taken in ethanol (3.0 mL) and exposed to sunlight for 2 h. The organic layer was concentrated under vacuo to afford (Z)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one hydrochloride as a white solid.
- Yield: 0.018 g, (90%)
- Mol. Wt.: 352.43
- LCMS (m/z): 353 [M+1], 375 [M+Na]
- HPLC Purity: 89.73%
- 1H NMR (400 MHz, CD3OD): δ 7.33 (t, J=7.6 Hz, 1H), 7.25 (d, J=7.6 Hz, 1H), 7.16 (d, J=7.6 Hz, 1H), 7.10 (s, 1H), 6.94 (d, J=1.8 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.74 (dd, J=8.2, 1.8 Hz, 1H), 6.67 (d, J=12.0 Hz, 1H), 5.91 (d, J=12.0 Hz, 1H), 4.80-4.70 (m, 1H), 4.13 (ABq, J=13.6 Hz, 2H), 4.08-3.98 (m, 1H), 3.08-2.95 (m, 1H), 2.80-2.65 (m, 2H), 1.82-1.74 (m, 1H), 1.68-1.54 (m, 1H), 1.45-1.36 (m, 1H), 0.80-0.65 (m, 1H).
-
- To a solution of (E)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one hydrochloride (0.08 g, 0.23 mmol) in methanol (10 mL), 10% Pd/C (0.02 g) was added and the reaction mixture was stirred under H2 atmosphere (using a 2 Lit. bladder) at room temperature for 1 h. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The crude compound was purified by prep-HPLC to yield TFA salt of 1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3,4-dihydroxyphenyl)propan-1-one as a white solid.
- Yield: (0.024 g, 30%)
- Mol. Wt.: 354.44
- LCMS (m/z): 377 [M+Na]
- HPLC Purity: 99.13%
- 1H NMR (400 MHz, CD3OD): δ 7.35 (t, J=7.6 Hz, 1H), 7.28-7.16 (m, 3H), 6.74 (d, J=8.0 Hz, 1H), 6.68 (s, 1H), 6.62 (d, J=8.0 Hz, 1H) 4.74-4.64 (m, 1H), 4.14 (ABq, J=13.6 Hz, 2H), 3.94-3.84 (m, 1H), 3.10-2.98 (m, 1H), 2.95-2.80 (m, 3H), 2.76-2.55 (m, 1H), 2.48-2.38 (m, 1H), 1.78-1.68 (m, 1H), 1.54-1.44 (m, 1H), 1.43-1.30 (m, 1H), 0.75-0.60 (m, 1H).
-
- Detailed experimental procedure and analytical data is as follows.
-
- To a solution of ethyl 3-(2,5-dihydro-1H-pyrrol-1-yl)benzoate (0.16 g, 0.74 mmol) in THF:water (3.0 mL, 2:1), NMO (0.095 g 0.81 mmol) and osmium tetroxide (0.002 g 0.007 mmol) were added. The reaction mixture was stirred at room temperature for 15 h. The reaction mixture was concentrated under vacuo and the residue obtained was partitioned between EtOAc and water. The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to yield the crude compound which was purified by silica gel column chromatography (10-40%, EtOAc in hexane) to yield ethyl 3-(3,4-dihydroxypyrrolidin-1-yl)benzoate as a white solid.
- Yield: 0.15 g, (83%)
- Mol. Wt.: 251.28
- LCMS (m/z): 252 [M+1].
-
- To a solution of ethyl 3-(3,4-dihydroxypyrrolidin-1-yl)benzoate (0.15 g, 0.59 mmol) in MeOH: H2O (5.0 mL, 4:1), LiOH (0.05 g, 1.19 mmol) was added and the resulting solution was stirred at room temperature for 4 h. The organic solvent was concentrated under vacuo and the resultant residue was acidified with 10% citric acid solution. The mixture was then extracted with ethyl acetate, the combined organic layer was dried over Na2SO4, concentrated under reduced pressure to give a residue which was triturated with diethyl ether to yield the 3-(3,4-dihydroxypyrrolidin-1-yl)benzoic acid as a white solid.
- Yield: 0.13 g, (98%)
- Mol. Wt.: 223.08
- LCMS (m/z): 224.00 [M+1].
-
- A mixture of tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.17 g, 0.58 mmol), 3-(3,4-dihydroxypyrrolidin-1-yl)benzoic acid (0.13 g, 0.58 mmol), EDCi (0.17 g, 0.87 mmol), HOBt (0.12 g, 0.87 mmol), DIEA (0.2 mL, 1.16 mmol) in DMF (4 mL) was stirred at room temperature for overnight. The reaction mixture was diluted with EtOAc, washed with brine and dried over Na2SO4. The organic layer concentrated under reduced pressure to give the crude compound which was purified by silica gel column chromatography (0-5%, MeOH in CHCl3) to tert-butyl 3-(1-(3-(3,4-dihydroxypyrrolidin-1-yl)benzoyl)piperidin-4-yl)benzylcarbamate as a white solid.
- Yield: 0.08 g, (27%)
- Mol. Wt: 495.61
- LCMS (m/z): 518 [M+Na]
-
- A solution of tent-Butyl 3-(1-(3-(3,4-dihydroxypyrrolidin-1-yl)benzoyl)piperidin-4-yl)benzylcarbamate (0.08 g, 0.16 mmol) in MeOH (2.0 mL) was treated with conc. HCl (0.1 mL) at room temperature for 1 h. The reaction mixture was then evaporated under vacuo and the residue was triturated with ether to yield (4-(3-(aminomethyl)phenyl)piperidin-1-yl)(3-(3,4-dihydroxypyrrolidin-1-yl)phenyl)methanone hydrochloride as a white solid.
- Yield: 0.04 g, (63%)
- Mol. Wt: 395.49
- LCMS (m/z): 418 [M+Na]
- HPLC Purity: 98.59%
- 1H NMR (400 MHz, CD3OD): δ 7.44-7.28 (m, 6H), 6.94-6.82 (m, 3H), 4.80-4.74 (m, 1H), 4.41-4.32 (m, 2H), 4.11 (s, 2H), 3.96-3.84 (m, 1H), 3.66 (dd, J=5.6 10.0 Hz, 2H), 3.39 (dd, J=5.6 10.0 Hz, 2H), 3.29-3.20 (m, 1H), 3.04-2.88 (m, 2H), 2.05-1.92 (m 1H), 1.90-1.64 (m, 3H)
-
- Detailed experimental procedure and analytical data is as follows.
-
- To an ice-cold solution of isophthalic acid (0.3 g, 1.8 mmol) in anhydrous DMF (5 mL), was added HOBt (0.36 g, 2.7 mmol). The reaction mixture was stirred for 10 minutes and EDCI (0.52 g, 2.7 mmol), tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.63 g, 2.16 mmol) and DIEA (0.62 mL, 3.6 mmol) were added. The resulting solution was allowed to stir at room temperature overnight. The reaction mixture was then diluted with EtOAc and was washed with H2O. The organic layer was dried over Na2SO4 and evaporated under vacuo to yield the crude product which was purified by silica gel column chromatography (5-10% MeOH in CHCl3) to afford 3-(4-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)piperidine-1-carbonyl)benzoic acid as a white solid.
- Yield: 0.35 g (44%)
- Mol. Wt.: 438.52
- LCMS (m/z): 461 [M+Na]
-
-
Molar Sr. No. Chemical Mol. Wt. Quantity Mmol Ratio 1 3-(4-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)piperidine- 438.52 0.2 g 0.46 1.0 1-carbonyl)benzoic acid 2 (3aR,6aS)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole 143.18 0.098 g 0.68 1.5 3 PyBOP 520.4 0.48 g 0.92 2.0 4 Pyridine — 1.2 mL — — 5 DMF — 5 mL — — - To a stirred solution of 3-(4-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)piperidine-1-carbonyl)benzoic acid (0.2 g, 0.46 mmol) in DMF (5 mL), pyridine (1.2 ml) and PyBOP (0.48 g, 0.92 mmol) were added. The reaction mixture was cooled to 0° C. and a solution of (3aR,6aS)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole (0.098 g, 0.68 mmol) in DMF (5 mL) was added. The reaction mixture was allowed to warm to room temperature and stirred for 16 h. After completion, the reaction mixture was quenched with saturated CuSO4 solution and extracted with Et2O. The combined organic layer was dried over Na2SO4 and evaporated under vacuo. The crude compound was purified by silica gel column chromatography (5-10% MeOH in CHCl3) to afford tert-butyl 3-(1-(3-((3aR,6aS)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5-carbonyl)benzoyl)piperidin-4-yl)benzylcarbamate as a white solid.
- Yield: 0.1 g (39%)
- Mol. Wt: 563.68
- LCMS (m/z): 586 [M+Na]
-
- To a stirred solution of tert-butyl 3-(1-(3-((3aR,6aS)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5-carbonyl)benzoyl)piperidin-4-yl)benzylcarbamate (0.08 g, 0.14 mmol) in MeOH (5 mL) was added 2 N HCl (0.1 mL) at 0° C. The resulting solution was warmed to room temperature and stirred for further 1 h. The reaction mixture was evaporated under vacuo to yield the crude product which was purified by prep-HPLC to afford the TFA salt of (4-(3-(aminomethyl)phenyl)piperidin-1-yl)(3-((3S,4R)-3,4-dihydroxypyrrolidine-1-carbonyl)phenyl)methanone as white solid.
- Yield: 0.02 g (33%)
- Mol. Wt.: 423.22
- LCMS (m/z): 424.25 [M+1], 446.25 [M+23]
- HPLC Purity: 99.58%
- 1H NMR (400 MHz, CD3OD): δ 7.68-7.62 (m, 1H), 7.61-7.54 (m, 3H), 7.44-7.34 (m, 3H), 7.32-7.26 (m, 1H), 4.82-4.74 (m, 1H), 4.31-4.26 (m, 1H), 4.20-4.14 (m, 1H), 4.11 (s, 2H), 3.88-3.80 (m, 1H), 3.77 (dd, J=12.8, 6.0 Hz, 1H), 3.63 (dd, J=10.8, 6.0 Hz, 1H), 3.57 (dd, J=12.8, 4.2 Hz, 1H), 3.50-3.40 (m, 2H), 3.04-2.88 (m, 2H), 2.05-1.94 (m, 1H), 1.90-1.60 (m, 3H).
-
- Detailed experimental procedure and analytical data is as follows.
-
- To an ice-cooled solution of 4-Bromo-2-hydroxybenzoic acid (2.0 g, 9.2 mmol) in dry THF (30 mL) under N2 atmosphere, BH3: DMS (1.8 mL, 18.4 mmol) was added dropwise and stirred for 10 min. Then reaction mixture was warmed to room temperature and heated at 70° C. overnight. The reaction mixture was cooled to room temperature and poured onto ice and extracted with EtOAc. The organic layer was washed with saturated NaHCO3 solution, dried over Na2SO4, concentrated under reduced pressure to yield the crude product which was purified by silica gel column chromatography (0-10%, EtOAc in hexane) to yield 5-bromo-2-(hydroxymethyl)phenol as a white solid.
- Yield: (1.5 g, 80%)
- Mol. Wt.: 203.03
- LCMS (m/z): 203, 205 [MH+]
-
- A solution of 5-bromo-2-(hydroxymethyl)phenol (1.5 g, 7.4 mmol), p-TSA (0.25 g 1.4 mmol) and 2,2-DMP (1.8 mL, 14.8 mmol) in acetone (15 mL) was stirred at room temperature for 4 h. Triethyl amine was added to the reaction mixture and stirred for 10 min. The reaction mixture was concentrated under reduced pressure to give the crude product which was purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield 7-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine as a white solid.
- Yield: 1.4 g, (78%)
- Mol. Wt.: 243.10
- LCMS (m/z): 243, 245 [MH+]
-
-
Sr. Mol. Molar No. Chemical Wt. Amount mmol Ratio 1 7-bromo-2,2-dimethyl-4H- 243.10 1.4 g 5.76 1.0 benzo[d][1,3] dioxine 2 Ethyl acrylate 100.11 1.22 mL 11.5 2.0 3 Triethyl amine 101.19 1.6 mL 11.5 2.0 4 Palladium acetate 224.50 0.064 g 0.28 0.05 5 Tri-o-tolyl phosphine 304.37 0.17 g 0.57 0.1 6 Acetonitrile — 15 mL — — - A solution of 7-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine (1.4 g, 5.76 mmol), ethyl acrylate (1.22 mL, 11.5 mmol), triethyl amine (1.6 mL, 11.5 mmol), tri-O-tolyl phosphine (0.17 g, 0.57 mmol) in acetonitrile (15 mL) was degassed using argon for 10 min. Palladium acetate (0.064 g, 0.28 mmol) was added and the reaction mixture was again degassed with argon for 10 min. The reaction mixture was refluxed at 80° C. for 5 h, cooled to room temperature, diluted with ethyl acetate and filtered over celite. The filtrate was concentrated under vacuo to give a residue which was purified by silica gel column chromatography (0-20%, EtOAc in hexane) to yield (E)-ethyl 3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acrylate as a white solid.
- Yield: 1.2 g, (80%)
- Mol. Wt.: 262.12
- LCMS (m/z): 263 [M+1].
-
- To a solution of (E)-ethyl 3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acrylate (1.0 g, 3.8 mmol) in MeOH:H2O (12 mL, 2:1), LiOH (0.32 g, 7.6 mmol) was added and the resulting solution was stirred at room temperature for 4 h. The reaction mixture was concentrated under vacuo and the residue was acidified with 10% citric acid solution and extracted with EtOAc. The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to give a residue which was triturated with diethyl ether to yield the (E)-3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acrylic acid as a white solid.
- Yield: 0.8 g, (89%)
- Mol. Wt.: 234.25
- LCMS (m/z): 235 [M+1]
-
-
Sr. Mol. Molar No. Chemical Wt. Amount mmol Ratio 1 (E)-3-(2,2-dimethyl-4H-benzo[d] 234.25 0.16 g 0.68 1.0 [1,3]dioxin-7-yl) acrylic acid 2 tert-butyl 3-(piperidin-4- 290.40 0.2 g 0.68 1.0 yl)benzylcarbamate 3 EDCi 191.70 0.2 g 1.02 1.5 4 HOBt 135.12 0.14 g 1.02 1.5 5 DIEA 129.25 0.3 mL 1.7 2.5 6 DMF — 4 mL — — - A mixture of tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.2 g, 0.68 mmol), (E)-3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acrylic acid (0.16 g, 0.68 mmol), EDCi (0.2 g, 1.02 mmol), HOBt (0.14 g, 1.02 mmol), DIEA (0.3 mL, 1.7 mmol) in DMF (4 mL) was stirred at room temperature for overnight. The reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude compound was purified by silica gel column chromatography (0-5%, MeOH in CHCl3) to obtain (E)-tert-butyl 3-(1-(3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acryloyl)piperidin-4-yl)benzylcarbamate as a white solid.
- Yield: 0.3 g, (88%)
- Mol. Wt.: 506.63
- LCMS (m/z): 529 [M+23]
-
- A solution of (E)-tert-butyl 3-(1-(3-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-7-yl)acryloyl)piperidin-4-yl)benzylcarbamate (0.2 g, 0.39 mmol) in MeOH (2 mL) was treated with conc. HCl (0.2 mL) at room temperature for 3 h. The reaction mixture was evaporated under vacuo and the residue was purified by prep-HPLC to yield the acetate salt of (E)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3-hydroxy-4-(hydroxymethyl)phenyl)prop-2-en-1-one as a white solid.
- Yield: 0.03 g, (20%)
- Mol. Wt.: 366.45
- LCMS (m/z): 389 [M+23]
- HPLC Purity: 99.77%
- 1H NMR (400 MHz, CD3OD): δ 7.50 (d, J=15.6 Hz, 1H) 7.40-7.26 (m, 5H), 7.13 (s, 1H), 7.09 (d, J=15.6 Hz, 1H), 6.99 (s, 1H), 4.84-4.72 (m, 1H), 4.66 (s, 2H), 4.45-4.34 (m, 1H), 4.06 (s, 2H), 3.37-3.25 (m, 1H), 2.97-2.80 (m, 2H), 2.02-1.92 (m, 2H), 1.78-1.62 (m, 2H).
-
- Detailed experimental procedure and analytical data is as follows.
-
- A solution of ethyl 3-aminobenzoate (3.0 g, 18.16 mmol), 3-bromo-2-methylprop-1-ene (4.57 mL 45.40 mmol) and sodium carbonate (2.30 g, 21.79 mmol) in ethanol: water (120 mL, 4:1) was heated in a sealed tube at 90° C. for 15 h. The reaction mixture was cooled to room temperature and concentrated under vacuo. The residue was diluted with EtOAc and washed with H2O. The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give a crude compound which was purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield ethyl 3-(bis(2-methylallyl)amino)benzoate as a white solid.
- Yield: 4.5 g, (91%)
- Mol. Wt.: 273.37
- LCMS (m/z): 274 [M+1].
-
- To a solution of ethyl 3-(bis(2-methylallyl)amino)benzoate (1.0 g, 3.66 mmol) in benzene (300 mL) under Argon atmosphere, Grubb's llnd generation catalyst (3.1 mg, 0.0036 mmol) was added. The reaction mixture was refluxed at 80° C. for 15 h. The reaction mixture was cooled to room temperature and concentrated under vacuo to give a crude product which was purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield ethyl 343,4-dimethyl-2,5-dihydro-1H-pyrrol-1-yl)benzoate as a white solid.
- Yield: 0.29 g, (33%)
- Mol. Wt.: 245.32
- LCMS (m/z): 246 [M+1].
-
- To a solution of ethyl 3-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-1-yl)benzoate (0.29 g, 1.2 mmol) in THF:water (6.0 mL, 2:1), NMO (0.15 g 1.32 mmol) and osmium tetroxide (0.003 g, 0.012 mmol) were added and reaction mixture was stirred at room temperature for 15 h. The reaction mixture was concentrated under vacuo and the residue obtained was partitioned between EtOAc and water. The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to yield the crude compound which was purified by silica gel column chromatography (0-40%, EtOAc in hexane) to afford ethyl 3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoate as a white solid.
- Yield: 0.15 g, (45%)
- Mol. Wt.: 279.33
- LCMS (m/z): 280 [M+1].
-
- To a solution of ethyl 3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoate (0.15 g, 0.53 mmol) in MeOH:H2O (3 mL, 2:1), LiOH (0.045 g, 1.07 mmol) was added and the resulting solution was stirred at room temperature for 1 h. The reaction mixture was concentrated under vacuo and the residue was acidified with 10% citric acid solution and extracted with EtOAc. The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to give a crude compound which was triturated with diethyl ether to yield the 3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoic acid as a white solid.
- Yield: 0.13 g, (97%)
- Mol. Wt.: 251.28
- LCMS (m/z): 252 [M+1].
-
-
Sr. Molar No. Chemical Mol. Wt. Quantity mmol Ratio 1 3-(3,4-dihydroxy-3,4- 251.28 0.13 g 0.52 1.0 dimethylpyrrolidin-1-yl) benzoic acid 2 tert-butyl 3-(piperidin-4- 290.40 0.15 g 0.52 1.0 yl)benzylcarbamate 3 EDCi 191.70 0.15 g 0.77 1.5 4 HOBt 135.12 0.1 g 0.77 1.5 5 DIEA 129.25 0.22 mL 1.2 2.0 6 DMF — 4 mL — — - A mixture of tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.15 g, 0.52 mmol), 3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoic acid (0.13 g, 0.52 mmol), EDCi (0.15 g, 0.77 mmol), HOBt (0.1 g, 0.77 mmol), DIEA (0.22 mL, 1.2 mmol) in DMF (4 mL) was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc, washed with brine and dried over Na2SO4. The EtOAc layer was concentrated under reduced pressure to afford a residue which was purified by silica gel column chromatography (0-5%, MeOH in CHCl3) to yield tert-butyl 3-(1-(3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoyl)piperidin-4-yl)benzylcarbamate as a white solid.
- Yield: 0.25 g, (92%)
- Mol. Wt: 523.66
- LCMS (m/z): 546 [M+Na]
-
- A solution of tert-butyl 3-(1-(3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)benzoyl)piperidin-4-yl)benzylcarbamate (0.15 g, 0.29 mmol) in MeOH (3 mL) was treated with conc. HCl (0.1 mL) at room temperature for 2 h. The reaction mixture was evaporated in vacuo and the resultant residue was triturated with ether to yield (4-(3-(aminomethyl)phenyl)piperidin-1-yl)(3-(3,4-dihydroxy-3,4-dimethylpyrrolidin-1-yl)phenyl)methanone hydrochloride as a white solid.
- Yield: 0.06 g, (50%)
- Mol. Wt: 423.55
- LCMS (m/z): 446 [M+Na]
- HPLC Purity: 97.27%
- 1H NMR (400 MHz, CD3OD): δ 7.44-7.22 (m, 5H), 6.70-6.60 (m, 2H), 6.52 (s, 1H), 4.11 (s, 2H), 4.00-3.85 (m, 1H), 3.38 (ABq, J=9.6 Hz, 4H), 3.25-3.15 (m, 1H), 3.02-2.86 (m, 2H), 2.05-1.92 (m, 1H), 1.88-1.58 (m, 3H), 1.30 (s, 6H).
-
-
- To an ice-cooled solution of 4-bromo-2-hydroxybenzoic acid (2.0 g, 9.21 mmol) in methanol (20 mL), thionyl chloride (1.3 mL, 18.43 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature and refluxed at 60° C. for 5 h. The reaction mixture was concentrated under vacuo, diluted with EtOAc, washed with saturated NaHCO3 solution followed by brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the crude product which was purified by silica gel column chromatography (0-10%, EtOAc in hexane) to yield methyl 4-bromo-2-hydroxybenzoate.
- White solid; Yield: 1.5 g, (70%)
- Mol. Wt.: 231.04
- LCMS (m/z): 231, 233 [M+1].
-
- To a solution of methyl 4-bromo-2-hydroxybenzoate (1.5 g, 6.5 mmol) in THF (50 mL) at −78° C. under N2 atmosphere, methyl lithium (13.0 mL, 38.9 mmol) was added. The reaction mixture was stirred for 30 min. before it was warmed to room temperature and stirred for 2 h. The reaction mixture was quenched with saturated NH4Cl solution and extracted with EtOAc. The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford crude product which was purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield 5-bromo-2-(2-hydroxypropan-2-yl)phenol.
- White solid; Yield: 1.2 g, (80%)
- Mol. Wt.: 231.09
- 1H NMR (400 MHz, CDCl3): δ 9.06 (s, 1H), 7.03 (s, 1H), 6.93 (ABq, J=8.4 Hz, 2H), 2.33 (s, 1H), 1.65 (s, 6H).
-
-
Sr. Mol. Molar No. Chemical Wt. Quantity mmol Ratio 1 5-Bromo-2-(2-hydroxy- 231.09 1.2 g 5.2 1.0 propan-2-yl) phenol 2 Ethyl Acrylate 100.11 1.13 mL 10.4 2.0 3 Triethyl amine 101.19 1.5 mL 10.4 2.0 4 Palladium acetate 224.50 0.12 g 0.52 0.1 5 Tri-o-tolyl phosphine 304.37 0.16 g 0.52 0.1 6 Acetonitrile — 50 mL — — - A solution of 5-bromo-2-(2-hydroxypropan-2-yl)phenol (1.2 g, 5.2 mmol), ethyl acrylate (1.13 mL, 10.4 mmol), triethyl amine (1.5 mL, 10.4 mmol), tri-O-tolylphosphine (0.16 g, 0.52 mmol) in acetonitrile (50 mL) was degassed using argon for 10 min. Palladium acetate (0.12 g, 0.52 mmol) was added and the reaction mixture was again degassed using argon for 10 min. The reaction mixture was then refluxed at 80° C. for 4 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate and the slurry was then filtered over celite. The filtrate was concentrated under vacuo to yield the crude product which was purified by silica gel column chromatography (0-5%, EtOAc in hexane) to yield (E)-ethyl 3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acrylate.
- White solid; Yield: 1.0 g, (77%)
- Mol. Wt.: 250.29
- LCMS (m/z): 251 [M+1].
-
- To a solution of (E)-ethyl 3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acrylate (0.3 g, 1.19 mmol) in THF: H2O (5 mL, 4:1), LiOH (0.2 g, 4.79 mmol) was added and the resulting solution was stirred at room temperature for 4 h. The organic solvent was concentrated under reduced pressure and the residue was acidified with 10% citric acid solution. The mixture was extracted with EtOAc and dried over Na2SO4 and concentrated under reduced pressure to yield a residue which was triturated with diethyl ether to afford the (E)-3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acrylic acid.
- White solid; Yield: 0.2 g, (76%)
- Mol. Wt: 222.24
- 1H NMR (400 MHz, CD3OD): δ 7.56 (d, J=16.0 Hz, 1H), 7.26 (d, J=8.0 Hz, 1H), 7.02 (d, J=8.0 Hz, 1H), 6.97 (s, 1H), 6.38 (d, J=16.0 Hz, 1H), 1.59 (s, 6H).
-
-
Sr. Molar No. Chemical Mol. Wt. Quantity mmol Ratio 1 (E)-3-(3-hydroxy-4-(2- 222.24 0.15 g 0.67 1.0 hydroxy-propan-2-yl) phenyl) acrylic acid 2 tert-butyl 3-(piperidin-4- 290.40 0.19 g 0.67 1.0 yl)benzylcarbamate 3 EDCI 191.70 0.19 g 1.01 1.5 4 HOBt 135.12 0.13 g 1.01 1.5 5 DIEA 129.25 0.3 mL 1.67 2.5 6 DMF — 4 mL — — - A mixture of tert-butyl 3-(piperidin-4-yl)benzylcarbamate (0.19 g, 0.67 mmol), (E)-3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acrylic acid (0.15 g, 0.67 mmol), EDCi (0.19 g, 1.01 mmol), HOBt (0.13 g, 1.01 mmol), DIEA (0.3 mL, 1.67 mmol) in DMF (4 mL) was stirred at room temperature overnight. The reaction mixture was extracted with EtOAc and washed with brine. The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford the crude compound which was purified by silica gel column chromatography (0.5%, MeOH in CHCl3) to yield (E)-tert-butyl 3-(1-(3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acryloyl)piperidin-4-yl)benzylcarbamate.
- White solid; Yield: 0.25 g, (33%)
- Mol. Wt: 494.62
- LCMS (m/z): 495 [M+1].
-
- A solution of (E)-tert-butyl 3-(1-(3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)acryloyl)piperidin-4-yl)benzylcarbamate (0.1 g, 0.2 mmol) in MeOH (2 mL) was treated with conc. HCl (0.2 mL) at room temperature for 1 h. The reaction mixture was concentrated in vacuo and the residue was purified by prep-HPLC to yield (E)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)prop-2-en-1-one and (E)-1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-3-(4-cyclopropyl-3-hydroxyphenyl)prop-2-en-1-one as a TFA salt.
- White solid; Yield: 0.002 g, (3%)
- Mol. Wt.: 366.45
- LCMS (m/z): 389 [M+23]
- HPLC Purity: 99.11%
- 1H NMR (400 MHz, CD3OD): δ 7.49 (d, J=15.6 Hz, 1H), 7.42-7.22 (m, 5H), 7.10 (d, J=16.4 Hz, 1H), 7.07 (d, J=8.0 Hz, 1H), 7.01 (s, 1H), 4.80-4.74 (m, 1H), 4.46-4.35 (m, 1H), 4.09 (s, 2H), 3.00-2.80 (m, 2H), 2.04-1.90 (m, 2H), 1.78-1.64 (m, 2H), 1.60 (s, 6H).
- The compound 1-{3-[4-(3-aminomethyl-phenyl)-piperidine-1-carbonyl]-phenyl}-3,4-dihydroxy-4-methyl-pyrrolidin-2-one hydrochloride (10) was prepared starting from 3-methyl-but-2-enoic acid methyl ester (1) as shown in
Scheme 27 below. In a similar way theother isomer Compound 13 was prepared as shown inScheme 28, also below. -
- To a solution of 3-methylbut-2-enoic acid methyl ester (20 g, 175.4 mmol) in carbon tetrachloride (88 mL) was added N-bromosuccinimide (31.2 g, 175.4 mmole) and benzoyl peroxide (235 mg) under nitrogen. The mixture was heated under reflux for 2 h. A small aliquot was worked up and the 1H NMR indicated the reaction to be complete. The reaction mixture was filtered to remove the succinimide which was washed with carbon tetrachloride (40 mL) and the combined filtrates were evaporated to give the crude title product (33.8 g) as a mixture of cis and trans isomers. The crude residue was used as such in the next reaction.
-
- To a solution of cis/trans mixture of bromo ester 5 (33.4 g, 175.13 mmole) in carbon tetrachloride (95 mL) was added triethylamine (26.4 g, 175.13 mmole) followed by 3-aminobenzoic acid methyl ester (4, 26.4 g, 175.13 mmole). The reaction mixture was then stirred at room temperature for 3 h. TLC analysis showed no new product. The mixture was then heated to reflux for 24 h. It was cooled to room temperature, diluted with methylene chloride (100 mL), washed with water (3×200 mL) to remove triethyl amine. The organic layer was dried with sodium sulfate, filtered and concentrated to dryness. The crude residue was purified by silica gel column chromatography using 20% ethyl acetate in hexane as eluent to give the pure title product (4.2 g, 10.4%). MP 87-89° C. 1H NMR (300 MHz, CDCl3): 8.24 (d, 2H, J=4.2 Hz), 8.05 (s, 1H), 7.77 (d, 1H, J=3.6 Hz), 7.44 (t, 1H), 5.97 (s, 1H), 4.35 (s, 2H), 3.92 (s, 3H), 2.16 (s, 3H).
-
- To a well stirred solution of (DHQD)2PHAL (150 mg, 0.19 mmol), potassium ferricyanide (10.9 g, 33 mmol), potassium carbonate (4.55 g, 33 mmol), potassium osmate dihydrate (100 mg, 0.27 mmol) and methylsulfonamide (1.045 g, 11 mmol) in 1:1 mixture of tert. butanol and water (125 mL) was added compound 5 (2.54 g, 11 mmol). The reaction mixture was stirred at room temperature overnight and was quenched with solid potassium sulfite (25 g). The mixture was stirred for one hour, ethyl acetate (100 mL) was added and stirring was continued for few minutes after which the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3×30 mL) and the combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated to give the crude residue which was purified by silica-gel column chromatography using 1 to 5% methanol in dichloromethane as the eluent. The pure
dihydroxy compound 6 thus obtained as an off-white solid (800 mg, 27.5%). MP 98-100° C. 1HNMR (300 MHz, CDCl3): δ 1.56 (s, 3H), 2.96 (s, OH), 3.58 (s, OH), 3.84 (dd, J=26 & 8 Hz, 2H), 3.92 (s, 3H), 4.22 (s, 1H), 7.46 (t, J=8.1 Hz, 1H), 7.84 (dd, J=8.1 & 3 Hz, 1H), 8.05-8.12 (m, 2H). ESMS: 266 (MH+). [α]D−23.3 (CH2Cl2, C=1.06). -
- To a solution of dihydroxy ester 6 (530 mg, 2 mmol) in methanol (10 mL) was added 1.25 M aqueous sodium hydroxide (2 mL) and the mixture was stirred at room temperature overnight. The solvent was evaporated and the residue dried by co-evaporation with toluene (2×10 mL). Methanol (10 mL) was added to the residue, and the residual NaCl was removed by filtration. The filtrate was evaporated to give the title compound as a sticky gum. (500 mg, 100%). 1HNMR (300 MHz, CD3OD): δ 1.50 (s, 3H), 3.70 (d, J=10.2 Hz, 1H), 3.81 (d, J=10.2 Hz, 1H), 4.24 (s, 1H), 7.49 (t, J=8.1 Hz, 1H), 7.81 (d, J=8.1 Hz, 1H), 7.93 (d, J=8.1 Hz, 1H), 8.28 (d, J=3 Hz, 1H). ESMS: 252 (MH+). It was used as such in the next reaction.
-
- To a solution of the dihydroxy acid 7 (450 mg, 1.8 mmol) and (3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester (8, 420 mg, 1.45 mmol) in CH2Cl2 (30 mL) was added EDCI (575 mg, 3 mmol) followed by N-hydroxybenzotriazole (30 mg, 0.25 mmol) and DIPEA (0.8 mL, 4.5 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was purified by silica-gel column chromatography using 1 to 5% methanol in dichloromethane as the eluent. The pure title compound thus obtained as off-white solid (320 mg, 42%). MP>105° C. (dec). 1H NMR (300 MHz, CD3OD): δ 1.44, (s, 9H), 1.48 (s, 3H), 1.65-2.05 (m, 5H), 2.83-3.35 (m, 4H), 3.69 (d, J=10.5 Hz, 1H), 3.82 (s, 1H), 3.85 (d, J=10.5 Hz, 1H), 4.20 (s, 2H), 7.09-7.25 (m, 5H), 7.46 (t, J=8.1 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H) and 7.90 (s, 1H). ESMS: 524 (MH+). [α]D−19.25 (CH2Cl2, 1.03).
-
- The Boc derivative 9 (112 mg, 0.21 mmol) was dissolved in CH2Cl2 (5 mL) and the solution was cooled in an ice-bath. To this was added 2 M HCl in ether (1.5 mL) and the mixture was stirred at room temperature overnight. On evaporation of the solvent, a white solid was obtained, which was dried at 50° C. overnight in a vacuum oven to give desired product as the hydrochloride salt. (82 mg, 85%) MP>185° C. (dec). IHNMR (300 MHz, CD3OD): 1.49 (s, 3H), 1.65-2.05 (m, 5H), 2.85-3.01 (m, 3H), 3.65-3.95 (m, 3H), 4.12 (s, 2H), 4.22 (s, 1H), 7.22-7.52 (m, 8H), 8.08 (s, 1H). ESMS: 424 (MH+).
-
- To a well stirred solution of (DHQ)2PHAL (150 mg, 0.19 mmol), potassium ferricyanide (10.9 g, 33 mmol), potassium carbonate (4.55 g, 33 mmol), potassium osmate dihydrate (100 mg, 0.27 mmol) and methylsulfonamide (1.045 g, 11 mmol) in a 1:1 mixture of tert. butanol and water (125 mL) was added compound 5 (2.54 g, 11 mmol). The reaction mixture was stirred at room temperature overnight and then quenched with solid potassium sulfite (25 g). It was stirred for one hour, after which ethyl acetate (100 mL) was added and the mixture was stirred for a few minutes then the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3×30 mL) and the combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated to give the crude diol. This was purified by silica-gel column chromatography using 1 to 5% methanol in dichloromethane as the eluent. The pure dihydroxy compound 11 was obtained as an off-white solid (773 mg, 26.5%). MP 95-97° C. IHNMR (300 MHz, CDCl3): δ 1.56 (s, 3H), 2.96 (s, OH), 3.58 (s, OH), 3.84 (dd, J=26 & 8 Hz, 2H), 3.92 (s, 3H), 4.22 (s, 1H), 7.46 (t, J=8.1 Hz, 1H), 7.84 (dd, J=8.1 & 3 Hz, 1H), 8.05-8.12 (m, 2H). ESMS: 266 (MH+). [α]D+23.59 (CH2Cl2, C=1.06).
-
- The ester 11 was hydrolyzed to the corresponding acid and converted to
amide 12 in a way similar to that reported forcompound 9. MP>68° C. (dec). [α]D+19.05 (CH2Cl2, 1.03). Mass and 1H NMR were in agreement with the proposed structure. -
- It was prepared in a similar way to that reported for
Compound 10 starting from 83 mg ofcompound 12. The hydrochloride salt of 13 obtained as a sticky solid. Mass and 1H NMR were in agreement with the proposed structure. - The following table contains exemplary compounds.
-
Homo/Hetero- Compound Dimerizing No. Structure Code Monomer 1 12 Hetero 2 NAFFLA-29 Hetero 3 T25e Hetero 4 T29- F Hetero 5 Lz-NA-25 Hetero 6 Lz-NA-26 Hetero 7 NAFFLA-25 Hetero 8 t42 Hetero 9 Hetero 10 Hetero 11 T126 Hetero 12 T45 Hetero 13 T113 Hetero 14 Hetero 15 T117 Hetero 16 T78spiro Hetero 17 T97 Hetero 18 Hetero 19 T100 Hetero 20 T101 Hetero 21 T102 Hetero 22 T96 Hetero 23 Hetero 24 Hetero 25 T104 Hetero 26 Hetero 27 Hetero 28 Hetero 29 Hetero 30 Hetero 31 T99 Hetero 32 T127 Hetero 33 T20 Hetero 34 Target 60 Hetero 35 T104 Hetero 36 T105 Hetero 37 T123 Hetero 38 T87 Hetero 39 T89 Hetero 40 T90 Hetero 41 T88 Hetero 42 T95 Hetero 43 T85 Hetero 44 Lz-NA-35 Hetero 45 Lz-NA-32 Hetero 46 Lz-NA-33 Hetero 47 NAFFLA-32 Hetero 48 NAFFLA-33 Hetero 49 T26 Homo 50 T6 Homo 51 T125 Hetero 52 Target 92- Spiro Hetero 53 T124 Hetero 54 Lz-NA-37 Hetero 55 T114 Hetero 56 T39 Hetero 57 T107 Hetero 58 Hetero 59 AzBOR-1 Hetero 60 AzBOR-2 Hetero 61 AzBOR-3 Hetero 62 AzBOR-4 Hetero 63 AzBOR-5 Hetero 64 AzBOR-6 Hetero 65 T54BA Hetero 66 T16 Hetero 67 T17 Hetero 68 T18 Hetero 69 T19 Hetero 70 T15 Hetero 71 T14-cis Hetero 72 T36-Gemdimethyl Hetero 73 T36-meta- Gemdimethyl Hetero 74 T38 Hetero 75 Target 63 Hetero 76 T79 Hetero 77 T80 Hetero 78 T91 Hetero 79 Target 61 Hetero 80 T118 Hetero 81 T119 Hetero 82 T107 Hetero 83 T108 Hetero 84 T109 Hetero 85 T110 Hetero 86 T116 Hetero 87 T117 Hetero 88 T131 Hetero 89 T132 Hetero 90 T112 Hetero 91 T133 Hetero 92 T98 Hetero 93 T99 Hetero 94 T100 Hetero 95 T101 Hetero 96 T102 Hetero 97 Hetero 98 Hetero 99 Hetero 100 Hetero 101 Hetero 102 Hetero 103 Hetero 104 Hetero 105 Hetero 106 Hetero 107 Hetero 108 Hetero 109 Hetero 110 Hetero 111 Hetero 112 Hetero 113 Hetero 114 T51 Hetero 115 Hetero 116 Hetero 117 Hetero 118 Hetero 119 Hetero 120 Hetero 121 Hetero 122 Hetero 123 Hetero 124 Hetero 125 T156 Hetero 126 Hetero 127 Hetero 128 Hetero 129 Hetero 130 Hetero 131 Hetero 132 Hetero 133 Hetero 134 Hetero 135 Hetero 136 Hetero 137 Hetero 138 Hetero 139 Hetero 140 Hetero 141 Hetero 142 Hetero 143 Hetero 144 Hetero 145 Hetero 146 Hetero 147 Hetero 148 Hetero 149 Hetero 150 Hetero 151 Hetero 152 Hetero 153 Hetero 154 Hetero 155 Hetero 156 Hetero 157 Hetero 158 Hetero 159 Hetero 160 Hetero 161 Hetero 162 Hetero 163 Hetero 164 Hetero 165 Hetero 166 Hetero 167 Hetero 168 Hetero 169 Hetero 170 Hetero 171 Hetero 172 Hetero 173 Hetero 174 Hetero 175 Hetero 176 Hetero 177 T143 Hetero 178 T144 Hetero 179 Hetero 180 T146 Hetero 181 T147 Hetero 182 T154 Hetero 183 Taget-104-Spiro Hetero 184 T-105-Spiro Hetero 185 T-107-Spiro Hetero 186 T-108-Spiro Hetero 187 T-109-Spiro Hetero 188 T-110-Spiro Hetero 189 T-112-Spiro Hetero 190 T-113-Spiro Hetero 191 T-114-Spiro Hetero 192 T-116-Spiro Hetero 193 T-117-Spiro Hetero 194 T-123-Spiro Hetero 195 T-131-Spiro Hetero 196 T-132-Spiro Hetero 197 T-133-Spiro Hetero 198 T-96 Hetero 199 T54BA-Spiro Hetero 200 T92OTB Hetero 201 T92OTBSpiro Hetero 202 T92PHSpiro Hetero 203 T92OPH Hetero 204 T85a Hetero 205 T136A Hetero 206 T75AOTB Hetero 207 T75AP Hetero 208 T75AOTBSpiro Hetero 209 T75ASpiro Hetero 210 T75APSpiro Hetero 211 T74Spiro Hetero 212 T126MonoMethyl Hetero 213 T142ENDOANTI Hetero 214 T141EXOANTI Hetero 215 T141ENDOANTI Hetero 216 T142ENDOSYN Hetero 217 T142EXOANTI Hetero 218 T141EXOSYN Hetero 219 T140RACEENDO Hetero 220 T139ENDO Hetero 221 T117Gem MonoMethylSpiro Hetero 222 T117MethylSpiro Hetero 223 T163 Hetero 224 T155-Spiro Hetero 225 T107-Spiro Hetero - Final targets with boronic acid functionality were synthesized. These compounds were synthesized by two approaches. In approach-1 the aryl boronic acids or their pinacolato boronate esters with carboxylic acid were coupled to protected core (Core-1 or Core-4 shown in synthetic scheme). Product was deprotected to obtain the target boronic acids. In approach-2 desired halo aryl carboxylic acids were first coupled to the appropriate protected core. The boronate ester/acid was introduced on the coupled product and deprotected to give the desired target boronic acids. The required aryl halo carboxylic acids in step-1 of both the approaches were either procured commercially or synthesized in-house by known methods in the literature. The details of the synthesis of these targets are given below.
- Required aryl boronic acids or their pinacolato boronate esters with carboxylic acid groups were synthesized and coupled with protected core (Core-1 or Core-4 shown in synthetic scheme). Coupled products were deprotected. During deprotection reaction of intermediates containing boronate ester functionality, either partial or complete hydrolysis of boronate esters to boronic acids occurred. Mixture of boronate ester and boronic acid was then subjected to purification by prep HPLC under acidic condition during which, remainder of the boronate ester was converted to boronic acid.
- The details of intermediates sourced/synthesized as per literature methods/synthesized by adapted methods are given below.
-
Code Structure A-54 2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid A-107 5,6-dimethyl-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1-biphenyl]-3-carboxylic acid A-109 6-chloro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylic acid A-116 4-(3-boronophenyl)-5-(methylthio)thiophene-2-carboxylic acid A-131 4′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylic acid A-132 3′-fluoro-5′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3 carboxylic acid A-133 2′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylic acid A-143 5-((2-boronobenzyl)(methyl)amino)-1-naphthoic acid A-146 3-((2-boronobenzyl)(methyl)amino)benzoic acid A-147 4-((2-boronobenzyl)(methyl)amino)benzoic acid A-154 6-((2-boronobenzyl)(methyl)amino)-1-naphthoic acid A-155 5′-borono-2′-(dimethylamino)-[1,1′-biphenyl]-3-carboxylic acid A-156 8-bromoquinoline-3-carboxylic acid Available commercially -
- To an ice-cold solution of 2-(3-fluoro-4-hydroxyphenyl)acetic acid (2.0 g, 11.75 mmol) in MeOH (40 mL), thionyl chloride (1.7 mL, 23.51 mmol) was added drop wise. The reaction mixture was warmed to room temperature and refluxed for 5 h. The reaction mixture was concentrated in vacuo and the residue obtained was diluted with ethyl acetate, washed with water and saturated sodium bicarbonate solution. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue which was purified by silica gel column chromatography (0-10% Ethyl acetate in Hexane) to yield methyl 2-(3-fluoro-4-hydroxyphenyl)acetate. White solid;
- Yield: 2.1 g, (95%).
- 1H NMR (400 MHz, CD3OD): δ 7.04-6.92 (m, 1H), 6.90-6.80 (m, 2H), 4.85 (bs, 1H), 3.65 (s, 3H), 3.52 (s, 2H)
- To an ice-cold solution of methyl 2-(3-fluoro-4-hydroxyphenyl)acetate (2.1 g, 11.41 mmol) in pyridine (40 mL), trifluoromethane sulphonic anhydride (5.7 mL, 34.23 mmol) was added drop wise. The reaction mixture was warmed to room temperature over the period of 3 h. The reaction mixture was concentrated under vacuo and the residue obtained was dried to afford methyl 2-(3-fluoro-4-(((trifluoromethyl)sulfonyl)oxy)phenyl)acetate. White solid;
- Yield: 3.3 g, (92%)
- 1H NMR (400 MHz, CD3OD): δ 7.48-7.32 (m, 2H), 7.28-7.18 (m, 1H), 3.75 (s, 2H), 3.70 (s, 3H)
- To a solution of methyl 2-(3-fluoro-4-(((trifluoromethyl)sulfonyl)oxy)phenyl)acetate (3.3 g, 10.43 mmol) in Dioxane (70 mL) was added Bis(Pinacolato)diborane (3.17 g, 12.52 mmol) and the reaction mixture was degassed under argon stream. To this solution, dichlorobis(triphenylphosphine) palladium (II) (0.25 g, 0.31 mmol), 1,1′-Bis(diphenylphosphino) ferrocene (0.17 g, 0.31 mmol) and potassium acetate (3.07 g, 31.3 mmol) were added and the mixture was stirred at 90° C. for 15 h under argon. After completion of reaction (TLC), the reaction mixture was cooled to room temperature and diluted with ethyl acetate, washed with water followed by brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give a residue which was purified by silica gel column chromatography on silica gel (0-30% Ethyl acetate in Hexane) to give methyl 2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate. White solid;
- Yield: 1.5 g (49%)
- 1H NMR (400 MHz, CDCl3): δ 7.40-7.30 (m, 1H), 7.18-7.08 (m, 2H), 4.77 (s, 2H), 3.73 (s, 3H), 1.35 (s, 12H)
- To a solution of methyl 2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (0.25 g, 0.85 mmol) in THF (15 mL) was added LiOH (0.07 g, 1.69 mmol) and the resulting solution was stirred at room temperature for 5 h. The reaction mixture was concentrated in vacuo, residue acidified with 10% citric acid solution and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and triturated with diethyl ether to yield the 2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid. White solid;
- Yield: 0.16 g (67%)
- MS (ES+): m/z=281 [MH+]
-
- To a mixture of bromine (20.5 g, 128.3 mmol) in CCl4 (225 mL) iron powder (1.98 g, 34.9 mmol) was added and cooled to 0° C. A solution of 3, 4 dimethyl benzoic acid (3.5 g, 23.3 mmol in 70 mL CCl4) was added drop wise and the reaction mixture was allowed to stir at room temperature overnight. TLC (
Mobile phase 30% ethyl acetate in n-hexane) indicated absence of starting material (RF 0.4) and product formation (Rf-0.35). The reaction mixture was quenched with sodium thiosulphate at 0° C. and stirred for 15 min. The reaction mixture was filtered through celite. The organic layer was washed with brine, dried over sodium sulphate, filtered, and concentrated in vacuo to give 3-bromo-4,5-dimethylbenzoic acid as a yellow solid. NMR is in agreement with the desired structure. Yield: (2.8 g, 52.8%). - 1H NMR (400 MHz, CDCl3): δ 4.04 (s, 3H), 7.12 (d, J=8.4 Hz, 1H), 8.07-8.10 (m, 2H), 9.90 (brs, 1H).
- To a degassed solution of palladium acetate (0.98 g, 4.37 mmol) Triphenyl phosphine (4.58 g, 17.5 mmol) in degassed 1,4 Dioxane (30 mL) was added to a degassed solution of 3-bromo-4,5-dimethylbenzoic acid (1 g, 4.37 mmol), Bispinacolato diborane (11 g, 43.7 mmol) and potassium acetate (1.28 g, 13.11 mmol in 70 mL Dioxane). The reaction mixture was heated at 90° C. for 16 h. TLC (
Mobile phase 30% ethyl acetate in n-hexane) indicated absence of starting material (RF 0.35) and product formation (Rf-0.45). The reaction mixture was filtered through celite and concentrated. The compound was extracted in ethyl acetate, washed with water. The organic layer was separated, dried over sodium sulphate, filtered, concentrated in vacuo and the crude residue purified by column chromatography on silica gel using hexane-ethyl acetate as eluent to give 3,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid. LCMS is in agreement with the desired structure. - Yield: (0.61 g 50.8%).
- MS: (ES+); m/z=277 [MH+]
- A solution of 3,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.61 g, 2.21 mmol) 1-bromo-3-iodobenzene (0.62 g, 2.21 mmol), potassium acetate (0.28 g, 2.87 mmol), cesium carbonate (2.15 g, 6.63 mmol) in degassed DMSO (10 mL) was degassed for 15 min. PdCl2 (dppf).DCM adduct (0.36 g, 0.44 mmol) was added and the reaction mixture was further degassed for 15 min. The reaction mixture was heated at 90° C. overnight. TLC (
Mobile phase 20% ethyl acetate in hexane) indicated absence of starting material (Rf 0.45) and product formation (Rf 0.3). The reaction mixture was quenched with water and the compound was extracted in ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered, concentrated in vacuo and purified by column chromatography on silica gel eluting with hexanes-ethyl acetate as eluent to give 3′-bromo-5,6-dimethyl-[1,1′-biphenyl]-3-carboxylic acid. - Yield: (0.32 g, 47.7%).
- MS (ES+): m/z=305/307 [MH+]
- To a degassed solution of palladium acetate (0.23 g, 1.05 mmol)
- Triphenyl phosphine (1.1 g, 4.21 mmol) in degassed 1,4 Dioxane (20 mL) was added to a degassed solution of 3′-bromo-5,6-dimethyl-[1,1′-biphenyl]-3-carboxylic acid (0.32 g, 1.05 mmol), Bispinacolato diborane (2.66 g, 10.5 mmol) and potassium acetate (0.3 g, 3.15 mmol in 30 mL Dioxane). The reaction mixture was heated at 90° C. for 16 h. TLC (
Mobile phase 30% ethyl acetate in n-hexane) indicated absence of starting material (RF 0.5) and product formation (Rf-0.55). The reaction mixture was filtered through celite and concentrated in vacuo. The compound was extracted in ethyl acetate, washed with water. The organic layer was separated, dried over sodium sulphate, filtered, concentrated in vacuo and purified by column chromatography on silica gel eluting with hexane-ethyl acetate as eluent to give 5,6-dimethyl-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylic acid. Purified material still contained pinacolato boronate peaks. This material was used in the next step without further purification. - Yield: (0.37 g, Crude)
- 1H NMR (400 MHz, DMSO-d6): δ 1.25 (t, J=7.0 Hz, 3H), 4.10-4.23 (q, J=7 Hz, 2H), 6.57 (d, J=16 Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 7.55 (d, J=16 Hz, 1H), 7.74-7.80 (dd, J=2.0 and 8.6 Hz, 1H), 8.06 (s, 1H), 8.28 (d, J=2 Hz, 1H), 8.50 (s, 1H), 13.5 (s, 1H).
-
- A solution of 3-bromo-4-chlorobenzoic acid (1.5 g, 6.43 mmol), potassium acetate (3.15 g, 32.1 mmol), and Bispinacolato diborane (8.14 g, 32.1 mmol) in degassed DMF (15 mL) was degassed for 15 min. PdCl2 (dppf) DCM adduct (0.52 g, 0.64 mmol) was added and the reaction mixture was further degassed for 15 min. The reaction mixture was heated at 90° C. overnight. TLC (
Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.2) and product formation (Rf-0.5). The reaction mixture was concentrated in vacuo, diluted with 2N NaOH and washed with ethyl acetate. The aqueous layer was acidified with 1N HCl and the compound was extracted in ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered, concentrated in vacuo, and the crude was purified by column chromatography on silica gel eluting with hexanes-ethyl acetate to give 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid as white solid. - Yield: (1.4 g 77%).
- 1H NMR (400 MHz, DMSO-d6): δ 7.07 (d, J=8.4 Hz, 1H), 7.90-8.00 (dd, J=2.0 and 8.8 Hz, 1H), 8.15 (s, 1H), 8.50 (d, J=2 Hz, 1H), 8.67 (brs, 1H), 9.82 (s, 1H), 13.9 (s, 1H).
- A solution of 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.6 g, 5.67 mmol) 3-bromo iodo benzene (1.59 g, 5.67 mmol), potassium acetate (0.72 g, 7.37 mmol), cesium carbonate (5.53 g, 17.02 mmol) in degassed DMSO (20 mL) was degassed for 15 min. PdCl2 (dppf).DCM adduct (0.46 g, 0.56 mmol) was added and the reaction mixture was further degassed for 15 min. The reaction mixture was heated at 90° C. overnight. TLC (
Mobile phase 50% ethyl acetate in hexane) indicated absence of starting material (Rf 0.5) and product formation (Rf 0.3). The reaction mixture was quenched with water and acidified with 1N HCl. Solid precipitated out which was filtered, dried and purified by column chromatography on silica gel eluting with hexanes-ethyl acetate to give 3′-bromo-6-chloro-[1,1′-biphenyl]-3-carboxylic acid as a white solid. - Yield: (1.12 g, 63.6%).
- 1H NMR (400 MHz, DMSO-d6): δ 7.07 (d, J=8.4 Hz, 1H), 7.90-8.00 (dd, J=2.0 and 8.8 Hz, 1H), 8.15 (s, 1H), 8.50 (d, J=2 Hz, 1H), 8.67 (brs, 1H), 9.82 (s, 1H), 13.9 (s, 1H).
- A solution of 3′-bromo-6-chloro-[1,1′-biphenyl]-3-carboxylic acid (1.12 g, 3.60 mmol), potassium acetate (1.05 g, 10.8 mmol), Bispinacolato diborane (2.73 g, 10.8 mmol) in degassed DMF (20 mL) was degassed for 15 min. PdCl2 (dppf) DCM adduct (0.14 g, 0.17 mmol) was added and the reaction mixture was further degassed for 15 min. The reaction mixture was heated at 90° C. overnight. TLC (
Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.2) and product formation (Rf-0.5). The reaction mixture was concentrated in vacuo, diluted with 2N NaOH and washed with ethyl acetate. The aqueous layer was acidified with 1N HCl and the compound was extracted in ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered, concentrated in vacuo and purified by column chromatography on silica gel eluting with hexanes-ethyl acetate to give 6-chloro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylicacid. - Yield: (0.83 g, 64%)
- 1H NMR (400 MHz, DMSO-d6): δ 1.25 (t, J=7.0 Hz, 3H), 4.10-4.23 (q, JJ=7 Hz, 2H), 6.57 (d, J=16 Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 7.55 (d, J=16 Hz, 1H), 7.74-7.80 (dd, J=2.0 and 8.6 Hz, 1H), 8.06 (s, 1H), 8.28 (d, J=2 Hz, 1H), 8.50 (s, 1H), 13.5 (s, 1H).
-
- 2,4-dibromo-5-methylthio thiophene was synthesized as per procedures available in the literature (Kano, Shinzo; Yuasa, Yoko; Yokomatsu, Tsutomu; Shibuya, Shiroshi Heterocycles, 1983, vol. 20, #10 p. 2035-2037)
- Lithiation of 2,4-dibromo-5-methylthio thiophene (28.13 g, 97.7 mmol) was done with n-BuLi (7.46 g, 116.64 mmol) at −78° C. in THF (562 mL after 5 min under stirring at same temperature was carefully added dry-ice and the temperature of the reaction mixture was allowed to raise to room temperature then the reaction mixture was quenched with dil HCl and concentrated. The residue obtained was diluted with dil HCl, and filtered and washed with methanol to get the product.
- Yield: 17.2 g, 70%
- MS (ES+): m/z=253.20/255.20 [MH+]
- Lithiation of bromo-5-(methylthio)thiophene-2-carboxylic acid (14.99 g, 59.25 mmol)was done with n-BuLi (11.37 g, 177.76 mmol) at −78° C. in THF (300 mL) after 30 min, under stirring at same temperature was carefully added tri-isopropyl borate (32.53 g, 177.76 mmol) drop wise and the temperature of the reaction mixture was allowed to raise to room temperature. The reaction mixture was quenched with dil HCl and concentrated in vacuo. The residue obtained was diluted with dil HCl, filtered and washed with water and re-dissolved in aq NaOH and re-precipitated by acidifying with dil HCl to get pure product.
- Yield: 10.36 g 0.80%
- MS (ES+): m/z=219.10 [MH+]
- To ice cold methanol (30 vol) was added conc. Sulphuric acid (2 vol) and then 4-borono-5-(methylthio)thiophene-2-carboxylic acid (9.9 g, 45.85 mmol)was added. The reaction mixture was heated to reflux till completion of reaction. After completion the reaction mixture was concentrated to its 25% vol and poured on crushed ice. The solid precipitated was filtered and washed with water to get pure product.
- Yield: 7.45 g, 70%
- MS (ES+): m/z=233.25 [MH+]
- Suzuki coupling of (5-(methoxycarbonyl)-2-(methylthio)thiophen-3-yl)boronic acid step-4 product (5 g, 21.54 mmol) with 3-bromo Iodobenzene (7.31 g, 25.85 mmol) was carried out in presence of Palladium (0) Tetrakis (Triphenyl phosphine) (10 mol %) in Dioxane (20 vol) water (5 vol) and sodium carbonate (4.56 g, 43.08 mmol) as base and heated at 80° C. for 15 hrs. After completion of reaction, the reaction mixture was filtered through a pad of celite and filtrate was concentrated in vacuo. The residue was diluted with water and extracted with ethyl acetate to get crude product. Crude product obtained was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexane.
- Yield: 3.69 g, 50%
- LCMS: Mol. Wt: −343.26; Peak observed: 343/345.10 [MH+]
- Stirred suspension of methyl 4-(3-bromophenyl)-5-(methylthio)thiophene-2-carboxylate, step-5 (2.6 g, 7.8 mmol)product in toluene (30 vol) was degassed with argon and charged with potassium acetate (3 eq), PdCl2-DPPF-CH2Cl2 (5 mol %) and Bis(Pinacolato)Diborane (4.93 g, 19.5 mmol), dppf (3 mol %). Reaction mass was heated to reflux & monitored by LCMS till most of the starting material was consumed. The mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to yield the crude product. The crude product was purified by column chromatography over silica gel eluting with 1-5% ethyl acetate in hexane.
- Yield: 2.14 g, 70%
- MS (ES+): m/z=391.15 [MH+]
- To ice cold methanol (30 mL) was added conc. Sulphuric acid (2 mL) and then methyl 5-(methylthio)-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiophene-2-carboxylate, step-6 product (2.1 g, 5.38 mmol) was added at 0° C. Reaction mixture was heated to reflux until completion of reaction. After completion the reaction mixture was concentrated to 25% of its vol and poured over crushed ice. The precipitate was filtered and washed with water to get pure product.
- Yield: 1.3 g, 80%
- MS (ES+): m/z=309.20 [MH+]
- A mixture of step-7 product (1.29 g, 4.21 mmol), Potassium hydroxide (2.36 g, 42.13 mmol), THF (10 mL) and water (20 mL) was heated to 60° C. for 2 h. The reaction was monitored by LCMS till most of the starting was consumed. The reaction mixture was concentrated in vacuo and diluted with water. The pH of the reaction mixture was then adjusted to ˜2 using Conc. HCl. resulting in a precipitate. The precipitate was filtered, washed with water and dried in vacuum oven.
- Yield: 744 mg, 60%
- MS (ES+): m/z=295.20 [MH+]
-
- 4′-fluoro-3′ methoxy biphenyl-3-carboxylic acid (1 g, 4.865 mmol) was dissolved in methanol (25 mL and the solution was cooled to 0° C. thionyl chloride (0.8 ml, 12.19 mmol) was added drop wise and then refluxed at 70° C. overnight. The methanol was concentrated in vacuo and the residue was diluted with ethyl acetate. The organic layer was washed with water (1×25 mL), 10% NaHCO3 solution then separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to get pure product (Off white solid)
- Yield: 1.01 g (95%)
- MS (ES+): m/z=261 [MH+]
- 1H NMR (400 MHz, CDCl3): δ 8.22 (s, 1H), 8.02 (d, J=7.7 Hz, 1H), 7.73 (d, J=87.6 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.22-7.08 (m, 3H), 3.96 (d, J=6.2 Hz, 6H).
- A stirred solution of methyl-4′-fluoro-3′-methoxy-[1,1′-biphenyl]-3-carboxylate (900 mg, 3.46 mmol) in dichloromethane (25 mL) was cooled to 0° C. and dropwise charged with boron tribromide (1.0 ml, 10.38 mmol) under a nitrogen atmosphere and stirred at room temperature for 5 hrs. The reaction mixture was cooled and quenched with methanol then concentrated in vacuo and charged with methanol and concentrated in vacuo several times to remove excess of bromine.
- Yield: 800 mg (94%),
- 1H NMR (400 MHz, DMSO-d6): δ 8.08 (t, J=1.9 Hz, 1H), 7.92 (d, J=87.7 Hz, 1H), 7.87-7.82 (m, 1H), 7.59 (t, J=7.8 Hz, 1H), 7.25 (d, J=6.0 Hz, 2H), 7.10 (ddd, J=8.3, 4.3, 2.4 Hz, 1H), 3.86 (s, 3H).
- A stirred solution of methyl-4′-fluoro-5′-hydroxy-[1,1′-biphenyl]-3-carboxylate (800 mg, 3.25 mmol) in dichloromethane (30 mL) was charged with DIPEA (1.7 ml, 9.76 mmol) at 0° C. then charged with triflic anhydride (1.67 ml, 9.76 mmol) and stirred at room temperature for 6 hr. The reaction mixture was quenched with water followed by wash with 1N HCl (25 mL) and brine solution. Organic layer was separated and dried over Na2SO4, filtered and concentrated in vacuo resulting in crude product, yellow oil. The crude compound was further purified by column chromatography on silica gel eluting with (n-hexane-ethyl acetate 9:1) to give 850 mg pure product as white solid.
- Yield: 850 mg (85%)
- 1H NMR (400 MHz, DMSO-d6): δ 8.24-8.19 (m, 1H), 8.13 (dd, J=7.1, 2.3 Hz, 1H), 8.01-7.97 (m, 2H), 7.91 (ddd, J=8.9, 4.8, 2.5 Hz, 1H), 7.75-7.62 (m, 2H), 3.90 (d, J=1.4 Hz, 3H).
- A solution of methyl-4′-fluoro-3′-(((trifluoromethyl)sulfonyl)oxy)-[1,1′-biphenyl]-3-carboxylate (500 mg, 1.322 mmol), potassium acetate (444 mg, 4.629 mmol), bis pinacolato diborane (3.34 g, 13.22 mmol) in anhydrous dioxane (15 mL) was degassed for 15 min. under argon. To this were added Pd(dppf)Cl2 (64.7 mg, 0.0793 mmol), dppf (43.4 mg, 0.0793 mmol) and again degassed for 10 min. and stirred at 80° C. for 12-14 hr. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate and washed with water followed by brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to get crude product. The crude product was further purified by column chromatography on silica gel eluting with (n-hexane-ethyl acetate 8:2) to get 650 mg product contaminated with some bis pinacolato diborane.
- Yield: 600 mg
- 1H NMR (400 MHz, DMSO-d6): δ 1.33 (s, 12H), 3.89 (s, 3H), 7.36-7.23 (m, 1H), 8.02-7.79 (m, 3H), 8.15-8.07 (m, 1H), 7.70-7.57 (m, 1H)
- To a solution of 4′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylate (600 mg, 1.685 mmol) in THF:water (10 mL) was added lithium hydroxide (212 mg, 5.056 mmol) and stirred at room temperature overnight. The solvent was concentrated in vacuo and the pH of residue was adjusted up to 2. Major product spot was isolated by acid base work-up.
- Yield: 200 mg
- 1H NMR (400 MHz, DMSO-d6): δ 13.12 (brs, 1H), 8.12 (t, J=1.9 Hz, 1H), 7.97-7.84 (m, 4H), 7.61 (t, J=7.7 Hz, 1H), 7.29 (t, J=8.7 Hz, 1H), 1.33 (s, 12H).
-
- 3′-Fluoro-5′ methoxy biphenyl-3-carboxylic acid (1 g, 4.865 mmol) was dissolved in methanol (25 ml) and solution was cooled to 0° C. Thionyl chloride (0.8 ml, 12.19 mmol) was added drop wise and reaction mixture was refluxed at 70° C. overnight. Methanol was removed in vacuo and the residue was diluted with ethyl acetate and washed with water (1×25 mL) followed by 10% NaHCO3 solution and separated. The organic layer dried over Na2SO4, filtered, and concentrated in vacuo to get pure product (off-white solid)
- Yield: 1 g (94%)
- MS (ES+): m/z=261.00 [MH+]
- 1H NMR (400 MHz, DMOS-d6): δ 8.17 (s, 1H), 8.01-7.92 (m, 2H), 7.62 (t, J=7.8 Hz, 1H), 7.17-7.03 (m, 2H), 6.88 (dt, J=11.0, 2.3 Hz, 1H), 3.87 (d, J=15.5 Hz, 6H).
- A stirred solution of methyl-3′-fluoro-5′-methoxy-[1,1′-biphenyl]-3-carboxylate (900 mg, 3.461 mmol) in dichloromethane (25 mL) was cooled to 0° C. and dropwise charged with boron tribromide (1 ml, 10.38 mmol) under a nitrogen atmosphere The reaction mixture was stirred at
room temperature 5 hr then cooled and quenched with methanol. The solvent was concentrated in vacuo and charged and stripped with methanol several times to remove excess of bromine. - Yield: 800 mg (93.4%).
- 1H NMR (400 MHz, DMSO-d6): δ 8.13 (s, 1H), 7.94 (dd, J=20.0, 7.7 Hz, 2H), 7.62 (t, J=7.8 Hz, 1H), 7.03-6.89 (m, 2H), 6.61 (d, J=10.6 Hz, 1H), 3.89 (s, 3H).
- A stirred solution of methyl-3′-fluoro-5′-hydroxy-[1,1′-biphenyl]-3-carboxylate (800 mg, 3.252 mmol) in dichloromethane (30 mL) was charged with DIPEA (1.7 ml, 9.756 mmol) at 0° C. followed by triflic anhydride (1.67 ml, 9.756 mmol) and stirred at room temperature for 6 hr. The reaction mixture was quenched with water and separated and the organic was wash with 1N HCl (25 mL) and brine solution. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo resulting in crude product, yellow oil) which was further purified by column chromatography on silica gel (n-hexane:ethyl acetate 9:1) to give 850 mg pure product as a white solid.
- Yield: 850 mg (85%).
- 1H NMR (400 MHz, DMSO-d6): δ 8.26 (s, 1H), 8.04 (t, J=6.3 Hz, 2H), 7.87-7.79 (m, 2H), 7.66 (q, J=9.0, 8.3 Hz, 2H), 3.90 (s, 3H).
- A solution of methyl-3′-fluoro-5′-(((trifluoromethyl)sulfonyl)oxy)-[1,1′-biphenyl]-3-carboxylate (500 mg, 1.322 mmol), potassium acetate (444 mg, 4.629 mmol), bis pinacolato diborane (3.34 g, 13.22 mmol) in anhydrous dioxane (15 mL) was degassed for 15 min. under argon and charged with Pd(dppf)Cl2 (64.7 mg, 0.0793 mmol) and dppf (43.4 mg, 0.0793 mmol) and degassed for 10 min. and stirred at 80° C. for 12-14 hr. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate and washed with water and brine and the organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to get crude product which was further purified by column chromatography on silica gel eluting with (n-hexane-ethyl acetate 8:2) to get 650 mg product contaminated with some bis pinacolato diborane.
- Yield: 650 mg.
- 1H NMR (400 MHz DMSO-d6): δ 1.32 (s, 12H), 3.9 (s, 3H), 7.38-7.40 (m, 1H), 7.63-7.74 (m, 3H), 7.99-8.01 (m, 2H), 8.18 (s, 1H)
- A solution of 3′-fluoro-5′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylate (250 mg, 0.7022 mmol) in THF:water (10 mL) was charged with lithium hydroxide (88 mg, 2.106 mmol) and stirred at room temperature overnight. The THF solvent was concentrated under vacuum and the pH of residue was adjusted up to 2 and the major product spot was isolated by acid-base work-up.
- Yield: 90 mg
- 1H NMR (400 MHz DMSO-d6): δ 1.32 (s, 12H), 3.9 (s, 3H), 7.38-7.40 (d, J=7.6 Hz, 1H), 7.63-7.74 (m, 1H), 7.99-8.01 (d, J=7.6 Hz, 1H), 8.18 (s, 1H), 13.12 (bs, 1H)
-
- A solution of 2′-fluoro-3′ methoxy biphenyl-3-carboxylic acid (1 g, 4.865 mmol) in methanol (25 mL) was cooled to 0° C. and dropwise charged with thionyl chloride (0.8 ml, 12.19 mmol) and refluxed at 70° C. overnight.
- The reaction was allowed to cool to room temperature and the solvent was concentrated in vacuo. The residue was diluted with ethyl acetate and the organic layer was washed with water (1×25 mL), 10% NaHCO3 Solution (1×15 ml) and separated and dried over Na2SO4, filtered, and concentrated in vacuo resulting in pure product (off white solid)
- Yield: 700 mg (66%),
- 1H NMR (400 MHz, CDCl3): δ 8.24-8.19 (m, 1H), 8.05 (dt, J=7.4, 1.5 Hz, 1H), 7.75 (dq, J=7.4, 1.8 Hz, 1H), 7.52 (t, J=7.8 Hz, 1H), 7.06-6.94 (m, 3H), 3.94 (s, 6H).
- A stirred solution of methyl2′-fluoro-3′-methoxy-[1,1′-biphenyl]-3-carboxylate (700 mg, 2.692 mmol) in dichloromethane (25 mL) was cooled to 0° C. and dropwise charged with boron tribromide (0.8 ml, 8.070 mmol) under a nitrogen atmosphere and stirred at room temperature for 5 hr. The reaction mixture was cooled and quenched with methanol and the solvent was evaporated and stripped with methanol several times to remove excess of bromine.
- Yield: 650 mg (98%),
- 1H NMR (400 MHz, DMSO-d6): δ 8.06 (s, 1H), 7.97 (d, J=7.6 Hz, 1H), 7.79 (d, J=7.6 Hz, 1H), 7.63 (td, J=7.7, 2.1 Hz, 1H), 7.09 (t, J=8.0 Hz, 1H), 7.00 (t, J=8.2 Hz, 1H), 6.92 (t, J=7.2 Hz, 1H), 3.87 (s, 3H).
- A stirred solution of methyl-2′-fluoro-3′-hydroxy-[1,1′-biphenyl]-3-carboxylate (650 mg, 2.640 mmol), 2,4-dibromo-5-methylthio thiophene, and DIPEA (1.41 ml, 7.920 mmol) in dichloromethane (30 mL) was cooled to 0° C. and charged with triflic anhydride (1.33 ml, 7.920 mmol) and stirred at room temperature for 6 hrs. The reaction mixture was quenched with water and separated and the organic was washed with 1N HCl (25 mL), brine, dried over Na2SO4, filtered, and concentrated in vacuo resulting in crude yellow oil. The crude compound was purified by column chromatography on silica gel eluting with (n-hexane-ethyl acetate 9:1) to give 850 mg pure compound as a white solid.
- Yield: 850 mg (85%).
- 1H NMR (400 MHz, DMSO-d6): δ 8.13 (d, J=2.2 Hz, 1H), 8.06 (d, J=7.8 Hz, 1H), 7.89 (d, J=7.7 Hz, 1H), 7.79-7.62 (m, 3H), 7.51 (t, J=8.1 Hz, 1H), 3.89 (s, 3H).
- A solution of methyl2′-fluoro-3′-(((trifluoromethyl)sulfonyl)oxy)-[1,1′-biphenyl]-3-carboxylate (400 mg, 1.038 mmol), potassium acetate (355 mg, 3.703 mmol), bis pinacolato diborane (1.34 g, 5.2810 mmol) in anhydrous dioxane (15 mL) was degassed for 15 min. under argon. The reaction mixture was charged with Pd(dppf)Cl2 (51 mg, 0.0634 mmol), dppf (35 mg, 0.0634 mmol) and again degassed for 10 min. and heated to 80° C. for 12-14 hrs. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate and washed with water followed by brine. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo resulting in crude product. The crude product was purified by column chromatography on silica gel eluting with (n-hexane-ethyl acetate 8:2) to get 600 mg product contaminated with some Bis pinacolato diborane.
- Yield: 600 mg.
- 1H NMR (400 MHz, DMSO-d6): δ 8.06-8.08 (m, 1H) 7.97 (d, J=6.8 Hz, 1H), 7.78 (d, J=7.6 Hz, 1H), 7.52-7.65 (m, 2H), 7.25-7.35 (m, 1H), 3.86 (s, 1H), 1.29 (s 12H)
- A solution of 2′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carboxylate (200 mg, 0.561 mmol) in THF: Water (10 mL) was charged with Solid lithium hydroxide (94 mg, 2.247) and stirred at room temperature overnight. The THF was concentrated in vacuo and the aqueous pH adjusted up to 2. Major product spot was isolated by acid base work-up.
- Yield: 130 mg (67.7%)
- 1H NMR (400 MHz, DMSO-d6): δ 1.31 (s, 12H), 3.92 (s, 1H), 7.33 (s, 1H), 7.59-7.98 (m, 6H), 8.08 (s, 1H), 13.04 (bs, 1H)
-
- To cold fuming nitric acid (3 ml, 660 mmol) at 0-5° C. was charged with α-naphthoic acid (1 gm, 5.8 mmol) portion-wise over a 15 min. period and stirred at 0-5° C. for 30 min. and then at room temperature for an additional 2 hr. The reaction mixture was poured into 20 ml of ice-cold water upon which a precipitate formed. The precipitate was filtered and washed with 10 ml of water. The solid obtained was dissolved in 10 ml of 8% sodium carbonate and stirred for 10 mins and filtered. Filtrate was acidified using 10% HCl (pH=2) and the precipitate was filtered and re-crystallized from ethanol, filtered and dried under vacuum to get a yellow solid.
- Yield: 1.14 g, 90.47%
- HPLC Purity: 98.09%,
- 1H NMR (400 MHz, DMSO-d6): δ 13.57 (s, 1H), 9.19 (d, J=8.8 Hz, 1H), 8.54-8.21 (m, 3H), 7.85 (dt, J=16.3, 7.8 Hz, 2H)
- A stirred solution of step-1 product (1 g, 4.60 mmol) in methanol (15 ml) was charged with conc. sulfuric acid and heated to reflux at 70° C. for 24 hrs.
- The solvent was concentrated in vacuo and the residue was basified to pH=8 using 10% sodium bicarbonate and extracted with ethyl acetate (3×20 ml). The combined organic layer was washed with brine (2×10 ml), dried over sodium sulfate, filtered and concentrated in vacuo resulting in crude product which was purified by column chromatography on silica gel to get a pale yellow color solid.
- Yield: 150 mg, 14.15%,
- HPLC Purity: 77.57%,
- 1H NMR (400 MHz, CDCl3): δ 9.26 (d, J=8.7 Hz, 1H), 8.67 (d, J=8.8 Hz, 1H), 8.30 (d, J=7.3 Hz, 1H), 8.21 (d, J=7.5 Hz, 1H), 8.18-8.07 (m, 1H), 7.71 (dt, J=22.9, 8.1 Hz, 1H), 4.05 (d, J=8.5 Hz, 3H).
- A stirred solution of 10% Pd—C (8 mg) in dry methanol (2 mL) was charged with a solution of step-2 product (80 mg, 0.340 mmol) in methanol (10 ml) under nitrogen and then the reaction was charged with a hydrogen pressure(bladder) for 24 hr at room temperature. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo to get yellow oil.
- Yield: 60 mg, 86.95%
- MS (ES+): m/z=202.05 [MH+]
- A stirred solution of step-3 product (120 mg, 1 eq) in methanol (20 mL) was charged with 2-formyl phenyl boronic acid (89 mg, 1 eq) and the reaction was stirred at room-temperature for 30 min. then charged with sodium cyanoborohydride (150 mg, 4 eq) and stirred at room-temperature for an additional 48 hrs. The solvent was concentrated in vacuo then partitioned between DCM (20 mL) and water (2×15 mL) and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to get the crude product which was purified by column chromatography on silica gel to get yellow color oil.
- Yield: 80 mg, 40%
- HPLC Purity: 82.57%,
- MS (ES+): m/z=336.15 [MH+]
- A stirred solution of the step-4 product (100 mg, 0.590 mmol) in ethanol (6 mL), water (2 mL), and acetic acid (2 mL) was charged with p-formaldehyde (14 mg, 0.590 mmol) and stirred at room-temperature for 15 mins then charged with sodium cyanoborohydride (75 mg, 2.30 mmol) portion-wise over a 15 min. period and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo and the residue was charged with water (10 mL) then acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with brine (2×10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get a yellow solid.
- Yield: 100 mg, 97.15%,
- MS (ES+): m/z=350.10 [MH+]
- A stirred solution of the step-5 product (100 mg, 1 eq) in THF (3 mL) and water (3 mL) was charged with solid lithium hydroxide (14 mg, 2 eq) and the reaction was stirred at room-temperature for 24 hrs. The THF was concentrated in vacuo and the aqueous was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×15 mL). The combined organic layers were washed with brine (2×10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get brown solid.
- Yield: 80 mg, 83.33%
- HPLC Purity: 32.52%,
- MS (ES+): m/z=336.10 [MH+]
-
- A stirred solution of methyl-3-amino benzoate (200 mg, 1.52 mmol) in methanol (5 mL) was charged with 2-formyl phenyl boronic acid (198 mg, 1.32 mmol) and stirred at room-temperature for 10 mins then charged with sodium cyano borohydride (332 mg, 5.29 mmol) portion-wise over a 15 min period and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo. The residue was dissolved in DCM (20 mL) and washed with water (2×15 mL), brine (2×15 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get the crude product which was purified by column chromatography on silica gel to get a brown solid.
- Yield: 250 mg, 66.31%
- MS (ES+): m/z=286.15 [MH+]
- 1H NMR (400 MHz, DMSO-d6): δ 7.55-7.39 (m, 1H), 7.37-7.26 (m, 4H), 7.23-7.10 (m, 4H), 4.58 (s, 2H), 4.12-3.99 (m, 1H), 3.83 (d, J=30.9 Hz, 3H), 1.99 (s, 2H)
- A stirred solution of the step-1 product (250 mg, 0.87 mmol) in ethanol (15 mL), water (5 mL), and acetic acid (5 mL) was charged with p-formaldehyde (40 mg, 1.30 mmol) and was stirred at room-temperature for 15 mins. The reaction mixture was charged with sodium cyanoborohydride (220 mg, 3.50 mmol) portion-wise over a 15 min. period and stirred at room-temperature for 24 hr. The solvent was concentrated in vacuo and to residue was charged with water (10 mL) and was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in yellow solid (Qty-160 mg).
- Yield: 160 mg, 61.06%,
- HPLC Purity: 85.56%,
- MS (ES+): m/z=300.00 [MH+]
- To a stirred solution of the step-2 product (160 mg, 0.53 mmol) in THF (5 mL) and water (2 mL) was charged with lithium hydroxide (26 mg, 1.00 mmol) and the reaction was stirred at room-temperature for 24 hr. The solvent was concentrated in vacuo and the residue was acidified to
pH 2 using 1N KHSO4 and extracted with ethyl acetate (3×15 mL). The combined organic layer was washed with brine (2×10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in a pale yellow solid. - Yield: 150 mg, 98.68%,
- MS (ES+): m/z=286.15 [MH+]
-
- A stirred solution of methyl-4-amino benzoate (200 mg, 1.52 mmol) in methanol (5 mL) was charged with 2-formyl phenyl boronic acid (198 mg, 1.32 mmol) and stirred at room-temperature for 10 mins then charged with sodium cyano borohydride (332 mg, 0.529 mmol) portion-wise over a 15 min. period and continued to stir at room-temperature for an additional 24 hr. The solvent was concentrated under vacuum and the residue was dissolved in DCM (20 mL) and washed with water (2×15 mL), brine (2×15 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in the crude product which was purified by column chromatography to get an off-white color solid.
- Yield: 270 mg, 71.61%
- MS (ES+): m/z=286.15 [MH+]
- 1H NMR (400 MHz, DMSO-d6): δ 7.89 (t, J=8.7 Hz, 2H), 7.67 (dd, J=13.5, 8.6 Hz, 2H), 7.46 (d, J=4.1 Hz, 2H), 7.38-7.24 (m, 2H), 4.59 (s, 2H), 4.10 (q, J=5.2 Hz, 1H), 3.81 (s, 3H), 1.23 (s, 2H)
- A stirred solution of the step-1 product (50 mg, 0.175 mmol) in ethanol (3 mL), water (1 mL) and acetic acid (1 mL) was charged with p-formaldehyde (8 mg, 0.26 mmol) and stirred at room-temperature for 15 min. The reaction was then charged with sodium cyanoborohydride (44 mg, 0.70 mmol) portion-wise over a 15 min period and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo and the residue was diluted in water (10 mL) and was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with brine (2×10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in an off-white solid.
- Yield: 50 mg, 96.15%
- MS (ES+): m/z=300.00 [MH+]
- A stirred solution of the step-2 product (250 mg, 0.83 mmol) in THF (10 mL) and water (4 mL) was charged with lithium hydroxide (40 mg, 1.6 mmol) and stirred at room-temperature for 24 hr. The solvent was concentrated in vacuo and the residue was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×15 mL). The combined organic layers were washed with brine (2×10 mL), dried over sodium sulfate filtered, and concentrated in vacuo resulting in yellow solid.
- Yield: 210 mg, 88.23%
- HPLC Purity: 82.94%,
- MS (ES+): m/z=286.15 [MH+]
-
- A stirred solution of methyl 6-amino-1-naphthoate (500 mg, 2.48 mmol) in methanol (20 mL) was charged with 2-formyl phenyl boronic acid (373 mg, 2.48 mmol) and stirred at room-temperature for 30 min. The reaction mixture was then charged with sodium cyanoborohydride (625 mg, 9.9 mmol) and stirred at room-temperature for an additional 48 hr. The solvent was concentrated in vacuo and residue was diluted with DCM (20 mL) and washed with water (2×15 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get the crude product which was purified by column chromatography to get yellow solid (Qty-600 mg).
- Yield: 600 mg, 72.02%
- MS (ES+): m/z=336.10 [MH+]
- HPLC Purity: 99.59%,
- 1H NMR (400 MHz, DMSO-d6): δ 9.66-9.60 (m, 1H), 8.67 (d, J=9.5 Hz, 1H), 8.36 (dd, J=9.7, 2.8 Hz, 2H), 8.06 (d, J=8.3 Hz, 2H), 7.92 (dd, J=15.9, 7.3 Hz, 2H), 7.74 (s, 1H), 7.49 (dq, J=15.2, 7.7 Hz, 3H), 7.35 (t, J=7.2 Hz, 1H), 4.69 (s, 2H), 4.00-3.88 (m, 3H)
- A stirred solution of the step-1 product (600 mg, 1.79 mmol) in ethanol (36 mL), water (12 mL), and acetic acid (12 mL) was charged with p-formaldehyde (81 mg, 2.68 mmol) and stirred at room-temperature for 15 mins. The reaction mixture was charged with sodium cyanoborohydride (450 mg, 7.16 mmol) portion-wise over a 15 min. period and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo and the residue was diluted with water (10 mL) and acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in a yellow solid (Qty-680 mg crude) which was used in the next step without further purification.
- Crude product used as such for next step
- HPLC Purity: 93.25%,
- MS (ES+): m/z=350.15 [MH+]
- 1H NMR (400 MHz, DMSO-d6): δ 8.52 (d, J=9.6 Hz, 1H), 8.14 (s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.77 (d, J=7.1 Hz, 1H), 7.53 (d, J=6.9 Hz, 1H), 7.40 (t, J=7.7 Hz, 1H), 7.32 (dd, J=9.4, 2.9 Hz, 1H), 7.21 (dq, J=15.0, 7.0 Hz, 3H), 7.05 (t, J=5.9 Hz, 2H), 4.80 (s, 2H), 3.89 (s, 3H), 3.07 (s, 3H)
- A stirred solution of the step-2 product (670 mg, 1.9 mmol) in THF (20 mL) and water (20 mL) was charged with lithium hydroxide (92 mg, 3.8 mmol) and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo and residue was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×25 mL). The combined organic layer was washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in a yellow solid.
- Yield: 600 mg, 93.33%,
- MS (ES+): m/z=336.10 [MH+]
- HPLC Purity: 80.32%,
- 1H NMR (400 MHz, DMSO-d6): δ 12.84 (s, 1H), 8.63 (d, J=9.5 Hz, 1H), 7.81 (dd, J=27.3, 7.8 Hz, 2H), 7.52 (d, J=7.1 Hz, 1H), 7.42-7.14 (m, 4H), 7.06 (d, J=6.1 Hz, 2H), 4.79 (s, 2H), 4.08-3.86 (m, 2H), 3.09 (d, J=23.7 Hz, 3H)
-
- A stirred solution of 4-bromo-2-iodo aniline (2 g, 6.71 mmol) and potassium carbonate (1.4 g, 10.14 mmol) in DMF (20 mL) was cooled to 0° C. and dropwise charged over a 20 min. period with iodomethane (1.9 g, 13.0 mmol) keeping the temperature between 0-5° C. then stirred at 0° C. for 1 hr and then at room-temperature for 48 hrs. The reaction mixture was charged with water (30 mL) and was extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine (2×25 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get the crude product which was purified by column chromatography to get a brown oil.
- Yield: 1.8 g, 82.19%
- HPLC Purity: 68.15%,
- MS (ES+): m/z=312/314 [MH+]
- A stirred solution of the step-1 product (1.8 g, 5.70 mmol) in ethanol (108 mL), water (36 mL), and acetic acid (36 mL) was charged with p-formaldehyde (260 mg, 8.60 mmol) and stirred at room-temperature for 15 min. The reaction mixture was portion-wise charged over a 20 min period with sodium cyanoborohydride (1.45 g, 23 mmol) and stirred at room-temperature for 24 hr. The solvent was concentrated in vacuo and the residue was diluted in water (20 mL) and was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×30 mL). The combined organic layer was washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in a yellow oil.
- Yield: 1.7 g, 90.42%
- HPLC Purity: 99.70%,
- MS (ES+): m/z=326 [MH+]
- A stirred solution of step-2 product (1.7 g, 5.20 mmol) in toluene (50 mL) was charged with a solution of sodium carbonate (1.11 g, 10.04 mmol) in water (15 mL), 3-ethoxycarbonyl phenyl boronic acid (939 mg, 5.20 mmol) and the reaction was degassed with argon for 1 hr and then charged with tetrakis (340 mg, 20w/w) and heated to 100° C. for 24 hr. The reaction was allowed to cool to room-temperature and charged with water (20 mL) and was extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to get 750 mg of the crude product which was purified by column chromatography to get desired product as colorless oil.
- Yield: 150 mg, 8.33%
- HPLC Purity: 96.76%,
- MS (ES+): m/z=348/350 [MH+]
- A stirred solution of the step-3 product (100 mg, 0.28 mmol) in THF (5 mL) and water (3 mL) was charged with lithium hydroxide (10 mg, 0.43 mmol) and stirred at room-temperature for 24 hrs. The solvent was concentrated in vacuo and the residue was acidified to pH=2 using 1N KHSO4 and extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with brine (2×10 mL), dried over sodium sulfate, filtered, and concentrated in vacuo resulting in an off-white solid.
- Yield: 70 mg, 76.92%
- HPLC Purity: 95.09%,
- MS (ES+): m/z=321/323 [MH+]
- To a stirred solution of carboxylic acid in DCM or DMF was added DMAP or DIPEA, EDCI, HOBt (in some cases). The solution was stirred for 15 min. at 0° C.-room temperature followed by addition of protected 4-(3-aminomethyl phenyl)piperidine or 5-aminomethyl Spiro[benzofuran-3,4′-piperidine]. Stirring was continued at room temperature and reaction was monitored by LCMS till most of the starting materials were consumed. Reaction mixture was then quenched with water and aq. layer was extracted twice with dichloromethane. The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product which was used for next step without further purification.
- The details of compounds synthesized by step-1a are as below:
-
Comp. Brief Reaction No. Structure conditions Analytical data B-132 Spiro A-132 (1eq), Spiro core (1 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), in Dichloromethane 50 vol. R.T. 12 hrs. 66% after acid-base work- upYield: −66% Mol. Wt: 642.56 MS (ES+): m/z = 583 (MH+− Boc + AcN) tert-butyl ((1′-(3′-fluoro-5′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- [1,1′-biphenyl]-3-carbonyl)-2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate B-133 Spiro A-133 (1eq), Spiro core (1 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), in Dichloromethane 50 vol. R.T. 12 hrs. 53.1% after acid- base work-up.Yield: −53% Mol. Wt: 642.56 MS (ES+): m/z = 583 (MH+− Boc + AcN) tert-butyl ((1′-(2′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- [1,1′-biphenyl]-3-carbonyl)-2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbam B-131- Spiro A-131 (1eq), Spiro core (1 eq.), EDCI (1.5 eq.), DMAP (0.5 eq.), in Dichloromethane 50 vol. R.T. 12 hrs. 62% after acid- base work-up.Yield: −62% Mol. Wt: 642.56 MS (ES+): m/z = 587 [MH+− t-Bu] tert-butyl ((1′-(4′-fluoro-3′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- [1,1′-biphenyl]-3-carbonyl)-2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbam B-107 A-107 370 mg, tert- butyl 3-(piperidin-4- yl)benzylcarbamate 1.2 eq., EDCI 1.5 eq. DMAP 0.5 eq. in Dichloromethane 80 vol. R.T. 12 hrs. yield: −53.8% after chromatographic purification over silica gel Mol. Wt: 652.37 MS (ES+): m/z = 653 [MH+] tert-butyl 3-(1-(5,6-dimethyl-3′-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carbonyl)piperidin-4-yl)benzylcarb B-107- Spiro A-107 150 mg, Spiro core 1.2 eq., EDCI 1.5 eq. DMAP 0.5 eq. in Dichloromethane 200 vol. R.T. 12 hrs. yield: −44.4% after chromatographic purification over silica gel Mol. Wt: 652.37 MS (ES+): m/z = 653 [MH+] tert-butyl ((1′-(5,6-dimethyl-3′-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carbonyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate B-54 A-54 (1eq.) tert-butyl 3-(piperidin-4-yl) benzylcarbamate (1.0 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM, rt, 15 h, Yield: 32% Mol. Wt: 552.48 MS (ES+): m/z = 553 [MH+] 1H NMR (400 MHz, CDCl3): δ 7.42-7.32 (m, 1H), 7.19-6.90 (m, 6H), 4.88-4.72 (m, 1H), 4.28 (s, 2H), 4.05-3.95 (m, 1H), 3.80 (s, 2H), 3.20-3.08 (m, 1H), 2.68-2.60 (m, 2H), 1.94-1.78 (m, 2H), 1.70-1.52 (m, 2H), 1.58 (s, 9H), 1.45 (s, 12H) tert-butyl 3-(1-(2-(3-fluoro-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)acetyl)piperidin-4-yl)benzylcarbamate B-54- Spiro A-54 (1eq.) tert-butyl 4-methoxy-3-(4- methylpiperidin-4- yl)benzylcarbamate (1.0 eq.), EDCI (1.5 eq.), DMAP (1.2 eq.), DCM, rt, 15 h, Yield: 34% Mol. Wt: 580.50 MS (ES+): m/z = 581 [MH+] tert-butyl ((1′-(2-(3-fluoro-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)acetyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate B-109- Spiro A-109 (1eq.) Spiro core 1.2 eq., EDCI 1.5 eq. HOBt 1.5 eq. DIPEA 2.5 eq. in DMF 70 vol. R.T. 12 hrs. yield: −60% after chromatographic purification over silica gel Mol. Wt: −658.3 MS (ES+): m/z = 681 [MH+ + Na] tert-butyl ((1′-(6-chloro-3′-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-3-carbonyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate indicates data missing or illegible when filed - The details of compounds synthesized by step-1b are as below.
-
Comp. No. Structure Brief Reaction conditions Analytical data B-116 Spiro tert-butyl ((2H- spiro[benzofuran-3,4′- piperidin]-5- yl)methyl)carbamate (1.3 eq.), EDCI•HCl (1.5 eq.), DMAP (2 eq.), DCM (20 vol), RT, 4 h, Yield: −60% Mol. Wt: 594.55 MS (ES+): m/z = 595.70 [MH+] B-146 A-146, tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1 eq), EDCI 1.5 eq. DMAP 1.1 eq., HOBt, 1.1 eq. in Dichloromethane 70 vol. R.T. 12 hrs. Yield: −50% Mol. Wt: −557.49 MS (ES+): m/z = 558.40 B-147 A-147, tert-butyl 3- (piperidin-4-yl) benzyl carbamate (1 eq), EDCI 1.5 eq. DMAP 1.1 eq., HOBt, 1.1 eq. in Dichloromethane 70 vol. R.T. 12 hrs Yield: −50% Mol. Wt: 557.49 MS (ES+): m/z = 558.40 [MH+] B-143 A-143, tert-butyl 3- (piperidin-4-yl) benzyl carbamate 1 eq., EDCI 1.5 eq. DMAP 1.1 eq., HOBt, 1.1 eq. in Dichloromethane 125 vol. R.T. 12 hrs.Yield: −96.5% Mol. Wt: 607.5 MS (ES+): m/z = 608.40 [MH+] B-154 A-154, tert-butyl 3- (piperidin-4-yl) benzyl carbamate 1 eq., EDCI 1.5 eq. DMAP 1.1 eq., HOBt, 1.1 eq. in Dichloromethane 125 vol. R.T. 12 hrsYield: −97.34% Mol. Wt: 607.5 MS (ES+): m/z = 608.35 [MH+] 1H NMR (400 MHz, dmso-d6): δ 8.13 (s, 2H), 7.69-7.62 (m, 3H), 7.51 (dd, J = 15.3, 8.2 Hz, 5H), 7.39- 6.89 (m, 5H), 4.88-4.70 (m, 2H), 4.16 (s, 2H), 3.16- 2.61 (m, 8H), 2.05- 1.49 (m, 6H), 1.27 (s, 9H) - Products from step-1a were stirred with aq. hydrochloric acid or trifluoracetic acid (TFA) in a co-solvent like dioxane, acetonitrile, methanol, THF, DCM etc. Reaction was monitored by LCMS till most of the starting material was consumed. Reaction mass was then concentrated in vacuo to remove the solvents and residue obtained was purified by reverse phase preparative HPLC. The pure fraction of mobile phase was lyophilized to get the products as TFA salts.
- In most of the cases boronate esters were hydrolyzed partly to get mixture of desired product and corresponding boronate esters. In such cases mixture was subjected to prep-HPLC purification under acidic condition during which, most of the boronate esters got converted to target boronic acids. Multiple purifications needed in such cases to isolate pure boronic acid.
- In some cases TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- The details of compounds synthesized by step (2a) are as below. All reactions were done on 100-200 mg scale.
-
Comp. No. Structure Brief Reaction conditions Analytical data 132 Spiro Acetonitrile (20 vol), TFA (10 vol) water (3 vol) 80° C., 12 hrs. Mol. Wt: 460.3 MS (ES+): m/z = 461 [MH+] HPLC Purity: 98.5% 1H NMR(400 MHz, DMSO-d6 (D2O): δ 1.55-1.78(m, 4H), 3.07-3.27 (m, 4H) 3.95(s, 2H), 4.39- 4.50(m, 2H), 6.81(d, J = 8.2 Hz, 1H),, 7.19(dd, J = 8.4, 2.0 Hz, 1H)), 7.36(s, 1H), 7.43(d, J = 7.6 Hz, 1H), 7.50(dd, J = 9.4, 2.7 Hz, 1H)), 7.55-7.59(m, 2H), 7.69(s, 1H), 7.78-7.80(d = 8.2, 1H), 7.93(s, 1H) - 133 Spiro Acetonitrile (20 vol), TFA (10 vol) water (3 vol) 80° C., 12 hrs. Mol. Wt: 460.3 MS (ES+): m/z = 461 [MH+] HPLC Purity: 99% 1H NMR(400 MHz, DMSO-d6(D2O): δ 1.55-1.78(m, 4H), 3.07- 3.27(m, 4H) 3.95(s, 2H), 4.39- 4.50(m, 2H), 6.81(d, J = 8.2 Hz, 1H), 7.21(d, J = 8.1 Hz, 1H), 7.36(s, 1H), 7.47-7.38 (m, 2H), 7.65-7.50(m, 5H), 7.93(s, 1H) 131-Spiro Acetonitrile (20 vol), TFA (10 vol) water (3 vol) 80° C., 12 hrs. Mol. Wt: 460.3 MS (ES+): m/z = 461 [MH+] HPLC Purity: 99.6% 1H NMR(400 MHz, DMSO-d6(D2O) δ 1.66-1.77(m, 4H), 3.07- 3.38(m, 4H) 3.93(s, 2H), 4.41- 4.49(m, 2H), 6.81(d, J = 8.2 Hz, 1H), 7.20(t, J = 8.8 Hz, 2H), 7.39(d, J = 9.0 Hz, 2H), 7.55(t, J = 7.7 Hz, 1H), 7.65(s, 1H), 7.73(d, J = 7.9 Hz, 2H), 7.85(d, J = 5.3 Hz, 1H) 109-spiro Dioxane 85 vol 30% HCl 2 vol. RT overnight isolate as TFA salt by prep HPLC Yield: −8%Mol. Wt: 476.17 MS (ES+): m/z = 477 [MH+], 479 [(M + 2)H+] HPLC Purity: 95.8% 1H NMR(400 MHz, DMSO-d6): δ 1.37(s, 9H), 1.53(br, 2H), 1.83 (br, 2H), 2.60-2.90(m, 2H), 3.10-3.30(m, 1H), 4.10(d, J = 5.6 Hz, 2H), 4.40(br, 1H), 4.63 (br, 1H), 6.91(d, J = 8.4 Hz, 1H), 7.00-7.40(m, 6H), 7.44(d, J = 15.2 Hz, 1H), 7.80(d, J = 8.8 Hz, 1H), 8.07(brs, 1H), 8.20(s, 1H), 8.48(brs, 1H), 13.5(s, 1H). 107 Dioxane 100 vol 30 % HCl 7 vol. RT overnight isolate as TFA salt by prep HPLC Yield: −30.7%Mol. Wt: 442.24 MS (ES+): m/z = 443 [MH+] HPLC Purity: 99.49% 1H NMR(400 MHz, DMSO-d6): δ 1.37(s, 9H), 1.53(br, 2H), 1.83 (br, 2H), 2.60-2.90(m, 2H), 3.10-3.30(m, 1H), 4.10(d, J = 5.6 Hz, 2H), 4.40(br, 1H), 4.63 (br, 1H), 6.91(d, J = 8.4 Hz, 1H), 7.00-7.40(m, 6H), 7.44(d, J = 15.2 Hz, 1H), 7.80(d, J = 8.8 Hz, 1H), 8.07(brs, 1H), 8.20(s, 1H), 8.48(brs, 1H), 13.5(s, 1H). 107-Spiro Dioxane 100 vol 30 % HCl 8 vol. RT overnight isolate as TFA salt by prep HPLC Yield: −10%Mol. Wt: −470.37 MS (ES+): m/z = 471 [MH+] HPLC Purity: 95.19% 1H NMR(400 MHz, DMSO-d6): δ 1.37(s, 9H), 1.53(br, 2H), 1.83 (br, 2H), 2.60-2.90(m, 2H), 3.10-3.30(m, 1H), 4.10(d, J = 5.6 Hz, 2H), 4.40(br, 1H), 4.63 (br, 1H), 6.91(d, J = 8.4 Hz, 1H), 7.00-7.40(m, 6H), 7.44(d, J = 15.2 Hz, 1H), 7.80(d, J = 8.8 Hz, 1H), 8.07(brs, 1H), 8.20(s, 1H), 8.48(brs, 1H), 13.5(s, 1H). 54-Boronic acid Conc. HCl (1 mL/g), 1,4-dioxane (30 mL/g), rt, 4 h, Yield: 67% White solid; Mol. Wt: 370.23 MS (ES+): m/z = 371 [MH+] HPLC Purity: 98.80% 1H NMR(400 MHz, D2O): 7.64(t, J = 7.2 Hz, 1H), 7.48-7.38(m, 1H), 7.33-7.28(m, 3H), 7.14 (d, J = 8.0 Hz, 1H), 7.10-7.02 (m, 1H), 4.59-4.52(m, 1H), 4.28-4.16(m, 3H), 3.96(ABq, J = 15.6 Hz, 2H), 3.32-3.21(m, 1H), 2.96-2.80(m, 2H), 1.93 (d, J = 12.0 Hz, 1H), 1.84(d, J = 14.8 Hz, 1H)), 1.65-1.54(m, 1H), 1.42-1.29(m, 1H) 54-Boronic acid Spiro Conc. HCl (1 mL/g), 1,4-dioxane (30 mL/g), rt, 4 h, Yield: 58% White solid; Mol. Wt: 398.24 MS (ES+): m/z = 399 [MH+] HPLC Purity: 98.34% 1H NMR(400 MHz, D2O): 7.65(t, J = 7.2 Hz, 1H), 7.26(d, J = 8.4 Hz, 1H), 7.21(s, 1H), 7.15(d, J = 7.6 Hz, 1H), 7.10-7.04(m, 1H), 6.90(d, J = 8.4 Hz, 1H), 4.57(s, 2H), 4.44-4.35(m, 1H), 4.11(s, 2H), 4.06-3.99 (m, 1H), 3.96(ABq, J = 16.0 Hz, 2H), 3.36-3.26(m, 1H), 3.00- 2.92(m, 1H), 1.88-1.70(m, 3H), 1.68-1.58(m, 1H) - Products from step-1b were stirred with aq. hydrochloric acid or Trifluoracetic acid (TFA) in a co-solvent like Dioxane, Acetonitrile, methanol, THF, DCM etc. Reaction was monitored by LCMS till most of the starting material was consumed. Reaction mass was concentrated under vacuum. The residue obtained was purified by reverse phase preparative HPLC. The pure fraction of mobile phase was lyophilized to get the products as TFA salts.
- In some cases TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- The details of compounds synthesized by above method (2 b) are as below. All reactions were done on 100-200 mg scale.
-
Comp. No. Structure Brief Reaction conditions Analytical data 116 Spiro TFA (20 eq.), dichloromethane (20 vol), R.T. 4 hr. Prep HPLC. isolated as TFA salt, Yield: −24% Mol. Wt: 494.15 MS (ES+): m/z = 494.95 [MH+] 1H NMR (400 MHz, DMSO- d6): δ 8.17(s, 4H), 7.95 (s, 1H), 7.78(d, J = 7.3 Hz, 1H), 7.60(d, J = 7.5 Hz, 1H), 7.46(dd, J = 15.9, 8.2 Hz, 3H), 7.24(d, J = 8.2 Hz, 1H),, 6.84(d, J = 8.2 Hz, 1H), 4.52(s, 2H), 4.27(d, J = 13.2 Hz, 2H), 3.92(d, J = 5.8 Hz, 2H). 2.58-2.45(m, 3H), 1.90-1.72(m, 4H), 146 dichloromethane (70 vol), TFA, (2 eq added at 0° C.) Stirring at R.T. for 24 hrs Purification by prep HPLC Yield: −10.34% Mol. Wt: 457.37, MS (ES+): m/z = 458.25 [MH+], HPLC Purity: 97.56% 1H NMR (400 MHz, DMSO- d6): δ 8.11(s, 2H), 7.51 (d, J = 7.3 Hz, 1H), 7.35 (d, J = 6.8 Hz, 2H), 7.22 (ddt, J = 31.5, 15.2, 6.9 Hz, 5H), 7.00(d, J = 7.7 Hz, 1H), 6.77(d, J = 8.1 Hz, 1H), 6.69-6.60(m, 2H), 4.64(d, J = 39.2 Hz, 2H), 4.15-3.80(m, 6H), 2.99(s, 3H), 2.78(t, J = 12.0 Hz, 1H), 1.62(t, J = 67.8 Hz, 6H). 147 dichloromethane (70 mL), TFA, (2 eq added at 0° C.) Stirring at R.T. for 24 hrs Purification by prep HPLC Yield: −10.34% Mol. Wt: 457.37, MS (ES+): m/z = 458.30 [MH+], HPLC Purity: 98.83% 1H NMR (400 MHz, DMSO- d6): δ 8.11(s, 2H), 7.51 (d, J = 7.3 Hz, 1H), 7.35 (d, J = 6.8 Hz, 2H), 7.22 (ddt, J = 31.5, 15.2, 6.9 Hz, 5H), 7.00(d, J = 7.7 Hz, 1H), 6.77(d, J = 8.1 Hz, 1H), 6.69-6.60(m, 2H), 4.64(d, J = 39.2 Hz, 2H), 4.15-3.80(m, 6H), 2.99(s, 3H), 2.78(t, J = 12.0 Hz, 1H), 1.62(t, J = 67.8 Hz, 6H) 143 dichloromethane (70 mL), TFA, (3 eq added at 0° C.) stirring at R.T. for 24 hrs Purification by prep HPLC after concentrating in vacuum Yield: −10.34% Mol. Wt: 507.43, MS (ES+): m/z = 508.30 [MH+] HPLC Purity: 99.5% 1H NMR (400 MHz, DMSO- d6): δ 8.36-8.28(m, 1H), 8.13(s, 2H), 7.51(q, J = 11.5, 8.7 Hz, 4H), 7.32 (tdd, J = 27.9, 17.0, 7.6 Hz, 8H), 4.84(t, J = 13.6 Hz, 1H), 4.39(s, 2H), 4.02(q, J = 5.9 Hz, 2H), 3.43-2.77(m, 5H), 2.70 (s, 3H), 2.03-1.28(m, 6H) 154 Dichloromethane (45 vol), TFA, (3 eq added at 0° C.) Stirring at R.T. for 24 hrs Purification by prep HPLC after concentrating in vacuum Yield: −19.07% Mol. Wt: 507.43, MS (ES+): m/z = 508.25 [MH+], HPLC Purity: 97.10% 1H NMR (400 MHz, DMSO- d6): δ 8.10(s, 3H), 7.68 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 15.8, 8.2 Hz, 2H), 7.40-7.17(m, 4H), 7.14 (d, J = 6.8 Hz, 2H), 7.05 (dd, J = 13.4, 5.3 Hz, 2H), 4.79(s, 2H), 4.02(s, 2H), 3.06(s, 3H), 2.82(m, 5H), 1.95-1.62(m, 6H) - Desired halo aryl carboxylic acids were first coupled with tert-butyl 3-(piperidin-4-yl)benzyl carbamate and coupled products were reacted with Bis Pinacolato diborane to get boronate esters which were hydrolyzed to corresponding boronic acids.
- The details of intermediates halo aryl carboxylic acids (A) sourced/synthesised as per literature methods/synthesised by developed methods are given above.
- To a stirred solution of carboxylic acid in DCM or DMF was added DMAP or DIPEA, EDCI, HOBt (in some cases). The solution was stirred for 15 min. at 0° C.-RT followed by addition of Core-1 or Core-4 as shown in synthetic scheme. Stirring was continued at room temperature and reaction was monitored by LCMS till most of the, starting materials were consumed. Solvents were concentrated under vacuum and reaction mixture was then quenched with water and aq. layer was extracted twice with dichloromethane/ethyl acetate and combined organic layers were optionally washed with dil. HCl whenever DIPEA was used and dried over sodium sulfate and concentrated under vacuum to afford the product which was purified by column chromatography. The details
-
Comp. No. Structure Brief Reaction conditions Analytical data B-144 carboxylic acid (0.34 g) 0.19 mmol) in DCM (~90 mL), HOBt (1.5 eq.) EDCI (1.5 eq.), DMAP (0.5 eq.) and tert-butyl 3-(piperidin-4-yl) benzyl carbamate (1.2 eq.) was stirred at R.T. for 12 hrs. Yield: −77% after chromatographic purification Mol. Wt: 687.23 MS (ES+): m/z = 588/590 [MH+ − Boc], B-51 5-bromoquinoline-8- carboxylic acid (0.05 g, 0.19 mmol) in DMF (100 mL), HOBt (1.5 eq.) EDCI (1.5 eq.), DIPEA (2 eq.) and tert-butyl 3-(piperidin- 4-yl) benzyl carbamate (1 eq.) were stirred at R.T. for 12 hrs Yield: −50% after chromatographic purification Mol. Wt: 523.15 MS (ES+): m/z = 546/548 [MH+ + Na]] B-155- Spiro A-155, spiro core (1 eq.), EDCI 1.5 eq. DMAP 1.1 eq., HOBt, 1.1 eq. in dichloromethane (75 mL) R.T. 12 hrs. Yield: −90.20% Mol. Wt: −620.58 MS (ES+): m/z = 620.30/622 [MH+] B-156 A156, tert-butyl 3- (piperidin-4-yl)benzyl carbamate (1.3 eq.), EDCI•HCl (1.5 eq.), DMAP (2 eq.), DCM(20 mL), RT, 4 h, Yield: −80% Mol. Wt: −524.45 MS (ES+): m/z = 524.20/526 [MH+] - Product of step-1, was converted to boronate ester by palladium (0) catalyzed reaction with bis pinacolato borane in 1,4-dioxane using potassium acetate as base. Reaction was monitored by LCMS till most of the starting material was consumed. After completion of reaction, the reaction mixture was filtered through celite and concentrated. Product was extracted in ethyl acetate, and ethyl acetate layer was washed with water. The organic layer was separated, dried over sodium sulfate concentrated and purified by column chromatography using hexane/ethyl acetate to yield the boronate esters contaminated with bis pinacolato borane, which were characterized by LCMS and subjected for next step without further purification
- The details of compounds synthesized are as below.
-
Comp. No. Structure Brief Reaction conditions Analytical data C-144 B-144 50 mg, Pd(OAc)2 1 eq. TPP 4 eq.,potassium acetate 3 eq.bis pinacolato diborane 10 eq. in dioxane, 90° C. for 16 h.Mol. Wt: 735.41 MS (ES+): m/z = 758 [MH+ + Na] C-51 B-51 50 mg, Pd(PPh3)4 0.1 eq. TPP 4 eq.,potassium acetate 3 eq.bis pinacolato diborane 5 eq. in dioxane, reflux for 12 h.Mol. Wt: 571.32 MS (ES+): m/z = 571 [MH+] C-155- Spiro B-155, bis pinacolato diborane(5 eq), KOAc (3.5 eq), Pd(dppf)Cl2 (0.06 eq), DMSO 60 mL, 80° C., 6 hr Yield: -crude Mol. Wt: 667.64 MS (ES+): m/z = 668.50 [MH+] C-156 B-156, bis pinacolato diborane (2.5 eq.), PdCl2 (dppf) (5 mol %), dppf (3 mol %), potassium acetate (3.0 eq.), Toluene (30 mL), Reflux, 5 hrs. Yield impure product was used for next step. Mol. Wt: 489.37 MS (ES+): m/z = 390.20 [MH+ − Boc] - Products of step-2 were stirred with dioxane and concentrated HCl at room temperature overnight, when LCMS indicated complete consumption of starting. The reaction mixture was concentrated, and purified by Preparative HPLC. The details of compounds synthesized are below. All reactions were done on 100-200 mg scale.
-
Comp. No. Structure Brief Reaction conditions Analytical data 144 dioxane 100 vol 30 % HCl 2 vol. RT overnight isolate as TFA salt by prep HPLC Yield: −26%Mol. Wt: 553.27 MS (ES+): m/z = 554 [MH+] HPLC Purity: 96.4% 1H NMR (400 MHz, DMSO-d6): δ 1.40-1.70 (br, 2H), 1.84 (br, 2H), 2.60-2.91 (m, 2H), 3.10-3.30 (m, 1H), 3.98 (d, J = 5.6 Hz, 2H), 4.40- 4.70 (br, 2H), 6.91 (d, J = 8.4 Hz, 1H), 7.20-7.50 (m, 6H), 7.78 (d, J = 8.8 Hz, 1H), 8.07 (br, 1H), 8.32 (br, 2H), 8.37 (br, 2H), 8.65 (br, 1H). 51 dioxane (100 vol) 30% HCl (2 vol). RT overnight isolate as TFA salt by prep HPLC Yield: −11.3% Mol. Wt: 389.19 MS (ES+): m/z = 390 [MH+] HPLC Purity: 99.8% 1H NMR (400 MHz, CD3OD): δ 1.70-2.00 (m, 4H), 2.85-3.00 (m, 2H), 3.75-3.85 (brd, 1H), 4.10 (s, 2H), 4.70-4.80 (brd, 2H), 6.80 (s, 1H), 7.02 (s, 1H), 7.26-7.44 (m, 4H), 7.95 (s, 1H) 155-Spiro C-155, Acetonitrile (80 vol), 2NHCl(3o vol) RT 12 hrs.Mol. Wt: 485.3 MS (ES+): m/z = 486.35 [MH+] HPLC Purity: 96.72% 1H NMR (400 MHz, DMSO-d6): δ 8.02 (s, 2H), 7.75-7.66 (m, 1H), 7.64 (s, 1H), 7.56 (m, 3H), 7.42 (s, 1H), 7.36 (d, J = 7.5 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.04 (dd, J = 8.0, 4.3 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 4.57-3.89 (m, 2H), 3.69 (m, 2H), 3.19 (d, J = 62.5 Hz, 4H), 2.5 (s, 6H), 1.90-1.64 (m, 3H), 1.21 (d, J = 37.9 Hz, 3H) 156 TFA (20 eq.), dichloromethane (20 vol), R.T. 4 hr. Prep HPLC. isolated as TFA salt Yield: −10% Mol. Wt: 389.26 MS (ES+): m/z = 390.10 [MH+] 1H NMR (400 MHz, DMSO-d6): δ 9.04 (s, 1H), 8.62 (s, 1H), 8.35 (d, J = 6.7 Hz, 1H), 8.19 (dd, J = 13.1, 7.2 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.35 (ddd, J = 27.0, 12.8, 7.9 Hz, 4H), 3.40-3.23 (m, 2H), 4.03 (q, J = 5.7 Hz, 2H), 3.40-3.23 (m, 1H), 2.93 (d, J = 36.1 Hz, 4H), 1.98-1.63 (m, 6H). - Thirteen final targets with amido phenol functionality were synthesized.
- Suitably substituted 2-hydroxy aromatic amides with carboxylic acid functionality were synthesized and coupled with the protected core followed by the deprotection of Boc protection on amino methyl functionality as in the reaction scheme below
- The details of intermediates (A) sourced/synthesised as per literature methods/synthesised by adapted methods are given below.
-
- A solution of 4-formyl-3-hydroxy benzoic acid (0.1 g, 0.6 mmol) in methanol (50 mL) was cooled to 0° C. and charged with thionyl chloride (0.097 g, 0.72 mmol) and heated at reflux for 6 h. TLC (
Mobile phase 5% methanol in chloroform) indicated absence of starting material (Rf 0.1) along with new spot (Rf 0.5). The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was partitioned between ethyl acetate and water and separated. The organic layer was dried over sodium sulfate concentrated, filtered, and concentrated in vacuo resulting in 95 mg desired product. - Yield: (95 mg, 87.9%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.93 (s, 3H), 7.4 (d, J=8.0 Hz, 1H), 7.5 (s, 1H), 7.7 (d, J=8.0 Hz, 1H)
- A solution of methyl 4-formyl-3-hydroxybenzoate (0.05 g, 0.27 mmol) and NaH2PO4.2H2O (0.11 g, 0.69 mmol) in DMSO: water, 2:1 (7.5 ml) was charged with sodium chlorite (0.075 g, 0.66 mmol) at 0° C. The reaction mixture was allowed to stir at room temperature for 12 h. The reaction mixture was acidified with 1N HCl till pH-2. and the precipitated white solid was filtered, washed with water several times and dried to give 2-hydroxy-4-(methoxycarbonyl)benzoic acid.
- Yield: (0.035 g, 65%).
- Mol Wt: 196;
- MS (ES+): m/z=197.2 [MH+]
- A solution of 2-hydroxy-4-(methoxycarbonyl)benzoic acid (0.20 g, 1 mmol) in THF (10 mL) was charged with thionyl chloride (0.121 g, 10 mmol) at 0° C. then the reaction mixture was heated to 45° C. for 4 h, The reaction mixture was concentrated in vacuo and the residue was diluted in dry DCM (5 ml) and charged with a solution of o-t-butyl amine.HCl (0.512 g, 4 mmol), TEA (0.412 g, 4 mmol) in DCM (15 ml) at 0° C. The reaction mixture was charged with 1N HCl solution (15 ml) and separated. The organic layer dried over sodium sulfate, filtered, and concentrated in vacuo to get 0.205 g crude product which was purified by column chromatography on silica gel using hexane-ethyl acetate as eluent to give methyl 4-(benzoyloxy)-3-formylbenzoate.
- Yield: (0.16 g, 58.8%)
- Mol Wt: 267
- MS (ES+): m/z=268.05 [MH+]
- A solution of step-3 product (0.160 g, 0.59 mmol) in THF:water (2:1) (15 mL) was charged with LiOH (0.043 g, 1.7 mmol) and stirred at room temperature for 6 h. The reaction mixture was concentrated in vacuo and the aqueous layer was and acidified with 1N HCl until pH-2. A solid precipitated out which was filtered and dried to give 4-(tert-butoxycarbamoyl)-3-hydroxybenzoic acid.
- Yield: (0.015 g, 44%).
- Mol Wt: 253
- MS (ES+): m/z=254.0 [MH+]
-
- A solution of 4-formyl-3-hydroxy benzoic acid (0.1 g, 0.6 mmol) in methanol (50 mL) at 0° C. was charged with thionyl chloride (0.097 g, 0.72 mmol) and the reaction mixture was heated at reflux for 6 hr. The reaction mixture was cooled and concentrated in vacuo and partitioned between ethyl acetate and water and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in 95 mg of the desired product.
- Yield: (0.095 g, 87.9%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.93 (s, 3H), 7.4 (d, J=8.0 Hz, 1H), 7.5 (s, 1H), 7.7 (d, J=8.0 Hz, 1H)
- A solution of methyl 4-formyl-3-hydroxybenzoate (0.05 g, 0.27 mmol) and NaH2PO4.2H2O (0.11 g, 0.69 mmol) in DMSO:water, 2:1 (7.5 ml) was cooled to 0° C. and charged with sodium chlorite (0.075 g, 0.66 mmol). The reaction mixture was allowed to stir at room temperature for 12 hr. then acidified to
pH 2 with 1N HCl. The precipitated white solid was filtered, washed with water several times and dried to give 2-hydroxy-4-(methoxycarbonyl)benzoic acid. - Yield: (0.035 g, 65%).
- Mol Wt: 196
- MS (ES+): m/z=197.2 [MH+]
- A solution of 2-hydroxy-4-(methoxycarbonyl)benzoic acid (0.05 g, 0.25 mmol) in THF (10 mL) was cooled to 0° C. and charged with thionyl chloride (0.303 g, 2.5 mmol) then the reaction mixture was heated to 45° C. for 4 hr. The reaction mixture was concentrated in vacuo and the residue was diluted with dry DCM (5 ml) and charged with a solution of o-phenyl amine.HCl (0.055 g, 0.38 mmol), NaHCO3 (0.038 mg, 0.45 mmol) and in DCM (15 ml) at 0° C. then the reaction was charged with 1N HCl solution (15 ml) and the organic was separated, dried over sodium sulfate, filtered, and concentrated in vacuo resulting in 0.07 g of crude product which was purified by column chromatography on silica gel eluting with hexane-ethyl acetate resulting in methyl 3-hydroxy-4-(phenoxycarbamoyl)benzoate.
- Yield: (0.5 g, 68%)
- Mol Wt: 287
- MS (ES+): m/z=288.1 [MH+]
- A solution of methyl 3-hydroxy-4-(phenoxycarbamoyl)benzoate (0.05 g, 0.17 mmol) in THF:water (2:1) (7.5 mL) was charged with LiOH (0.012 g, 0.51 mmol) and stirred at room temperature for 6 h. The reaction mixture was concentrated and the aqueous was acidified to
pH 2 with 1N HCl and the precipitate was filtered and dried to give 3-hydroxy-4-(phenoxycarbamoyl)benzoic acid. - Yield: (0.03 g, 63.8%).
- Mol Wt: 273
- MS (ES+): m/z=274.0 [MH+]
-
- A solution of 2-hydroxy-4-methylbenzoic acid (5 g, 32.8 mmol) and acetic anhydride (1.5 mL) in acetone (12.5 mL) at −8° C. was charged with concentrated sulfuric acid (0.05 mL) and stirred at room temperature overnight. The reaction mixture was concentrated to in vacuo to obtain a dark brown solid which was repeatedly washed with hexane and diethyl ether to get yellow solid. The solid was then purified by column chromatography on silica gel using chloroform/hexane as eluent to give crude product which was washed with saturated solution of sodium bicarbonate to give 2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one.
- Yield: (4.5 g, 71.4%),
- MS (ES+): m/z=193 [MH+]
- A solution of 2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one (4.5 g, 23.4 mmol) in carbon tetrachloride (200 mL) was charged with N-bromosuccinimide (4.83 g, 27.1 mmol) and AIBN (0.8 g, 4.92 mmol) and the mixture was refluxed for 2 hr. The reaction mixture was washed with water and the compound was extracted in dichloromethane. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo and the crued was purified by column chromatography using hexane ethyl acetate as eluent resulting in 7-(bromomethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one.
- Yield: (1.8 g, 28.3%),
- MS (ES+): m/z=271 [MH+]
- A solution of 7-(bromomethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.8 g, 6.64 mmol) in dichloromethane (15 mL) was added slowly to a suspension of sodium cyanide (0.57 g, 11.6 mmol in 1.2 mL water) and TBAB (0.08 g, 0.26 mmol). The reaction mixture was allowed to stir at room temperature for 48 h. The reaction mixture was quenched with water and the organic layer was separated, washed with water and brine. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo and the crude purified by column chromatography using hexane ethyl acetate as eluent resulting in 2-(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-7-yl)acetonitrile.
- Yield: (0.5 g, 35%).
- MS (ES+): m/z=218 [MH+]
- A solution of 2-(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-7-yl)acetonitrile (0.55 g, 2.53 mmol) in ethanol (4.5 mL) was charged with 30% KOH (4.5 mL) and heated at 60° C. for 3 h. The reaction mixture was concentrated in vacuo, and the aqueous was acidified with 1N HCl and the compound was extracted in ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo resulting in 4-(carboxymethyl)-2-hydroxybenzoic acid as a yellow solid.
- Yield: (0.42 g, 85.7%).
- 1H NMR (400 MHz, DMSO-d6): δ 1.25 (t, J=7.0 Hz, 3H), 4.10-4.23 (q, J=7 Hz, 2H), 6.57 (d, J=16 Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 7.55 (d, J=16 Hz, 1H), 7.74-7.80 (dd, J=2.0 and 8.6 Hz, 1H), 8.06 (s, 1H), 8.28 (d, J=2 Hz, 1H), 8.50 (s, 1H), 13.5 (s, 1H).
- A solution of 4-(carboxymethyl)-2-hydroxybenzoic acid (0.25 g, 1.27 mmol) in acetone (4 mL), was charged with TFAA (4 mL) and TFA (6 mL) and heated at 100° C. for 24 h. The reaction mixture was concentrated in vacuo to give 2-(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-7-yl)acetic acid. The crude compound was used as such for the next step without further purification.
- Yield: (0.55 g, Crude),
- MS (ES+): m/z=237 [MH+]
-
- A solution of 4-hydroxy benzoic acid (2 g, 14.4 mmol) in TFA (8 mL) was charged with HMTA (2 g, 14.4 mmol) and heated at 85° C. for 3 h. TLC (
Mobile phase 30% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.3) and product formation (Rf 0.5). The reaction mixture was cooled and charged with 1N HCl (75 mL) and was extracted in diethyl ether. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo and the crude was purified by column chromatography using hexane ethyl acetate as eluent resulting 3-formyl-4-hydroxybenzoic acid. - Yield: (0.6 g, 33.8%).
- 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, 1H, J=8.8 Hz), 8.18-8.20 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11.39 (s, 1H).
-
- A solution of methyl-4-hydroxy benzoate (2 g, 13.15 mmol) and anhydrous magnesium chloride (1.87 g, 19.7 mmol) in acetonitrile (100 mL) was charged with triethyl amine (7 mL, 49.9 mmol). The reaction mixture was then charged with para formaldehyde (8 g, 89.4 mmol) in a single portion and the reaction mixture was heated at reflux for 24 hr. The reaction mixture was cooled and quenched with 1N HCl and extracted with ethyl acetate. The organic layer was washed with water and separated dried over sodium sulfate, filtered, and concentrated in vacuo and the crude material was purified by column chromatography using hexane ethyl acetate as eluent to give methyl 3-formyl-4-hydroxybenzoate as white solid.
- Yield: (0.51 g, 22%).
- 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, J=8.8 Hz, 1H), 8.18-8.20 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11.39 (s, 1H).
- A solution of methyl 3-formyl-4-hydroxybenzoate (1.8 g, 0.01 mol) in dichloromethane (120 mL) was cooled to 0° C. and charged with DMAP (0.12 g, 0.001 mol), triethylamine (5.5 mL, 0.04 mol) and benzoyl chloride (2.3 mL, 0.02 mol). The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was quenched with water. The organic layer was separated and washed with water and the organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by column chromatography using hexane/ethyl acetate as eluent resulting in methyl 4-(benzoyloxy)-3-formylbenzoate.
- Yield: (1.4 g, 49.2%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 7.06 (d, J=8.8 Hz, 1H), 8.02-8.07 (dd, J=1.6 and 8.6 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H).
- A solution of methyl 4-(benzoyloxy)-3-formylbenzoate (0.05 g, 0.17 mmol) and NaH2PO4.2H2O (0.068 g, 0.44 mmol) in DMSO:H2O, 2:1 (6 mL) was charged with sodium chlorite (0.038 g, 0.42 mmol) and was allowed to stir at room temperature for 2 hr. The reaction mixture was acidified to
pH 2 with 1N HCl and the white precipitate was filtered, washed with water several times and dried to give 2-(benzoyloxy)-5-(methoxycarbonyl)benzoic acid as the desired product. - Yield: (0.05 g, 96.1%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 7.06 (d, J=8.8 Hz, 1H), 8.02-8.07 (dd, J=1.6, 8.6 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H).
- A solution of 2-(benzoyloxy)-5-(methoxycarbonyl)benzoic acid (0.3 g, 1.00 mmol) in DCM (15 mL) was charged with DMAP (0.061 g, 0.5 mmol), EDCI (0.28 g, 1.5 mmol) and o-(tert-butyl)hydroxylamine hydrochloride (0.18 g, 1.5 mmol) and the mixture was stirred at room temperature for 2 hr. The reaction mixture was washed with water (3×), 2N HCl 3 (3×) and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in crude material that was purified by column chromatography on silica gel using hexane/ethyl acetate as eluent to give methyl 4-(benzoyloxy)-3-(tert-butoxycarbamoyl)benzoate.
- Yield: (0.2 g, 54%).
- MS (ES+): m/z=372 [MH+]
- A solution of methyl 4-(benzoyloxy)-3-(tert-butoxycarbamoyl)benzoate (0.05 g, 0.13 mmol) in acetone (1.2 mL) was charged with 1N NaOH (1.2 mL) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the aqueous was acidified to
pH 2 using 1N HCl. A solid precipitated out and was filtered and dried to give 3-(tert-butoxycarbamoyl)-4-hydroxybenzoic acid. - Yield: (0.015 g, 44%).
- MS (ES+): m/z=254 [MH+]
-
- A suspension of 4-hydroxy-3-methylbenzoic acid (1 g, 6.57 mmol) suspended in methanesulfonic acid (5 mL) was cooled to 0° C. and portionwise charged with hexamethylenetetramine (1.84 g, 13.15 mmol) and warmed to warmed to room temperature followed by heating at 90° C. for 5 hr then cooled to room temperature and stirred overnight. The reaction mixture was poured into ice cooled water and the compound was extracted in ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo to give 3-formyl-4-hydroxy-5-methylbenzoic acid as yellow solid.
- Yield: (0.5 g, 42.3%).
- 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, J=8.8 Hz, 1H), 8.19 (dd, 1H, J=1.6 Hz, 8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11.39 (s, 1H).
- A solution of 3-formyl-4-hydroxy-5-methylbenzoic acid (0.2 g, 1.11 mmol) in methanol (4 mL) was charged with conc. sulfuric acid (0.14 mL) and refluxed for 16 hr. The reaction mixture was concentrated and the aqueous was extracted in ethyl acetate. The combined organic layer was washed with saturated solution of sodium bicarbonate dried over sodium sulfate, filtered, concentrated in vacuo to give methyl 3-formyl-4-hydroxy-5-methylbenzoate as an off white solid.
- Yield: (0.18 g, 85.7%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 7.06 (d, J=8.8 Hz, 1H), 8.02-8.07 (dd, J=1.6, 8.6 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H).
- A solution of methyl 3-formyl-4-hydroxy-5-methylbenzoate (0.5 g, 2.57 mmol) in dichloromethane (50 mL) was cooled to 0° C. and charged with DMAP (0.031 g, 0.25 mmol), triethylamine (1.4 mL, 1.03 mmol), and benzoyl chloride (0.6 mL, 5.15 mmol) then allowed to stir at room temperature overnight. The reaction mixture was quenched with water and the organic layer was separated and washed with water. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo and the crude was purified by column chromatography on silica gel using hexanes/ethyl acetate as eluent to give methyl 4-(benzoyloxy)-3-formyl-5-methylbenzoate.
- Yield: (0.5 g, 65.7%).
- 1H NMR (400 MHz, CDCl3): δ 3.91 (s, 3H), 3.92 (s, 3H), 7.03 (d, J=8.8 Hz, 1H), 8.05-8.09 (dd, J=1.8, 8.6 Hz, 1H), 8.16 (s, 1H), 9.48 (s, 1H), 12.2 (s, 1H)
- A solution of methyl 4-(benzoyloxy)-3-formyl-5-methylbenzoate (0.5 g, 1.67 mmol) and NaH2PO4.2H2O (0.65 g, 4.19 mmol) in DMSO:water (2:1) (30 mL) was charged with sodium chlorite (0.36 g, 4.02 mmol) and allowed to stir at room temperature for 2 hr. The reaction mixture was acidified to
pH 2 with 1N HCl upon which a white precipitate formed. The precipitate was filtered, washed with water several times and dried to give 2-(benzoyloxy)-5-(methoxycarbonyl)-3-methylbenzoic acid as the desired product. - Yield: (0.4 g, 77%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.70 (s, 3H), 7.05 (d, J=8.4 Hz, 1H), 7.89-7.93 (dd, J=1.4, 8.6 Hz, 1H), 8.26 (s, 1H).
- A solution of 2-(benzoyloxy)-5-(methoxycarbonyl)-3-methylbenzoic acid (0.2 g, 0.63 mmol), DMAP (0.077 g, 0.63 mmol), EDCI (0.18 g, 0.95 mmol) in DCM (20 mL) was charged with o-methyl hydroxylamine hydrochloride (0.08 g, 0.95 mmol) and stirred at room temperature for 2 hr. The reaction mixture was washed with water (3×), 2N HCl (3×) and separated. The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo and the crude was further purified by column chromatography on silica gel using hexanes/ethyl acetate as eluent to give methyl 4-(benzoyloxy)-3-(methoxycarbamoyl)-5-methylbenzoate.
- Yield: (0.12 g, 57.1%)
- 1H NMR (400 MHz, CDCl3): δ 1.46 (s, 9H), 1.64-2.00 (m, 4H), 2.70-2.82 (m, 1H), 2.90-3.40 (br, 2H), 4.29 (s, 2H), 4.50-5.00 (br, 2H), 6.97 (d, J=8.4 Hz, 1H), 7.00-7.20 (m, 4H), 7.26-7.30 (m, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.70 (s, 1H), 10.7 (s, 1H), 12.1 (s, 1H).
- A solution of methyl 4-(benzoyloxy)-3-(methoxycarbamoyl)-5-methylbenzoate (0.12 g, 0.34 mmol) in acetone (2.5 mL) was charged with 1N NaOH (2.5 mL) and stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the aqueous was acidified to
pH 2 with 1N HCl. Upon acidifiacation a precipitate formed and was filtered and dried to give 4-hydroxy-3-(methoxycarbamoyl)-5-methylbenzoic acid. - Yield: (0.03 g, 38.4%),
- MS (ES+): m/z=226 [MH+]
-
- Formylation of methyl 2-hydroxy-5-methylbenzoate was carried out as per procedure described in the literature. (J. Org. Chem. 1999, 64, 5858-5866). Subsequent O-Acetylation carried out by stirring the hydroxyl aldehyde with Ac2O, NEt3 in DCM.
- Step-1 product was dissolved in 40 vol DMSO:water (4:1), sodium dihydrogen phosphate (5 eq) and charged with sodium chlorite (5 eq) and stirred at room temperature and monitored by LCMS till starting material was consumed (15 hrs). Reaction mixture was then concentrated, residue was acidified with aqueous HCl and product extracted in ethyl acetate. Ethyl acetate extract dried over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product which was sufficiently pure for the use in next step.
- Yield: −93%, White solid;
- Mol. Wt: 252.22
- MS (ES+): m/z=253 [MH+]
- A solution of step-2 product in 20 vol DCM was charged with EDCI (1.5 eq.) and stirred at room temperature for 10 minutes followed by addition of DMAP (1.5 eq) and O-Methyl hydroxylamine hydrochloride (1.5 eq) and stirred at room temperature for 15 hr. The reaction mixture was diluted with ethyl acetate, washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product which was purified by column chromatography on silica gel eluting with (0-10%, ethyl acetate in hexanes) to yield methyl 2-hydroxy-3-(methoxycarbamoyl)-5-methylbenzoate.
- Yield: −88%, White solid;
- Mol. Wt: 239.22
- MS (ES+): m/z=240 [MH+]
- A solution of step-3 product in THF:water (2:1) was charged with LiOH (3.0 eq.) and stirred at room temperature for 5 hr, The reaction mixture was concentrated and the aqueous was acidified to
pH 2 with 1N HCl and the precipitate was filtered and dried to give white solid product. - Yield: −85% White solid;
- Mol. Wt: 225.20
- MS (ES+): m/z=226 [MH+]
- Couplings of desired suitably substituted carboxylic acids were carried out with protected 4-(3-aminomethyl phenyl)piperidine or 5-aminomethyl spiro[benzofuran-3,4′-piperidine] as per conditions mentioned in the table below. Work-up of reactions was carried out as described in general methods. Details of the compound are given in the table below.
-
Comp. No. Structure Brief Reaction conditions Analytical data B-75a-O—t-Bu EDCI (1.5 eq.), DMAP (1.2 eq), DCM (~200 Vol), phenyl piperidine core(1 eq), Stirring at RT For 3 hrs, Crude product used for next step without purification Yield: −96%, Mol. Wt.: 525.64 MS (ES+): m/z = 526.35 [MH+] B-75a-O—t-Bu Spiro EDCI (1.5 eq.), DMAP (1.2 eq), DCM (~200 Vol), phenyl piperidine core(1 eq), Stirring at RT For 3 hrs, Crude product used for next step without purification Yield: −82.5%, Mol. Wt.: 553.65 MS (ES+): m/z = 586.350 [MH+ + Na] B-75a-O—Ph EDCI (1.5 eq.), DMAP (1.2 eq), DCM (~200 Vol), phenyl piperidine core(1 eq), Stirring at RT For 3 hrs, Crude product used for next step without purification Yield: −90%, Mol. Wt.: 545.63 MS (ES+): m/z = 558.3 [MH+ + Na] B-75a-O—Ph- spiro EDCI (1.5 eq.), DMAP (1.2 eq), DCM (~300 Vol), phenyl piperidine core(1 eq), Stirring at RT For 3 hrs, Crude product used for next step without purification Yield: −96%, Mol. Wt.: 573.64 MS (ES+): m/z = 596.20 [MH+ + Na] B-75a Spiro EDCI (1.5 eq.), DMAP (1.2 eq), DCM (~200 Vol), phenyl piperidine core(1 eq), Stirring at RT For 3 hrs, Crude product used for next step without purification Yield: −86%, Mol. Wt.: 511.57 MS (ES+): m/z = 534.25 [MH+ + Na] B-92-O—t-bu EDCI (1.5 eq.), DMAP (0.5 eq), DCM (~300 Vol), phenyl piperidine core(1 eq), Stirring at RT For 4 hrs, Crude product used for next step without purification Yield: −64.5%, Mol. Wt.: 525.64 MS (ES+): m/z = 426 [MH+ − Boc] B-92-O—t-Bu spiro EDCI (1.5 eq.), DMAP (0.5 eq), DCM (~300 Vol), Spiro core (1.2 eq), Stirring at RT For 4 hrs, Crude product used for next step without purification Yield: −89.8%, Mol. Wt.: 553.65 MS (ES+): m/z = 576 [MH+ + Na] B-92 Spiro EDCI (1.5 eq.), DMAP (0.5 eq), DCM (~100 Vol), Spiro core (1.2 eq), Stirring at RT For 4 hrs, Crude product purified by column chromatography using hexane ethyl acetate Yield: −51.6%, Mol. Wt.: 511.57 MS (ES+): m/z = 534 [MH+ + Na] B-114 Spiro EDCI (1.5 eq.), DMAP (0.5 eq), DCM (~150 Vol), Spiro core (1.2 eq), Stirring at RT For 4 hrs, Crude product purified by column chromatography using hexane ethyl acetate Yield: −71.4%, Mol. Wt.: 525.59 MS (ES+): m/z = 526 [MH+] B-136a tert-butyl-3-(piperidin-4-yl) benzyl carbamate (1.1 eq.), PyBOP (1.5 eq.), pyridine (2.0 eq.), DMF (30 mL/g), rt, 15 h, Yield: 30%, White solid; Mol. Wt: 497.58 MS (ES+): m/z = 498 [MH+] - Products of step-1 were deprotected as per conditions mentioned in the table below. The details of the compounds synthesized are as below. All reactions were done on 100-200 mg scale.
-
Comp. No. Structure Brief Reaction conditions Analytical data 75a-O—t-Bu DCM(~175 vol), TFA (6 Vol), stirring at RT for 3 h, Followed by concentration and purification by prep HPLC Yield: 41%, Mol. Wt. 425.52, MS (ES+): m/z = 426.25 [MH+] HPLC: 97.9% (200-400 nm) 1H NMR (400 MHz, DMSO- d6, D2O): δ 7.76 (s, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 6.7 Hz, 1H), 7.30 (dt, J = 25.5, 8.2 Hz, 1H), 7.07 (dd, J = 13.7, 7.5 Hz, 2H), 6.95 (d, J = 8.4 Hz, 1H), 4.01 (q, J = 5.6 Hz, 2H) 3.20 (m, 3H), 2.86 (s, 2H), 1.91- 1.53 (m, 4H), 1.25 (s, 9H). 75a-O—Ph DCM(~50 vol), TFA (6 Vol), stirring at RT for 3 h, Followed by concentration and purification by prep HPLC Yield: 10%, Mol. Wt. 445.41, MS (ES+): m/z = 446.20 [MH+] HPLC: 96.68% (200-400 nm) 1H NMR (400 MHz, DMSO- d6, D2O): δ 7.94 (s, 1H), 7.81 (s, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 6.7 Hz, 1H), 7.30 (dt, J = 25.5, 8.2 Hz, 5H), 7.07 (dd, J = 13.7, 7.5 Hz, 2H), 6.95 (d, J = 8.4 Hz, 1H), 3.97 (s, 2H), 3.20 (m, 3H), 2.86 (s, 2H), 1.91 -1.53 (m, 4H). 75a-O—t-Bu Spiro DCM(~100 vol), TFA(6 Vol), stirring at RT for 3 h, Followed by concentration and purification by prep HPLC Yield: 48%, Mol. Wt. 453.53, MS (ES+): m/z = 517.20 [MH+ + Na + AcN] HPLC: 99.13% (200-400 nm) 1H NMR (400 MHz, DMSO-d6): δ 11.09 (s, 1H), 8.05 (d, J = 16.0 Hz, 3H), 7.77 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 8.3, 1.9 Hz, 1H), 6.96-6.84 (m, 2H), 4.50 (d, J = 4.5 Hz, 2H), 4.36 (d, J = 13.3 Hz, 1H), 3.95 (q, J = 5.6 Hz, 2H), 3.29-3.01 (m, 4H), 1.76 (q, J = 22.4, 20.8 Hz, 4H), 1.25 (s, 9H) 75a Spiro DCM(~100 vol), TFA(6 Vol), stirring at RT for 3 h, Followed by concentration and purification by prep HPLC Yield: 74%, Mol. Wt. 411.45, MS (ES+): m/z = 434.3 [MH+ + Na], HPLC: 97.85% (200-400 nm) 1H NMR (400 MHz, DMSO-d6): δ 8.04 (s, 3H), 7.71 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.23 (dd, J = 8.3, 2.0 Hz, 1H), 6.95-6.81 (m, 2H), 4.50 (d, J = 5.4 Hz, 2H), 4.35 (d, J = 12.9 Hz, 1H), 4.01 (s, 3H), 3.67 (s, 3H), 3.15 (dt, J = 58.2, 12.2 Hz, 4H), 1.90-1.60 (m, 4H). 75a-O—Ph- spiro DCM(~50 vol), TFA(6 Vol), stirring at RT for 3 h, Followed by concentration and purification by prep HPLC Yield: 29%, Mol. Wt. 473.52 , MS (ES+): m/z = 474.20 [MH+] HPLC: 99.80% (200-400 nm) 1H NMR (400 MHz, DMSO-d6): δ 8.03 (s, 3H), 7.79 (d, J = 7.9 Hz, 1H), 7.43 (s, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.06 (t, J = 7.3 Hz, 2H), 7.01-6.85 (m, 3H), 6.84 (s, 1H), 4.51 (d, J = 3.7 Hz, 2H), 4.36 (s, 1H), 3.95 (q, J = 5.5 Hz, 2H), 3.58 (s, 2H), 3.10 (s, 2H), 1.74 (d, J = 37.8 Hz, 4H). 92-O—t-Bu dioxane ~200 vol, conc. HCl 3.5 vol, 4 hrs stirring at RT, Followed by concentration and purification by prep HPLC Yield: 50%, Mol. Wt. 425.52, MS (ES+): m/z = 448 [MH+ + Na], HPLC: 94.5% (220 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91-3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 92-O—t-Bu spiro dioxane ~75 vol, conc. HCl 3.5 vol, 4 hrs stirring at RT, Followed by concentration and purification by prep HPLC Yield: 38%, Mol. Wt. 453.53, MS (ES+): m/z = 476 [MH+ + Na] HPLC: 99.0% (220 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91-3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 92 Spiro dioxane ~100 vol, conc. HCl 4 vol, 12 hrs stirring at RT, Followed by concentration and purification by prep HPLCYield: 27%. Mol. Wt: −411.45, MS (ES+): m/z = 412 [MH+] HPLC: 95.5% (220 nm), 1H NMR (400 MHz, DMSO-d6): δ 1.50- 1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91-3.30 (br, 2H), 3.50- 3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 114 Spiro dioxane ~100 vol, conc. HCl 4 vol, 4 hrs stirring at RT, Followed by concentration and purification by prep HPLCYield: 33.3%, Mol Wt.: −425.48 MS (ES+): m/z = 448 [MH+ + Na] HPLC: 95.98% (220 nm), 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91-3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 136a conc. HCl (1 mL/g), 1,4- dioxane (30 mL/g), rt, 4 h, Yield: 86% White solid; Mol. Wt: 397.47 MS (ES+): m/z = 398 [MH+] HPLC Purity: 93.44% 1H NMR (400 MHz, CD3OD): δ 7.50-7.22 (m, 6H), 4.16-4.06 (m, 3H), 3.83 (s, 3H), 3.58- 3.45 (m, 1H), 3.21-3.10 (m, 1H), 3.04-2.85 (m, 2H), 2.32 (s, 3H), 2.14-1.70 (m, 4H) - Carboxy O-methyl salicylaldehydes/Protected salicylic acids were first coupled with the protected core. Subsequent O-methylation & oxidation (In case of aldehydes) or deprotection (In case of protected salicylic acids) of the coupled product yielded carboxylic acid which was coupled with suitable amine and then Boc protection on amino methyl functionality was carried out to get the desired products. In case of O-Methyl compounds O-de-methylation and Boc deprotection was carried out together using boron tribromide as in the reaction scheme below.
- A stirred solution of protected salicylic acid/salicylaldehyde in DCM was charged with EDCI, HOBt (in some cases) and DMAP or DIPEA. The solution was stirred for 15 min. at 0° C. followed by addition of protected core. Stirring was continued at room temperature and reaction was monitored by LCMS till most of the starting materials were consumed. Reaction mixture was then quenched with water and aq. layer was extracted with dichloromethane and combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum to afford the crude product, which were sufficiently pure to be used for next step.
-
Comp. No. Structure Brief Reaction conditions Analytical data B-92-Spiro- O—Ph EDCI (1.5 eq.), DMAP (0.5 eq), DCM (100 Vol), spiro core (1.2 eq), Stirring at RT For 4 hrs, Crude product used for next step without purification Yield: −53.5%, Mol. Wt.: 466.53 MS (ES+): m/z = 489 [MH+ + Na] B-92-O—Ph EDCI (1.5 eq.), DMAP (0.5 eq), DCM (100 Vol), phenyl piperidine core (1 eq), Stirring at RT For 4 hrs, Crude product used for next step without purification Yield: −72%, Mol. Wt.: 438.52 MS (ES+): m/z = 502 [MH+ + Na + AcN] B-85a EDCI (1.5 eq.), HOBt (1.5 eq), DMF (15 Vol), DIPEA (4 eq), phenyl piperidine core (1.2 eq), Stirring at RT For 4 hrs, Crude product purified by column chromatography using hexane ethyl acetate. Yield: −50%, Mol. Wt.: 508.61 MS (ES+): m/z = 531 [MH+ + Na] - A solution of step-1 product in dioxane:water was charged with lithium hydroxide and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated in vacuo and the aqueous layer was acidified with 1N HCl upon which a precipitate formed. The precipitate was filtered, washed with hexane and dried to give step-2 product.
-
Comp. No. Structure Brief Reaction conditions Analytical data D-85a LiOH (10 eq) dioxane: water (1:1) ~45 vol. Stirring at RT for 4 hrs. Solvents concentrated under vacuum distillation and subsequent acidification with 1N HCl resulted in solid which was used for next step without purification. Yield: −58.3% Mol. Wt.: 468.54 MS (ES+): m/z = 491 [MH+ + Na] - A solution of step-1 product and potassium carbonate in acetone was charged with methyl iodide and heated at 70° C. for 4 hr. The reaction mixture was filtered and concentrated in vacuo and the compound was extracted in dichloromethane and washed with water. The organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated to give step-4 product. The crude product was used as such for the next step without purification.
-
Comp. No. Structure Brief Reaction conditions Analytical data D-92-Spiro- O—Ph Acetone (60 vol), potassium carbonate (3 eq), methyl iodide (1.2 eq), 70°C., 4 hrs, isolated by distillation of solvent, dilution with water and extraction with dichloromethane and concentration. Crude product used for next step Yield: −95% (Crude) Mol. Wt.: 480.55 LCMS (m/z): 503 [MH+ + Na] D-92-O—Ph Acetone (60 vol), potassium carbonate (3 eq), methyl iodide (2 eq), 70°C., 4 hrs, Isolated by distillation of solvent, dilution with water and extraction with dichloromethane and concentration. Crude product used for next step Yield: 100% (Crude), 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, J = 8.8 Hz, 1H), 8.18-8.20 (dd, J = 1.6 Hz, J = 8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11.39 (s, 1H). - A solution of step-3 product and NaH2PO4.2H2O in DMSO:water was charged with sodium chlorite and allowed to stir at room temperature for 2 hr. The reaction mixture was acidified to
pH 2 with 1N HCl upon which a precipitate formed. The white precipitate was filtered, washed with water several times and dried to give step-3 product -
Comp. No. Structure Brief Reaction conditions Analytical data D-92-Spiro- O—Ph sodium chlorite (2.4 eq), Sodium dihydrogen phosphate dehydrate (2.5 eq), DMSO (40 vol), Water (20 vol), Stirring at R.T. for 2 hrs, followed by acidification with 1N HCl to pH-2 & Filtration to get solid product which was sufficient pure to be used for next step Yield: 88.2%, 1H NMR (400 MHz, DMSO- d6): δ 3.70 (s, 3H), 7.05 (d, J = 8.4 Hz, 1H), 7.89- 7.93 (dd, J = 1.4, 8.6 Hz, 1H), 8.26 (s, 1H). D-92-O—Ph sodium chlorite (2.4 eq), Sodium dihydrogen phosphate dehydrate (2.5 eq), DMSO (20 vol), Water (10 vol), Stirring at R.T. for 2 hrs, followed by acidification with 1N HCl to pH-2 & Filtration to get solid product which was sufficient pure to be used for next step Yield: 57%, 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, 1H, J = 8.8 Hz), 8.18-8.20 (dd, J = 1.6 Hz, 8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11. 39 (s, 1H). - A solution of step-2 and step-4 in dioxane/pyridine, and Boc anhydride was charged with O-phenylhydroxylamine and stirred at room temperature overnight. Reaction mixture was concentrated in vacuo and given for prep purification to give step-5 product.
-
Comp. No. Structure Brief Reaction conditions Analytical data D-92-Spiro- O—Ph dioxane (20 vol), pyridine (1 eq), Boc anhydride (1.3 eq.) O-phenyl hydroxylamine (1.3 eq) Stirring R.T., 12 hrs, Purified by prep HPLC after concentration in vacuum. Yield: −17.8% Mol. Wt.: 587.66 MS (ES+): m/z = 488 [MH+ − Boc] D-92-O—Ph dioxane (25 vol), pyridine (1 eq), Boc anhydride (1.3 eq.) O-phenyl hydroxylamine (1.3 eq) Stirring R.T., 12 hrs, Purified by prep HPLC after concentration in vacuum. Yield: −26.7 Mol. Wt.: 559.65 MS (ES+): m/z = 460 [MH+ − Boc] D-85a EDCI (1.5 eq), HOBt (1.5 eq) DMF (35 vol), Triethyl amine (4 eq) O- methyl hydroxylamine. HCl (1.2 eq), Stirring at RT for 12 hrs, Product purified by prep. HPLC after usual work-up. Yield: −8 % Mol. Wt.: 497.58 MS (ES+): m/z = 520 [MH+ + Na] - A solution of step-5 in dichloromethane was charged with BBr3 in DCM and the reaction mixture was allowed to stir at room temperature for 3 hrs. The reaction mixture was concentrated and purified by prep HPLC to give final target compounds.
-
Comp. No. Structure Brief Reaction conditions Analytical data D-92-Spiro- O—Ph 1M BBr3 in DCM (1.5 eq) stirring at RT for 3 hrs, Purification by prep HPLC after concentrating in vacuum Yield: 24%, Mol. Wt.: −473.52, MS (ES+): m/z = 474 [MH+] HPLC: 96.1% (220 nm) 1H NMR (400 MHz, DMSO- d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91- 3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20- 7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 92-O—Ph 1M BBr3 in DCM (1.5 eq) stirring at RT for 3 hrs, Purification by prep HPLC after concentrating in vacuum Yield:: −10%, Mol. Wt. 445.51 MS (ES+): m/z = 446 [MH+] HPLC: 86.8% (220 nm) 1H NMR (400 MHz, DMSO- d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91- 3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73 (s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20- 7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 85a dioxane ~180 vol, Conc. HCl 12 vol, 12 hrs stirring at RT, Followed by concentration and purification by prep HPLCYield: −64%, Mol. Wt.: −397.47, MS (ES+): m/z = 398 [MH+] HPLC: (200-400 nm) 96.6%. 1H NMR (400 MHz, DMSO- d6): δ 1.40-1.70 (br, 2H), 1.84 (br, 2H), 2.60-2.91 (m, 2H), 3.10-3.30 (m, 1H), 3.98 (d, J = 5.6 Hz, 2H), 4.40-4.70 (br, 2H), 6.91 (d, J = 8.4 Hz, 1H), 7.20-7.50 (m, 6H), 7.78 (d, J = 8.8 Hz, 1H), 8.07 (br, 1H), 8.32 (br, 2H), 8.37 (br, 2H), 8.65 (br, 1H). - Eleven Final Targets with phenolic & hydroxymethyl phenol functionality were synthesized. Title compounds were synthesized by two different approaches as given below.
- Functionalized dihydroxy aromatic carboxylic acids were coupled with the required core and coupled product was deprotected as described in the scheme below.
- The details of intermediates sourced/synthesised as per literature methods/synthesised by adapted methods are given below.
-
Target Structure A-74 2,2-dimethyl-4H-benzo[d][1,3]dioxine-7- carboxylic acid Draft_experimental_SAI(Pune) Shipment after 2nd Sep. 2010 pg No-23 A-96 7,8-dihydroxy-2-oxo-2H-chromene-4-carboxylic acid A-98 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid A-99 2-(8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-7-yl)acetic acid A-104 3,4-dihydroxy-5-methoxybenzoic acid Procured from commercial source 113 Spiro 2,2,8-trimethyl-4H-benzo[d][1,3]dioxine-6-carboxylic acid 126 3-methoxy-4-(2-methoxypropan-2-yl)benzoic acid A-127 2,3-dihydroxy-4-methoxybenzoic acid -
- A solution of pyrogallol (0.5 g, 3.96 mmol) in toluene (10 mL) was charged with triphenyl phosphine (2.07 g, 7.93 mmol) and cooled to −5° C. and stirred for 10 min. then dropwise charged with a solution of DMAP (1.12 g, 7.93 mmol) in toluene (5 mL) and stirred at room temperature for 30 min, then refluxed for 8 hr. The reaction mixture was concentrated in vacuo and purified by column chromatography on silica gel eluting with hexanes/ethyl acetate resulting in
methyl 7,8-dihydroxy-2-oxo-2H-chromene-4-carboxylate. - Yield: (0.16 g, 17%)
- MS (ES+): m/z=237 [MH+]
- A solution of
methyl 7,8-dihydroxy-2-oxo-2H-chromene-4-carboxylate (0.1 g, 0.42 mmol) and acetic acid (3 mL) was charged with conc. HCl (1 mL) and heated at 90° C. for 2 hr. The reaction mixture was concentrated in vacuo to obtain a solid which was washed with pentane and dried to give 7,8-dihydroxy-2-oxo-2H-chromene-4-carboxylic acid. The crude product was used in the next step without further purification. - Yield: (0.095 g, Crude).
- MS (ES+): m/z=223 [MH+]
-
- A solution of pyrogallol (1 g, 7.93 mmol) and
dimethyl 1,3-acetone di carboxylate (1.4 mL, 9.52 mmol) in toluene (10 mL) was charged with pTSA (0.15 g, 0.79 mmol) and heated in a Schott Duran bottle at 60° C. overnight. TLC (Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.4) and product formation (Rf 0.3). The reaction mixture was concentrated in vacuo and the residue was washed with diethyl ether:hexanes (80:20 mix). The solid was filtered and dried to give methyl 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetate. - Yield: (0.65 g, 32.8%),
- MS (ES+): m/z=251 [MH+]
- A solution of methyl 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetate (0.1 g, 0.4 mmol) in acetic acid (1.5 mL) was charged with conc. HCl (0.75 mL) and heated at 90° C. for 2 hr. The reaction mixture was concentrated to dryness to give 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid. The product was used in the next step without further purification.
- Yield: (0.085 g, Crude).
- MS (ES+): m/z=237 [MH+]
-
- A solution of sesamol (0.5 g, 3.62 mmol) in toluene (10 mL) and diethyl acetyl succinate (0.87 mL, 4.30 mmol) in toluene (10 mL) was charged with p-TSA.H2O (0.34 g, 1.79 mmol) and heated at 80° C. overnight. TLC (
Mobile phase 50% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.6) and product formation (Rf 0.4). The reaction mixture was concentrated and the compound was extracted in ethyl acetate, washed with brine. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated in vacuo and purified by column chromatography on silica gel eluting with hexanes/ethyl acetate resulting in ethyl 2-(8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-7-yl)acetate. - Yield: (0.6 g, 57%)
- MS (ES+): m/z=313 [MH++Na]
- A solution of ethyl 2-(8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-7-yl)acetate (0.2 g, 0.68 mmol) in acetic acid (6 mL) was charged with conc. HCl (2 mL) and heated at 90° C. for 2 hr. The reaction mixture was concentrated in vacuo to obtain a solid which was washed with pentane and dried to give 2-(8-methyl-6-oxo-6H-[1,3]dioxolo[4,5-g]chromen-7-yl)acetic acid. The product was used in the next step without further purification.
- Yield: (0.17 g, crude).
- 1H NMR (400 MHz, DMSO-d6): δ 7.34 (d, J=2.4 Hz, 1H), 7.10 (d, J=2.4 Hz, 1H), 6.17 (d, J=2.5 Hz, 2H), 3.57 (s, 2H), 2.64 (s, 3H)
-
- A suspension of 4-hydroxy-3-methylbenzoic acid (1 g, 6.57 mmol) in methanesulfonic acid (5 mL) was cooled to 0° C. and portion wise charged with hexamethylenetetramine (1.84 g, 13.15 mmol) and warmed to room temperature followed by heating at 90° C. for 5 hr then cooled to room temperature and stirred overnight. TLC (
Mobile phase 10% methanol in dichloromethane) indicated absence of starting material (Rf 0.6) and product formation (Rf 0.5). The reaction mixture was poured into ice cooled water and the compound was extracted in ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo to give 3-formyl-4-hydroxy-5-methylbenzoic acid as yellow solid. - Yield: (0.5 g, 42.3%).
- 1H NMR (400 MHz, CDCl3): δ 3.93 (s, 3H), 7.04 (d, 1H, J=8.8 Hz), 8.18-8.20 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 8.32 (s, 1H), 9.56 (s, 1H), 11.39 (s, 1H).
- A solution of 3-formyl-4-hydroxy-5-methylbenzoic acid (0.2 g, 1.11 mmol) in methanol (4 mL) was charged with conc. sulfuric acid (0.14 mL) and refluxed for 16 hr. TLC (
Mobile phase 5% methanol in dichloromethane) indicated absence of starting material (Rf 0.2) and product formation (Rf 0.7). The reaction mixture was concentrated in vacuo and the aqueous was extracted with ethyl acetate. The organic layer was washed with saturated solution of sodium bicarbonate, dried over sodium sulfate, filtered, and concentrated in vacuo resulting in methyl 3-formyl-4-hydroxy-5-methylbenzoate as an off white solid. - Yield: (0.18 g, 85.7%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 7.06 (d, J=8.8 Hz, 1H), 8.02-8.07 (dd, J=1.6, 8.6 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H).
- A solution of methyl 3-formyl-4-hydroxy-5-methylbenzoate (0.18 g, 0.92 mmol) in methanol (10 mL) was cooled to 0° C. and charged with sodium borohydride (0.035 g, 0.92 mmol) and stirred at 0° C. for 45 min. TLC (
mobile phase 40% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.7) and product formation (Rf 0.5). The reaction mixture was quenched with saturated solution of ammonium chloride and concentrated in vacuo. The residue was partitioned between ethyl acetate and water and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in methyl 4-hydroxy-3-(hydroxymethyl)-5-methylbenzoate as white solid. The compound was used in the next step without further purification. - Yield: (0.16 g, 88.8%).
- 1H NMR (400 MHz, CDCl3): δ 3.91 (s, 3H), 3.92 (s, 3H), 7.03 (d, J=8.8 Hz, 1H), 8.05-8.09 (dd, J=1.8, 8.6 Hz, 1H), 8.16 (s, 1H), 9.48 (s, 1H), 12.2 (s, 1H)
- A solution of methyl 4-hydroxy-3-(hydroxymethyl)-5-methylbenzoate (0.9 g, 4.59 mmol) and 2,2 dimethoxy propane (1.7 mL, 13.77 mmol) in acetone (30 mL) was charged with pyridinium-para-toluene sulfonate (0.11 g, 0.45 mmol) and stirred room temperature overnight. TLC (
Mobile phase 30% ethyl acetate in n-hexane) indicated absence of starting material (Rf 0.3) and product formation (Rf 0.5). The reaction mixture was concentrated in vacuo and the crude was purified by column chromatography on silica gel eluting with hexanes/ethyl acetate resulting inmethyl - Yield: (0.96 g, 88.8%).
- 1H NMR (400 MHz, DMSO-d6): δ 3.70 (s, 3H), 7.05 (d, J=8.4 Hz, 1H), 7.89-7.93 (dd, J=1.4, 8.6 Hz, 1H), 8.26 (s, 1H).
- A solution of
methyl Mobile phase 30% ethyl acetate in hexane) indicated absence of starting material (Rf 0.5) and product formation (Rf 0.3). The reaction mixture was concentrated in vacuo and acidified with 10% citric acid resulting in a white precipitate which was filtered to give 2,2,8-trimethyl-4H-benzo[d][1,3]dioxine-6-carboxylic acid as white solid. The precipitate was washed with water, dried and used in the next step without further purification. - Yield: (0.82 g, 91.1%).
- 1H NMR (400 MHz, CDCl3): δ 1.46 (s, 9H), 1.64-2.00 (m, 4H), 2.70-2.82 (m, 1H), 2.90-3.40 (br, 2H), 4.29 (s, 2H), 4.50-5.00 (br, 2H), 6.97 (d, J=8.4 Hz, 1H), 7.00-7.20 (m, 4H), 7.26-7.30 (m, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.70 (s, 1H), 10.7 (s, 1H), 12.1 (s, 1H).
-
- An ice-cold solution of 5-bromo-2-(2-hydroxypropan-2-yl)phenol (3.8 g, 16.44 mmol) in anhydrous DMF (10 mL) was charged with sodium hydride (1.18 g, 49.33 mmol) followed by methyl iodide (2.6 mL, 41.1 mmol) and stirred at room temperature for 2 hr. The reaction mixture was then partitioned between dichloromethane and water and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in crude product which was purified by column chromatography on silica gel eluting with (0-10% ethyl acetate in hexanes) to afford 4-bromo-2-methoxy-1-(2-methoxypropan-2-yl)benzene as a white solid
- Yield: 3.4 g (80%)
- Mol. Wt.: 258.03
- MS (ES+): m/z=258/260 [MH+]
- A solution of 4-bromo-2-methoxy-1-(2-methoxypropan-2-yl)benzene (1.0 g, 3.87 mmol) in THF (50 mL) was cooled to −78° C. under nitrogen atmosphere then charged with, n-butyl lithium, 1.6 M (7.26 mL, 11.62 mmol) stirred at this temperature for 30 min. The reaction mixture was then charged with ethyl chloroformate (0.74 mL, 7.74 mmol) and allowed to warm to room temperature and stirred for an additional 3 hr. The reaction mixture was quenched with sat.NH4Cl solution and extracted with dichloromethane. The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in the crude product which was purified by column chromatography on silica gel eluting with (0-5%, ethyl acetate in hexanes) to yield ethyl 3-methoxy-4-(2-methoxypropan-2-yl)benzoate as a white solid.
- Yield: 0.6 g (31%)
- Mol. Wt.: 252.31
- MS (ES+): m/z=253 [MH+]
- A solution of ethyl ethyl 3-methoxy-4-(2-methoxypropan-2-yl)benzoate (0.6 g, 2.38 mmol) in MeOH:water (4:1) (10.0 mL) was charged with NaOH (0.19 g, 4.75 mmol) and was heated to reflux for 3 hr. The organic solvent was concentrated in vacuo and the resultant residue was acidified with 10% citric acid solution then extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate, filtered and concentrated in vacuo resulting in a residue which was triturated with diethyl ether to yield 3-methoxy-4-(2-methoxypropan-2-yl)benzoic acid.
- White solid;
- Yield: 0.41 g (77%)
- Mol. Wt.: 224.25
- MS (ES+): m/z=225 [MH+]
-
- A solution of 2,3,4-trimethoxybenzoic acid (2.0 g, 9.42 mmol) in acetic acid (12.0 mL) was charged with 55% hydriodic acid (5.0 ml) at room temperature and then heated to 80° C. for 10 hr. The pH of the reaction mixture was adjusted to 1.5 by addition of aqueous sodium hydroxide upon which a precipitate formed. The precipitate was filtered and the resulting solid was washed with water and dried in vacuo to give 2,3-dihydroxy-4-methoxybenzoic acid as a white solid
- Yield: 1.31 g (76%)
- Mol. Wt.: 184.15
- MS (ES+): m/z=185 [MH+]
- Coupling of carboxylic acids (A) was carried out with Core-1 or Core-4 as shown in general synthetic scheme above. Work-up of reactions were carried out as described in the general methods. The details of the compounds synthesized are shown below.
- Reactions were done on 100-200 mg scale
-
Com- pound Brief reaction No. Structure conditions Analytical data B-96 Carboxylic acid (1 eq.), DMF (~25 vol), EDCI (1.5 eq.) HOBT (1.5 eq) Core (1.0 eq.) and DIPEA (4.0 eq.) stirring at R.T. 12 hrs. Purified by Prep. HPLC White solid; Yield: 6% Mol. Wt: 494.54, MS (ES+): m/z = 517 [MH+ + Na] tert butyl 3-(1-(7,8-dihydroxy-2-oxo-2H-chromene-4-carbonyl) piperidin-4-yl)benzylcarbamate B-98 Carboxylic acid (1 eq.), DMF (~25 vol), EDCI (1.5 eq.) HOBT (1.5 eq) Core (1.0 eq.) and DIPEA (4.0 eq.) stirring at R.T. 12 hrs. Purified by Prep. HPLC White solid; Yield: 13.6% Mol. Wt: 508.56 MS (ES+): m/z = 531 [MH+ + Na] tert butyl 3-(1-(2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl) acetyl)piperidin-4-yl)benzylcarbamate B-99 carboxylic acid (1 eq.), DMF (~25 vol), EDCI (1.5 eq.) HOBt (1.5 eq) Core (1.0 eq.) and DIPEA (4.0 eq.) stirring at RT 12 hr. Purified by column chromatographyYield: (0.1 g, 28%) MS (ES+): m/z = 557 [MH+ + Na] tert butyl 3-(1-(2-(6,7-dihydroxy-4-methyl-2-oxo-2H-chromen-3-yl) acetyl)piperidin-4-yl)benzylcarbamate B-127 carboxylic acid (1 eq.) DMF (20 vol) PyBOP (2 eq.) TEA (2 eq) tert-butyl 3- (piperidin-4-yl)benzyl- carbamate (1.5 eq.) RT, 15 hr. purified by silica gel column chromatography (0- 2%, methanol in chloroform) White solid; Yield: 61% Mol. Wt: 456.53 MS (ES+): m/z = 479 [MH+ + Na] tert-butyl 3-(1-(2,3-dihydroxy-4-methoxybenzoyl) piperidin-4-yl)benzylcarbamate B-104 carboxylic acid (1 eq.), DMF (~25 vol), EDCI (1.5 eq.) HOBt (1.5 eq) Core (1.2 eq.) and DIPEA (2.5 eq.) stirring at RT 12 hr. purified by silica gel column chromatography using 0-5%, methanol in dichloromethaneWhite solid; Yield: 44% Mol. Wt: 456.53 MS (ES+): m/z = 479 [MH+ + Na] tert-butyl 3-(1-(3,4-dihydroxy-5-methoxybenzoyl) piperidin-4-yl)benzylcarbamate B-104- spiro carboxylic acid (1 eq.), DMF (~25 vol), EDCI (1.5 eq.) DMAP (0.5 eq) Core (1.1 eq.) stirring at RT 12 hr. purified by prep HPLCWhite solid; Yield: 12% Mol. Wt: 484.54 MS (ES+): m/z = 507 [MH+ + Na] tert-butyl ((1′-(3,4-dihydroxy-5-methoxybenzoyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate - Products of step-1 were deprotected as per conditions mentioned in the table below. The details of the compounds synthesized are as below. Reactions were done on 100-200 mg scale
-
Compound Brief reaction No. Structure conditions Analytical data 96 Methanol ~80 vol, conc. HCl ~8 vol, 12 hrs stirring at RT, followed lyophilization Yield: 34%, Mol. Wt: 394.54 MS (ES+): m/z = 395.10 [MH+] HPLC: 96.4% (254 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.40-1.90 (m, 4H), 2.28 (s, 3H), 2.60-2.89 (m, 2H), 3.16-3.27 (m, 1H), 4.00 (bs, 2H), 4.05 (s, 2H), 4.21 (brd, 1H), 4.51 (brd, 1H), 6.84 (d, J = 8.8 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.25-7.43-(m, 4H), 8.36 (br, 2H) 98 methanol ~100 vol, conc. HCl ~15 vol, 12 hrs stirring at RT, followed by lyophilization Yield: 60%, Mol Wt. 408.45 MS (ES+): m/z = 409 [MH+] HPLC: 98.6% (220 nm) 1H NMR (400 MHz, DMSO-d6): δ 1.40-1.90 (m, 4H), 2.28 (s, 3H), 2.60-2.89 (m, 2H), 3.16-3.27 (m, 1H), 4.10 (bs, 2H), 4.18 (s, 2H), 4.21 (brd, 1H), 4.51 (brd, 1H), 6.84 (d, J = 8.8 Hz, 1H), 7.13-(d, J = 8.8 Hz, 1H), 7.25-7.43-(m, 4H), 8.36 (br, 2H) 99 dichloromethane~100 vol, BBr3, RT-0° C., 12 hr, trituration with methanol followed by Prep HPLC. Yield: 33%. MS (ES+): m/z = 423 [MH+] HPLC: 99.92% (220 nm) 1H NMR (400 MHz, CD3OD): δ 7.43-7.28 (m, 4H), 7.12 (s, 1H), 6.75 (s, 1H), 4.67 (d, J = 12.8 Hz, 1H), 4.33 (d, J = 13.3 Hz, 1H), 4.11 (s, 2H), 3.91- 3.70 (m, 2H), 2.92 (tt, J = 12.1, 3.7 Hz, 2H), 2.79 (td, J = 13.4, 12.7, 2.7 Hz, 1H), 2.37 (s, 3H), 2.04-1.79 (m, 3H), 1.66 (qd, J = 12.9, 4.2 Hz, 1H). 127 dioxane ~15 vol, conc. HCl 1 vol, 3 hrs stirring at RT, Followed by concentration and purification by prep HPLCWhite solid; Yield: 16% Mol. Wt.: 356.42, MS (ES+): m/z = 357 [MH+] HPLC Purity: 98.83% 1H NMR (400 MHz, D2O): δ 7.46-7.33 (m, 3H), 7.29 (d, J = 7.6 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 4.15 (s, 2H), 3.95-3.80 (m, 4H), 3.25-3.02 (m, 2H), 3.00-2.88 (m, 1H), 2.00-1.82 (m, 2H), 1.78-1.62 (m, 2H) 104 methanol 22 vol, conc.HCl 18 vol, 12 hrs stirring at RT, followed by concentration and trituration with hexanes and diethyl etherYield: 88%, MS (ES+): m/z = 379 [MH+ + Na] HPLC: 98.8% (254 nm) 1H NMR (400 MHz, CD3OD): δ 1.70-2.00 (m, 4H), 2.85-3.00 (m, 2H), 3.75-3.85 (brd, 1H), 4.10 (s, 2H), 4.70-4.80 (brd, 2H), 6.80 (s, 1H), 7.02 (s, 1H), 7.26-7.44 (m, 4H), 7.95 (s, 1H). 104-Spiro methanol ~75 vol, conc. HCl 11 vol, 12 hrs stirring at RT, Followed by concentration and trituration with hexane followed by diethyl ether Yield: 93%, Mol Wt. 384.43 MS (ES+): m/z = 407 [MH+ + Na] HPLC: 98.28% (220 nm) 1H NMR (400 MHz, CD3OD): δ 1.70-2.00 (m, 4H), 2.85-3.00 (m, 2H), 3.75-3.85 (brd, 1H), 4.10 (s, 2H), 4.70-4.80 (brd, 2H), 6.80 (s, 1H), 7.02 (s, 1H), 7.26-7.44 (m, 4H), 7.95 (s, 1H). - Protected dihydroxy acids were synthesized and coupled with the core and later protecting groups were cleaved to get the target compounds. The details of intermediates (A) sourced/synthesised as per literature methods/synthesised by adapted methods are given above.
- Coupling of carboxylic acids (A) was carried out with Core-1 or Core-4 as shown in the synthetic scheme. The details of the synthesis are given as below. Reactions were done on 100-200 mg scale
-
Compound Brief reaction Analytical No. Structure conditions data B-74-spiro carboxylic acid (1 eq.), DCM (~150 vol), EDCI (1.5 eq.) DMAP (1.2 eq) Core (1 eq.) stirring at RT 12 hr. followed by concentration, used crude product as it is for next step.Yield: 95% Mol. Wt.: 508.61 MS (ES+): m/z = 408.25 [MH+ − boc] tert-butyl ((1′-(2,2-dimethyl-4H-benzo[d][1,3]dioxine-7-carbonyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate B-113 Spiro carboxylic acid (1 eq.), DMF (~85 vol), EDCI (1.5 eq.) DMAP (1 eq) Core (1 eq.) stirring at RT 12 hr. purified by purified by column chromatography using hexanes/ethyl acetateYield: 80% Mol. Wt.: 522.63 MS (ES+): m/z = 545 [MH+ + Na] tert-butyl ((1′-(2,2,8-trimethyl-4H-benzo[d][1,3]dioxine-6-carbonyl)- 2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate B-126 carboxylic acid (1 eq.), DMF (~85 vol), EDCI (1.5 eq.) DMAP (1 eq) Core (1 eq.) stirring at RT 12 hr. purified by silica gel column chromatography (0-5%, methanol in chloroform)White solid; Yield: 37% Mol. Wt.: 496.64 MS (ES+): m/z = 497.3 [MH+] tert butyl 3-(1-(3 methoxy-4-(2 methoxypropan-2-yl) benzoyl)piperidin-4-yl)benzylcarbamate - Products of step-1 were deprotected as per conditions mentioned in the table below. The details of the compounds synthesized are as below. Reactions were done on 100-200 mg scale
-
Compound Brief reaction No. Structure conditions Analytical data 74 Spiro methanolic HCl ~25 vol, 6 h stirring at room temperature, Followed by concentration and purification by prep HPLC Yield: 19%, Mol Wt.: −368.43 MS (ES+): m/z = 391.05 [MH+ + Na] HPLC: 99.02% (254 nm). 1H NMR (400 MHz, DMSO-d6): δ 1.73(m, 4H), 3.20(m, 2H), 3.95(d, J = 5.2 Hz, 2H), 4.31(m, 2H), 4.49(s, 4H), 6.82(t, J = 9.6, 8.0 Hz 3H), 7.22(d, J = 7.6 Hz, 1H), 7.35(d, J = 7.6 Hz, 1H), 7.42(s, 1H), 8.04(bs, 3H), 9.6(bs,1 h). 113 Spiro dioxane ~20 vol, conc. HCl ~3 vol, 4 hrs stirring at RT, Followed by concentration and purification by prep HPLC Yield: 52.6%, Mol Wt.: 382.45 MS (ES+): m/z = 405 [MH+ + Na] HPLC: 99.64% (220 nm), 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.90 (m, 4H), 2.75-2.90 (m, 1H), 2.91-3.30 (br, 2H), 3.50-3.60 (br, 2H), 3.73-(s, 3H), 4.00-4.10 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 7.20-7.40 (m, 4H), 7.47 (d, J = 8.4 Hz, 1H), 7.77 (s, 1H), 8.20 (br, 2H), 11.7 (br, 1H), 11.9 (br, 1H). 126 BBr3 (2 eq.) in dichloromethane (50 vol) added at 0° C. and further stirring at RT for 7 hrs. Products isolated by concentration in vacuo and subsequent purification by prep HPLC White solid; Yield: 13%, Mol. Wt.: 368.47, MS (ES+): m/z = 369 [MH+] HPLC Purity: 86.46%, 1H NMR (400 MHz, CD3OD): δ 7.44-7.26 (m, 5H), 6.86 (d, J = 8.4 Hz, 1H), 6.82 (s, 1H), 4.80-4.72 (m, 1H), 4.10 (s, 2H), 4.00- 3.86 (m, 1H), 3.26- 3.15 (m, 1H), 3.00- 2.85 (m, 2H), 2.04- 1.66 (m, 4H), 1.61 (s, 6H) 126 mono methyl White solid; Yield: 26%, Mol. Wt.: 382.50, MS (ES+): m/z = 383 [MH+] HPLC Purity: 97.66%, 1H NMR (400 MHz, CD3OD): 7.64 (d, J = 8.0 Hz, 1H), 7.44- 7.32 (m, 3H), 7.29 (d, J = 6.4 Hz, 1H), 7.06- 6.98 (m, 2H), 4.10 (s, 2H), 3.98-3.84 (m, 4H), 3.04-2.86 (m, 2H), 2.06-1.64 (m, 4H), 1.59 (s, 6H) T-163 J. Org. Chem, 1987, 52, 1670-1373 - Sixteen Final Targets with cis-diol functionality were synthesized. Racemic bicyclo[2.2.1]-5-heptene/octene-2-carboxylic acids either in pure Endo/Exo form or their mixtures were coupled with protected 4-(3-aminomethyl phenyl)piperidine coupled products were converted to diols by cis hydroxylation to get anti and syn isomers of racemic Endo and Exo isomers. Later Boc protection on the amino methyl functionality was cleaved under acidic conditions to get the target compounds. (Scheme-1)
- Also analogues of these diols with 3-amino benzoyl linkage between the core and diol were synthesized by first coupling racemic bicyclo[2.2.1]-5-heptene/octene-2-carboxylic acids with 3-amino methyl benzoate and subsequent hydrolysis to get corresponding carboxylic acid which was processed as per the reaction sequence mentioned below. (Scheme-2)
- Wherever possible, Endo-Exo/anti-syn isomers were separated by chromatographic techniques and characterized. Remaining compounds isolated as mixtures.
- Racemic bicyclo [2.2.1]-5-heptene-2-carboxylic acid was procured from Aldrich chemical company which was containing major Endo isomer. Endo & Exo isomers of racemic bicyclo [2.2.1]-5-octene-2-carboxylic acids were synthesized as per procedure reported in the literature. (Chem. Pharm. Bull. 44, 296-306, 1996)
- The details of intermediates (A) sourced/synthesised as per literature methods/synthesised by adapted methods are given below.
- Coupling of 3-amino methyl benzoate and racemic bicyclo[2.2.1]-5-heptene/octene-2-carboxylic acids is described below.
-
- An ice-cold solution of 5-norbornene-2-carboxylic acid (1.0 eq.) in dichloromethane (30 Vol) was charged with 4-dimethylaminopyridine (DMAP) (0.5 eq.), hydroxy benzotriazole (HOBt) (1. eq.), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride EDCI.HCl (1.5 eq) and stirred at 0° C. for 30 minutes then charged with methyl-3-aminobenzoate (1.2 eq.) and stirred at room temperature for an additional for 2 hr. The mixture was partitioned between dichloromethane and water and separated. The combined organic layer was washed with water (2×25 mL), 2N HCl (1×25 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product colorless oil; (mixture of endo+exo) which was used for next step without further purification.
- Yield: 51%
- Mol. Wt: 271.31, MS (ES+): m/z=272 [MH+]
- A solution of ester (1.0 eq.) in THF:H2O (1:1)(15 vol) was charged with LiOH (3.0 eq.) and stirred at room temperature for 2-3 hr. The reaction mixture was concentrated in vacuo and the residue was diluted with water and extracted with DCM. The aqueous layer was separated and acidified with 2N HCl and extracted with DCM. The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give a mixture of Endo+Exo acid derivatives.
- Yield: 78%
- Mol. Wt: 257.28, MS (ES+): m/z=258 [MH+]
-
- An ice-cold solution of carboxylic acid (1.0 eq.) in dichloromethane (30 mL/g) was charged with triethyl amine (3.0 eq.) and thionyl chloride (1.5 eq.) and stirred at 0° C. for 30 minutes then charged with methyl-3-aminobenzoate (1.0 eq.) and allowed to warm to stir at room temperature overnight. Reaction mixture was diluted with dichloromethane, washed with saturated sodium bicarbonate solution. The combined organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to afford the crude product which was purified by column chromatography on silica gel eluting with (0-10%, ethyl acetate in hexane) to afford endo-amide or exo-amide derivatives.
- A solution of ester (1.0 eq.) in MeOH:water (30 mL/g, 4:1) was charged with NaOH (2.0 eq.) was refluxed for 2 hr. The reaction mixture was concentrated in vacuo and the residue was acidified with 10% citric acid solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give Endo acid or Exo acid derivatives.
-
-
Com- Brief pound reaction Analytical No. Structure Names conditions data A-139 (Endo + Exo) olefin Major compound: (±) endo tert-butyl 3-(1-(3- bicyclo[2.2.1]hept-5-ene-2- carboxamido)benzoyl) piperidin- 4-yl)benzylcarbamate Minor compound: (±) exo tert-butyl 3-(1-(3- bicyclo[2.2.1]hept-5-ene-2- carboxamido)benzoyl) piperidin- 4-yl)benzylcarbamate Carboxylic acid (1.0 eq.), 4-(3- aminomethyl- phenyl) piperidine, (1.3 eq.), EDCI (1.5 eq.), HOBt (1 eq) DMAP (1 eq.), DCM RT 2 hrColorless oil, Yield: 87.25%, Mol. Wt.: 529.67 MS (ES+): m/z = 552 [MH+ + Na] A-140 (Endo + Exo) olefin Major compound: (±) endo tert-butyl 3-(1- bicyclo[2.2.1]hept-5-ene-2- carbonyl)piperidin-4- yl)benzylcarbamate Minor compound: (±) exo tert-butyl 3-(1- bicyclo[2.2.1]hept-5-ene-2- carbonyl)piperidin-4- yl)benzylcarbamate Carboxylic acid (1.0 eq.), 4-(3- aminomethyl- phenyl) piperidine, (1.00 eq.), EDCI (1.5 eq.), HOBt (1 eq) DMAP (1 eq.), DCM RT, 3 hr Colorless oil, Yield: 31.57%, Mol. Wt.: 410.55 MS (ES+): m/z = 433 [MH+ + Na] A-141 Endo (±) endo tert-butyl 3-(1-(3- bicyclo[2.2.2]oct-5-ene-2- carboxamido)benzoyl) piperidin-4-yl)benzyl- carbamate Carboxylic acid (1.0 eq.) in anhydrous DMF (30 mL/g), EDCI (1.5 eq.), HOBt (1.5 eq.), tert-butyl 3-(piperidin-4- yl)benzyl- carbamate (1.0 eq.), DIEA (2.5 eq.) Stirring at RT for 15 hr White solid; Yield: 90% Mol. Wt.: 543.70 LCMS (m/z): 544 [MH+] A-141 Exo (±) exo tert-butyl 3-(1-(3- bicyclo[2.2.2]oct-5-ene-2- carboxamido)benzoyl) piperidin-4-yl)benzyl- carbamate White solid; Yield: 93% Mol. Wt.: 543.70 MS (ES+): m/z = 544 [MH+] A-142 Endo (±) endo tert-butyl 3-(1- bicyclo[2.2.2]oct-5-ene-2- carbonyl)piperidin-4- yl)benzylcarbamate Anhydrous DMF (30 mL/g), EDCI (1.5 eq.)., HOBt (1.5 eq.), tert-butyl 3-(piperidin-4- yl)benzyl- carbamate (1.0 eq.), DIEA (2.5 eq.), Stirring at R.T for 15 hrs Purified by column chromatography over silica get (0-15%, ethyl acetate in hexane) White solid; Yield: 36% Mol. Wt.: 424.58 MS (ES+): m/z = 425 [MH+] A-142 Exo (±) exo tert-butyl 3-(1- bicyclo[2.2.2]oct-5-ene-2- carbonyl)piperidin-4- yl)benzylcarbamate White solid; Yield: 54% Mol. Wt.: 424.58 LCMS (m/z): 425 [MH+] - Reaction conditions for cis hydroxylation and compounds synthesized are as in the table below.
-
Compound Brief reaction Analytical No. Structure Names conditions data B-139 Racemic (Endo + Exo) Major compound: (±) endo tert- butyl 3-(1-(3--5,6-syn- dihydroxybicyclo[2.2.1]heptane- 2- carboxamido)benzoyl)piperidin- 4-yl)benzylcarbamate Major compound: (±) exo tert- butyl 3-(1-(3--5,6-syn- dihydroxybicyclo[2.2.1]heptane- 2- carboxamido)benzoyl)piperidin- 4-yl)benzylcarbamate THF (50 mL/g) and water (40 mL/g), OsO4 (0.02 eq.), NMO (1.1 eq.) Stirring at RT for 3 hr. Extraction with ethyl acetate and concentration in vacuo and subsequent purification by column chromatography using 0-2%, methanol in chloroform White solid; Yield: 94% Mol. Wt: 563.68 MS (ES+): m/z = 586 [MH+ + Na] B-140 Racemic (Endo + Exo) Major compound: (±) endo tert- butyl 3-(1-5,6-syn- dihydroxybicyclo[2.2.1]heptane- 2-carbonyl)piperidin-4- yl)benzylcarbamate. Major compound: (±) exo tert- butyl 3-(1-5,6-syn- dihydroxybicyclo[2.2.1]heptane- 2-carbonyl)piperidin-4- yl)benzylcarbamate. THF (50 mL/g) and water (40 mL/g), OsO4 (0.02 eq.), NMO (1.1 eq.) Stirring at RT for 3 hr. Extraction with ethyl acetate and concentration in vacuo and subsequent purification by column chromatography using 0-2%, methanol in chloroform White solid; Yield: 35% Mol. Wt: 444.56 MS (ES+): m/z = 467 [MH+ + Na] B-141 Racemic Endo anti (±) endo tert-butyl 3-(1-(3- (-5,6-anti- dihydroxybicyclo[2.2.2]octane- 2- carboxamido)benzoyl)piperidin- 4-yl)benzylcarbamate THF (50 mL/g) and water (40 mL/g), OsO4 (0.02 eq.), NMO (1.1 eq.) Stirring at RT for 3 hr. Extraction with ethyl acetate and concentration in vacuo and subsequent purification by column chromatography using 0-2%, methanol in chloroform White solid; Yield: 47% Mol. Wt: 577.71 MS (ES+): m/z = 578 [MH+] B-141 Racemic Exo syn (±) exo tert-butyl 3-(1-(3- (-5,6-syn- dihydroxybicyclo[2.2.2]octane- 2- carboxamido)benzoyl)piperidin- 4-yl)benzylcarbamate White solid; Yield: 35% Mol. Wt: 577.71 MS (ES+): m/z = 578 [MH+] B-141 Racemic Exo anti (±) exo tert-butyl 3-(1-(3- (-5,6-anti- dihydroxybicyclo[2.2.2]octane- 2- carboxamido)benzoyl)piperidin- 4-yl)benzylcarbamate White solid; Yield: 15% Mol. Wt: 577.71 MS (ES+): m/z = 578 [MH+] B-142 Racemic Endo anti (±) endo tert-butyl 3-(1-(-5,6- anti- dihydroxybicyclo[2.2.2]octane- 2-carbonyl)piperidin-4- yl)benzylcarbamate THF (60 mL/g) and water (40 mL/g), OsO4 (0.02 eq.), NMO (1.1 eq.) Stirring at RT for 3 hr. After completion. Extraction with ethyl acetate and concentration in vacuo and subsequent purification by column chromatography using 0-2%, methanol in chloroform White solid; Yield: (19%) Mol. Wt.: 458.59 LCMS (m/z): 459 [MH+] B-142 Racemic Endo syn (±) endo tert-butyl 3-(1-(-5,6- syn- dihydroxybicyclo[2.2.2]octane- 2-carbonyl)piperidin-4- yl)benzylcarbamate White solid; Yield: (12%) Mol. Wt.: 458.59, MS (ES+): m/z = 459 [MH+] B-142 Racemic Exo anti (±) exo tert-butyl 3-(1-(-5,6- anti- dihydroxybicyclo[2.2.2]octane- 2-carbonyl)piperidin-4- yl)benzylcarbamate THF (60 mL/g) and water (20 mL/g), OsO4 (0.02 eq.), NMO (1.1 eq.) Stirring at RT for 3 hr. After completion. Extraction with ethyl acetate and concentration in vacuo and subsequent purification by column chromatography using 0-2%, methanol in chloroform White solid; Yield: 71% Mol. Wt.: 458.59, MS (ES+): m/z = 459 [MH+] - Reaction conditions for deprotection and compounds synthesized are as in the table below.
-
Compound Brief reaction Analytical No. Structure Names conditions data 139 Endo olefin (±) endo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)bicyclo [2.2.1]hept-5-ene- 2-carboxamide. trifluoro acetic acid (4 eq.). in dichloromethane. Stirring at room temp. for 12 hr. conc. for removal of DCM, and purification by prep HPLC. TLC (10% methanol in chloroform. White Solid, Yield: 31.2%, Mol. Wt.: 429.55 MS (ES+): m/z = 430 [MH+] 1H NMR (400 MHz, DMSO-d6(D2O): δ 7.71 (d, J = 2.5 Hz, 1H), 7.54 - 7.51 (m, 1H), 7.39- 7.25 (m, 5H), 7.03 (d, J = 7.4 Hz, 1H), 6.15 (dd, J = 5.7, 2.9 Hz, 1H), 5.83 (dd, J = 5.5, 2.8 Hz, 1H), 4.61 (s, 1H), 4.00 (s, 2H), 3.70 (s, 1H), 3.21 (d, J = 42.8 Hz, 2H), 3.03 (dt, J = 8.4, 4.0 Hz, 1H), 2.85 (d, J = 11.9 Hz, 3H), 1.81 (tt, J = 11.8, 9.3, 4.3 Hz, 2H), 1.48 (d, J = 70.9 Hz, 4H), 1.31 (d, J = 2.2 Hz, 2H) 139 Exo olefin (±) exdo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)bicyclo [2.2.1]hept-5-ene- 2-carboxamide. trifluoro acetic acid (4 eq.). in dichloromethane. Stirring at room temp. for 12 hr. Conc. for removal of DCM, and purification by prep HPLC. TLC (10% methanol in chloroform. White Solid, Yield: 31.2%, Mol. Wt.: 429.55 MS (ES+): m/z = 430 [MH+] 1H NMR (400 MHz, DMSO-d6): δ 8.19 (s, 3H), 7.78- 7.74 (m, 1H), 7.58- 7.50 (m, 1H), 7.36 (td, J = 7.6, 4.0 Hz, 3H), 7.28 (t, J = 7.7 Hz, 2H), 7.06 (d, J = 7.5 Hz, 1H), 6.21- 6.15 (s, 2H), 4.62 (s, 1H), 4.00 (s, 2H), 3.24- 3.11 (m, 1H), 2.87 (m, 5H), 2.31- 2.22 (m, 1H), 1.87 (dt, J = 11.6, 3.9 Hz, 2H), 1.77- 1.48 (m, 3H), 1.30- 1.21 (m, 3H). 140 Endo olefin (±) endo (4-(3- (aminomethyl)phenyl) piperidin-1-yl) (-bicyclo[2.2.1]hept-5- en-2-yl)methanone trifluoro acetic acid (4 eq.). in dichloromethane. Stirring at room temp. for 12 hr. conc. for removal of DCM, and purification by prep HPLC. TLC (10% Methanol in chloroform. Colorless oil, Yield: 10.4%, Mol. Wt.: 310.43 MS (ES+): m/z = 311 [MH+] 1H NMR (400 MHz, DMSO-d6): δ 7.29 (dt, J = 27.0, 6.5 Hz, 4H), 6.15- 6.04 (m, 1H), 5.95- 5.85 (m, 1H), 4.42 (d, J = 12.6 Hz, 1H), 4.17 (d, J = 13.7 Hz, 1H), 3.97 (s, 2H), 3.19- 2.99 (m, 4H), 2.79 (d, J = 10.5 Hz, 2H), 1.96- 1.68 (m, 3H), 1.57- 1.33 (m, 2H), 1.27 (q, J = 8.1 Hz, 3H) 140 Exo olefin (±) exo (4-(3- (aminomethyl)phenyl) piperidin-1-yl) (-bicyclo[2.2.1]hept-5- en-2-yl)methanone trifluoro acetic acid (4 eq.). in dichloromethane. Stirring at room temp. for 12 hr. conc. for removal of DCM, and purification by prep HPLC. TLC (10% methanol in chloroform. Colorless oil, Yield: 47.39%, Mol. Wt: 310.43 MS (ES+): m/z = 311 [MH+] 1H NMR (400 MHz, DMSO-d6, D2O): δ 7.30 (dd, J = 28.1, 7.8 Hz, 4H), 6.16 (s, 2H), 4.00 (s, 2H), 3.24-3.05 (m, 5H), 2.90- 2.72 (m, 3H), 1.78 (s, 4H), 1.46 (d, J = 8.4 Hz, 2H), 1.25 (d, J = 14.1 Hz, 2H). 139 Racemic Endo (±) endo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)-5,6- syn- dihydroxybicyclo[2.2.1] heptane-2- carboxamide trifluoro acetic acid (3 eq.). in dichloromethane. Stirring at room temp. for 12 hr. conc. for removal of DCM, and purification by prep HPLC. TLC (10% methanol in chloroform. Colorless oil, Yield: 13.5%, Mol. Wt: 463.57 MS (ES+): m/z = 464 [MH+] 1H NMR (400 MHz, DMSO-d6, D2O): δ 8.13 (s, 2H), 7.77 (s, 1H), 7.56 (dd, J = 14.7, 8.0 Hz, 1H), 7.41-7.26 (m, 5H), 7.10- 7.05 (m, 1H), 4.54 (d, J = 73.9 Hz, 1H), 4.02 (q, J = 5.6 Hz, 2H), 2.95- 2.43 (m, 6H), 2.37 (d, J = 4.2 Hz, 1H), 2.25 (dd, J = 8.4, 5.0 Hz, 1H), 2.05 (d, J = 20.7 Hz, 1H), 1.90- 1.68 (m, 4H), 1.63-1.48 (m, 5H), 1.21 (dd, J = 21.5, 10.0 Hz, 2H), 140 Racemic Endo (±) endo (4-(3- (aminomethyl)phenyl) piperidin-1-yl)-(5,6- syn- dihydroxybicyclo[2.2.1] heptan-2- yl)methanone trifluoro acetic acid (3 eq.). in dichloromethane. Stirring at room temp. for 12 hr. Conc. for removal of DCM, and purification by prep HPLC. TLC (10% methanol in chloroform. Colorless oil, Yield: 32.05%, Mol. Wt: 344.45 MS (ES+): m/z = 345 [MH+] 1H NMR (400 MHz, DMSO-d6): δ 7.39- 7.23 (m, 4H), 4.57 (d, J = 13.3 Hz, 1H), 4.14 (s, 1H), 3.99 (d, J = 3.4 Hz, 2H), 3.23- 3.04 (m, 1H) 2.96 (d, J = 6.0 Hz, 1H), 2.82 (d, J = 11.9 Hz, 1H), 2.65 (d, J = 12.4 Hz, 2H), 2.15 (s, 1H), 1.98 (d, J = 4.2 Hz, 1H), 1.92 (s, 1H), 1.85- 1.71 (m, 2H), 1.61 (d, J = 11.1 Hz, 1H), 1.54-1.36 (m, 5H), 1.21 (s, 1H) 141 Endo olefin (±) endo N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)bicyclo [2.2.2]oct-5-ene-2- carboxamide 1,4-dioxane (30 mL/g), conc. HCl (1 mL/g) Stirring at room temperature for 3 h., Reaction mixture was evaporated under vacuo and purified by preparative HPLC White solid; Yield: 44%, Mol. Wt: 443.58, MS (ES+): m/z = 444 [MH+], HPLC Purity: 99.83%, 1H NMR (400 MHz, CD3OD): δ 7.81 (s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.45- 7.32 (m, 4H), 7.29 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 6.8 Hz, 1H), 6.31 (t, J = 6.8 Hz, 1H), 6.16 (t, J = 6.8 Hz, 1H), 4.84- 4.72 (m, 1H), 4.11 (s, 2H), 3.95- 3.83 (m, 1H), 3.27-3.16 (m, 1H), 3.00-2.72 (m, 4H), 2.68- 2.55 (m, 1H), 2.04- 1.50 (m, 8H), 1.38-1.20 (m, 2H) 141 Exo olefin (±) exo N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)bicyclo [2.2.2]oct-5-ene-2- carboxamide White solid; Yield: 75%, Mol. Wt: 443.58, MS (ES+): m/z = 444 [MH+], HPLC Purity: 96.84%, 1H NMR (400 MHz, CD3OD): δ 7.87 (s, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.44- 7.34 (m, 4H), 7.31 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.40 (t, J = 6.8 Hz, 1H), 6.35 (t, J = 6.8 Hz, 1H), 4.11 (s, 2H), 3.98- 3.84 (m, 1H), 3.04- 2.88 (m, 2H), 2.80-2.70 (m, 1H), 2.62-2.48 (m, 2H), 2.08- 1.60 (m, 8H), 1.48- 1.35 (m, 1H), 1.34-1.20 (m, 1H), 1.18-1.05 (m, 1H) 142 Endo olefin (±) endo (4-(3- (aminomethyl)phenyl) piperidin-1-yl) (-bicyclo[2.2.2]oct-5- en-2-yl)methanone (±) exo (4-(3- (aminomethyl)phenyl) piperidin-1-yl) (-bicyclo[2.2.2]oct-5- en-2-yl)methanone White solid; Yield: 39%, Mol. Wt.: 324.46 MS (ES+): m/z = 325 [MH+], HPLC Purity: 99.71%, 1H NMR (400 MHz, CDCl3): δ 8.37 (bs, 2H), 7.30-7.10 (m, 4H), 6.30- 6.18 (m, 2H), 4.62-4.50 (m, 1H), 4.08-3.90 (m, 3H), 3.16- 3.00 (m, 1H), 2.82- 2.48 (m, 6H), 1.92-1.66 (m, 3H), 1.63-1.36 (m, 4H), 1.33- 1.21 (m, 2H) 142 Exo olefin White solid; Yield: 44%, Mol. Wt: 324.46 MS (ES+): m/z = 325 [MH+], HPLC Purity: 99.50%,1H NMR (400 MHz, CD3OD): δ 7.44- 7.24 (m, 4H), 6.44 6.28 (m, 2H), 4.80-4.68 (m, 1H), 4.20-4.02 (m, 3H), 3.23- 3.12 (m, 1H), 2.96- 2.82 (m, 1H), 2.80-2.67 (m, 2H), 2.63-2.52 (m, 2H), 2.12- 1.86 (m, 3H), 1.82- 1.51 (m, 4H), 1.48-1.03 (m, 3H) 141 Racemic Endo anti (±) endo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)-5,6- anti- dihydroxybicyclo[2.2.2] octane-2- carboxamide. White solid; Yield: 36%, Mol. Wt: 477.60 MS (ES+): m/z = 478 [MH+], HPLC Purity: 95.87%, 1H NMR (400 MHz, CD3OD): δ 7.85 (s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.45- 7.34 (m, 4H), 7.29 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 7.2 Hz, 1H), 4.82- 4.72 (m, 1H), 4.11 (s, 2H), 4.06- 3.98 (m, 1H), 3.95-3.85 (m, 1H), 3.04-2.72 (m, 4H), 2.08- 1.68 (m, 9H), 1.50- 1.24 (m, 2H) 141 Racemic Exo syn (±) exo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)-5,6- syn- dihydroxybicyclo[2.2.2] octane-2- carboxamide. White solid; Yield: 30%, Mol. Wt: 477.60 MS (ES+): m/z = 478 [MH+], HPLC Purity: 95.54%, 1H NMR (400 MHz, CD3OD): δ 8.52 (s, 1H), 7.85 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.44- 7.33 (m, 3H), 7.29 (d, J = 7.2 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 4.10 (s, 2H), 3.98- 3.80 (s, 3H), 3.14- 2.87 (m, 2H), 2.70-2.59 (m, 1H), 2.24-2.11 (m, 1H), 2.06- 1.94 (m, 2H), 1.90- 1.69 (m, 5H), 1.66-1.30 (m, 2H) 141 Racemic Exo anti (±) exo-N-(3-(4-(3- (aminomethyl)phenyl) piperidine-1- carbonyl)phenyl)-5,6- anti- dihydroxybicyclo[2.2.2] octane-2- carboxamide. White solid; Yield: 15%, Mol. Wt: 477.60 MS (ES+): m/z = 478 [MH+], HPLC Purity: 99.57%, 1H NMR (400 MHz, CD3OD): δ 8.54 (s, 1H), 7.84 (s, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.44- 7.32 (m, 3H), 7.29 (d, J = 7.2 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 4.09 (s, 2H), 3.97- 3.82 (m, 3H), 3.38- 3.18 (m, 1H), 3.10-2.88 (m, 2H), 2.05-1.62 (m, 8H), 1.45- 1.29 (m, 2H) 142 Racemic Endo anti (±) endo (4-(3- (aminomethyl)phenyl) piperidin-1-yl)(-5,6- anti- dihydroxybicyclo[2.2.2] octan-2- yl)methanone White solid; Yield: 37%, Mol. Wt.: 358.47 MS (ES+): m/z = 359 [MH+], HPLC Purity: 95.59%, 1H NMR (400 MHz, CD3OD): δ 7.42- 7.20 (m, 4H, 4.75- 4.65 (m, 1H), 4.58-4.38 (m, 1H), 4.18-4.06 (m, 3H), 4.00- 3.86 (m, 1H), 3.27- 3.12 (m, 1H), 3.08-3.00 (m, 1H), 2.94-2.82 (m, 1H), 2.80- 2.67 (m, 1H), 2.06- 1.76 (m, 8H), 1.74-1.54 (m, 2H), 1.50-1.28 (m, 2H) 142 Racemic Endo syn (±) endo (4- (3(aminomethyl)phen- yl)piperidin-1-yl) (-5,6-syn- dihydroxybicyclo[2.2.2] octan-2- yl)methanone White solid; Yield: 31%, Mol. Wt.: 358.47 MS (ES+): m/z = 359 [MH+], HPLC Purity: 99.24%, 1H NMR (400 MHz, CD3OD): δ 7.42- 7.24 (m, 4H), 4.76- 4.66 (m, 1H), 4.20-4.04 (m, 3H), 3.86-3.72 (m, 2H), 3.10- 3.00 (m, 1H), 2.96- 2.84 (m, 1H), 2.80-2.68 (m, 1H), 2.34-1.48 (m, 13H) 142 Racemic Exo Anti (±) endo (4- (3(aminomethyl)phen- yl)piperidin-1-yl) (-5,6-anti- dihydroxybicyclo[2.2.2] octan-2- yl)methanone White solid; Yield: 12%, Mol. Wt.: 358.47, MS (ES+): m/z = 359 [MH+], HPLC Purity: 95.03%, 1H NMR (400 MHz, CD3OD): δ 7.42- 7.20 (m, 4H), 4.78- 4.64 (m, 1H), 4.40-4.16 (m, 1H), 4.10-3.97 (m, 3H), 3.94- 3.80 (m, 1H), 3.75- 3.55 (m, 1H), 3.23-3.03 (m, 1H), 2.90-2.60 (m, 2H), 2.10- 1.50 (m, 10H), 1.42-1.20 (m, 2H) - Five Final targets with benzoxaborol functionality were synthesized 112 Spiro, T-117 Spiro, T-117 Spiro methyl and T-117-gem mono methyl, were synthesized with benzoxaborol functionality. Synthetic approaches for all the targets were not very similar, so every target is described with its respective scheme and procedure as given below.
- 1-bromo-6-iodo-2-methylbenzene was synthesized as per procedures available in the literature (Bioorganic and Medicinal Chemistry, 16, 6764-6777, 2008; J. Am. Chem. Soc., 122, 6871-6883, 2000.)
- Suzuki coupling of Step-1 product (8.5 g, 28.6 mmol) with m-carbethoxy phenyl boronic acid (6.65 g, 34.32 mmol)) was carried out in presence of palladium (0) tetrakis (triphenyl phosphine) (10 mol %) in dioxane (20 vol) and sodium carbonate (6.06 g, 57.2 mmol) as the base. After completion of reaction, the reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue obtained was partitioned between ethyl acetate and water and separated. The aqueous was re-etracted with ethyl acetate and the combined organic fractions were dried over sodium sulfate, filtered and concentrated in vacuo. The crude product obtained was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexanes.
- Yield: 80%
- Mol. Wt: 319.19
- MS (ES+): m/z=319.2/321.2 [MH+]
- A stirred suspension of step-2 (7.0 g, 21.9 mmol) in toluene (30 vol) was degassed with argon then charged with potassium acetate (6.47 g, 65.7 mmol), PdCl2-dppf-CH2Cl2 (5 mol %) and bis(pinacolato)diborane (13.9 g, 54.75 mmol) and the reaction was refluxed. The reaction mixture was the filtered through a pad of celite and the filtrate was concentrated in vacuo resulting in crude product. The crude product was purified by column chromatography over silica gel eluting with 1-5% ethyl acetate in hexane.
- Yield: 80%
- Mol. Wt: 366.26
- MS (ES+): m/z=367.20 [MH+]
- A stirred solution of step-3 product (6.0 g, 16.3 mmol) in carbon tetrachloride
- (20 vol) was charged with dibenzoyl peroxide (075 g, 3.2 mmol) and N-bromo succinimide (1.2 eq) and heated to 75° C. for 5 hr. The reaction mixture was partitioned between water dichloromethane and separated. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo resulting in crude product. The crude product was purified by column chromatography over silica gel eluting with 1-5% ethyl acetate in hexanes.
- Yield: 80%
- Mol. Wt: 445.15
- MS (ES+): m/z=446.20/447.20 [MH+]
- A stirred solution of Step-4 product (5.8 g, 13 mmol) in acetonitrile (30 vol) was charged with trifluoro acetic acid (10 vol) and water (5 vol) and heated to 91° C. and monitored by LCMS. The reaction mixture was concentrated in vacuo and the residue was partitioned between water and ethyl acetate and separated. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by column chromatography over silica gel eluting with 10-35% ethyl acetate in hexanes.
- Yield: 60%
- Mol. Wt: 282.10
- MS (ES+): m/z=283.25 [MH+]
- A mixture of step-5 product (2 g, 7.08 mmol) in THF (10 vol) & water (20 vol) was charged with lithium hydroxide (1.7 g, 70.8 mmol) and heated to 60° C. The reaction mixture was concentrated in vacuo. The reaction mixture was diluted with water and was adjusted to
pH 2 using conc. HCl upon which a precipitate formed. The precipitate was filtered, washed with water and dried in vacuum oven. - Yield: 60%
- Mol. Wt: 254.05
- MS (ES+): m/z=255.10 [MH+]
- A mixture of step-6 product (250 mg, 0.98 mmol), tert-butyl((2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate (404 mg, 1.27 mmol), EDCI (280 mg, 1.47 mmol), DMAP (240 mg, 1.96 mmol) in dichloromethane (20 vol) was stirred at room temperature and was monitored by LCMS. The reaction mixture was concentrated in vacuo diluted with water and the pH was adjusted to 4 using dil. HCl upon which a precipitate formed. The precipitate was filtered and washed with water and dried in vacuum oven.
- Yield: 60%
- Mol. Wt: −554.44,
- MS (ES+): m/z=555.10 [MH+]
- Product of step-7 (370 mg, 0.66 mmol) was dissolved in dichloromethane (20 vol) and TFA (20 vol) and stirred at room temperature until complete. The reaction mixture was concentrated in vacuo and the crude residue was purified by preparative HPLC to give Target 112.
- Yield: 33%
- Mol. Wt: 454.33
- MS (ES+): m/z=455.20 [MH+]
- HPLC purity: 96%
- 1H NMR (400 MHz, DMSO-d6): δ 8.29 (s, 2H), 7.81 (d, J=6.9 Hz, 1H), 7.64-7.41 (m, 7H), 7.26 (d, J=8.2 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 5.13 (s, 2H), 4.44 (d, J=46.7 Hz, 4H), 4.13-3.88 (m, 4H), 3.69 (d, J=16.3 Hz, 1H), 3.14 (s, 2H), 1.74 (d, J=42.6 Hz, 4H).
- A solution of (5-(methoxycarbonyl)-2-(methylthio)thiophen-3-yl)boronic acid (8 g, 34.48 mmol), 2,6-dibromobenzyl alcohol (11 g, 41.37 mmol), palladium (0) tetrakis (triphenyl phosphine) (10 mol %), and sodium carbonate (7.3 g, 68.96 mmol) in dioxane (20 vol) was degassed and heated until complete. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was partitioned between water and ethyl acetate and separated. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in crude product. The crude product was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexanes.
- Yield: 20%
- Mol. Wt: 373.29
- MS (ES+): m/z=373.10/375.10 [MH+]
- A stirred suspension of step-1 product (1.9 g, 5.09 mmol) in toluene (30 vol) was degassed with argon and charged with potassium acetate (1.5 g, 15.27 mmol), PdCl2-dppf-CH2Cl2 (5 mol %), dppf (3 mol %) and bis(pinacolato) diborane (3.21 g, 12.72 mmol) and degassed again then heated to reflux & monitored by LCMS till most of the starting material was consumed. The mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo resulting in crude product. The crude product was purified by column chromatography over silica gel eluting with 1-5% ethyl acetate in hexanes.
- Yield: 40%
- Mol. Wt: 320.19
- MS (ES+): m/z=321.10 [MH+]
- A mixture of step-2 product (650 mg, 2.03 mmol, potassium hydroxide (570 mg, 10.15 mmol) in THF (10 vol) and water (20 vol) was heated to 60° C. Reaction was monitored by LCMS till most of the starting material was consumed. The reaction mixture was concentrated in vacuo and the residue was diluted with water and the pH was adjusted to 2 using conc. HCl upon which a precipitate formed. The precipitate was filtered and washed with water and dried in vacuum oven.
- Yield: 35%
- Mol. Wt: 306.17
- MS (ES+): m/z=307.20 [MH+]
- A mixture of step-3 product (150 mg, 0.490 mmol), tert-butyl((2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate (202 mg, 0.63 mmol), EDCI (142 mg, 0.735 mmol), DMAP (120 mg, 0.98 mmol) in dichloromethane (20 vol) was stirred at room temperature and monitored by LCMS till most of the starting material was consumed. The reaction mixture was concentrated in vacuo and diluted with water and adjusted to pH ˜4 using dil. HCl upon which a precipitate formed. The precipitate was filtered and washed with water and dried in vacuum oven.
- Yield: 55%
- Mol. Wt: 606.17
- MS (ES+): m/z=607.20 [MH+]
- same as step-4, only tert-butyl 3-(piperidin-4-yl)benzyl carbamate used instead of ((2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate
- Yield: 51%
- Mol. Wt: 578.55
- MS (ES+): m/z=579.3 [MH+]
- Product of step-4 (160 mg, 0.263 mmol) was dissolved in dichloromethane (20 vol)-TFA (20 eq) a stirred at room temperature. After completion of reaction, the reaction mixture was concentrated in vacuo and purified by preparative HPLC to give Target-117 Spiro.
- Yield: 30%,
- Mol. Wt: 506.44
- MS (ES+): m/z=507.15 [MH+]
- HPLC purity: 99.2%
- 1H NMR (400 MHz, DMSO-d6): δ 9.38 (s, 1H), 8.19-8.06 (m, 2H), 7.87 (d, J=7.3 Hz, 1H), 7.52 (t, J=7.4 Hz, 1H), 7.37 (d, J=7.5 Hz, 1H), 7.30-7.29 (m, 1H), 7.20 (d, J=8.2 Hz, 1H), 6.90 (s, 1H), 6.78 (d, J=8.2 Hz, 1H), 5.00 (d, J=26.4 Hz, 2H), 4.26 (s, 2H), 3.96 (p, J=5.6 Hz, 2H), 2.89-2.75 (m, 4H), 2.50 (s, 3H), 1.25 (s, 4H).
- same as step-5 only tert-butyl 3-(piperidin-4-yl)benzyl carbamate used instead of ((2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate
- Yield: 20%,
- Mol. Wt: 478.43
- MS (ES+): m/z=479.15 [MH+]
- HPLC data: 96.79%
- 1H NMR (400 MHz, CDCl3): δ 8.16 (bs, 1H), 8.03 (m, 1H), 7.79 (d, J=6.8 Hz, 1H), 7.51-7.42 (m, 3H), 7.03-6.97 (m, 3H), 6.62 (s, 1H), 5.34 (m, 1H), 4.16 (s, 2H) 3.77 (m, 2H), 3.63-3.48 (m, 4H), 2.72 (bs, 1H), 2.57 (s, 3H), 2.2-2.0 (m, 4H)
- Suzuki coupling of (5-(methoxycarbonyl)-2-(methylthio)thiophen-3-yl)boronic acid (5 g, 21.54 mmol) with 2-bromo-6-iodotoluene (7.6 g, 25.85) was carried out in presence of palladium (0) tetrakis (triphenyl phosphene) (10 mol %), and sodium carbonate (4.56 g, 43.08 mmol) in dioxane (20 vol) and heated at 80° C. for 3 hr. After completion of reaction, the reaction mixture was filtered through a pad of celite and filtrate was concentrated in vacuo. The residue obtained was partitioned between water and ethyl acetate and separated. The organic was dried over sodium sulfate, filtered, and concentrated in vacuo resulting in product. The crude product obtained was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexane.
- Yield: 70%
- Mol. Wt: 357.29
- MS (ES+): m/z=357.10/359.10 [MH+]
- A mixture of step-1 product (5 g, 13.9 mmol) in THF (10 eq) & water (20 vol) was charged with potassium hydroxide (7.8 g, 13.9 mmol) was heated to 60° C. for 2 hr. The reaction was monitored by LCMS till most of the starting material was consumed. The reaction mixture was concentrated in vacuo and diluted with water and the pH was adjusted to 2 using conc. HCl. Upon which a precipitate formed. The precipitate was filtered, washed with water and dried in vacuum oven.
- Yield: 80%
- Mol. Wt: 343.26
- MS (ES+): m/z=343.10/345.10 [MH+]
- A solution of Step-2 product (1 g, 2.9 mmol) in in THF (30 vol) was cooled to −78° C. and charged with n-BuLi (556 mg, 8.7 mmol) and stirred at −78° C. for 30 min. Stirring at same temperature the reaction was dropwise charged with tri-isopropyl borate (1.58 mg, 8.7 mmol) and then allowed to warm to room temperature. The reaction mixture was quenched with dil HCl and concentrated in vacuo. The residue obtained was diluted with dil HCl, filtered and washed with water. The residue was redissolved in aq NaOH and reprecipitated by acidifying with dil HCl to get pure product.
- Yield: 20%
- Mol. Wt: 308.18
- MS (ES+): m/z=309.10 [MH+]
- A mixture of step-3 product (150 mg, 0.486 mmol), tert-butyl((2H-spiro [benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate (200 mg, 0.632 mmol), EDCI (140 mg, 0.729 mmol), DMAP (120 mg, 0.972) in dichloromethane (20 vol) was stirred at room temperature. The reaction was monitored by LCMS until most of the starting material was consumed. The reaction mixture was concentrated in vacuo and diluted with water and the pH was adjusted to ˜4 using dil. HCl upon which a precipitate formed. The precipitate was filtered, washed with water and dried in vacuum oven.
- Yield: 60%
- Mol. Wt: 608.58
- MS (ES+): m/z=609.20 [MH+]
- Product of step-4 (164 mg, 0.27 mmol) was dissolved in dichloromethane (20 vol)-TFA (20 eq) and stirred at room temperature until completion of reaction and then concentrated in vacuo and purified by preparative HPLC to give the Target-117 Spiro Methyl.
- Yield: 31.6%
- Mol. Wt: −508.46
- MS (ES+): m/z=509.15 [MH+]
- HPLC purity: 98.4%
- 1H NMR (400 MHz, DMSO-d6): δ 8.23 (s, 2H), 7.55 (d, J=7.1 Hz, 1H), 7.22 (t, J=7.6 Hz, 2H), 7.17-7.07 (m, 2H), 7.00 (s, 1H), 6.77 (d, J=8.3 Hz, 1H), 4.29 (s, 2H), 3.94 (q, J=5.8 Hz, 2H), 2.85 (t, J=12.3 Hz, 4H), 2.60 (s, 3H), 2.30 (s, 3H), 1.32 (bs, 6H)
- A solution of (5-(methoxycarbonyl)-2-(methylthio)thiophen-3-yl)boronic acid (5 g, 21.54 mmol), 2-bromo-6-iodobenzaldehyde (8 g, 25.85 mmol), palladium(0) tetrakis (triphenyl phosphine) (10 mol %), sodium carbonate (4.53 g, 43.08 mmol) in dioxane (20 vol) was degassed and heated at 80° C. for 24 hr. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was diluted with water and extracted with ethyl acetate to get crude product. The crude product was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexane.
- Yield: 60%
- Mol. Wt: 371.27
- MS (ES+): m/z=371.10/373.10 [MH+]
- A mixture of step-1 product (3.5 g, 9.4 mmol) in THF (10 eq) & water (20 vol) was charged with potassium hydroxide (2.1 g, 37.6 mmol) and heated to 60° C. for 2 hr. The reaction mixture was concentrated in vacuo and diluted with water and the pH was adjusted to ˜2 using conc. HCl upon which a precipitate formed. The precipitate was filtered, washed with water and dried in vacuum oven.
- Yield: 80%
- Mol. Wt: 357.24
- MS (ES+): m/z=357.20/359.20 [MH+]
- Solution of Step-2 product (2.57 g, 7.2 mmol) in THF (30 vol) was cooled to 0° C. and charged with methylmagnesiumbromide (944 mg, 7.92 mmol) and stirred for 30 min The reaction mixture was quenched with dil HCl at 0° C. and concentrated in vacuo. The residue was diluted with dil HCl, filtered and washed with water. The crude product was purified by column chromatography over silica gel using 5-10% ethyl acetate in hexane.
- Yield: 95%
- Mol. Wt: 373.29
- MS (ES+): m/z=373.10/375.10 [MH+]
- A stirred suspension of step-3 product (2.5 g, 6.69 mmol) in toluene was degassed with argon and charged with potassium acetate (1.96 g, 20.07 mmol), PdCl2-dppf-CH2Cl2 (5 mol %) and bis(pinacolato)diborane (4.23 g, 16.72 mmol) and heated to reflux and monitored by LCMS till most of the starting material was consumed. The mixture was the filtered through a pad of celite and the filtrate was concentrated in vacuo to give the crude product. The crude product was purified by column chromatography over silica gel using 1-5% ethyl acetate in hexanes.
- Yield: 80%
- Mol. Wt: 320.19
- MS (ES+): m/z=321.10 [MH+]
- A mixture of step-4 product (700 mg, 2.18 mmol), tert-butyl((2H-spiro[benzofuran-3,4′-piperidin]-5-yl)methyl)carbamate (900 mg, 2.83 mmol), EDCI (617 mg, 13.27 mmol), DMAP (536 mg, 4.36 mmol) in dichloromethane (20 vol) was stirred at room temperature and the reaction was monitored by LCMS till most of the starting material was consumed. The reaction mixture was concentrated and diluted with water and the aqueous was adjusted to
pH 4 using dil. HCl upon which a precipitate formed. The precipitate was filtered, washed with water and dried in vacuum oven - Yield: 50%
- Mol. Wt: 620.59
- MS (ES+): m/z=621.20 [MH+]
- Product of step-5 (600 mg, 0.96 mmol) was dissolved in dichloromethane (20 vol)-TFA (20 eq) and stirred at room temperature. The reaction mixture was concentrated in vacuo and purified by preparative HPLC to give Target-117 Gem mono methyl spiro.
- Yield: 31.6%
- Mol. Wt: 520.47\
- MS (ES+): m/z=521.25 [MH+]
- HPLC purity: 99.3%
- 1H NMR (400 MHz, DMSO-d6): δ 8.17 (s, 4H), 7.95 (s, 1H), 7.78 (d, J=7.3 Hz, 1H), 7.60 (d, J=7.5 Hz, 1H), 7.46 (dd, J=15.9, 8.2 Hz, 3H), 7.24 (d, J=8.2 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 5.55 (q, J=6.4 Hz, 1H), 4.31 (d, J=8.0 Hz, 2H), 4.08-3.87 (m, 2H), 3.03 (t, J=12.3 Hz, 1H), 2.39-2.28 (m, 1H), 2.62 (s, 3H), 1.28 (d, J=52.8 Hz, 4H), 1.04 (d, J=6.7 Hz, 3H)
- The details of the Final Targets synthesized are as below.
-
Target Structure Analytical Data 112 Spiro Mol. Wt: 454.33 MS (ES+): m/z = 455.20 [MH+] HPLC data: 96% 1H NMR (400 MHz, DMSO-d6): δ 8.29 (s, 2H), 7.81 (d, J = 6.9 Hz, 1H), 7.64-7.41 (m, 7H), 7.26 (d, J = 8.2 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 5.13 (s, 2H), 4.44 (d, J = 46.7 Hz, 4H), 4.13-3.88 (m, 4H), 3.69 (d, J = 16.3 Hz, 1H), 3.14 (s, 2H), 1.74 (d, J = 42.6 Hz, 4H). (5-(aminomethyl)-2H-spiro[benzofuran-3,4′-piperidin]- 1′-yl)(3-(1-hydroxy-1,3-dihydrobenzo[c][1,2] oxaborol-4-yl)phenyl)methanone 117-Spiro Mol. Wt: 506.44 MS (ES+): m/z = 507.15 [MH+] HPLC data: 99.2% 1H NMR (400 MHz, DMSO-d6): δ 9.38 (s, 1H), 8.19-8.06 (m, 2H), 7.87 (d, J = 7.3 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.30-7.29 (m, 1H), 7.20 (d, J = 8.2 Hz, 1H), 6.90 (s, 1H), 6.78 (d, J = 8.2 Hz, 1H), 5.00 (d, J = 26.4 Hz, 2H), 4.26 (s, 2H), 3.96 (d, J = 5.6 Hz, 2H), 2.89-2.75 (m, 4H), 2.50 (s, 3H), 1.25 (s, 4H). (5-(aminomethyl)-2H-spiro[benzoturan-3,4′-piperidine]- 1′-yl)(4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-4- yl)-5-(methylthio)thiophen-2-yl)methanone 117 Mol. Wt: 478.43 MS (ES+): m/z = 479.15 [MH+] HPLC data: 96.79% 1H NMR (400 MHz, CDCl3): δ 8.16 (bs, 1H), 8.03 (m, 1H), 7.79 (d, J = 6.8 Hz, 1H), 7.51- 7.42 (m, 3H), 7.03-6.97 (m, 3H), 6.62 (s, 1H), 5.34 (m, 1H), 4.16 (s, 2H)3.77(m, 2H), 3.63-3.48 (m, 4H), 2.72 (bs, 1H), 2.57 (s, 3H), 2.2-2.0 (m, 4H) (4-(3-(aminomethyl)phenyl)piperidin-1-yl)(4- (1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol- 4-yl)-5-(methylthio)thiophen-2-yl)methanone 117-Spiro- methyl Mol. Wt: 508.46 MS (ES+): m/z = 509.15 [MH+] HPLC Data: 98.4% 1H NMR (400 MHz, DMSO-d6): δ 8.23-(s, 2H), 7.55 (d, J = 7.1 Hz, 1H), 7.22 (t, J = 7.6 Hz, 2H), 7.17-7.07 (m, 2H), 7.00 (s, 1H), 6.77 (d, J = 8.3 Hz, 1H), 4.29 (s, 2H), 3.94 (q, J = 5.8 Hz, 2H), 2.85 (t, J = 12.3 Hz, 4H), 2.60 (s, 3H), 2.30 (s, 3H), 1.32 (bs, 6H) (3-(5-(5-(aminomethyl)-2H-spiro[benzofuran- 3,4′-piperidin]-1′-ylcarbonyl)-2-(methylthio) thiophen-3-yl)-2-methylphenyl)boronic acid 117-Gem- Monomethyl- Spiro Mol. Wt: 520.47 MS (ES+): m/z = 521.25 [MH+] HPLC data: 99.3% 1H NMR (400 MHz, DMSO-d6): δ 8.17 (s, 4H), 7.95 (s, 1H), 7.78 (d, J = 7.3 Hz, 1H), 7.60 (d, J = 7.5 Hz, 1H), 7.46 (dd, J = 15.9, 8.2 Hz, 3H), 7.24 (d, J = 8.2 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H) , 5.55 (q, J = 6.4 Hz, 1H), 4.31 (d, J = 8.0 Hz, 2H), 4.08-3.87 (m, 2H), 3.03-(t, J = 12.3 Hz, 1H), 2.39-2.28 (m, 1H), 2.62 (s, 3H), 1.28 (d, J = 52.8 Hz, 4H), 1.04 (d, J = 6.7 Hz, 3H), (5-(aminomethyl)-2H-spiro[benzofuran-3,4′-piperidin]- 1′-yl)(4-(1-hydroxy-3-methyl-1,3-dihydrobenzo[c] [1,2]oxaborol-4-yl)-5-(methylthio)thiophen-2-yl)methanone - A stirred solution of carboxylic acid from step-3 in DCM or DMF was added and EDCI, HOBt (in some cases) and DMAP or DIPEA was for 15 min. at 0° C. followed by addition of protected core. Stirring was continued at room temperature and reaction was monitored by LCMS until most of the starting materials were consumed. Reaction mixture was then quenched with water and aq. layer was extracted with dichloromethane and combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product which was either used for next step without purification or purified by chromatographic techniques.
- Desired ester was dissolved in mixture of Water and solvents like THF/methanol/acetone that are miscible in water then charged with lithium/sodium hydroxide and stirred at room temperature and monitored by TLC & LCMS until most of the starting material was consumed. Solvent was concentrated in vacuo and partitioned between ethyl acetate and water and separated. The aqueous layer was washed with ethyl acetate (1×) and acidified with 2N HCl and extracted with ethyl acetate again. The acidic ethyl acetate extract was dried over sodium sulfate, filtered, and concentrated in vacuo to get crude product. In most of the cases products were sufficient pure to be used for the next step.
- Desired compound was stirred with aq. hydrochloric acid or trifluoracetic acid (TFA) in a co-solvent like acetonitrile, methanol, THF, DCM etc. Reaction was monitored by LCMS until most of the starting materials were consumed. The reaction mixture was concentrated in vacuo to remove the solvents and residue obtained was purified by reverse phase preparative HPLC. In some cases products were purified by column chromatography over silica gel.
- The pure fraction of mobile phase was lyophilized to get the products as TFA salts. TFA salts were converted to hydrochloride salts by stirring with 2N HCl for 30 min under nitrogen atmosphere followed by lyophilization.
- Sometimes only Boc deprotection observed to be taking place with boronate ester functionality intact. In such cases further hydrolysis of isolated Boc de-protected boronate esters were carried out followed by purification using preparative HPLC.
- While specific embodiments have been discussed, the above specification is illustrative and not restrictive. Many variations will become apparent to those skilled in the art upon review of this specification. The full scope of the embodiments should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained.
Claims (42)
X1—Y1—Z1 (Formula I)
X2—Y2—Z2 (Formula II),
X1—Y1—Z1 (Formula I)
X1—Y1—Z1 (Formula I)
X2—Y2—Z2 (Formula II),
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/110,056 US20140194383A1 (en) | 2011-04-07 | 2012-04-09 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473093P | 2011-04-07 | 2011-04-07 | |
PCT/US2012/032809 WO2013058824A1 (en) | 2011-04-07 | 2012-04-09 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
US14/110,056 US20140194383A1 (en) | 2011-04-07 | 2012-04-09 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/032809 A-371-Of-International WO2013058824A1 (en) | 2011-04-07 | 2012-04-09 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/929,528 Continuation US11970448B2 (en) | 2011-04-07 | 2020-07-15 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140194383A1 true US20140194383A1 (en) | 2014-07-10 |
Family
ID=48141232
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/110,056 Abandoned US20140194383A1 (en) | 2011-04-07 | 2012-04-09 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
US16/929,528 Active US11970448B2 (en) | 2011-04-07 | 2020-07-15 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/929,528 Active US11970448B2 (en) | 2011-04-07 | 2020-07-15 | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Country Status (4)
Country | Link |
---|---|
US (2) | US20140194383A1 (en) |
EP (1) | EP2694707B1 (en) |
JP (1) | JP2014512364A (en) |
WO (1) | WO2013058824A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016115360A1 (en) * | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
US9931407B2 (en) | 2015-05-12 | 2018-04-03 | Blinkbio, Inc. | Silicon based drug conjugates and methods of using same |
US10064880B2 (en) | 2016-06-09 | 2018-09-04 | Blinkbio, Inc. | Silanol based therapeutic payloads |
US10912786B2 (en) | 2011-04-07 | 2021-02-09 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
WO2022031772A1 (en) * | 2020-08-07 | 2022-02-10 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
WO2022031777A3 (en) * | 2020-08-07 | 2022-03-17 | Cornell University | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
US11970448B2 (en) | 2011-04-07 | 2024-04-30 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
DK2950644T3 (en) | 2013-01-30 | 2017-09-04 | Agrofresh Inc | USE OF BENZOXABOROLS AS VOLATIVE ANTIMICROBIAL AGENTS IN MEAT, PLANTS OR PARTS |
US8669207B1 (en) | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
CN103880679B (en) * | 2014-03-13 | 2015-02-11 | 河北科技大学 | Synthesis method of 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid |
CN105017140B (en) * | 2014-04-28 | 2017-12-29 | 复旦大学 | Anthranilamide compound and its production and use |
EP3426029B1 (en) | 2016-03-07 | 2023-08-30 | AgroFresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
CN107573297A (en) * | 2017-08-31 | 2018-01-12 | 桂林南药股份有限公司 | A kind of preparation method of the acidic hydrolysis impurity of Linezolid |
CN109678701B (en) * | 2019-01-22 | 2021-08-20 | 安徽德信佳生物医药有限公司 | Preparation method of vilanterol intermediate |
JP7335849B2 (en) * | 2019-07-17 | 2023-08-30 | 信越化学工業株式会社 | Diester compound having a dimethylcyclobutane ring, method for producing the same, and method for producing a dimethylcyclobutane compound derived therefrom |
ES2951876T3 (en) * | 2019-07-17 | 2023-10-25 | Shinetsu Chemical Co | Diester compound having a dimethylcyclobutane ring, a process for preparing the same, and a process for preparing dimethylcyclobutane compound derived from the diester compound |
AU2020408039A1 (en) * | 2019-12-20 | 2022-08-18 | Arbutus Biopharma Corporation | Synthetic processes and intermediates |
CN114315787A (en) * | 2021-12-30 | 2022-04-12 | 广州佳途科技股份有限公司 | Preparation method and application of vilanterol EP impurity 2 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63222153A (en) | 1987-03-11 | 1988-09-16 | Kanegafuchi Chem Ind Co Ltd | Novel alpha-cyanocinnamic acid amide derivative |
US5236919A (en) | 1989-02-28 | 1993-08-17 | Imperial Chemical Industries Plc | Quinoxalinyl derivatives suitable for use in leukotriene mediated disease |
CN1165577C (en) | 1997-05-30 | 2004-09-08 | 株式会社资生堂 | Copolymer containing reactive silyl groups, composition containing same and method of treating with same |
US6432632B2 (en) | 1997-09-05 | 2002-08-13 | Matsushita Electric Industrial Co., Ltd. | Fluorescence polarization method |
US6326478B1 (en) | 1998-07-08 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
KR100858642B1 (en) | 2000-05-22 | 2008-09-17 | 아벤티스 파마슈티칼스 인크. | Arylmethylamine derivatives for use as tryptase inhibitors |
GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
GB0111459D0 (en) | 2001-05-10 | 2001-07-04 | Isis Innovation | Universal fluorescent sensors |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
JP3841398B2 (en) | 2001-12-17 | 2006-11-01 | 富士写真フイルム株式会社 | Negative resist composition |
WO2004071641A2 (en) | 2003-02-10 | 2004-08-26 | Pointilliste, Inc. | Self-assembling arrays and uses thereof |
EP1723159B1 (en) | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
US7511139B2 (en) | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
TW200800201A (en) | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
US8129366B2 (en) | 2005-12-13 | 2012-03-06 | Daiichi Sankyo Company, Limited | VLA-4 inhibitory drug |
AU2006331765A1 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor |
US8239007B2 (en) | 2007-04-13 | 2012-08-07 | Ethicon Endo-Surgert, Inc. | Biocompatible nanoparticle compositions and methods |
AU2008282557A1 (en) | 2007-07-27 | 2009-02-05 | Ensemble Discovery Corporation | Detection assays and use thereof |
UA108596C2 (en) | 2007-11-09 | 2015-05-25 | Peptide deformylase inhibitors | |
WO2009067202A1 (en) * | 2007-11-21 | 2009-05-28 | Janssen Pharmaceutica, N.V. | Spiropiperidines for use as tryptase inhibitors |
WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
JP2011516547A (en) | 2008-04-09 | 2011-05-26 | コーネル ユニバーシティー | Coferon and its production and use |
FR2955324A1 (en) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES |
CA2774476A1 (en) | 2009-10-07 | 2011-04-14 | Francis Barany | Coferons and methods of making and using them |
EP2694707B1 (en) | 2011-04-07 | 2018-08-15 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
JP2014511865A (en) | 2011-04-07 | 2014-05-19 | コーネル ユニバーシティー | Silyl monomer that can be multimerized in aqueous solution and use thereof |
US20140161729A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Cofluorons and methods of making and using them |
-
2012
- 2012-04-09 EP EP12842368.8A patent/EP2694707B1/en active Active
- 2012-04-09 US US14/110,056 patent/US20140194383A1/en not_active Abandoned
- 2012-04-09 JP JP2014504078A patent/JP2014512364A/en active Pending
- 2012-04-09 WO PCT/US2012/032809 patent/WO2013058824A1/en active Application Filing
-
2020
- 2020-07-15 US US16/929,528 patent/US11970448B2/en active Active
Non-Patent Citations (4)
Title |
---|
CAPLUS printout of U.S. Patent No. 7,713,994, published on 5/11/2010. * |
Chemical Abstract Registry No. 1000524-64-0, indexed in the Registry File on STN CAS ONLINE Jan. 23, 2008. * |
Costall et al., Characterisation of the Mechanisms for Hyperactivity Induction from the Nucleus accumbens by Phenylethylamine Derivatives. Psychopharmacology, 1976, 48, 225-231. * |
Federal Register, 2011, Vol. 76, No. 27, pg. 7166. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10912786B2 (en) | 2011-04-07 | 2021-02-09 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
US11970448B2 (en) | 2011-04-07 | 2024-04-30 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
WO2016115360A1 (en) * | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
US9931407B2 (en) | 2015-05-12 | 2018-04-03 | Blinkbio, Inc. | Silicon based drug conjugates and methods of using same |
US11291731B2 (en) | 2015-05-12 | 2022-04-05 | Blinkbio, Inc. | Silicon based drug conjugates and methods of using same |
US11497757B2 (en) | 2016-06-09 | 2022-11-15 | Blinkbio, Inc. | Silanol based therapeutic payloads |
US10716801B2 (en) | 2016-06-09 | 2020-07-21 | Blinkbio, Inc. | Silanol based therapeutic payloads |
US10293053B2 (en) | 2016-06-09 | 2019-05-21 | Blinkbio, Inc. | Silanol based therapeutic payloads |
US10064880B2 (en) | 2016-06-09 | 2018-09-04 | Blinkbio, Inc. | Silanol based therapeutic payloads |
WO2022031772A1 (en) * | 2020-08-07 | 2022-02-10 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
WO2022031777A3 (en) * | 2020-08-07 | 2022-03-17 | Cornell University | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
GB2614978A (en) * | 2020-08-07 | 2023-07-26 | Univ Cornell | Therapeutically useful cure-pro molecules for E3 ligase mediated degradation of proteins, and methods of making and using them |
GB2614977A (en) * | 2020-08-07 | 2023-07-26 | Univ Cornell | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making usage |
GB2614978B (en) * | 2020-08-07 | 2024-10-23 | Univ Cornell | Therapeutically useful cure-pro molecules for E3 ligase mediated degradation of proteins, and methods of making and using them |
Also Published As
Publication number | Publication date |
---|---|
EP2694707B1 (en) | 2018-08-15 |
EP2694707A1 (en) | 2014-02-12 |
US20200354319A1 (en) | 2020-11-12 |
US11970448B2 (en) | 2024-04-30 |
EP2694707A4 (en) | 2014-09-10 |
JP2014512364A (en) | 2014-05-22 |
WO2013058824A1 (en) | 2013-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11970448B2 (en) | Monomers capable of dimerizing in an aqueous solution, and methods of using same | |
US10660893B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
US9994537B2 (en) | Piperazine carbamates and methods of making and using same | |
US10912786B2 (en) | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | |
US11161856B2 (en) | Spirocycle compounds and methods of making and using same | |
US10519134B2 (en) | Pyrazole compounds and methods of making and using same | |
JP7162622B2 (en) | pyrazole MAGL inhibitor | |
US10759790B2 (en) | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | |
US11655217B2 (en) | Pyrazole MAGL inhibitors | |
US10221158B2 (en) | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | |
TW201329048A (en) | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors | |
US20190084969A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
JP2023513373A (en) | P2X3 modulators | |
US20230219897A1 (en) | Pyrazole magl inhibitors | |
EP2925737B1 (en) | Tricyclic compounds for use in the treatment and/or control of obesity | |
JP2022537403A (en) | Pharmaceutically Active Pyrazolo-Pyridone Modulators of DCN1/2-Mediated Curineddylation | |
US20150087043A1 (en) | Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same | |
US20150080570A1 (en) | Alpha,beta-unsaturated monomers capable of multimerization in an aqueous solution, and methods of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COFERON, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARNOLD, LEE DANIEL;REEL/FRAME:031480/0207 Effective date: 20120531 Owner name: CORNELL UNIVERSITY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARANY, FRANCIS;PINGLE, MANEESH;GIARDINA, SARAH F.;REEL/FRAME:031480/0110 Effective date: 20120530 Owner name: PURDUE RESEARCH FOUNDATION, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERGSTROM, DONALD E.;REEL/FRAME:031480/0149 Effective date: 20120606 |
|
AS | Assignment |
Owner name: PURDUE RESEARCH FOUNDATION, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERGSTROM, DONALD E.;REEL/FRAME:031829/0870 Effective date: 20120606 |
|
AS | Assignment |
Owner name: BLINKBIO, INC., NEW YORK Free format text: CHANGE OF NAME;ASSIGNOR:COFERON, INC.;REEL/FRAME:042422/0240 Effective date: 20150814 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: CORNELL UNIVERSITY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BLINKBIO, INC.;REEL/FRAME:051136/0135 Effective date: 20191025 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |